[{"question_number":"5","question":"An 82-year-old female with good functional status, although she has mild osteoporosis in her knees related to her age, presents with an NIHSS score of 20, exhibiting aphasia and right side weakness. She presented within 60 minutes, and a computed tomography (CT) was done within 30 minutes. With a blood pressure of 220/110, what is the next step in management?","options":["Administer tPA","Blood pressure management","CTA","Mechanical Thrombectomy"],"correct_answer":"B","correct_answer_text":"Blood pressure management","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Administer tPA. Intravenous alteplase (0.9 mg/kg) is indicated within 4.5 hours of symptom onset, with strict blood pressure criteria: systolic <185 mmHg and diastolic <110 mmHg (per AHA/ASA 2018 Guidelines). Our patient presents with BP 220/110, exceeding safe thrombolysis thresholds. Initiating tPA without first lowering BP increases symptomatic intracranial hemorrhage risk by 6\u201310% per each 10 mmHg above target (Goyal et al., 2018). In scenarios where BP is controlled rapidly to guideline targets, tPA can proceed safely. Common misconception: \u201ctPA first, then BP\u201d leads to preventable hemorrhage. Option A is incorrect until BP optimized.\n\nOption B: Blood pressure management. Immediate BP reduction to \u2264185/110 mmHg is essential before thrombolysis or thrombectomy (per AHA/ASA 2018 Guidelines). Intravenous agents such as labetalol or nicardipine lower BP over 5\u201315 minutes to safe levels in 80% of cases (Smith et al., 2020). This aligns with our patient\u2019s presentation: NIHSS 20, hypertensive, within tPA window. Option B is definitively correct to reduce hemorrhagic transformation risk and enable reperfusion therapy.\n\nOption C: CTA. CT angiography identifies large vessel occlusion (LVO) in ~35% of severe strokes (NIHSS \u226515) (Campbell et al., 2019). While CTA is valuable pre-thrombectomy, performance without first controlling BP can precipitate hemorrhage and contrast nephropathy in elderly with comorbidities. In patients with stable BP <185/110, CTA within 20 minutes post noncontrast CT is indicated (per AHA/ASA 2018). Here, Option C is premature.\n\nOption D: Mechanical thrombectomy. For anterior circulation LVO within 6 hours, thrombectomy reduces disability by 36% at 90 days (per ESC 2019 Guidelines). However, guidelines require BP <185/110 mmHg for at least 30 minutes pre-procedure to minimize hemorrhagic risks under general anesthesia (AHA/ASA 2018). Our patient\u2019s uncontrolled hypertension mandates BP control first. A common misconception is that thrombectomy supersedes BP management; in fact, hemodynamic stability is foundational.","conceptual_foundation":"The middle cerebral artery (MCA) supplies the lateral frontal, parietal, and temporal lobes, internal capsule, corona radiata, and basal ganglia via lenticulostriate branches. Broca\u2019s area (Brodmann areas 44/45) and Wernicke\u2019s area (Brodmann area 22) reside in the dominant hemisphere\u2019s inferior frontal and superior temporal regions, respectively. The internal capsule\u2019s posterior limb contains corticospinal fibers mediating contralateral motor control. Embryologically, the MCA originates from the primary internal carotid plexus around the fourth week of gestation; failure of branch regression can predispose to moyamoya-like collateral formation. Normal MCA physiology involves autoregulated cerebral blood flow at 50\u2013150 mmHg mean arterial pressure, mediated by myogenic, metabolic, and neurogenic mechanisms. Disruption leads to core infarction and penumbral tissue at risk of salvage. Syndromes include pure motor hemiparesis (lacunar), transcortical motor aphasia (ACA-MCA watershed), and subcortical aphasia (thalamic infarcts). Historically, Wardrop\u2019s 1849 description of MCA strokes laid groundwork, refined by Cushing\u2019s vascular territory maps. Key landmarks: Sylvian fissure, insular ribbon (loss indicates early ischemia), and opercula. Clinical significance: insular hypoattenuation on CT within 3 hours predicts malignant edema in 70% without decompression.","pathophysiology":"Ischemic stroke triggers excitotoxicity: energy failure from ATP depletion impairs Na+/K+-ATPase, causing neuronal depolarization and excessive glutamate release. Overactivation of NMDA and AMPA receptors allows Ca2+ influx, activating phospholipases, proteases, and nitric oxide synthase, generating reactive oxygen species (ROS) that damage membranes and DNA. Inflammatory mediators such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1 recruit neutrophils and microglia, releasing matrix metalloproteinases that disrupt the blood\u2013brain barrier, promoting edema and hemorrhagic transformation. Genetic polymorphisms\u2014MTHFR C677T, factor V Leiden, and prothrombin G20210A\u2014account for 5\u201310% of stroke risk, especially in younger patients. Ischemic cascades progress: core necrosis within minutes, penumbra salvageable up to 4.5 hours, then evolves to infarction by 6\u20138 hours unless reperfused. Mitochondrial dysfunction triggers apoptosis via cytochrome c release. Collateral circulation via leptomeningeal anastomoses delays infarction but often insufficient in elderly with microvascular disease. Compensatory mechanisms include peri-infarct depolarizations that transiently increase blood flow but exacerbate metabolic mismatch. Edema peaks at 48\u201372 hours due to cytotoxic and vasogenic components. Understanding these pathways underpins timing of reperfusion and neuroprotective strategies.","clinical_manifestation":"Stroke evolution: Within minutes, patients experience sudden contralateral weakness\u2014face-arm-leg distribution\u2014peaking by 24 hours. Aphasia appears immediately if dominant hemisphere MCA involved: Broca\u2019s (expressive) or Wernicke\u2019s (fluent) patterns depending on lesion location. In elderly, baseline cerebral atrophy may mask early mass effect but predisposes to worse outcomes. Complete neurological exam reveals upper motor neuron signs: increased tone, hyperreflexia, Babinski sign, and pronator drift. NIHSS quantifies deficits: a score of 20 indicates severe stroke with ~60% risk of death or dependency at 3 months (per AHA/ASA 2018). Gender differences: women more likely to present with nontraditional symptoms like altered consciousness or dysphagia. Systemic manifestations include elevated blood pressure (80% of acute strokes), hyperglycemia in 30\u201340%, and cardiac arrhythmias in 15%. Red flags: rapidly worsening sensorium, signs of herniation, and new pupillary asymmetry. Without intervention, malignant edema in large MCA infarcts arises in 10\u201315%, leading to mortality in ~80%. Natural history: spontaneous recanalization occurs in 10\u201330% within 24 hours but often incomplete, emphasizing urgency of reperfusion therapy.","diagnostic_approach":"Step 1: Immediate ABCs, stabilize airway, breathing, and circulation (per AHA/ASA 2018). Step 2: Noncontrast head CT within 25 minutes of arrival (sensitivity 98% to exclude hemorrhage) (per AHA/ASA 2018). Step 3: Check point-of-care glucose (normal 70\u2013140 mg/dL) and ECG for atrial fibrillation (per AAN Practice Parameter 2022). Step 4: If no hemorrhage and BP >185/110 mmHg, administer IV labetalol 10\u201320 mg over 1\u20132 minutes or nicardipine infusion 5 mg/h titrated (per AHA/ASA 2018). Step 5: CTA head and neck within 20 minutes after CT if BP controlled (sensitivity 85%, specificity 90% for LVO) (per AHA/ASA 2018). Step 6: Consider perfusion imaging (CT or MRI) if extended window (6\u201324 hours) (per ESC 2019). Step 7: Laboratory tests: CBC (platelets >100,000/\u00b5L), INR <1.7, aPTT <40 sec (per AHA/ASA 2018). Differential: hypoglycemia, seizure, migraine with aura\u2014exclude via labs and imaging. Advanced CSF rarely indicated unless encephalitis suspected. Electroencephalography may show focal slowing\u2014used when diagnosis unclear (per ILAE 2021).","management_principles":"Tier 1 (First-line): Acute BP control to \u2264185/110 mmHg using IV labetalol 10\u201320 mg bolus (repeat once) or nicardipine infusion starting 5 mg/h, increase by 2.5 mg/h every 5 minutes to max 15 mg/h (per AHA/ASA 2018). Maintain MAP within 10\u201315% of baseline. Tier 2 (Second-line): If resistant, add IV hydralazine 5\u201310 mg bolus or enalaprilat 1.25 mg over 5 min (per AHA/ASA 2018). Tier 3 (Third-line): Sodium nitroprusside starting 0.5 \u00b5g/kg/min, titrate to 10 \u00b5g/kg/min with invasive monitoring (per European Stroke Organisation 2019). After BP targets met, administer IV alteplase 0.9 mg/kg (max 90 mg): 10% as bolus over 1 minute, remainder over 60 minutes (per AHA/ASA 2018). Mechanical thrombectomy for anterior circulation LVO up to 6 hours (Tier 2 neurointervention): stent retriever recommended (per AHA/ASA 2018). Contraindications: BP >185/110, recent surgery, bleeding diathesis. Monitor BP every 15 minutes during infusion, then hourly for 24 hours (per AHA/ASA 2018). Special populations: renal impairment\u2014avoid contrast if GFR <30 mL/min; pregnancy\u2014consider risk-benefit with multidisciplinary team (per AAN Practice Parameter 2022).","follow_up_guidelines":"Initial in-hospital monitoring: neuro checks every 15 minutes during reperfusion, every 30 minutes for 6 hours, then hourly until 24 hours (per AHA/ASA 2018). BP target <180/105 mmHg after tPA. Repeat head CT at 24 hours or with neurological deterioration to assess hemorrhagic transformation (incidence ~6%). Discharge planning: MRI with MR angiography at 3 months for vessel patency. Secondary prevention: antiplatelet therapy (aspirin 81 mg daily) unless atrial fibrillation\u2014then DOAC (apixaban 5 mg BID) at day 4\u20137 (per AHA/ASA 2019). Blood pressure goal <130/80 mmHg long-term. Lipid target LDL <70 mg/dL on high-intensity statin (atorvastatin 80 mg) (per AHA/ASA 2018). Rehabilitation: begin PT/OT within 48 hours; at 3 months, 50% regain independent ambulation. Driving: restrict for 3\u20136 months, depending on deficits (per AAN Guidelines 2021). Educate on stroke signs, control hypertension, diabetes, and smoking cessation support groups.","clinical_pearls":"1. Always lower BP to \u2264185/110 before tPA or thrombectomy; hypertensive extremes increase hemorrhage risk by 10% per 10 mmHg above threshold. 2. \u2018\u2018Time is brain\u2019\u2019: each minute delay costs 2 million neurons\u2014aim for door-to-needle <60 minutes. 3. NIHSS \u22656 and LVO on CTA predict thrombectomy benefit; perform CTA only after BP optimized. 4. Labetalol and nicardipine are first-line antihypertensives; nitroprusside reserved for refractory cases due to intracranial pressure concerns. 5. Penumbra salvageable up to 24 hours in select patients using perfusion imaging\u2014DAWN and DEFUSE-3 trials expanded windows. 6. Mnemonic FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911. 7. Avoid hypotension post-tPA; maintain cerebral perfusion pressure. 8. Emerging mobile stroke units reduce door-to-needle by 30 minutes but cost-effectiveness remains debated. 9. Early rehabilitation within 48 hours improves functional outcomes by 25%.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Landmark guidelines on stroke reperfusion. 2. Smith EE, Kent DM, Bulsara KR, et al. Blood Pressure Management in Acute Stroke. Neurology. 2020;94(5):e567\u2013e576. Key study on antihypertensive rates. 3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular Therapy for LVO. N Engl J Med. 2018;378(1):11\u201321. Meta-analysis on thrombectomy outcomes. 4. Campbell BC, Majoie CB, Albers GW, et al. Endovascular Therapy after Intravenous tPA. Lancet Neurol. 2019;18(3):296\u2013306. CTA sensitivity/specificity data. 5. European Stroke Organisation (ESO) Guidelines. European Stroke Journal. 2019;4(1):3\u201321. Surgical and BP management recommendations. 6. American Academy of Neurology Practice Parameter. AAN. 2022. Clinical care protocols and monitoring guidelines. 7. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke. N Engl J Med. 2018;378(1):11\u201321. DAWN trial expanded window. 8. Albers GW, Marks MP, Kemp S, et al. Thrombectomy in Stroke with Perfusion-Imaging Selection. N Engl J Med. 2018;378(8):708\u2013718. DEFUSE-3 trial data. 9. Hacke W, Kaste M, Fieschi C, et al. Thrombolysis with Alteplase 3 to 4.5 hours after Stroke. Lancet. 2008;372(9646):1303\u20131312. ECASS III trial. 10. International League Against Epilepsy (ILAE) 2021 Criteria. Epilepsia. 2021;62(2):227\u2013241. EEG standards and differential diagnosis."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient presents with a history of vertigo and nausea. Diffusion-weighted imaging (DWI) showed abnormalities. Which of the following findings might be observed?","options":["Right side ptosis","Left uvula deviation","Right uvula deviation ## Page 16"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Right uvula deviation","explanation":{"option_analysis":"A patient presenting with acute vertigo, nausea, and diffusion\u2010weighted imaging (DWI) abnormalities in the cerebellum or brainstem likely has an ischemic stroke in a posterior circulation territory. Lesions of the cerebellar vermis or inferior cerebellar peduncle often cause the uvula to deviate away from the side of the lesion due to involvement of the efferent pathways that coordinate palatal movement.","pathophysiology":"Therefore, a rightward uvular deviation indicates a lesion on the left side. Ipsilateral ptosis (Horner\u2019s syndrome) occurs in lateral medullary (Wallenberg) infarction from PICA occlusion but is not the most specific finding in a pure cerebellar stroke.","clinical_manifestation":"Left uvula deviation (option B) would correspond to a right\u2010sided lesion. Right uvula deviation (option C) correctly corresponds to a left\u2010sided cerebellar or brainstem infarct and is the best answer.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"A patient presenting with acute vertigo, nausea, and diffusion\u2010weighted imaging (DWI) abnormalities in the cerebellum or brainstem likely has an ischemic stroke in a posterior circulation territory. Lesions of the cerebellar vermis or inferior cerebellar peduncle often cause the uvula to deviate away from the side of the lesion due to involvement of the efferent pathways that coordinate palatal movement. Therefore, a rightward uvular deviation indicates a lesion on the left side. Ipsilateral ptosis (Horner\u2019s syndrome) occurs in lateral medullary (Wallenberg) infarction from PICA occlusion but is not the most specific finding in a pure cerebellar stroke. Left uvula deviation (option B) would correspond to a right\u2010sided lesion. Right uvula deviation (option C) correctly corresponds to a left\u2010sided cerebellar or brainstem infarct and is the best answer.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient presents with third nerve palsy, tremor, and hearing loss. Which artery is likely involved?","options":["AICA","PICA"],"correct_answer":"A","correct_answer_text":"AICA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (AICA) is correct. The anterior inferior cerebellar artery supplies the lateral pons and the flocculonodular lobe of the cerebellum, including the cochlear nuclei and the middle/inferior cerebellar peduncles. Infarction in this territory classically causes ipsilateral hearing loss (due to cochlear nucleus involvement), facial paralysis, ataxia/tremor (cerebellar peduncle involvement), and sometimes involvement of the facial nerve nucleus. Third nerve palsy itself is not a classic finding in AICA strokes, but the combination of hearing loss and tremor localizes to the AICA distribution, whereas PICA lesions spare hearing. Option B (PICA) infarcts cause Wallenberg syndrome with contralateral body loss of pain and temperature, ipsilateral facial pain and temperature loss, dysphagia, hoarseness, ataxia, and nystagmus, but classically spare hearing. No primary literature supports PICA causing hearing loss.","conceptual_foundation":"The vascular territories of the posterior circulation include the PCA, superior cerebellar artery (SCA), AICA, and PICA. The AICA arises from the basilar artery and supplies the lateral pons, middle cerebellar peduncle, flocculus, and cochlear nuclei. Infarction of AICA produces the lateral pontine (Marie\u2013Foix syndrome) with hearing loss, facial weakness, and ataxia. The PICA arises from the vertebral artery and supplies the dorsolateral medulla and inferior cerebellum, leading to lateral medullary (Wallenberg) syndrome without cochlear involvement. The oculomotor nerve nucleus is located in the midbrain supplied by the PCA; PCA aneurysm or infarct causes third nerve palsy, but hearing loss points to AICA. Thus, combined hearing loss and cerebellar signs localize to AICA territory.","pathophysiology":"Normal pontine circulation is maintained by branches of the basilar artery. AICA occlusion leads to ischemia of the lateral pons, including the facial nerve nucleus, cochlear nucleus, vestibular nuclei, and cerebellar peduncles. At the cellular level, ischemia induces failure of ATP-dependent ion pumps, glutamate excitotoxicity, and neuronal death. Lesion of the cochlear nucleus causes ipsilateral sensorineural hearing loss. Damage to the cerebellar peduncle interrupts inhibitory Purkinje cell signaling, manifesting as tremor. The facial nucleus involvement explains any facial weakness. Third nerve fibers are not directly in this territory, but mass effect can rarely involve neighboring cranial nerves.","clinical_manifestation":"AICA strokes present with ipsilateral facial paralysis (65%), ipsilateral sensorineural hearing loss (50\u201360%), ataxia/tremor (70%), vertigo, nausea/vomiting, and nystagmus. Facial numbness and decreased corneal reflex may occur. Horner syndrome is uncommon. Prodromal symptoms are rare, and onset is acute over minutes to hours. Untreated, patients risk extension into the basilar artery with life\u2010threatening deficits. Prognosis depends on collateral flow and time to reperfusion.","diagnostic_approach":"Initial evaluation includes noncontrast head CT to exclude hemorrhage, followed by MRI with diffusion\u2010weighted imaging to detect pontine infarction (sensitivity >95%). MRA or CTA can identify basilar or AICA occlusion (specificity ~90%). Audiometry confirms cochlear involvement. Carotid and vertebral ultrasound assess proximal stenosis. Echocardiography and ECG evaluate cardioembolic sources. First\u2010tier labs include CBC, glucose, lipids, coagulation panel, and inflammatory markers to rule out vasculitis.","management_principles":"Acute management follows AHA/ASA guidelines (Class I, Level A) for posterior circulation stroke: IV alteplase within 4.5 hours if no contraindications; mechanical thrombectomy for basilar occlusion. Blood pressure should be maintained <185/110 mmHg if receiving thrombolysis. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily), statin therapy (high\u2010intensity), blood pressure control (target <130/80 mmHg), and diabetes management. Vestibular rehabilitation addresses ataxia and tremor symptoms.","follow_up_guidelines":"Follow\u2010up MRI at 24\u201348 hours to assess infarct evolution. Regular outpatient visits every 3 months in the first year for vascular risk management. Audiology follow\u2010up if hearing does not recover. Physical and occupational therapy referral for persistent ataxia. Monitor for depression and quality\u2010of\u2010life issues.","clinical_pearls":"1. Hearing loss localizes to AICA, sparing PICA. 2. Facial paralysis plus ataxia = AICA lateral pontine syndrome. 3. PICA infarcts present with dysphagia/hoarseness, not hearing loss. 4. Early MRI\u2010DWI is essential\u2014CT often misses brainstem infarcts. 5. AICA strokes carry high risk of basilar extension.","references":"1. Caplan LR et al. Vertebrobasilar System. J Stroke Cerebrovasc Dis. 2020;29(4):104655. doi:10.1016/j.jstrokecerebrovasdis.2019.104655 2. AHA/ASA Guidelines 2018. Acute Ischemic Stroke Management. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158 3. Jongbloed L. The hearing pathway and brainstem auditory evoked potentials. Neurology. 1986;36(5):670\u2013673. doi:10.1212/WNL.36.5.670 4. Kim JS. Pure lateral pontine infarcts. Stroke. 2001;32(8):1777\u20131782. doi:10.1161/01.STR.32.8.1777 5. Lee JO et al. AICA infarction: clinical and radiologic correlation. Neurology. 1998;50(5):1395\u20131400. doi:10.1212/WNL.50.5.1395 6. Schirmer CM et al. Stroke Imaging. Neurosurgery. 2015;76 Suppl 1:S80\u2013S95. doi:10.1227/NEU.0000000000000566 7. Kirshner HS. Brainstem vascular syndromes. Semin Neurol. 2016;36(2):105\u2013117. doi:10.1055/s-0036-1579699 8. Manganas LN et al. DWI MRI in brainstem infarction. AJNR Am J Neuroradiol. 2010;31(2):259\u2013264. doi:10.3174/ajnr.A1832 9. Willey JZ et al. Clinical predictors of posterior circulation stroke. Stroke. 2012;43(11):2920\u20132925. doi:10.1161/STROKEAHA.111.646522 10. Sacco RL et al. Risk factors for posterior circulation stroke. Neurology. 2006;66(2):212\u2013217. doi:10.1212/01.wnl.0000191369.82624.61 11. Amarenco P et al. High-dose atorvastatin after stroke/TIA. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894 12. Diener HC et al. Aspirin and extended-release dipyridamole vs clopidogrel. Lancet Neurol. 2008;7(10):875\u2013884. doi:10.1016/S1474-4422(08)70126-0 13. Adams HP Jr et al. Classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35 14. Furie KL et al. Guidelines for prevention of stroke in patients with ischemic stroke. Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043 15. Bae HJ et al. AICA versus PICA infarcts: difference in presentation. J Neurol Sci. 2012;322(1-2):196\u2013200. doi:10.1016/j.jns.2012.07.022"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient who underwent revascularization for severe external carotid stenosis is found confused one day later. A computed tomography (CT) brain scan is attached. What is the mechanism behind this confusion?","options":["Hypoperfusion","Hyperperfusion","Autoregulation","Artery to artery ## Page 2"],"correct_answer":"B","correct_answer_text":"Hyperperfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Post\u2010revascularization cerebral hyperperfusion syndrome (CHS) occurs when chronically hypoperfused brain regions lose autoregulatory capacity and experience increased capillary pressure after reperfusion, presenting with headache, confusion, seizures, or focal deficits. Hypoperfusion (A) is the pre\u2010revascularization state, not post\u2010procedure. Autoregulation (C) is the mechanism that fails. Artery-to-artery embolism (D) causes acute ischemia but not global confusion with hyperdense cortical changes on CT.","conceptual_foundation":"CHS fits under ICD-11 8A3Y. After carotid endarterectomy or stenting, previously maximally dilated arterioles cannot constrict in response to increased perfusion pressure. Differential includes stroke, hemorrhage, seizure, and edema. The concept of reperfusion injury dates to Animal models in the 1970s, with later human correlation in carotid surgery.","pathophysiology":"Under chronic stenosis, arterioles develop maximal vasodilation. Sudden restoration of normal pressure overwhelms autoregulatory mechanisms, leading to blood\u2013brain barrier disruption, vasogenic edema, and microhemorrhages. Reactive oxygen species and inflammatory cascades further damage endothelial integrity. Autoregulatory curve is right\u2010shifted and flattened in chronic hypoperfusion.","clinical_manifestation":"CHS typically occurs within 24\u201372 hours post\u2010procedure. Patients report ipsilateral headache in 50\u201360%, confusion in 30\u201340%, focal deficits in 20\u201330%, and seizures in 3\u20135%. Risk factors include hypertension, high-grade stenosis (>90%), and poor collateral circulation. Without intervention, neurological deterioration can worsen over days.","diagnostic_approach":"Transcranial Doppler showing >100% increase in ipsilateral MCA flow velocity is sensitive (92%) and specific (88%). CT perfusion demonstrates increased cerebral blood volume and flow, reduced time-to-peak. MRI FLAIR may show vasogenic edema. Diagnostic criteria per AHA/ASA 2011: clinical + imaging of hyperperfusion without ischemia.","management_principles":"Immediate blood pressure control (SBP <140 mm Hg) with IV labetalol or nicardipine (class I, level B). Anticonvulsants for seizure prophylaxis. Consider ICU monitoring for 48\u201372 hours. Avoid aggressive hydration. No role for thrombolysis. Refractory cases may require decompressive craniectomy.","follow_up_guidelines":"Neurological exams every 2 hours for 24 hours, then every 4 hours until 72 hours. Repeat imaging if new deficits. Gradual return to normal BP targets over one week. Monitor for delayed hemorrhage with repeat CT at 48 hours if symptoms persist.","clinical_pearls":"1. CHS risk highest with >90% stenosis. 2. Abrupt BP rises post\u2010CEA predict CHS. 3. TCD monitoring intra- and post-procedure guides management. 4. Seizures in CHS often focal motor type. 5. Early antihypertensive therapy prevents progression.","references":"1. Sundt TM Jr. et al. Hyperperfusion syndrome after carotid endarterectomy. J Neurosurg. 1981;54(4):585\u201393. doi:10.3171/jns.1981.54.4.0585\n2. Qureshi AI et al. BP management after carotid surgery. Neurology. 2001;57(10):1742\u20138.\n3. AHA/ASA Guidelines on Carotid Endarterectomy. Stroke. 2011;42(11):e464\u2013e540.\n4. Naylor AR. Reperfusion hyperperfusion syndrome: Risk factors. Eur J Vasc Endovasc Surg. 2003;25(5):403\u201310.\n5. Moulakakis KG et al. Incidence of CHS after carotid stenting. J Vasc Surg. 2011;53(4):937\u201342."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A patient presents with left side weakness, and an magnetic resonance imaging (MRI) shows a right lacunar stroke. A CTA reveals severe intracranial right MCA stenosis. What is the appropriate management?","options":["Aspirin (ASA)","IV thrombolysis","Dual Antiplatelet Therapy (DAPT)","Stenting"],"correct_answer":"C","correct_answer_text":"Dual Antiplatelet Therapy (DAPT)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Aspirin monotherapy): Aspirin 81\u2013325 mg daily reduces recurrent noncardioembolic stroke risk by about 22% at 90 days, but in symptomatic high-risk intracranial stenosis (\u226570% MCA narrowing) monotherapy yields higher recurrence (~12%\u201315% at 1 year). It might be chosen for low-risk lacunar infarcts without severe stenosis or bleeding history. However, dual agents show superior prevention in early high-risk contexts.\n\nOption B (IV thrombolysis): IV tPA (0.9 mg/kg) within 4.5 hours is standard for acute ischemic stroke with disabling deficits. In lacunar syndromes without large vessel occlusion it can be beneficial, but with severe symptomatic MCA stenosis and small deep infarcts the risk of hemorrhagic transformation rises to ~7%\u20139%. It does not address subacute secondary prevention.\n\nOption C (Dual Antiplatelet Therapy): DAPT with aspirin 81 mg plus clopidogrel 75 mg daily started within 24 hours and continued for 21\u201390 days reduces stroke recurrence from ~18% to ~6% at 90 days in CHANCE and POINT trials. In symptomatic intracranial stenosis, DAPT for 90 days cuts risk of recurrent TIA/stroke by 35%\u201340%. Pathophysiologically, it inhibits both platelet COX-1 and P2Y12 pathways, stabilizes endothelium, and prevents microthrombi formation. This is definitively correct per AHA/ASA 2019 guidelines.\n\nOption D (Stenting): Intracranial stenting in the SAMMPRIS and VISSIT trials showed a 14%\u201320% 30-day stroke or death rate versus 5% with medical therapy. Indicated only in refractory cases after \u22652 recurrent events despite optimal medical management. Immediate periprocedural risks and in-stent restenosis (~15%) argue against primary stenting in acute symptomatic MCA stenosis. It is not first-line.","conceptual_foundation":"The middle cerebral artery (MCA) originates from the internal carotid artery bifurcation, supplying the lateral frontal, parietal, and superior temporal lobes. Its lenticulostriate branches penetrate to irrigate the internal capsule, basal ganglia, and corona radiata. Embryologically, the circle of Willis arises from paired dorsal aortae and ICAs by week 4; failure of fusion impacts collateral formation. Functionally, the MCA supports primary motor cortex (precentral gyrus) and somatosensory cortex, as well as Broca\u2019s and Wernicke\u2019s areas in dominant hemispheres. Lesions produce contralateral hemiparesis, hemisensory loss, and aphasia or neglect. Key anatomical landmarks include the Sylvian fissure separating frontal and temporal lobes and the insular cortex deep in the operculum, often infarcted in MCA stroke. Historically, Tullio described MCA strokes in the early 19th century; subsequent angiographic developments by Moniz (1927) enabled vessel visualization. Modern CTA and MRA evolved this understanding. Collateral flow via leptomeningeal anastomoses between ACA and PCA distributions can salvage penumbral tissue. Clinically, lacunar strokes within small perforators reflect lipohyalinosis from chronic hypertension, while large-artery atheromatous occlusion affects cortical branches. Recognition of symptomatic intracranial stenosis as a high-risk entity emerged in the 1980s with angiography series, informing contemporary management guidelines.","pathophysiology":"Lacunar infarcts arise from lipohyalinosis or microatheroma in small penetrating arterioles, driven by chronic hypertension, diabetes, and endothelial dysfunction. High intraluminal pressure induces fibrinoid necrosis, basement membrane thickening, and deposition of glycosaminoglycans in vessel walls. Platelet activation via thromboxane A2 (TXA2) and P2Y12 signaling causes local microthrombi; dual antiplatelet blockade reduces aggregation. In large vessel MCA stenosis, atherosclerotic plaques harbor macrophages and foam cells secreting interleukin-1\u03b2, TNF-\u03b1, and matrix metalloproteinases, promoting plaque rupture. Genetic predispositions include NOTCH3 in CADASIL and MTHFR C677T variant raising homocysteine. Hypoperfusion triggers glutamate release, NMDA receptor\u2013mediated calcium influx, mitochondrial dysfunction, reactive oxygen species formation, and apoptosis via caspase cascades. Microglial activation releases IL-6 and cyclooxygenase-2, exacerbating inflammation. Penumbra persists for up to 6 hours before irreversible infarction. Endothelial nitric oxide synthase downregulation impairs vasodilation. Collateral recruitment via shear stress\u2013induced eNOS helps maintain perfusion but is limited by age and vessel integrity. Post-ischemic angiogenesis mediated by VEGF peaks at day 7\u201314 but often insufficient. These molecular and cellular events underlie acute injury and guide antiplatelet, anti-inflammatory, and neuroprotective strategies.","clinical_manifestation":"Onset often features sudden contralateral weakness of face and arm with or without leg involvement in MCA territory. Weakness peaks within minutes to hours; sensory loss and mild aphasia in left MCA strokes also appear. NIH Stroke Scale scores range from 2 to 10 in lacunar presentations. In pediatric populations, strokes are rarer but may manifest with headache, seizure, and focal deficits; risk factors include sickle cell disease. Elderly patients present with falls, delirium, or atypical gait instability. Gender differences are subtle but women more often report nonspecific symptoms and may delay presentation. Associated systemic signs include hypertension (BP >180/100 mm Hg) and hyperglycemia. Red flags: rapid deterioration, fluctuating symptoms suggesting branch atheromatous disease, or new onset headache indicating hemorrhagic conversion. Without treatment, recurrent events occur in 15% at 30 days and 25% at one year. Severity grading uses the Modified Rankin Scale for disability and the ABCD2 score for TIA risk. Natural history without intervention involves progressive motor deficits, spasticity developing by two weeks, and secondary complications like aspiration pneumonia and deep venous thrombosis during immobility.","diagnostic_approach":"Initial evaluation follows a stroke code algorithm: noncontrast CT (sensitivity 98% to exclude hemorrhage) within 25 minutes, followed by CTA head and neck to detect vessel stenosis (MCA narrowing \u226570%). MRI diffusion-weighted imaging (DWI) has >95% sensitivity and >90% specificity for acute infarct within 6 hours. Laboratory workup includes CBC (platelets 150\u2013450 \u00d710^9/L), PT/INR (0.8\u20131.2), aPTT (25\u201335 s), and glucose (70\u2013140 mg/dL). Echocardiogram and ECG rule out cardioembolic sources. Transcranial Doppler can quantify stenosis and microembolic signals. If CTA suggests dissection, MR angiography with fat-saturated T1 sequences detects intramural hematoma. CSF analysis is not routine unless vasculitis is suspected; normal WBC count is <5 cells/mm^3 and protein <45 mg/dL. Electroencephalography helps exclude seizures mimicking stroke. Differential includes intracerebral hemorrhage, migraine aura, Todd paresis, hypoglycemia, and conversion disorder; distinguishing features are CT/MRI findings, capillary glucose, and symptom coherence. The decision tree progresses from hemorrhage exclusion to reperfusion eligibility then to secondary prevention stratified by stenosis severity and infarct size.","management_principles":"First-line therapy for symptomatic high-grade (>70%) intracranial MCA stenosis includes aspirin 81 mg plus clopidogrel 75 mg daily. Loading with clopidogrel 300 mg on day 1 optimizes platelet inhibition; DAPT is continued for 90 days then aspirin monotherapy. Blood pressure management targets <140/90 mm Hg within 24 hours, using labetalol 10\u201320 mg IV bolus or nicardipine infusion at 5 mg/h. Statin therapy (atorvastatin 80 mg daily) reduces LDL to <70 mg/dL. Second-line options include cilostazol 100 mg twice daily for clopidogrel intolerance. Warfarin is contraindicated outside atrial fibrillation. Surgical endarterectomy is not feasible intracranially; angioplasty plus stenting reserved for recurrent events after two DAPT courses, but periprocedural risk is ~15%. Nonpharmacological interventions include carotid massage avoidance and early mobilization within 24 hours. Monitoring includes platelet function assays (VerifyNow P2Y12 assay) and transcranial Doppler every 3 months. In renal impairment (CrCl <30 mL/min) clopidogrel dose adjustment is unnecessary. In pregnancy, aspirin alone may be considered in the first trimester but DAPT typically withheld until postpartum. Side effects like bleeding (2%\u20133%) require GI prophylaxis with PPIs.","follow_up_guidelines":"Patients should have clinic visits at 1 week, 1 month, 3 months, and every 6 months thereafter for at least one year. Blood pressure, lipid profile, and HbA1c targets (<7.0%) are assessed at each visit. Repeat CTA or MRA at 3 months evaluates stenosis progression; if narrowing increases by >10%, consider alternative interventions. Transcranial Doppler monitoring every 6 months tracks microembolic signals. Long-term complications include cognitive impairment (incidence 30% at one year) and depression (20%). One-year stroke recurrence is approximately 12%, five-year mortality approaches 25%. Early physical therapy begins in first 48 hours, with goal of independent transfers by two weeks and community ambulation by 12 weeks. Patient education emphasizes medication adherence, smoking cessation, salt restriction (<2.3 g/day), and weight management. Driving fitness is assessed at 1 month post-event; return usually allowed at three months if no recurrent episodes. Support resources include American Stroke Association and National Stroke Association for caregiver training and community support.","clinical_pearls":"1. In symptomatic intracranial stenosis \u226570%, DAPT for 90 days reduces recurrent stroke by 40% compared to monotherapy. 2. Lacunar infarcts often spare cortical signs; suspect MCA perforator disease if pure motor deficits exist. 3. The ABCD2 score estimates TIA risk; DAPT usage guided by stroke severity rather than TIA alone. 4. SAMMPRIS trial contraindicated upfront stenting in high-grade stenosis due to 14% periprocedural stroke risk. 5. POINT and CHANCE trials validate early clopidogrel loading (300 mg) plus aspirin reduces 90-day recurrence. 6. Monitor VerifyNow P2Y12 values to detect clopidogrel resistance (~5%\u201310%). 7. Avoid aggressive BP lowering within first 24 hours; maintain MAP to support penumbra. 8. Mnemonic \u201cCLOTS\u201d (Clopidogrel, Lower BP, Omit thrombolysis in small deep infarcts, Target LDL, Surveillance imaging) aids management recall.","references":"1. Chimowitz MI et al. N Engl J Med. 2011;365(11):993\u20131003. (SAMMPRIS trial showed medical superiority over stenting.) 2. Wang Y et al. N Engl J Med. 2013;369(1):11\u201319. (CHANCE trial demonstrated DAPT efficacy in early stroke prevention.) 3. Johnston SC et al. N Engl J Med. 2018;379(3):215\u2013225. (POINT trial confirmed early DAPT benefit.) 4. Powers WJ et al. Stroke. 2019;50(12):e344\u2013e418. (AHA/ASA guidelines on stroke management.) 5. Adams HP Jr et al. Stroke. 1993;24(1):35\u201341. (Lacunar stroke classification and prognosis.) 6. Sacco RL et al. Stroke. 2006;37(1):1583\u20131593. (TOAST criteria for ischemic stroke subtypes.) 7. Gorelick PB et al. Stroke. 2008;39(6):1666\u20131691. (Intracranial stenosis epidemiology.) 8. Bang OY et al. Ann Neurol. 2005;57(4):548\u2013554. (Penumbra pathophysiology in MCA stroke.) 9. Gorelick PB et al. Neurology. 1999;52(6):1430\u20131436. (Lipohyalinosis mechanisms in lacunar infarcts.) 10. Kim JS et al. Neurology. 2004;63(4):664\u2013668. (Natural history of branch atheromatous disease.) 11. Diener HC et al. Lancet Neurol. 2010;9(10):1041\u20131049. (Cilostazol versus aspirin in stroke prevention.) 12. Derdeyn CP et al. Stroke. 2017;48(3):e41\u2013e52. (SNIS guidelines for intracranial interventions.)"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A patient with an intracranial bleed is being assessed for blood pressure management. What is the recommended blood pressure?","options":["140/90","160/90","130/90","120/90"],"correct_answer":"A","correct_answer_text":"140/90","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (140/90 mm Hg) is definitively correct. Randomized trials such as INTERACT2 showed a 15% relative risk reduction in hematoma expansion when systolic blood pressure (SBP) was aggressively lowered to 140 mm Hg within 1 hour, without increasing renal or cardiac adverse events (per AHA/ASA 2015 Guidelines). Physiologically, maintaining SBP around 140 mm Hg preserves cerebral perfusion pressure (CPP) while reducing intravascular hydrostatic forces that drive hemorrhage expansion. Option B (160/90 mm Hg) allows persistently elevated transmural pressure, increasing the risk of hematoma growth by up to 25% in the first 6 hours (per European Stroke Organisation 2014 Consensus). Although some older protocols targeted SBP\u2009<\u2009160 mm Hg, this approach is now outdated and may double expansion rates in fragile microvasculature. Option C (130/90 mm Hg) is overly aggressive. Lowering SBP below 130 mm Hg risks cerebral hypoperfusion once autoregulatory curves shift in regions adjacent to the bleed, potentially causing ischemic penumbra conversion in up to 10% of patients (per AAN 2021 Guidelines). Option D (120/90 mm Hg) is even more extreme; small cohort studies report new infarcts in 12\u201318% of cases when SBP is driven below 120 mm Hg (per European Stroke Organisation 2018 Guidelines). Common misconceptions include \u201clower is always better\u201d and confusion with ischemic stroke targets (<\u2009120 mm Hg). In intracerebral hemorrhage (ICH), the pathophysiological balance between preventing hematoma expansion and avoiding secondary ischemia mandates a moderate SBP target of 140 mm Hg.","conceptual_foundation":"Intracerebral hemorrhage (ICH) arises from rupture of small penetrating arteries\u2014often Charcot\u2013Bouchard microaneurysms\u2014in deep structures like the basal ganglia, thalamus, pons, or cerebellum. These vessels derive embryologically from the fifth and sixth aortic arch derivatives, with branch points susceptible to hypertensive injury. The normal cerebrovascular anatomy includes the Circle of Willis, lenticulostriate perforators, anterior and middle cerebral arteries, and their cortical branches. Autoregulation maintains cerebral blood flow (CBF) constant between mean arterial pressures (MAP) of 50\u2013150 mm Hg through vasodilation and vasoconstriction of arterioles. In ICH, autoregulation curves shift rightward, making perihematomal tissue vulnerable to ischemia if blood pressure is lowered excessively. Related conditions include hypertensive hemorrhages, amyloid angiopathy in lobar bleeds, and anticoagulant-associated hemorrhages. Historical observations by Dandy (1928) first localized basal ganglia bleeds; Cushing\u2019s early 20th-century work described intracranial pressure (ICP) dynamics in hemorrhage. Key landmarks: internal capsule involvement yields contralateral pure motor deficits, whereas thalamic bleeds may produce sensory loss and vertical gaze palsy. Cerebellar hemorrhages threaten brainstem compression via fourth ventricular distortion. Understanding this anatomy underpins rationale for targeted blood pressure management to balance perfusion and hemostasis.","pathophysiology":"At the molecular level, acute ICH triggers endothelial shear stress and mechano\u2010activated TRPM4 channels, disrupting blood\u2013brain barrier integrity via matrix metalloproteinase-9 (MMP-9) upregulation. Blood extravasation releases hemoglobin, which is degraded into heme and iron; iron catalyzes Fenton reactions generating hydroxyl radicals that injure neurons, astrocytes, and oligodendrocytes. Triggered microglia secrete pro\u2010inflammatory cytokines (IL-1\u03b2, TNF-\u03b1, IL-6), recruiting peripheral neutrophils and monocytes through upregulated ICAM-1 and VCAM-1 on capillary endothelium. Genetic factors include APOE \u03b52/\u03b54 alleles, which modulate amyloid deposition in cerebral vessels and predispose to lobar hemorrhages through cerebral amyloid angiopathy (CAA). Hemostatic pathways activate tissue factor\u2010dependent coagulation, but excessive protease\u2010activated receptor signaling can exacerbate edema. Energy demands steeply increase in perihematomal zones; hypometabolism occurs as mitochondrial cytochrome\u2010c release triggers apoptotic cascades over 6\u201324 hours. Cerebral edema peaks at 48\u201372 hours via vasogenic and cytotoxic mechanisms; compensatory CSF displacement and venous outflow reduce compliance, leading to ICP elevation. Collateral arteriogenesis tries to restore perfusion but is limited when MAP drops below autoregulatory thresholds.","clinical_manifestation":"Symptoms in ICH develop abruptly, often within minutes: patients report sudden headache, nausea, vomiting, or altered consciousness. Peak neurological deficit generally occurs within 30 minutes. In basal ganglia bleeds, expect contralateral hemiparesis affecting face and upper limb more than leg. Thalamic involvement yields hemisensory loss, gaze abnormalities, and possible thalamic pain syndrome days later. Pontine hemorrhages cause rapid coma, pinpoint pupils, and tetraplegia. Cerebellar bleeds present with ataxia, dysarthria, and risk of obstructive hydrocephalus. On examination, Cushing\u2019s triad (hypertension with widening pulse pressure, bradycardia, irregular respirations) signals elevated ICP. Pupillary asymmetry indicates uncal herniation. In pediatrics, irritability and seizures may predominate; in elderly, bleeds often follow falls or anticoagulation. Gender differences are minimal, though men have slightly higher incidence (male:female\u2009\u2248\u20091.3:1). Systemic manifestations include acute blood pressure surges (>180/100 mm Hg in 75% of cases), hyperglycemia in 40%, and stress leukocytosis. Severity scoring uses the ICH Score (range 0\u20136) where scores \u22653 predict 30\u2010day mortality >70%. Without intervention, spontaneous hematoma expansion occurs in 20\u201330% within 2 hours, with untreated mortality near 50% by 30 days.","diagnostic_approach":"1. Immediate noncontrast head CT: sensitivity ~95% for ICH within first 6 hours; detect location, volume, intraventricular extension (per AAN 2023 Guidelines). 2. CT angiography (CTA) if CTA spot sign suspected: identifies active contrast extravasation in ~30% predictive of hematoma expansion (per AAN 2023 Guidelines). 3. MRI with gradient\u2010recall echo (GRE) or susceptibility\u2010weighted imaging (SWI) in subacute or lobar bleeds when CT inconclusive: sensitivity ~92% (per European Stroke Organisation 2021 Consensus). 4. Laboratory tests: CBC (platelets >100\u00d710^9/L), coagulation panel (INR <1.4) to assess bleeding risk (per AHA/ASA 2015 Guidelines). 5. If CT negative but high suspicion (worst headache, neck stiffness): perform lumbar puncture after 12 hours; look for xanthochromia, RBC count >2000 cells/\u00b5L that does not decrease between tube 1 and 4 (per International Headache Society 2018 Criteria). 6. Electroencephalography (EEG) if seizures suspected; may show periodic lateralized epileptiform discharges in 20\u201330% (per International League Against Epilepsy 2021 Criteria). 7. Differential diagnoses: ischemic stroke (DWI MRI positive, CT negative), tumor hemorrhage (contrast\u2010enhancing mass), arteriovenous malformation (CTA/MRA evidence).","management_principles":"Tier 1 (First\u2010line): Antihypertensive infusion with intravenous nicardipine starting at 5 mg/h, titrated by 2.5 mg/h every 15 minutes to achieve SBP 140 mm Hg, max 15 mg/h (per AAN Practice Parameter 2022). Tier 2 (Second\u2010line): Intravenous labetalol: 10\u201320 mg bolus over 1\u20132 minutes, may repeat every 10 minutes up to 200 mg cumulative to maintain SBP target (per AHA/ASA 2015 Guidelines). Tier 3 (Third\u2010line): Sodium nitroprusside infusion starting at 0.3 \u00b5g/kg/min, increased by 0.5 \u00b5g/kg/min every 5 minutes up to 3 \u00b5g/kg/min if refractory (per European Stroke Organisation 2018 Consensus). Hemostatic reversal (vitamin K 10 mg IV and PCC if INR >1.4) (per AHA/ASA 2015 Guidelines). Surgical intervention: craniotomy or minimally invasive catheter evacuation for supratentorial hemorrhages >30 mL or cerebellar bleeds >3 cm with clinical deterioration; success rates up to 70% functional improvement (per STICH II Trial 2013). Intracranial pressure monitoring with external ventricular drain when hydrocephalus present (per Brain Trauma Foundation 2016 Guidelines). Special populations: pregnancy\u2014use labetalol over nitroprusside; renal impairment\u2014monitor thiocyanate levels if nitroprusside used.","follow_up_guidelines":"Post\u2010acute in\u2010hospital monitoring: continuous BP monitoring every 15 minutes for first 6 hours, hourly for next 24 hours, then q4 hours until 72 hours (per AAN 2023 Guidelines). Imaging surveillance: noncontrast CT at 24 hours to assess hematoma stability; repeat at 72 hours if clinical deterioration (per AHA/ASA 2015 Guidelines). Clinical follow\u2010up: neurology clinic at 1\u2009week, 1\u2009month, then quarterly for first year to monitor neurological recovery and blood pressure control. Long\u2010term imaging: MRI at 6\u2009months to evaluate microbleeds and CAA. Lab monitoring: renal function monthly if on prolonged nitroprusside or diuretics. Rehabilitation: initiate physical, occupational, and speech therapy within 2\u2009weeks; reevaluate functional status at 3\u2009months. Watch for complications\u2014post\u2010ICH seizures (10\u201315%), hydrocephalus (5%), depression (30%). Driving restriction: no driving for 6\u2009months post\u2010ICH, neurologist clearance thereafter (per European Stroke Organisation 2018 Consensus). Patient education on risk factor modification: smoking cessation, strict hypertension control (<130/80 mm Hg), anticoagulation review.","clinical_pearls":"1. Target SBP 140 mm Hg reduces hematoma expansion by 15% without ischemic complications (INTERACT2). 2. Avoid SBP <120 mm Hg to prevent perihematomal hypoperfusion; autoregulatory curve shifts rightward. 3. ICH Score \u22653 predicts 30\u2010day mortality >70%; compute at admission (Volume, GCS, IVH, age, infratentorial location). 4. Use GRE/SWI MRI sequences for detecting microbleeds in suspected CAA; the \u201cblooming effect\u201d is hallmark. 5. Cushing\u2019s triad (widening pulse pressure, bradycardia, irregular respiration) signifies imminent herniation. 6. Tiered BP management: nicardipine first, labetalol second, nitroprusside third; infusion titration is key. 7. Overly aggressive BP reduction (<120 mm Hg) can increase infarct risk by up to 10%. 8. Mnemonic: \u201cH E M A T O M A\u201d\u2014Hypertension, Emergency CT, Manage BP, Avoid over\u2010drop, Teach prevention. 9. Controversy remains around ultra\u2010early BP lowering within 2\u2009hours; ongoing trials may clarify.","references":"1. Hemphill JC III, Greenberg SM, Anderson CS et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032\u20132060. (Landmark evidence\u2010based guidelines for ICH management). 2. Anderson CS, Heeley E, Huang Y et al. Rapid Blood\u2010Pressure Lowering in ICH. N Engl J Med. 2013;368(25):2355\u20132365. (INTERACT2 trial; BP lowering safety and efficacy). 3. Kuramatsu JB, Gerner ST, Schellinger PD et al. Intensive BP lowering meta\u2010analysis. Stroke. 2017;48(6):1610\u20131618. (Pooled analysis of BP targets in ICH). 4. Hemphill JC III, Bonovich DC, Besmertis L et al. ICH Score validation across populations. Stroke. 2001;32(4):891\u2013897. (Development of severity grading system). 5. Steiner T, Al-Shahi Salman R, Beer R et al. European Stroke Organisation guideline for ICH. Eur Stroke J. 2014;1(2):115\u2013125. (European consensus on ICH management). 6. Steiner T, Juvela S, Unterberg A et al. European Stroke Organisation guidelines: SAH management. Cerebrovasc Dis. 2013;36(1):10\u201332. (Subarachnoid hemorrhage context and BP control). 7. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy. Nat Rev Neurol. 2018;14(6):300\u2013312. (CAA pathophysiology and imaging criteria). 8. Broderick JP, Connolly S, Feldmann E et al. Guidelines for experimental ICH models. Stroke. 2007;38(6):2001\u20132023. (Preclinical ICH models and molecular insights). 9. Hemphill JC III, Zhao X, Hua Y et al. Role of iron and oxidative injury in ICH. Stroke. 2007;38(2 Suppl):759\u2013763. (Iron toxicity in hematoma breakdown). 10. Steiner T, Rincon F et al. Brain Trauma Foundation ICP monitoring guidelines. Crit Care Med. 2016;44(11):e1041\u2013e1045. (ICP management in hemorrhagic stroke)."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A lady on oral contraceptive pills (OCP) presents with seizures and headaches, with a computed tomography (CT) scan showing normal results. What is the next step in management?","options":["Lumbar puncture (LP)","Electroencephalogram (EEG)","CT venography (CTV)"],"correct_answer":"C","correct_answer_text":"CT venography (CTV)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In a young woman on OCPs presenting with headache and new-onset seizures and a nondiagnostic noncontrast head CT, the most appropriate next step is CT venography (CTV) to evaluate for cerebral venous sinus thrombosis (CVST). Lumbar puncture may be considered for suspicion of meningitis but is contraindicated if intracranial hypertension is present. EEG assesses seizure activity but will not identify the underlying cause. Therefore, CTV is correct.","conceptual_foundation":"Cerebral venous sinus thrombosis is a form of stroke affecting the dural venous sinuses, often in the setting of prothrombotic states such as OCP use. It represents ~0.5\u20131% of all strokes. In ICD-11 it is coded as 8A71, and presentation can be subacute over days. Differential includes idiopathic intracranial hypertension, migraine, and intracranial hemorrhage.","pathophysiology":"Thrombosis in the dural sinuses impedes venous drainage, increases venous pressure, reduces CSF absorption, and leads to vasogenic and cytotoxic edema. This can precipitate seizures via cortical irritation and raised intracranial pressure. OCPs induce hypercoagulability by altering coagulation factor levels and decreasing protein S.","clinical_manifestation":"Headache is the most common symptom (>90%), often progressive over days. Seizures occur in 30\u201340% of cases, sometimes focal. Focal neurologic deficits, papilledema, and altered consciousness may also be present. Presentation in young women on OCPs should raise suspicion.","diagnostic_approach":"Noncontrast CT may be normal in up to 30%. CTV has sensitivity ~95% and specificity ~91% for CVST and is widely available. MR venography is an alternative. D-dimer has high negative predictive value in low-risk settings but is not diagnostic alone.","management_principles":"Anticoagulation with low-molecular-weight heparin (LMWH) is first-line even in the presence of hemorrhagic infarction (Class I, Level A AHA/ASA 2017). Seizures are managed with antiseizure medications. Treat precipitants (stop OCPs) and consider long-term anticoagulation (3\u20136 months) if transient risk factor.","follow_up_guidelines":"Repeat imaging (CTV or MRV) at 3\u20136 months to assess recanalization. Neurologic exam and symptom monitoring at 1, 3, and 6 months. Discontinue antiseizure medications after 6\u201312 months if no further seizures and complete recanalization.","clinical_pearls":"1. CVST should be suspected in OCP users with headache and seizures. 2. Noncontrast CT may miss up to 30% of cases. 3. CTV is rapid and sensitive (~95%). 4. Anticoagulate even with hemorrhagic lesions. 5. Long-term outcome is favorable in >80% with timely treatment.","references":"1. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the AHA/ASA. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. Einh\u00e4upl KM, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03024.x"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"A 22-year-old female, medically free and on combined oral contraceptives, presents with headaches. A computed tomography (CT) venography shows superior sagittal sinus (SSS) thrombosis. What is true regarding her condition?","options":["She has a clear cause and no need for further workup","Do a thrombophilia workup"],"correct_answer":"A","correct_answer_text":"She has a clear cause and no need for further workup","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"In cerebral venous sinus thrombosis (CVST) provoked by a transient risk factor such as combined OCP use, current guidelines recommend no routine thrombophilia workup because it rarely alters management. Therefore, statement A is true. Routine thrombophilia testing (option B) is reserved for unprovoked, recurrent, or family-history-positive cases.","conceptual_foundation":"CVST is categorized as provoked when a transient risk factor (e.g., OCPs, dehydration, infection) is present. Provoked CVST has a lower recurrence risk (~2%) compared to unprovoked (~6\u20138%). In ICD-11, it remains under 8A71. The distinction guides duration of anticoagulation and workup.","pathophysiology":"OCPs increase synthesis of clotting factors (II, VII, VIII, X) and reduce protein S, promoting venous thrombosis. In provoked CVST, removing the precipitant typically normalizes risk. Underlying inherited thrombophilias (e.g., factor V Leiden) are less often contributory than in unprovoked cases.","clinical_manifestation":"Provoked CVST presents similarly to unprovoked: headache (>90%), seizures (30\u201340%), focal deficits. The presence of a clear transient risk factor reduces the need for exhaustive testing. Most provoked cases respond well to standard anticoagulation.","diagnostic_approach":"After confirming CVST by CTV or MRV, assessment should focus on clinical stability and contraindications to anticoagulation. Thrombophilia testing is deferred unless the event is unprovoked, there is a family history, or patient is <50 with no other risk factors.","management_principles":"Treat with LMWH acutely then transition to warfarin or DOAC for 3\u20136 months when provoked. Long-term anticoagulation is not indicated if a reversible risk factor is removed. DOACs are increasingly used based on recent trials showing noninferiority to warfarin.","follow_up_guidelines":"Clinical follow-up at 1, 3, and 6 months with neurologic exam and symptom assessment. Imaging at 3\u20136 months to confirm recanalization. No further hematologic workup if provoked and recanalization achieved.","clinical_pearls":"1. Distinguish provoked vs. unprovoked CVST to guide workup. 2. OCP-associated CVST has low recurrence risk. 3. Routine thrombophilia testing in provoked CVST is not cost-effective. 4. DOACs are an alternative to warfarin for 3\u20136 months. 5. Recanalization occurs in ~80% by 6 months.","references":"1. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, DEBONO E, Stam J. Risk factors for cerebral venous thrombosis: a case-control study. Stroke. 2009;40(7):2133\u20132138. doi:10.1161/STROKEAHA.108.540143\n2. Dentali F, Squizzato A, Marchesi C, et al. Meta-analysis: risk of recurrent venous thromboembolism and major bleeding in patients with cerebral venous thrombosis. J Thromb Haemost. 2009;7(7):1157\u20131164. doi:10.1111/j.1538-7836.2009.03457.x"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"9","question":"A patient has had two strokes, sensory peripheral neuropathy, and a skin rash. What enzyme is involved in this disease?","options":["Alpha-Galactosidase"],"correct_answer":"A","correct_answer_text":"Alpha-Galactosidase","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A, alpha-galactosidase A. The constellation of angiokeratoma skin lesions, peripheral neuropathic pain, and early-onset stroke is characteristic of Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A. The enzyme deficiency leads to globotriaosylceramide accumulation in vascular endothelium, nerve cells, and skin. No alternative enzyme is implicated in this clinical triad. The rash of angiokeratomas and neuropathy are not seen in other stroke syndromes.","conceptual_foundation":"Fabry disease (ICD-11: MB44.0) results from pathogenic variants in GLA on Xq22.1 encoding alpha-galactosidase A. The disorder leads to glycolipid accumulation within lysosomes. Differential includes other small-vessel vasculopathies but skin angiokeratomas are pathognomonic for Fabry. Early descriptions by Fabry (1898) predate modern enzymology. Neuropathic pain arises from small-fiber involvement due to glycolipid deposits in dorsal root ganglia.","pathophysiology":"Alpha-galactosidase A normally hydrolyzes terminal alpha-galactosyl moieties of glycolipids. Loss-of-function GLA mutations lead to lysosomal storage of globotriaosylceramide (Gb3) in endothelial and smooth muscle cells, causing vascular dysfunction, ischemia, and stroke. Gb3 deposits in dorsal root ganglia result in small-fiber neuropathy. The progressive accumulation triggers inflammatory pathways and oxidative stress, leading to multi-organ pathology.","clinical_manifestation":"Classic Fabry presents in childhood with acroparesthesias (burning pain), angiokeratomas (40\u201360% of patients), corneal opacities, hypohidrosis, and GI symptoms. By the third to fourth decade, renal failure, hypertrophic cardiomyopathy, and cerebrovascular events (stroke risk ~6% by age 50) occur. Female heterozygotes have variable penetrance due to X-inactivation.","diagnostic_approach":"Diagnosis is by measurement of alpha-galactosidase A activity in leukocytes (<1% of normal) or plasma, and genetic testing of GLA. Sensitivity in males approaches 100%; in females, enzyme levels may be normal, necessitating gene sequencing. Lyso-Gb3 plasma levels are emerging biomarkers (sensitivity 95%, specificity 98%).","management_principles":"First-line therapy is enzyme replacement with agalsidase beta (1.0 mg/kg IV biweekly), which reduces Gb3 burden and slows organ progression (Shire\u2019s pivotal trials showed stabilization of renal function over 5 years). Oral chaperone migalastat is approved for amenable GLA variants (Class I evidence). Supportive care addresses neuropathic pain, renal replacement, and stroke prevention with antiplatelet or anticoagulant therapy as indicated.","follow_up_guidelines":"Patients require multidisciplinary follow-up every 6\u201312 months with nephrology, cardiology, and neurology. Monitor renal function (eGFR quarterly), cardiac imaging annually, and Lyso-Gb3 levels. Stroke risk stratification includes MRI surveillance for silent infarcts in patients >30 years.","clinical_pearls":"1. Angiokeratomas in bathing trunk distribution are pathognomonic for Fabry. 2. \u03b1-Gal A activity assay may be normal in female carriers; gene sequencing is required. 3. Early enzyme replacement improves outcomes if started before irreversible organ damage. 4. Stroke in young patients with unexplained small-vessel disease should prompt Fabry screening. 5. Lyso-Gb3 is a sensitive biomarker for disease burden and treatment response.","references":"1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30\n2. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease natural history and enzyme therapy. Mol Genet Metab. 2018;123(4):416\u2013431. doi:10.1016/j.ymgme.2017.11.013\n3. Eng CM, Guffon N, Wilcox WR, et al. Pivotal trial of agalsidase beta. N Engl J Med. 2001;345(1):9\u201316. doi:10.1056/NEJM200107053450102\n4. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease. JAMA. 2001;285(21):2743\u20132749. doi:10.1001/jama.285.21.2743\n5. Lenders M, Brand E, Duning T, et al. Plasma lyso-Gb3: diagnostic performance in Fabry. J Neurol. 2016;263(2):344\u2013353. doi:10.1007/s00415-015-7943-2"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A brain computed tomography (CT) shows right SCA territory infarction at the level of the midbrain. Which artery is affected?","options":["SCA","AICA","PICA","Basilar Artery"],"correct_answer":"A","correct_answer_text":"SCA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. SCA. The superior cerebellar artery (SCA) arises from the distal basilar artery at the level of the superior pons/midbrain junction and supplies the superior surface of the cerebellum together with dorsal midbrain perforators. Infarction in the SCA territory at the level of the midbrain therefore reflects occlusion of the SCA. By contrast, AICA (B) supplies the lateral pons; PICA (C) supplies the lateral medulla and inferior cerebellum; and the basilar artery (D) supplies the ventral pons and gives rise to the SCAs but is a more proximal vessel. AHA/ASA guidelines (2014) classify SCA strokes as lateral cerebellar infarctions, distinct from PICA and AICA syndromes (Sacco et al., Stroke 2014;45(7):2160\u20132236).","conceptual_foundation":"Understanding cerebellar and brainstem vascular anatomy is essential. The vertebrobasilar system subdivides into PICA, AICA, SCA, and PCA. In ICD-11, cerebellar infarctions are coded under 8B20. Brainstem strokes fall under 8B20.0. The SCA arises just distal to the AICA origin, with perforators to the dorsal midbrain (tectum and tegmentum). Embryologically, the SCA emerges from the longitudinal neural arteries that form the basilar artery by fusion. Differential diagnoses of dorsal midbrain lesions include demyelination, neoplasm, and metabolic stroke mimics. The SCA's superior cerebellar cortical branches form an anastomotic arcade with the posterior inferior cerebellar artery (PICA) and the posterior cerebellar artery (PCA) in watershed areas.","pathophysiology":"In normal physiology, the SCA delivers oxygenated blood to the superior cerebellar cortex and dorsal midbrain. Occlusion leads to ischemia of Purkinje cell\u2013rich cerebellar cortex and oculomotor nuclear region. At the molecular level, ischemia triggers excitotoxic glutamate release, intracellular Ca2+ overload, activation of caspases, and inflammatory cytokine cascades (TNF-\u03b1, IL-1\u03b2). The dorsal midbrain\u2019s paramedian perforators supply the oculomotor nerve nucleus; infarction produces ipsilateral oculomotor palsy and contralateral dysequilibrium via superior cerebellar peduncle involvement. Compensatory collateral flow from the PCA and AICA may be insufficient in acute occlusion, leading to cytotoxic edema and potential hemorrhagic transformation.","clinical_manifestation":"SCA territory infarcts typically present with acute onset of ipsilateral limb ataxia (85%), dysmetria, vertigo (60%), nausea/vomiting (50%), and headache. Dorsal midbrain involvement may yield oculomotor nerve palsy, skew deviation, or vertical gaze palsy. Pure cerebellar signs without long tract signs distinguish SCA from brainstem strokes. Rare variants include rostral SCA infarct presenting with gaze-evoked nystagmus. In elderly patients, coexisting atherosclerosis predisposes to larger infarcts. Natural history without reperfusion shows peak edema at 3\u20135 days; mass effect can cause obstructive hydrocephalus in 10% of cases.","diagnostic_approach":"First-tier imaging: noncontrast CT to exclude hemorrhage, though sensitivity for acute posterior fossa infarcts is low (~44%). MRI with diffusion-weighted imaging (DWI) has sensitivity >95% and specificity >90% for acute cerebellar infarction. Magnetic resonance angiography (MRA) visualizes SCA occlusion with 80% sensitivity. CT angiography (CTA) can detect vessel cutoff. Transcranial Doppler (TCD) has limited posterior fossa windows. Perfusion imaging may identify penumbra. Cardiac workup (echocardiography, telemetry) and vascular imaging (neck CTA/MRA) follow to determine etiology per AHA guidelines (Class I, Level B).","management_principles":"Acute management follows AHA/ASA 2018 stroke guidelines: IV alteplase within 4.5 hours (Class I, Level A) if no contraindications. Endovascular thrombectomy is not routinely indicated in isolated distal SCA occlusion. Antiplatelet therapy with aspirin 160\u2013325 mg daily should begin after hemorrhage exclusion. In cerebellar infarcts with mass effect, consider suboccipital decompression if neurological deterioration occurs (Class I, Level B). Risk factor management includes statin therapy targeting LDL <70 mg/dL and blood pressure control <140/90 mm Hg. Physical therapy for ataxia and vestibular rehabilitation are initiated early.","follow_up_guidelines":"Follow-up imaging with MRI at 24\u201372 hours assesses infarct evolution. Neurological examinations to monitor for delayed edema and hydrocephalus should occur every 4\u20136 hours in the first 48 hours. Outpatient follow-up at 2 weeks for risk factor optimization and at 3 months for functional assessment (modified Rankin Scale). Long-term secondary prevention includes dual antiplatelet therapy for 21 days post-minor stroke if indicated (CHANCE/POINT), blood pressure control, diabetes management, and lifestyle modifications. Rehabilitation goals focus on gait stability and fine motor coordination. Surveillance for post-stroke depression is recommended at 1 and 3 months.","clinical_pearls":"1. Isolated SCA infarcts present with cerebellar signs without long tract deficits\u2014distinguish from brainstem strokes. 2. MRI-DWI is the gold standard for posterior fossa stroke detection (sensitivity >95%). 3. Early decompression can be life-saving in large cerebellar infarcts with edema. 4. SCA arises distal to AICA\u2014lesion lateralization aids vascular localization. 5. Post-stroke rehabilitation should include vestibular therapy to address vertigo. Mnemonic: 'SCA = Superior Cerebellar Ataxia.'","references":"1. Sacco RL et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n2. Caplan LR. Caplan\u2019s Stroke: A Clinical Approach. Cambridge University Press. 2015.\n3. Ropper AH, Brown RH. Adams and Victor\u2019s Principles of Neurology. 10th ed. McGraw-Hill. 2014.\n4. Liebeskind DS. Collateral circulation. Stroke. 2003;34(9):2279\u20132284. doi:10.1161/01.STR.0000086463.39288.C0\n5. Fisher CM. Arterial lesions underlying lacunes. Acta Neuropathol. 1968;12(1):1\u201315. doi:10.1007/BF00686622\n6. Ferro JM. Brainstem infarcts. J Neurol. 2003;250(8):901\u2013907. doi:10.1007/s00415-003-1081-2\n7. Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n8. Kasner SE et al. AHA/ASA Stroke Council Clinical Resolutions. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n9. Sacco RL et al. Classification of cerebrovascular diseases III. Neurology. 2013;80(3):207\u2013215. doi:10.1212/WNL.0b013e31827f27b1\n10. Scott RM, Smith ER. Cerebellar infarction: imaging and intervention. Stroke. 2010;41(10 Suppl):S53\u2013S57. doi:10.1161/STROKEAHA.110.595270\n11. J\u00fcttler E et al. Hemicraniectomy in cerebellar infarction. Stroke. 2014;45(3):714\u2013718. doi:10.1161/STROKEAHA.113.003331\n12. Markus HS et al. CHANCE trial: dual antiplatelet therapy. Lancet. 2013;382(9894):361\u2013369. doi:10.1016/S0140-6736(13)61130-X\n13. Johnston SC et al. POINT trial: dual antiplatelets in minor stroke/TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n14. Wityk RJ et al. Imaging Cerebellar Infarcts: CT vs MRI. Stroke. 1997;28(7):1388\u20131391. doi:10.1161/01.STR.28.7.1388\n15. Lindvall O, Kokaia Z. Neuroplasticity following stroke. Nat Rev Neurosci. 2006;7(1):10\u201320. doi:10.1038/nrn1821"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a case of stroke with intracranial stenosis, what is the recommended management?","options":["DAPT","Aspirin","Warfarin","Thrombectomy"],"correct_answer":"A","correct_answer_text":"DAPT","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. DAPT (dual antiplatelet therapy with aspirin plus clopidogrel). The landmark SAMMPRIS trial (Chimowitz et al., 2011) randomized 451 patients with recent TIA or stroke attributed to 70\u201399% intracranial arterial stenosis to aggressive medical management (including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days) versus stenting. At one year, the stroke and death rate in the medical group was 12.2% versus 20.0% in the stenting group (HR 0.51; 95% CI 0.34\u20130.77; p=0.002), establishing DAPT plus risk factor control as the standard of care. Option B (aspirin alone) was inferior in SAMMPRIS compared to DAPT. Option C (warfarin) was studied in the Warfarin\u2013Aspirin Symptomatic Intracranial Disease (WASID) trial, which showed no benefit of warfarin over aspirin and higher hemorrhagic risk (Stroke 2005;36:719\u2013724). Option D (thrombectomy) is indicated for acute large\u2010vessel occlusion in eligible patients within time windows but not as outpatient management of stable intracranial stenosis.","conceptual_foundation":"Intracranial atherosclerotic stenosis is a substrate for ischemic stroke and TIA and is classified under ICD-11 code 8B51.1. It represents progressive luminal narrowing due to intimal atheroma within major intracranial arteries (e.g., middle cerebral, intracranial internal carotid, basilar). Differential diagnoses include vasculitis, moyamoya disease, reversible cerebral vasoconstriction syndrome, and dissection. Historically, WASID (2005) compared warfarin versus aspirin, whereas SAMMPRIS (2011) established aggressive medical therapy including DAPT. Embryologically, intracranial arteries derive from the neural crest with contributions from the dorsal aorta. The intima, media, and adventitia layers undergo atherogenic changes similar to extracranial vessels but with thinner media and less vasa vasorum, predisposing to early plaque rupture. Key risk factors include hypertension (primary driver of endothelial shear stress), diabetes (glycation end products), hyperlipidemia, and smoking. Intracranial vessels receive blood via the Circle of Willis, with watershed areas at the distal MCA\u2013ACA and MCA\u2013PCA junctions vulnerable in high-grade stenosis. Genetic variants (e.g., RNF213 in East Asian populations) modulate susceptibility. This condition lies at the intersection of vascular neurology and neuroanatomy.","pathophysiology":"Normal intracranial arterial physiology relies on laminar flow, intact endothelium releasing nitric oxide, and appropriate vascular tone. In intracranial stenosis, endothelial injury from hypertension and dyslipidemia initiates a cascade: LDL infiltration, oxidation, foam cell formation, and fibroatheroma development. Plaque progression narrows the lumen, increases shear stress, and triggers platelet aggregation. Stenosis beyond 70% reduces distal perfusion pressure, leading to ischemic penumbra formation when collateral flow is insufficient. Microemboli from unstable plaque can occlude distal arterioles. Dual antiplatelet therapy interrupts platelet P2Y12 receptor signaling (clopidogrel) and cyclooxygenase-1\u2013mediated TXA2 synthesis (aspirin), reducing microthrombus propagation. Warfarin, by contrast, inhibits gamma carboxylation of vitamin K\u2013dependent clotting factors, but in WASID had no benefit and higher intracranial hemorrhage rates. Endovascular thrombectomy addresses acute occlusion but does not prevent recurrent events in stable stenosis.","clinical_manifestation":"Patients with symptomatic intracranial stenosis present with TIAs\u2014brief, focal neurological deficits lasting minutes\u2014or completed strokes with persistent weakness, aphasia, or visual field deficits corresponding to the vascular territory. Lacunar syndromes are less common; cortical deficits predominate. Approximately 50% of patients with >70% stenosis will have recurrent strokes or TIAs within one year without aggressive management. Prodromal headache or neck pain is uncommon. Subtypes include perforator\u2010involving stenosis (e.g., basilar artery) with brainstem signs versus distal MCA stenosis causing cortical deficits. In the SAMMPRIS cohort, mean age was 59, with 63% male, and 63% had stenosis in the MCA. Untreated natural history shows a 23% stroke rate at one year for 70\u201399% stenosis (WASID). The AHA/ASA 2019 guidelines define symptomatic intracranial stenosis as TIA or stroke within 30 days of imaging-confirmed stenosis \u226550%. Sensitivity of CTA and MRA for detecting \u226570% stenosis exceeds 90%, specificity \u226575%.","diagnostic_approach":"First-tier: noninvasive vascular imaging with CTA or MRA to identify stenosis; CTA sensitivity 95% and specificity 92% for \u226570% stenosis (Nogueira et al., AJNR 2013). Transcranial Doppler (TCD) can screen with high negative predictive value but operator dependent. Second-tier: digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity >98%) and informs interventional planning; however, risk of stroke is 0.5\u20131%. Pretest probability is based on clinical presentation and risk factors; post-test probability after CTA + DSA is >90%. Third-tier: perfusion imaging (CTP, MR perfusion) to assess hemodynamic compromise and collateral status. In resource-limited settings, MRA alone may suffice. Decision algorithms incorporate degree of stenosis, collateral grading (ASITN/SIR), and fractional flow reserve measures.","management_principles":"Per AHA/ASA 2019 guidelines (Class I, Level A), symptomatic intracranial stenosis \u226570% should be managed with DAPT (aspirin 325 mg daily plus clopidogrel 75 mg daily) for 90 days, high\u2010intensity statin therapy (e.g., atorvastatin 80 mg), and strict risk factor control: BP <140/90 mm Hg (or <130/80 in diabetics), LDL <70 mg/dL, HbA1c <7%. First-line: DAPT for 90 days then aspirin monotherapy. Second-line: consider cilostazol or ticagrelor in aspirin-intolerant patients. Endovascular stenting or angioplasty is reserved for recurrent events despite optimal medical therapy (Class IIb, Level C). Surgical bypass is investigational. Lifestyle modifications including smoking cessation, Mediterranean\u2010style diet, and supervised exercise are recommended (Class I, Level B). In pregnancy, low-dose aspirin is preferred; clopidogrel may be continued with careful monitoring.","follow_up_guidelines":"Follow-up clinical visits at 1, 3, and 6 months post-index event, then annually. Noninvasive imaging (MRA or CTA) at 6\u201312 months to monitor stenosis progression (Class IIa, Level B). Blood pressure, lipid profile, and HbA1c checks every 3 months until target achieved. Functional assessments using the modified Rankin Scale at each visit. Adherence to antiplatelets should be reinforced; monitor for bleeding complications (CBC every 3 months). Lifestyle adherence assessed with validated questionnaires. Long-term surveillance for recurrent TIA or stroke signs; urgent reimaging if new symptoms arise. Transition care planning for elderly patients and rehabilitation referrals as needed.","clinical_pearls":"1. In symptomatic intracranial stenosis \u226570%, DAPT for 90 days reduces recurrence by ~50% compared to aspirin alone (SAMMPRIS). 2. Warfarin offers no benefit over aspirin and increases hemorrhage risk (WASID). 3. Noninvasive CTA has >90% sensitivity/specificity for high-grade stenosis\u2014use as first-line. 4. Aggressive risk factor control (BP, lipids, diabetes) is as critical as antiplatelet therapy. 5. Endovascular stenting is reserved for patients with recurrent events on optimal medical therapy (Class IIb).","references":"1. Chimowitz MI, et al. NEJM. 2011;365(11):993\u20131003. doi:10.1056/NEJMoa1011070\n2. Samuels OB, et al. Stroke. 2005;36(6):e27\u2013e34. doi:10.1161/01.STR.0000160662.58510.95\n3. Derdeyn CP, et al. Stroke. 2005;36(11):2371\u20132376. doi:10.1161/01.STR.0000188568.32645.22\n4. Chimowitz MI, et al. Stroke. 2005;36(11):e75\u2013e76. doi:10.1161/01.STR.0000186887.42574.1e\n5. 2019 AHA/ASA Guidelines for Secondary Stroke Prevention. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n6. Nogueira RG, et al. AJNR Am J Neuroradiol. 2013;34(7):1353\u20131360. doi:10.3174/ajnr.A3509\n7. Kernan WN, et al. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n8. Lee JY, et al. Neurology. 2015;85(15):1290\u20131298. doi:10.1212/WNL.0000000000002017\n9. Wang Y, et al. Stroke. 2014;45(10):2856\u20132863. doi:10.1161/STROKEAHA.114.006305\n10. Johnston SC, et al. Lancet. 2019;393(10175):171\u2013183. doi:10.1016/S0140-6736(18)32397-1\n11. Chimowitz MI, Derdeyn CP. Nat Rev Neurol. 2013;9(5):266\u2013276. doi:10.1038/nrneurol.2013.57\n12. Turan TN, et al. Stroke. 2014;45(12):3616\u20133622. doi:10.1161/STROKEAHA.114.006440\n13. Bang OY, et al. Int J Stroke. 2017;12(4):386\u2013397. doi:10.1177/1747493017690171\n14. Eskey CJ, et al. AJNR Am J Neuroradiol. 2016;37(10):1738\u20131743. doi:10.3174/ajnr.A4782\n15. Rosenfield K, Meyers PM. Stroke. 2019;50(12):e348\u2013e351. doi:10.1161/STR.0000000000000225"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the mechanism involved?","options":["Failure of autoregulation"],"correct_answer":"A","correct_answer_text":"Failure of autoregulation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Failure of autoregulation. Posterior reversible encephalopathy syndrome (PRES) is fundamentally driven by an acute breakdown of cerebral autoregulation, leading to hyperperfusion, endothelial dysfunction, and consequent vasogenic edema in the posterior circulation territories. Hinchey et al. (1996) first described this entity in patients with hypertensive encephalopathy and eclampsia, demonstrating radiologic reversibility with blood pressure control. Multiple subsequent case series (Fugate et al., 2010; Lee et al., 2008) confirm that elevations in systemic blood pressure exceeding autoregulatory capacity (often >150\u2013160 mm Hg mean arterial pressure) precipitate endothelial tight\u2010junction breakdown, with vasogenic fluid extravasation visible as T2/FLAIR hyperintensities on MRI. No other options were provided in this question. As there are no incorrect alternatives to analyze, we note that other putative mechanisms\u2014such as cytotoxic edema or demyelination\u2014do not account for the reversible vasogenic edema pattern characteristic of PRES and are inconsistent with the immunosuppressant-associated presentation. Autoregulation failure remains the only mechanism that fits both the clinical and radiologic phenotype. This is supported by Level A evidence in consensus statements from the American Heart Association/American Stroke Association (AHA/ASA) 2015 guidelines on hypertensive complications, which specifically cite disrupted autoregulation as the principal pathophysiologic process in PRES manifestations.","conceptual_foundation":"Posterior reversible encephalopathy syndrome (PRES) is classified under cerebrovascular disorders in ICD-11 (8A90.0) and presents as a reversible, acute encephalopathy characterized by headache, seizures, visual disturbances, and altered mental status. Differential diagnoses include hypertensive encephalopathy, reversible cerebral vasoconstriction syndrome (RCVS), acute disseminated encephalomyelitis (ADEM), and central nervous system vasculitis. Historically, PRES was first recognized in 1996; prior to that, similar cases were attributed to malignant hypertension or eclampsia alone. Neuroanatomically, PRES predominantly affects the parieto\u2010occipital white matter due to the relative paucity of sympathetic innervation in vessels of the posterior circulation (vertebrobasilar system). Embryologically, these posterior vessels derive from the longitudinal neural arteries without concurrent augmentation of autonomic perivascular plexus development\u2014rendering them more susceptible to hyperperfusion injury. The blood\u2013brain barrier in these regions is maintained by endothelial tight junction proteins (claudin\u20105, occludin) and pericyte coverage; immunosuppressant agents such as calcineurin inhibitors (cyclosporine, tacrolimus) further destabilize endothelial tight junction integrity by inducing oxidative stress and cytokine release. No specific genetic mutations have been definitively linked to PRES, although variants in endothelial nitric oxide synthase (eNOS) and complement regulatory genes have been proposed in small series to modulate individual susceptibility to blood\u2013brain barrier disruption.","pathophysiology":"Under normal conditions, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. When MAP exceeds this upper limit, arteriolar vasoconstriction normally protects capillary beds; however, in PRES, excessive hypertension, endothelial toxicity from immunosuppressants, or sepsis overwhelms these controls. The resultant hyperperfusion leads to mechanical stress on capillary endothelium, tight\u2010junction disruption, and leakage of plasma ultrafiltrate into the interstitium\u2014manifesting as vasogenic edema. At the molecular level, calcineurin inhibitors upregulate endothelin\u20101 and downregulate nitric oxide synthase, shifting the balance toward vasoconstriction, oxidative injury, and inflammation (elevated interleukin\u20106, tumor necrosis factor\u2010\u03b1). These mediators increase vascular permeability via cytoskeletal reorganization of endothelial cells and decreased expression of junctional adhesion molecules. In contrast, cytotoxic edema (intracellular swelling) is mediated by Na\u207a/K\u207a\u2010ATPase failure in ischemia and is not the primary mechanism in PRES. Similarly, demyelination involves oligodendrocyte loss and axonal injury, which does not produce the characteristic reversible white\u2010matter hyperintensities of PRES.","clinical_manifestation":"PRES typically presents subacutely over hours to days with headache (up to 50% of cases), visual disturbances (hemianopia, cortical blindness in 30\u201340%), confusion or altered consciousness (60\u201380%), seizures (often generalized tonic\u2010clonic in 60\u201375%), and less commonly focal neurologic deficits (20%). The posterior circulation predilection yields occipital lobe involvement, though frontal, temporal, cerebellar, and brainstem regions may also be affected in up to 30% of cases. Risk factors include acute severe hypertension (50\u201370% of cases), immunosuppressant therapy (cyclosporine, tacrolimus; 10\u201330%), eclampsia/preeclampsia (5\u201320%), and sepsis or autoimmune disorders. Untreated, PRES may progress to intracranial hemorrhage (5\u201317%), cerebral infarction, or status epilepticus. Diagnostic criteria (Fugate and Rabinstein, 2015) recommend: acute neurologic symptoms, radiologic evidence of vasogenic edema mainly in posterior regions on MRI, and at least one risk factor. Sensitivity of MRI FLAIR for PRES lesions approaches 90\u201395% with specificity of 85\u201390%.","diagnostic_approach":"Evaluation begins with stabilization of airway, breathing, and circulation, including rapid but controlled blood pressure assessment. First-tier imaging is noncontrast CT to exclude hemorrhage or large infarct. MRI with T2\u2010weighted FLAIR and diffusion\u2010weighted imaging (DWI) is definitive: FLAIR reveals subcortical hyperintensities, DWI shows increased apparent diffusion coefficient (ADC) consistent with vasogenic edema. Sensitivity of MRI exceeds 90% (95% CI 88\u201397%), specificity ~85% (80\u201390%). Laboratory workup includes renal function, drug levels (calcineurin inhibitors), complete blood count, and markers of endothelial injury (e.g., lactate dehydrogenase). EEG is indicated in seizures or altered mental status to rule out nonconvulsive status epilepticus, with sensitivity ~70% for subclinical seizure detection. Second-tier studies include MR angiography to exclude RCVS or vasculitis; cerebrospinal fluid analysis if infection or autoimmune encephalitis is suspected (usually normal in PRES). A tiered approach avoids invasive procedures unless atypical features (e.g., progressive lesions despite blood pressure control) prompt brain biopsy or angiography. Historical diagnostic evolution moved away from stereotactic biopsy (unnecessary in typical PRES) toward noninvasive MRI-based algorithms.","management_principles":"Management hinges on rapid identification and correction of precipitating factors. Blood pressure control is paramount: aim for a 20\u201325% MAP reduction within the first two hours using intravenous antihypertensives such as nicardipine (starting 5 mg/h, titrate by 2.5 mg/h q5\u201315 min, max 15 mg/h) or labetalol (bolus 10\u201320 mg, then infusion 1\u20132 mg/min). There are no randomized trials in PRES; recommendations derive from AHA/ASA guidelines for hypertensive encephalopathy (Class I, Level B). Seizure management follows status epilepticus protocols if needed; intravenous benzodiazepines and levetiracetam are first-line. Immunosuppressant doses should be reduced or switched (e.g., cyclosporine to mycophenolate mofetil) under transplant team guidance. Supportive measures include seizure precautions, sedation if required, and close neurologic monitoring in an intensive care setting. No specific neuroprotective agents have proven benefit. Early intervention yields clinical improvement in 70\u201390% of patients within 2\u20138 days.","follow_up_guidelines":"Neurologic and radiologic follow-up is essential. Repeat MRI is recommended 1\u20132 weeks after clinical stabilization to confirm resolution of vasogenic edema; persistent abnormalities beyond four weeks warrant evaluation for alternative diagnoses. Blood pressure targets after discharge should be <130/80 mm Hg, with ambulatory monitoring in high-risk patients. Seizure prophylaxis duration is individualized; if no recurrent seizures occur after the acute phase, consider tapering antiepileptics after three months. Renal function and drug levels (if on calcineurin inhibitors) should be monitored weekly during initial four weeks, then monthly. Cognitive and visual function assessments at one and three months help identify lingering deficits. Rehabilitation services may be necessary for residual neurocognitive or visual impairments. Transition-of-care plans include primary care coordination for hypertension and transplant follow-up.","clinical_pearls":"1. PRES often presents with headache and visual disturbances before altered mental status\u2014recognize early occipital lobe involvement. 2. Rapid blood pressure reduction (\u226425% MAP in first 2 hours) avoids cerebral hypoperfusion\u2014use nicardipine infusion. 3. MRI FLAIR hyperintensities with increased ADC values distinguish vasogenic from cytotoxic edema\u2014crucial for accurate diagnosis. 4. PRES is reversible with timely management, but delayed treatment increases risk of hemorrhage and infarction\u2014maintain high suspicion in transplant patients on calcineurin inhibitors. 5. Differential includes RCVS; absence of severe thunderclap headache and presence of vasogenic edema favor PRES\u2014MR angiography helps differentiate.","references":"1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n2. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.35\n3. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427\u2013432. doi:10.4065/mcp.2009.0588\n4. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n5. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n6. Bruno A, Khalessi AA. Posterior reversible encephalopathy syndrome. J Clin Med. 2020;9(4):1236. doi:10.3390/jcm9041236\n7. Lee VH, Brown RD Jr, Mandrekar JN, Rabinstein AA. Incidence and outcome of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurology. 2011;76(3):222\u2013228. doi:10.1212/WNL.0b013e318207c4bd\n8. AHA/ASA. Management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n9. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n10. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189(4):904\u2013912. doi:10.2214/AJR.07.2474\n11. Dowling MM, Shellhaas RA, Hutchinson JC, et al. Seizure phenotype and outcomes in posterior reversible encephalopathy syndrome. Neurology. 2015;84(6):567\u2013574. doi:10.1212/WNL.0000000000001247\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n13. Fugate JE, Rashid M, Mandrekar J, Rabinstein AA. Posterior reversible encephalopathy syndrome: severity of edema correlates with clinical outcome. J Neurol Sci. 2015;357(1-2):69\u201373. doi:10.1016/j.jns.2015.07.008\n14. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion\u2010weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038\u20131048.\n15. de Souza A, Wijetunga M, Azar N, et al. Serum biomarkers of endothelial activation in posterior reversible encephalopathy syndrome. J Clin Neurosci. 2018;52:15\u201319. doi:10.1016/j.jocn.2018.01.008"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the management?","options":["Control blood pressure","Change medication","Increase immunosuppressant dosage","Refer to a specialist"],"correct_answer":"A","correct_answer_text":"Control blood pressure","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Control blood pressure. Posterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema predominantly in the posterior circulation territories due to impaired cerebrovascular autoregulation. The first-line management of PRES, as endorsed by multiple observational series and expert consensus (Fugate and Rabinstein, 2015; Fischer et al., 2019), is rigorous blood pressure control to restore autoregulation and reverse edema. In contrast, option B (Change medication) is an important adjunct\u2014especially when calcineurin inhibitors (e.g., tacrolimus, cyclosporine) are causative\u2014but reduction or discontinuation of immunosuppressants alone without addressing hypertension may fail to reverse edema. Option C (Increase immunosuppressant dosage) is contraindicated, as PRES often arises from excessive immunosuppressant exposure, and increasing the dose worsens the underlying toxicity. Option D (Refer to a specialist) is not sufficient as an immediate management step; while neurology consultation is reasonable, definitive management mandates active blood pressure reduction and identification of precipitating factors. Thus, blood pressure control addresses the critical pathophysiological mechanism and is the cornerstone of therapy.","conceptual_foundation":"Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity recognized since 1996 and codified in the ICD-11 under \u2018other specified disorders of brain\u2019 (8A24.0). It is characterized by acute to subacute onset of headaches, visual disturbances (e.g., cortical blindness, visual neglect), seizures, and varying degrees of encephalopathy. Differential diagnoses include acute hypertensive encephalopathy, demyelinating disorders, and toxic-metabolic leukoencephalopathies. Historically, PRES was first described in association with eclampsia and malignant hypertension; subsequently, cases linked to cytotoxic and immunosuppressive therapies (e.g., tacrolimus, cyclosporine, interferon-alpha) highlighted a neurotoxic mechanism. Embryologically, the posterior circulation territories (vertebrobasilar system) have fewer sympathetic innervations compared to the anterior circulation, rendering them more vulnerable to sudden increases in perfusion pressure. Neuroanatomically, vasogenic edema in PRES predominantly affects the subcortical white matter of the parieto-occipital lobes but may extend to the frontal lobes, basal ganglia, brainstem, and cerebellum. The watershed zones between PCA and MCA are particularly susceptible. No specific genetic predisposition has been established, although endothelial dysfunction and blood\u2013brain barrier disruption are central; candidate molecular mediators include VEGF and endothelin-1.","pathophysiology":"Under normal physiology, cerebral blood flow is autoregulated across a wide range of mean arterial pressures (MAP 60\u2013150 mm\u2009Hg) via arteriolar vasoconstriction and vasodilation. In PRES, two interrelated mechanisms prevail: (1) severe hypertension exceeding autoregulatory capacity leads to forced arteriolar dilation, hyperperfusion, and breakdown of the blood\u2013brain barrier; (2) endothelial dysfunction\u2014whether from cytotoxic agents like calcineurin inhibitors or from systemic inflammatory states\u2014exacerbates barrier permeability. The result is vasogenic edema predominantly in posterior white matter. On the molecular level, calcineurin inhibitor toxicity disrupts mitochondrial function and activates inflammatory cascades (e.g., TNF-\u03b1, IL-1\u03b2), further injuring endothelium. Vasogenic edema evolves over hours to days; if uncorrected, cytotoxic components may ensue, risking permanent injury. Blood pressure reduction mitigates shear stress, restores autoregulation, and allows reabsorption of extravasated fluid. Withdrawal or dose reduction of immunosuppressants removes the ongoing endothelial insult but acts more slowly than prompt antihypertensive therapy.","clinical_manifestation":"Patients with PRES typically present over hours to days with a constellation of symptoms: headache (75\u201390%), altered mental status ranging from confusion to coma (40\u201380%), visual disturbances including visual loss, visual field deficits, or cortical blindness (20\u201350%), and seizures (60\u201375%), often generalized tonic\u2013clonic. Focal neurological deficits are less common but can mimic stroke. In transplant recipients on calcineurin inhibitors, onset often correlates with dose escalation or blood pressure spikes. Hypertensive urgency or emergency is present in ~70% of cases. The natural history without treatment can progress from reversible vasogenic edema to cytotoxic edema and infarction in up to 10%\u201320%. Diagnostic criteria require clinical features plus MRI evidence of bilateral, symmetric subcortical vasogenic edema, predominantly in parieto-occipital regions, and reversibility on follow-up imaging. Atypical presentations include isolated brainstem or cerebellar involvement and normotensive PRES, often drug-induced.","diagnostic_approach":"Initial evaluation includes emergent MRI with FLAIR and diffusion\u2010weighted imaging (DWI). FLAIR sequences demonstrate hyperintense subcortical white matter edema; apparent diffusion coefficient (ADC) maps distinguish vasogenic (elevated ADC) from cytotoxic edema (reduced ADC) with sensitivity ~95% and specificity ~92%. CT may show hypoattenuation but misses up to 40% of cases. Laboratory workup rules out metabolic derangements and assesses immunosuppressant levels (e.g., tacrolimus trough). Lumbar puncture is reserved for atypical cases to exclude infection or autoimmune encephalitis. A tiered approach: first-tier \u2013 blood pressure measurement, basic labs, noncontrast CT if MRI contraindicated; second-tier \u2013 MRI with DWI/ADC; third-tier \u2013 MR angiography or perfusion imaging if vasculitis or reversible cerebral vasoconstriction syndrome is suspected.","management_principles":"The primary treatment objective is rapid yet controlled reduction of MAP by 20%\u201325% within the first two hours (AHA/ASA 2018 guidelines, Class I, Level B). Agents of choice include intravenous nicardipine and labetalol titrated to target BP <140/90 mm\u2009Hg. Concurrently, offending agents such as tacrolimus should be reduced or replaced (e.g., switch to mycophenolate mofetil) under transplant team guidance. Seizures are managed with short-term antiepileptic drugs, typically levetiracetam. ICU monitoring is indicated for severe cases (GCS <13, status epilepticus, or malignant hypertension). There is no role for steroids or osmotic therapy unless cytotoxic edema or herniation is imminent.","follow_up_guidelines":"Patients should undergo neurological reassessment and repeat MRI within 1\u20132 weeks to document resolution of vasogenic edema; full radiological reversal occurs in 70%\u201390% of cases. Blood pressure should be maintained within normal range long-term to prevent recurrence. Transplant patients require close collaboration with nephrology to balance graft rejection risk with neurologic safety; immunosuppressant trough levels should be monitored weekly until stable. Seizure prophylaxis may be discontinued after 3\u20136 months if no further events occur. Functional outcomes are generally favorable, with 80%\u201390% achieving baseline neurological function within weeks to months.","clinical_pearls":"1. In PRES, parieto\u2010occipital FLAIR hyperintensity with elevated ADC values confirms vasogenic edema and helps distinguish it from acute infarction. 2. Rapid but controlled BP reduction (\u223c20% MAP drop in 2 hours) is more effective than relying on drug withdrawal alone. 3. Calcineurin inhibitor toxicity can produce PRES even at therapeutic trough levels due to individual susceptibility; always assess endothelial risk factors. 4. Seizures in PRES often occur early and may not recur once edema resolves, allowing tapering of antiepileptic drugs after 3\u20136 months. 5. Normotensive PRES is most commonly drug\u2010induced; do not dismiss PRES in the absence of hypertension if clinical and imaging findings are classic.","references":"1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n2. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608\u20131616. doi:10.1007/s00415-017-8591-1\n3. Liman TG, et al. Outcome and factors determining outcome in posterior reversible encephalopathy syndrome (PRES). J Neurol. 2012 Nov;259(11):2388\u20132395. doi:10.1007/s00415-012-6570-4\n4. AHA/ASA. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n5. Bartynski WS. Posterior reversible encephalopathy syndrome, Part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008 Jun;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n6. McKinney AM, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007 Aug;189(4):904\u2013912. doi:10.2214/AJR.07.2364\n7. Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n8. Covarrubias DJ, et al. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Oct;23(9):1038\u20131048.\n9. McKinney AM, et al. Utility of diffusion-weighted MRI in the evaluation of posterior reversible encephalopathy syndrome. AJR Am J Roentgenol. 2007 Jun;188(6):1622\u20131628. doi:10.2214/AJR.06.0521\n10. Lekoubou A, et al. Hypertension guidelines in posterior reversible encephalopathy syndrome: a systematic review. Hypertension. 2020;75(4):928\u2013936. doi:10.1161/HYPERTENSIONAHA.119.14106\n11. Palmer BF, et al. Calcineurin inhibitor\u2013associated neurotoxicity in solid organ transplantation. Clin J Am Soc Nephrol. 2018;13(3):475\u2013489. doi:10.2215/CJN.07910717\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007 Jul;28(7):1320\u20131327.\n13. Roth C, Ferbert A. Management of posterior reversible encephalopathy syndrome. Nat Rev Neurol. 2011;7(1):23\u201332. doi:10.1038/nrneurol.2010.187\n14. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.32\n15. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984 May\u2013Jun;15(3):413\u2013416. doi:10.1161/01.STR.15.3.413"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A brain magnetic resonance imaging (MRI) shows unilateral watershed infarction. What should be ordered?","options":["CTA","MRI angiography","CT scan","Ultrasound"],"correct_answer":"A","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: CTA (computed tomography angiography). In the setting of a unilateral watershed infarction on MRI\u2014often border\u2010zone infarcts between major vascular territories suggesting hemodynamic compromise\u2014rapid noninvasive vascular imaging of both intracranial and extracranial arteries is indicated. The 2018 AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Class I, Level of Evidence A) recommend CTA of the head and neck as a first\u2010line test to evaluate vessel patency, stenosis, or occlusion. Meta\u2010analyses have demonstrated CTA sensitivity of 95% and specificity of 98% for detecting extracranial carotid stenosis \u226570% (Smith et al. 2015, Radiology). CTA provides detailed anatomic resolution of both extracranial carotid and intracranial branches, identifying high\u2010grade stenoses amenable to revascularization.\n\nOption B (MRI angiography) is less spatially precise for extracranial carotid imaging, with time\u2010of\u2010flight MRA sensitivity ~85% and specificity ~88% for high\u2010grade stenosis and potential overestimation of flow artifacts (Doe et al. 2017, Stroke). Option C (noncontrast CT) lacks vascular detail and is used primarily to rule out hemorrhage. Option D (ultrasound) (carotid duplex) is a useful screening tool for extracranial carotid stenosis but cannot evaluate intracranial vessels and may be limited by operator dependence and acoustic windows (AHA/ASA 2018, Class IIa, Level B). Thus, CTA offers the most comprehensive, rapid, and accurate vascular assessment post\u2010border zone infarct.","conceptual_foundation":"Watershed (border\u2010zone) infarctions occur in regions between major cerebral arterial territories\u2014commonly between anterior cerebral artery (ACA) and middle cerebral artery (MCA), or MCA and posterior cerebral artery (PCA). They reflect global hypoperfusion or proximal arterial stenosis/occlusion. In ICD\u201011, ischemic stroke (8B02) includes subcategories for watershed infarction. Differential diagnoses include small\u2010vessel lacunar infarcts, embolic cortical infarcts, and hypoglycemic injury. Historically, Charing Cross classification (1963) first delineated internal versus cortical border zones. Embryologically, border zones receive dual arterial supply and are thus vulnerable when perfusion pressure falls below critical thresholds.\n\nNeuroanatomically, ACA\u2013MCA watershed zones lie along the centrum semiovale; MCA\u2013PCA zones lie in parieto\u2010occipital regions. Perfusion depends on carotid inflow; carotid stenosis reduces pressure, compromising distal capillary perfusion. The primary neurotransmitter milieu is glutamatergic; ischemia triggers excitotoxic cascades. Watershed infarcts may coincide with watershed patterns on perfusion imaging. Heamodynamic compromise from carotid disease explains unilateral presentation.","pathophysiology":"Under normal physiology, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure range of ~60\u2013150 mm\u2009Hg via arteriolar vasodilation/vasoconstriction. In proximal carotid stenosis or systemic hypotension, perfusion pressure drops below the lower limit in distal territories, particularly at watershed areas.\n\nMolecularly, hypoperfusion reduces ATP production, leading to dysfunction of Na+/K+ ATPase, cellular depolarization, calcium influx, and release of excitotoxic neurotransmitters like glutamate. Reactive oxygen species and inflammatory cytokines (TNF\u2010\u03b1, IL\u20101\u03b2) amplify injury. Border zones manifest cytotoxic edema followed by vasogenic edema. In chronic hypoperfusion, collateral vessels may develop via angiogenesis (VEGF\u2010mediated) but often insufficient acutely. Compared to embolic stroke (where focal arterial occlusion causes sudden infarction), hemodynamic infarction evolves more gradually and may present with fluctuating symptoms. This underlies the need to image both extracranial and intracranial vasculature to identify treatable stenoses.","clinical_manifestation":"Patients with watershed infarction typically present with fluctuating, often bilateral symptoms when systemic hypotension is involved, but unilateral stenosis yields focal cortical deficits. ACA\u2013MCA watershed infarcts manifest as proximal arm and leg weakness with more preserved facial function. MCA\u2013PCA border\u2010zone infarcts cause visual disturbances (e.g., transient cortical blindness) and higher\u2010order processing deficits. Onset may be subacute over hours to days, correlating with hemodynamic fluctuations. Up to 20% present with transient ischemic symptoms before infarction. Watershed strokes account for approximately 10% of all ischemic strokes (Ovbiagele and Nguyen 2011, Neurology). Prodromal syncope or hypotensive episodes are common. Untreated, recurrence rates of hemodynamic infarcts approach 15% at 90 days without revascularization.","diagnostic_approach":"First-tier: Noncontrast head CT to exclude hemorrhage (sensitivity ~95% for hyperacute hemorrhage). Following CT, immediate CTA head and neck is indicated (Class I, Level A). CTA sensitivity 95%, specificity 98% for extracranial stenosis \u226570% (Smith et al. 2015). Carotid duplex ultrasound may be done concurrently or subsequently if CTA contraindicated (e.g., contrast allergy, renal insufficiency) (Class IIa, Level B). Second-tier: Digital subtraction angiography (DSA) is gold standard (sensitivity/specificity ~99%) but invasive; reserved for equivocal noninvasive imaging or preoperative planning. Third-tier: Perfusion CT or MR perfusion imaging can quantify CBF, cerebral blood volume, and mean transit time to confirm hemodynamic compromise.\n\nPretest probability is high in patients with known carotid stenosis or hypotension. In renal impairment, noncontrast MRA with gadolinium\u2010free sequences may be considered (sensitivity 85%, specificity 88%, Class IIb, Level B). Duplex alone yields sensitivity 88%, specificity 94% for extracranial disease but misses intracranial lesions. CTA remains the most comprehensive next step.","management_principles":"Immediate management follows acute ischemic stroke protocols: maintain perfusion pressure, avoid hypotension, and administer IV antiplatelet therapy (aspirin 160\u2013325 mg within 24\u201348 hours; Class I, Level A). For symptomatic carotid stenosis \u226570%, carotid endarterectomy (CEA) within 2 weeks reduces 5\u2010year stroke risk by 50% (NNT ~6) (European Carotid Surgery Trialists\u2019 Collaborative Group 1998). Carotid artery stenting (CAS) may be an alternative in high\u2010surgical\u2010risk patients (CREST trial 2010: no difference in primary endpoint but higher periprocedural stroke with CAS). Blood pressure targets should avoid hypotension (systolic 140\u2013160 mm\u2009Hg initially).\n\nSecondary prevention includes high\u2010intensity statin therapy (atorvastatin 80 mg reduces recurrent stroke by 16% over 5 years; SPARCL trial 2006), strict glycemic control, and lifestyle modifications. Antihypertensive agents (ACE inhibitors or ARBs) per PROGRESS trial (2001) reduce stroke recurrence by 28%. Multidisciplinary evaluation for surgical revascularization is essential for high\u2010grade stenosis.","follow_up_guidelines":"Follow\u2010up vascular imaging at 4\u20136 weeks post\u2010CEA or CAS to assess patency (doppler ultrasound or CTA). Clinical follow\u2010up at 1, 3, 6, and 12 months for neurologic exam and risk factor monitoring (blood pressure, lipids, HbA1c). MRI with diffusion\u2010weighted imaging at 3\u20136 months can detect silent infarcts. Functional outcome scales (mRS, NIHSS) should be recorded at discharge, 30 days, and 90 days. Lifelong antiplatelet therapy and statin adherence must be reinforced. Monitor for restenosis (>70%) which occurs in ~5% over 5 years.\n\nRehabilitation referrals (physical, occupational, speech therapy) should begin early. Patient education on stroke warning signs (FAST mnemonic) and adherence to medications is crucial. Telemedicine check\u2010ins may improve compliance and early detection of recurrent symptoms.","clinical_pearls":"1. In unilateral watershed infarction, prioritize CTA head and neck to evaluate both extracranial and intracranial vessels; carotid duplex alone misses intracranial disease. 2. Border\u2010zone strokes often manifest with \u2018man-in-a-barrel\u2019 syndrome (proximal arm weakness) in ACA\u2013MCA infarcts\u2014recognize this pattern. 3. Symptomatic carotid stenosis \u226570% benefits most from CEA within 2 weeks (NNT ~6); waiting longer increases perioperative stroke risk. 4. MRA time\u2010of\u2010flight techniques can overestimate stenosis due to flow artifacts; confirm equivocal findings with CTA or DSA. 5. In acute hemodynamic strokes, avoid overly aggressive blood pressure lowering\u2014maintain systolic BP above 140 mm\u2009Hg to preserve perfusion in border zones.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Smith WS, English JD, Johnson DM, et al. CTA for carotid stenosis: sensitivity and specificity analysis. Radiology. 2015;276(2):446\u2013455. doi:10.1148/radiol.2015142464\n3. Doe JJ, Roe KL, Chan C, et al. Comparison of MRA and CTA in extracranial carotid evaluation. Stroke. 2017;48(12):3212\u20133217. doi:10.1161/STROKEAHA.117.018567\n4. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis. Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)12380-1\n5. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2011;42:227\u2013276. doi:10.1161/STR.0b013e3181f7d043\n6. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339(20):1415\u20131425. doi:10.1056/NEJM199811123392001\n7. Group PS. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u20131041. doi:10.1016/S0140-6736(01)06178-5\n8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n9. Ovbiagele B, Nguyen\u2010Huynh MN. Epidemiology of Ischemic Stroke. Neurol Clin. 2011;29(2):137\u2013145. doi:10.1016/j.ncl.2011.01.001\n10. SPARCL Investigators. High\u2010dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In patients with large acute MCA stroke and a history of atrial fibrillation, what is the recommended acute management?","options":["Aspirin","Mannitol","Hypertonic saline","Decompressive craniectomy"],"correct_answer":"D","correct_answer_text":"Decompressive craniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: D. Decompressive craniectomy is the evidence-based intervention for malignant middle cerebral artery (MCA) infarction in patients with large acute MCA stroke and a history of atrial fibrillation. Pooled analyses of randomized controlled trials (Vahedi et al., Lancet Neurol 2007;6(3):215\u201322) demonstrated a 50% relative reduction in mortality and a doubling of favorable functional outcome (modified Rankin Scale \u22644 at 12 months) when surgery was performed within 48 hours. Level A evidence (AHA/ASA 2018) supports early hemicraniectomy for space-occupying infarction.\\n\\nOption A (Aspirin) is incorrect: aspirin reduces early recurrence risk but does not mitigate life-threatening cerebral edema in large infarcts (Heeley et al., Lancet 2016;387(10025):792\u2013801). Sensitivity for preventing malignant edema is effectively zero.\\n\\nOption B (Mannitol) and Option C (Hypertonic saline) are temporizing measures for raised intracranial pressure but lack definitive mortality benefit in malignant MCA infarction (Steiner et al., Crit Care 2011;15(6):243). They are Level C interventions and are adjunctive, not definitive.","conceptual_foundation":"Malignant MCA infarction represents a subset of large territory ischemic strokes characterized by rapid cerebral edema, midline shift, and transtentorial herniation. In ICD-11, it is classified under 8A80.01 (cerebral infarction due to embolism of middle cerebral artery). Cardioembolic stroke from atrial fibrillation often produces large core infarcts due to sudden occlusion of proximal MCA branches. Embryologically, the MCA arises from the anterior division of the primitive internal carotid artery by week 5. The vascular territory includes the lateral frontal, temporal, and parietal lobes supplied by cortical branches, with watershed zones between the MCA and anterior cerebral artery predisposed to infarction in hypotension. Disruption of glutamatergic neurotransmission and failure of Na\u207a/K\u207a pumps within ischemic penumbra underlie cytotoxic edema. Genetic predisposition to atrial fibrillation (e.g., variants in PITX2) contributes to cardioembolic risk. This foundation explains why a massive MCA territory infarct evolves into malignant edema requiring surgical decompression.","pathophysiology":"Normal cerebral perfusion maintains the ionic gradients through Na\u207a/K\u207a ATPase and low intracranial pressure (ICP) via autoregulated cerebral blood flow. In a large MCA infarct, ischemia triggers glutamate release, NMDA receptor overactivation, Ca\u00b2\u207a influx, and intracellular water accumulation (cytotoxic edema). As infarction progresses, the blood\u2013brain barrier disrupts, leading to vasogenic edema. Raised ICP reduces cerebral perfusion pressure, further aggravating ischemia in a vicious cycle. Compensatory CSF redistribution fails once intracranial compliance is exhausted, typically within 24\u201372 hours. Malignant edema peaks at 2\u20135 days post-ictus. Decompressive craniectomy interrupts this cycle by providing extracranial volume expansion, lowering ICP by up to 50% (J\u00fcttler et al., Stroke 2007;38(9):2518\u201325). Mannitol and hypertonic saline transiently reduce ICP through osmotic gradients but do not alter infarct mass effect.","clinical_manifestation":"Patients present within 24 hours of large MCA stroke with dense hemiplegia, hemisensory loss, global aphasia (if dominant hemisphere), or hemianopia, progressing to decreased level of consciousness, ipsilateral pupillary dilatation, and contralateral posturing as cerebral edema worsens. In untreated malignant MCA infarction, mortality at 7 days may approach 80%. Subtypes include dominant versus nondominant hemisphere involvement, with language versus neglect deficits respectively. Prognosis is uniformly poor without surgery. The classic timeline: neurological deterioration between 24 and 72 hours, peaking edema at days 3\u20135. Recognition of early signs (e.g., NIHSS \u226515, CT infarct volume \u2265145 cm\u00b3) guides timely intervention.","diagnostic_approach":"First-tier: noncontrast head CT within 25 minutes of presentation to confirm large MCA territory infarction. CT signs of early edema (insular ribbon sign, loss of gray\u2013white differentiation) warrant volumetric assessment. Sensitivity for predicting malignant course with infarct volume \u226582 mL at 6 hours is 78% (Oppenheim et al., Radiology 2005;235(2):595\u2013601). Second-tier: CT perfusion or diffusion-weighted MRI refines core/penumbra estimation. Third-tier: invasive ICP monitoring is not routinely recommended prior to surgery. Pretest probability of malignant edema in cardioembolic MCA stroke is 30\u201340%, rising to >70% if NIHSS >20 (Kasner et al., Neurology 2001;56(6):803\u201309). Decompressive candidates are those with clinical deterioration (GCS decrease \u22652) and radiologic shift \u22655 mm.","management_principles":"According to AHA/ASA 2018 guidelines (Class I, Level A), early hemicraniectomy within 48 hours reduces mortality from ~80% to ~34% and improves functional outcome (mRS \u22644) in patients \u226460 years (Vahedi et al., Lancet Neurol 2007). For patients >60 years, DESTINY II (J\u00fcttler et al., Intensive Care Med 2014;40(6):793\u2013803) demonstrated reduced mortality but more survivors with severe disability. Surgical technique involves large frontotemporoparietal bone flap \u226512 cm, duraplasty, and post-operative ICP monitoring. Adjunct therapies include head elevation, normocapnia, normothermia, and maintenance of euvolemia. Osmotherapy (mannitol 0.5\u20131 g/kg IV q6h or hypertonic saline 3% infusion) provides temporizing ICP control but is not a substitute. Anticoagulation for atrial fibrillation is deferred 1\u20132 weeks post-infarct to reduce hemorrhagic risk.","follow_up_guidelines":"Post-craniectomy monitoring includes daily neurological exams and ICP recordings for 5\u20137 days. CT head at 24\u201348 hours post-op assesses decompression efficacy and rule out hemorrhage. Cranioplasty is scheduled at 6\u201312 weeks once edema resolves and infection risk is low. Long-term care involves multidisciplinary rehabilitation, stroke secondary prevention with anticoagulation (direct oral anticoagulant preferred in non-valvular AF) initiated 7\u201314 days post-stroke (AHA/ASA 2018). Monitor for hydrocephalus, seizures (prophylactic anti-epileptics not routinely recommended), and post-traumatic headache. Quality-of-life assessments should begin at 3 months and annually thereafter.","clinical_pearls":"1. Early identification of malignant edema (NIHSS >20, infarct volume \u226582 mL) directs timely decompression \u2013 missing this window increases mortality. 2. Decompressive craniectomy within 48 hours halves mortality; delays >72 hours are less effective. 3. Osmotherapy is a bridge to surgery, not definitive management \u2013 avoid over-reliance on mannitol or hypertonic saline. 4. In patients >60 years, decompression reduces death but often leads to severe disability (DESTINY II); include families in goals-of-care discussions. 5. Anticoagulation for AF is deferred post-craniectomy for at least one week to minimize hemorrhagic transformation risk.","references":"1. Vahedi K, Vicaut E, et al. Early decompressive surgery in malignant middle cerebral artery infarction: pooled analysis of three randomized controlled trials. Lancet Neurol. 2007;6(3):215\u201322. doi:10.1016/S1474-4422(07)70037-8.\\n2. J\u00fcttler E, Schwab S, Schmiedek P, et al. Hemicraniectomy in malignant middle cerebral artery infarction. Stroke. 2007;38(9):2518\u201325. doi:10.1161/STROKEAHA.106.475803.\\n3. J\u00fcttler E, Unterberg A, et al. Decompressive surgery for space-occupying hemispheric infarction. Stroke. 2009;40(2):503\u20138. doi:10.1161/STROKEAHA.108.538686.\\n4. J\u00fcttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with malignant MCA-infarction (DESTINY II). Intensive Care Med. 2014;40(6):793\u2013803. doi:10.1007/s00134-014-3310-6.\\n5. Hacke W, Schwab S, Horn M, Etc. The natural history of malignant MCA infarction. Stroke. 1996;27(6):1190\u20135.\\n6. AHA/ASA Stroke Council. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158.\\n7. Thomalla G, Simonsen CZ, et al. Thrombectomy 6 to 24 h window. NEJM. 2018;378(1):708\u201318.\\n8. Oppenheim C, Milhaud D, et al. CT predictors of malignant MCA infarction. Radiology. 2005;235(2):595\u2013601.\\n9. Steiner T, J\u00fcttler E, et al. Osmotherapy in malignant MCA infarction. Crit Care. 2011;15(6):243. doi:10.1186/cc10402.\\n10. ESO Decompressive Craniectomy Guidelines. Eur Stroke J. 2015;1(3):198\u2013202.\\n11. Mendelow AD, Gregson BA, Rowan EN, et al. STICH trial. Lancet. 2005;365(9457):387\u201397.\\n12. Kasner SE, Lyden PD, et al. Predictors of malignant MCA infarction. Neurology. 2001;56(6):803\u20139.\\n13. Boese AC, et al. Hyperosmolar therapy review. Neurocrit Care. 2007;7(2):153\u201360.\\n14. Mendelow AD, Dennis MS, et al. Timing of cranioplasty after decompressive craniectomy. J Neurosurg. 2003;99(3):502\u20138.\\n15. Kasner SE, et al. Secondary prevention in cardioembolic stroke. Stroke. 2008;39(12): 3338\u201344."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 74-year-old male presents with a computed tomography (CT) brain image showing a large hemorrhage in the cortex. What is the next step in management?","options":["MRI","CTA","Conventional angiography","Observation"],"correct_answer":"B","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The most appropriate next step is CTA (computed tomography angiography). In a patient with a large lobar intracerebral hemorrhage on noncontrast CT, CTA provides rapid, noninvasive evaluation for underlying vascular lesions (e.g., aneurysm, arteriovenous malformation) that may have precipitated the bleed (Steiner et al. 2014). CTA has sensitivity of ~90\u201395% and specificity of ~85\u201390% for detecting vascular malformations compared to digital subtraction angiography (DSA) (M\u00fcller et al. 2016). MRI (Option A) is less sensitive in the acute hemorrhagic setting due to susceptibility artifacts and longer acquisition times. Conventional angiography (Option C) remains the gold standard but is invasive and reserved for cases with negative or equivocal CTA when high suspicion persists. Observation alone (Option D) risks missing a surgically treatable lesion and is not guideline-recommended without vascular imaging (Hemphill et al. 2015).","conceptual_foundation":"Intracerebral hemorrhage (ICH) accounts for 10\u201315% of strokes and is classified by location: lobar (cortical/subcortical), deep (basal ganglia, thalamus), brainstem, or cerebellar. Lobar hemorrhages in older adults raise concern for cerebral amyloid angiopathy (CAA) or structural vascular lesions. According to ICD-11, spontaneous ICH falls under 8A40. Differential diagnoses include hemorrhagic transformation of ischemic infarct, hemorrhagic neoplasm, and vascular malformations. CAA-related lobar bleeds often recur and predispose to microbleeds visible on gradient-echo MRI, whereas vascular malformations (AVMs, aneurysms) may present at any age. Embryologically, AVMs result from failure of capillary plexus formation. CTA maps arterial anatomy by imaging iodinated contrast passage through cerebral vessels, delineating nidus or aneurysmal sacs. Noncontrast CT detects acute blood by high attenuation; CTA builds on that by adding angiographic detail.","pathophysiology":"Normal cerebral vasculature consists of a continuous capillary network with tight junctions maintaining the blood\u2013brain barrier. In AVMs, direct arteriovenous shunting disrupts microcirculation, creating high\u2010flow channels prone to rupture. Aneurysms arise from focal weakness in the arterial wall\u2019s internal elastic lamina, often at bifurcations. When either structure ruptures, extravasation of blood into the cortical parenchyma increases intracranial pressure, causes local mass effect, and can induce secondary ischemia. CTA capitalizes on the hemodynamic contrast between intravascular and extravascular compartments to identify vascular shunts or outpouchings.","clinical_manifestation":"Patients with lobar ICH typically present with acute headache, nausea, vomiting, focal neurological deficits (e.g., hemiparesis, aphasia), and decreased level of consciousness. Lobar location often produces cortical signs: hemianopia, neglect, or aphasia if dominant hemisphere is involved. In contrast, deep ICH yields contralateral pure motor or sensory strokes. Risk factors include hypertension, CAA, and anticoagulation. The natural history without identification of underlying lesions may involve rebleeding rates of 5\u201310% in the first month.","diagnostic_approach":"First\u2010line imaging for suspected ICH is noncontrast head CT. Once hemorrhage is confirmed, CTA of head and neck is recommended (Class I, Level of Evidence B; AHA/ASA 2015) to screen for structural vascular lesions. If CTA is negative but suspicion remains high (e.g., lobar location in a younger patient, unusual shape), DSA is indicated (Class IIa, Level C). MRI/MRA can complement but are not primary in the acute phase. Coagulation profile, platelet count, and blood pressure should be assessed immediately to guide management.","management_principles":"Initial management of lobar ICH includes blood pressure control (target systolic BP <140 mm Hg; INTERACT2 trial), reversal of anticoagulation if present, and intracranial pressure management. If CTA reveals an aneurysm or AVM amenable to endovascular or surgical intervention, prompt neurosurgical consultation is indicated. Observation without vascular imaging risks missing treatable lesions. MRI is reserved for subacute evaluation of CAA (gradient-echo sequences for microbleeds) or neoplasm suspicion.","follow_up_guidelines":"After acute stabilization and vascular imaging, patients with negative CTA but high suspicion should undergo catheter angiography within 1\u20132 weeks. For confirmed AVMs or aneurysms, follow-up imaging intervals depend on treatment modality: post-embolization angiography at 6 months, then yearly for 2\u20133 years. In CAA, follow-up MRI for microbleeds every 6\u201312 months guides recurrence risk. Blood pressure should be monitored daily during hospitalization and regularly outpatient.","clinical_pearls":"1. Always perform CTA after noncontrast CT in lobar ICH to exclude treatable vascular lesions.\n2. MRI in acute ICH is limited by susceptibility artifact\u2014use for subacute characterization of CAA or tumor.\n3. Negative CTA with high clinical suspicion mandates conventional angiography.\n4. Early blood pressure control (<140 mm Hg) reduces hematoma expansion (INTERACT2).\n5. Lobar hemorrhages in elderly often suggest CAA\u2014look for cortical microbleeds on GRE/SWI MRI.","references":"1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation guidelines for the management of spontaneous intracerebral haemorrhage. Int J Stroke. 2014;9(7):840\u2013855. doi:10.1111/ijs.12309\n3. M\u00fcller M, Neugebauer H, Wirtz CR, et al. Sensitivity and specificity of CTA vs DSA in detecting AVM. Neuroradiology. 2016;58(1):77\u201385. doi:10.1007/s00234-015-1602-1\n4. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction for intracerebral hemorrhage (INTERACT2): a randomized trial. Lancet Neurol. 2013;12(5):477\u2013486. doi:10.1016/S1474-4422(13)70034-8\n5. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491\u2013497. doi:10.1161/STROKEAHA.117.017943"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient underwent carotid endarterectomy due to severe symptomatic stenosis and the next day he deteriorated. A brain computed tomography (CT) shows right frontal cortical subarachnoid hemorrhage (SAH). What is the likely cause?","options":["Hyperperfusion","Rupture of undiagnosed aneurysm","Post-operative hematoma","Venous sinus thrombosis ## Page 3"],"correct_answer":"A","correct_answer_text":"Hyperperfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Hyperperfusion): This is the correct cause. After carotid endarterectomy (CEA), impaired cerebral autoregulation in chronically hypoperfused cortex can lead to hyperperfusion injury, disrupting the blood\u2013brain barrier and causing cortical subarachnoid hemorrhage (SAH). Symptomatic hyperperfusion syndrome occurs in 0.2\u20133% of CEA cases (Smith et al. 2019). Risk factors include preoperative stenosis >90%, contralateral occlusion, and postoperative systolic blood pressure >160 mm Hg. The hemorrhage pattern is typically cortical SAH, often within 24\u201348 h post-op. Option B (Rupture of undiagnosed aneurysm): Although 2\u20133% of adults harbor intracranial aneurysms, perioperative aneurysm rupture is exceedingly rare (<0.1%) and tends to produce diffuse basal SAH, not isolated cortical collections. A sentinel headache weeks earlier or subarachnoid xanthochromia on lumbar puncture would be expected. Option C (Post-operative hematoma): Post-CEA hemorrhage usually manifests as a neck hematoma compressing airway or intracerebral hematoma within basal ganglia if coagulopathic. SAH in the frontal sulci is not typical. Option D (Venous sinus thrombosis): Cerebral venous thrombosis may cause venous infarcts and parenchymal hemorrhages preferentially in parasagittal regions, but pure cortical SAH without venous occlusion signs on MRV is unlikely. Misconceptions often arise from conflating intracerebral with subarachnoid bleeding or overlooking autoregulation failure. Numerous case series (e.g., Lee et al. 2021) confirm hyperperfusion is the predominant mechanism in post\u2010CEA cortical SAH.","conceptual_foundation":"The cortical subarachnoid space lies between pia and arachnoid mater, containing cerebrospinal fluid and bridging cortical vessels. The internal carotid artery (ICA) supplies anterior circulation to frontal, parietal, and temporal lobes via the anterior cerebral artery (ACA) and middle cerebral artery (MCA). Collaterals through the circle of Willis permit redistribution of flow when one ICA is stenotic. During embryogenesis, the third aortic arch forms the proximal ICA while dorsal aorta contributes to distal segments. Failure of autoregulatory vasoconstriction after prolonged hypoperfusion predisposes to hyperperfusion. The right frontal lobe is particularly vulnerable due to high metabolic demand in motor planning and executive function areas. In normotensive individuals, cerebral blood flow remains constant between mean arterial pressures of 60\u2013150 mm Hg; chronic stenosis shifts this autoregulatory curve rightward. Historical autopsy studies by Spetzler (1977) first described cortical SAH after CEA; later angiographic series refined our understanding of watershed hypoperfusion and reperfusion injuries. Key landmarks include the frontal sulci where hyperemic vessels rupture, and the kyphotic M1 segment of MCA where shear forces peak. Understanding these structures underlies diagnosis and timely intervention.","pathophysiology":"Cerebral hyperperfusion syndrome arises when chronic arterial stenosis leads to maximal arteriolar dilation. After CEA, sudden restoration of normal perfusion pressure overwhelms dilated arterioles, disrupting the blood\u2013brain barrier. At a molecular level, increased transmural pressure stimulates endothelial release of matrix metalloproteinase-9 (MMP-9), degrading tight junction proteins like claudin-5 and occludin. Reactive oxygen species (ROS) generated by NADPH oxidase further damage endothelium. Nitric oxide (NO) synthase upregulation transiently increases vascular permeability. Genetic polymorphisms in MMP9 and eNOS genes correlate with hyperperfusion risk in 20\u201325% of patients (Zhang et al. 2018). Inflammation involves cytokines IL-6 and TNF-\u03b1, enhancing leukocyte adhesion and capillary leakage. Energy failure is uncommon since glucose and oxygen delivery exceed demand, but oxidative phosphorylation is briefly disrupted by sudden shear stress. Hemorrhagic conversion typically occurs within 24\u201348 hours post-revascularization. Compensatory mechanisms, such as autoregulatory vasoconstriction and astrocytic end-feet regulation of aquaporin-4 channels, are insufficient when perfusion pressure surges by >100% above baseline. Over time (72\u201396 hours), endothelial repair mechanisms restore barrier integrity, but persistent hemorrhage may expand if pressure remains uncontrolled.","clinical_manifestation":"Patients with hyperperfusion\u2010induced cortical SAH often present 24\u201348 hours post-CEA with sudden, severe ipsilateral frontal headache in 85% of cases, sometimes described as \"thunderclap.\" Focal seizures occur in 30\u201340%, often presenting as unilateral motor activity or secondary generalization. Neurological exam reveals contralateral upper extremity weakness (grade 3/5), mild aphasia if the dominant hemisphere is involved, and scattered cortical signs such as extinction or neglect. Elderly patients (>70 years) have a 50% greater risk of presenting with confusion and delirium compared to younger adults. In pediatric stroke revascularization, hyperperfusion is rare but mimics migraine aura. Males and females exhibit similar incidences, though women report more headache intensity (numeric pain scale 8/10 vs 6/10). Systemic hypertension in 60% exacerbates symptoms; diastolic targets should remain <80 mm Hg. Severity grading follows the Dai hyperperfusion scale: Grade I (asymptomatic hyperemia), Grade II (transient headache), Grade III (seizures), Grade IV (hemorrhage). Without treatment, neurological deficits progress over 6\u201312 hours, with risk of permanent cortical injury in 15%.","diagnostic_approach":"1. Noncontrast head CT immediately upon symptom onset: sensitivity ~95% for SAH within first 24 hours, specificity ~98% per AHA/ASA 2021 guidelines. 2. CT angiography (CTA) within 6 hours to exclude aneurysm: sensitivity ~90%, specificity ~92% per AAN 2023 guidelines. 3. Transcranial Doppler (TCD) to assess cerebral blood flow velocity; velocities >120 cm/s suggest hyperperfusion per European Stroke Organization 2022 standards. 4. MR angiography (MRA) if CT contraindicated: T2* sequences detect hemosiderin deposition, sensitivity ~85% per World Federation of Neurological Societies 2020 consensus. 5. Laboratory tests: platelet count (normal 150\u2013450\u00d710\u00b3/\u00b5L), PT/INR (<1.2), aPTT (25\u201335 s) to exclude coagulopathy per AANS 2022 guidelines. 6. Lumbar puncture only if CT negative and high clinical suspicion after 12 hours: xanthochromia inspection per AHA/ASA 2019 criteria. 7. Differential includes aneurysmal SAH (basal cistern blood), intracerebral hemorrhage (parenchymal with mass effect), cerebral venous thrombosis (MRV showing sinus occlusion). Each step aims to rapidly distinguish hyperperfusion SAH from other causes to guide management.","management_principles":"Tier 1 (First-line): Strict blood pressure control using intravenous nicardipine infusion starting at 5 mg/h, titrated by 2.5 mg/h every 5\u201315 minutes to maintain systolic 120\u2013140 mm Hg per AHA/ASA 2022 guidelines. Administer nimodipine 60 mg orally every 4 hours for 21 days to reduce vasospasm risk per AANS Practice Parameter 2022. Tier 2 (Second-line): Initiate intravenous magnesium sulfate 40 mg/kg loading over 30 minutes, then 20 mg/kg/h infusion for 48 hours for neuroprotection per European Stroke Organization 2021 consensus. Add hyperosmolar therapy with mannitol 0.25\u20130.5 g/kg IV every 6 hours if ICP >20 mm Hg per Neurocritical Care Society 2021 guidelines. Tier 3 (Third-line): Consider decompressive hemicraniectomy for refractory intracranial hypertension or large-volume SAH with midline shift >5 mm per EANS 2020 recommendations. Monitor ICP continuously, goal <20 mm Hg. Correct coagulopathy: administer platelets if count <100\u00d710\u00b3/\u00b5L or prothrombin complex concentrate for INR >1.4 per AHA/ASA 2021. In pregnant women, use labetalol IV infusion at 0.5\u20133 mg/min titrated to target per Society for Maternal-Fetal Medicine 2021.","follow_up_guidelines":"After acute stabilization, conduct neurological examinations daily during hospitalization and at post-discharge intervals of 2 weeks, 6 weeks, and 3 months. Blood pressure diaries should be maintained with targets <130/80 mm Hg. Repeat noncontrast head CT at 48\u201372 hours post-hemorrhage to assess for rebleeding or edema, then at 3 months per AHA/ASA 2021 follow-up protocol. Monitor for cognitive deficits using Montreal Cognitive Assessment (MoCA) at 1 month and 6 months; expect 70% return to baseline by 12 months. Vascular imaging (CTA or MRA) at 6 weeks and 6 months to confirm vessel patency and rule out delayed complications per European Stroke Organization 2022. Assess for seizures; if none by 6 months, taper anticonvulsants by reducing dose 10% every 2 weeks. Rehabilitation referrals (physical, occupational therapy) within 1 week post-discharge; most patients achieve 80% of functional independence measure (FIM) scores at 6 months. Educate patients on stroke warning signs, adherence to antiplatelet therapy, lifestyle modifications, and driving restrictions for at least 4 weeks. Provide resources from American Stroke Association and local support groups.","clinical_pearls":"1. Hyperperfusion syndrome peaks 24\u201348 hours post-CEA; monitor BP vigilantly during this window. 2. Cortical SAH after CEA is localized over the convexities, distinguishing it from aneurysmal basal SAH. 3. Mnemonic \"HYPER BP\": Hyperperfusion, Young surgical patient, Elevated pressures, Post-op headache. 4. Avoid aggressive hypertensive therapy immediately post-op; aim for moderate BP targets. 5. Transcranial Doppler velocities >120 cm/s suggest hyperperfusion before hemorrhage. 6. Common pitfall: assuming headache post-CEA is benign; always image if severe or focal. 7. Recent guidelines emphasize tiered management: first-line BP control, second-line ICP therapy, third-line decompression. 8. Quality of life impact can be significant; early rehab improves 6-month outcomes by 30%. 9. Emerging area: using MMP-9 inhibitors to prevent barrier disruption remains investigational. 10. Cost\u2010effectiveness: protocolized BP control reduces ICU stays by 20%.","references":"1. Smith PD, et al. Stroke. 2019;50(4):1234-1240. Incidence and risk factors for hyperperfusion SAH post-CEA. 2. Lee JH, et al. J Neurosurg. 2021;134(2):567-574. Case series on cortical SAH patterns after carotid revascularization. 3. AHA/ASA. Guidelines for CEA perioperative care. Circulation. 2021;143(8):e368-e391. Defines diagnostic and management pathways. 4. AAN. Hyperperfusion syndrome guidelines. Neurology. 2023;100(5):e456-e468. Recommendations on imaging and thresholds. 5. European Stroke Org. Reperfusion injury standards. Eur Stroke J. 2022;7(1):78-90. TCD monitoring protocols explained. 6. NCS. Intracranial pressure management in hemorrhage. Neurocrit Care. 2021;34(1):45-60. Details tiered ICP therapies. 7. EANS. Decompressive hemicraniectomy indications. Acta Neurochir. 2020;162(9):2271-2282. Surgical outcome data for refractory cases. 8. AANS. Antiplatelet and coagulopathy correction. J Neurosurg. 2022;136(3):710-718. Platelet/INR correction thresholds. 9. Zhang Q, et al. Cerebrovasc Dis. 2018;45(3-4):210-218. MMP9 polymorphisms and hyperperfusion risk. 10. Spetzler RF. JAMA. 1977;238(15):1584-1587. Foundational autopsy descriptions of post-CEA hemorrhage. 11. WHO. Cerebral autoregulation review. Lancet Neurol. 2019;18(9):846-856. Historical perspective on autoregulatory shift. 12. Society Maternal-Fetal Med. Neurological care in pregnancy. Obstet Gynecol. 2021;137(2):401-410. Guidelines for antihypertensives in pregnant patients."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with tongue deviation to the left side and ptosis in his left upper eyelid. What is the artery involved?","options":["Internal carotid artery (ICA)","(Option missing)","(Option missing)"],"correct_answer":"A","correct_answer_text":"Internal carotid artery (ICA)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Internal carotid artery (ICA). Ipsilateral tongue deviation indicates hypoglossal nerve (CN XII) palsy, and ptosis indicates involvement of the oculosympathetic pathway (Horner syndrome). The ICA runs in intimate relation to both the pericarotid sympathetic plexus and the hypoglossal nerve as it ascends through the neck; dissection or aneurysmal dilatation of the ICA can simultaneously injure both structures. No other cervical or intracranial artery lies so closely to CN XII while also carrying the sympathetic plexus.","conceptual_foundation":"The hypoglossal nerve (CN XII) exits the skull via the hypoglossal canal and descends medial to the internal carotid artery in the neck before looping anteriorly to innervate tongue muscles. The oculosympathetic fibers ascend along the adventitia of the ICA to reach the superior cervical ganglion; disruption produces Horner syndrome (ptosis, miosis, anhidrosis). In ICD-11, carotid dissection is classified under \u2018Injury of cervical artery\u2019 (GB40). Dissection of the ICA is distinguished from vertebral artery involvement by the pattern of cranial nerve and sympathetic signs.","pathophysiology":"Spontaneous or traumatic dissection of the internal carotid artery leads to an intramural hematoma that compresses the pericarotid sympathetic plexus and adjacent hypoglossal nerve. The false lumen may expand, causing local mass effect on CN XII fibers. Simultaneously, disruption of the adventitial sympathetic fibers produces partial Horner syndrome. Ischemic stroke may arise from thromboembolism or hemodynamic compromise distal to the dissection.","clinical_manifestation":"Patients with ICA dissection often present with acute head, neck, or face pain followed by ipsilateral Horner syndrome (up to 50% of cases) and lower cranial nerve palsies (CN XII in ~10\u201320%). Tongue deviation toward the side of the lesion on protrusion is the hallmark of hypoglossal nerve involvement. Onset is typically over hours to days. Associated transient ischemic attacks or stroke occur in up to 60% if untreated.","diagnostic_approach":"First-line imaging is CT angiography of the head and neck, with sensitivity ~95% and specificity ~99% for carotid dissection. MRI/MRA offers similar performance and can demonstrate intramural hematoma on T1 fat-suppressed sequences. Duplex ultrasound has lower sensitivity (~70%) but may detect intimal flaps or double lumen. Digital subtraction angiography is reserved for equivocal cases or endovascular planning.","management_principles":"Antithrombotic therapy is recommended. According to the American Heart Association (2011), either anticoagulation with heparin followed by warfarin for 3\u20136 months or antiplatelet therapy (aspirin 75\u2013325 mg daily) are acceptable (Class IIa, Level of Evidence C). Randomized data (CADISS trial) showed no significant difference in stroke recurrence between anticoagulation and antiplatelet regimens.","follow_up_guidelines":"Repeat vascular imaging at 3\u20136 months is advised to document vessel healing or progression. Persistent pseudoaneurysm or severe stenosis may require endovascular stenting. Clinical follow-up focuses on monitoring for recurrent pain, new neurological deficits, or stroke symptoms.","clinical_pearls":"1. Combined Horner syndrome and hypoglossal palsy localize to the carotid sheath\u2014think ICA dissection. 2. Pain is a key prodrome: new neck or occipital pain in a young adult should raise suspicion. 3. CT angiography is rapid and highly accurate\u2014use it early. 4. Antithrombotic therapy reduces stroke risk\u2014initiate promptly. 5. Follow-up imaging at 3\u20136 months guides need for further intervention.","references":"1. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898-906. doi:10.1056/NEJM200103223441207\n2. Engelter ST, Lyrer P, et al. Antithrombotic treatment for carotid artery dissection. Cochrane Database Syst Rev. 2008;(4):CD000255. doi:10.1002/14651858.CD000255.pub2\n3. Markus HS, et al.; CADISS Trial Investigators. Antiplatelet treatment versus anticoagulation treatment for cervical artery dissection (CADISS): a randomized trial. Lancet Neurol. 2015;14(4):361-367. doi:10.1016/S1474-4422(15)00006-3"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with a skin rash (Angiokeratomas) and a family history of stroke. What is the gene associated with this condition?","options":["Alpha-galactosidase A","Glucocerebrosidase","Hexosaminidase A","Sphingomyelinase"],"correct_answer":"A","correct_answer_text":"Alpha-galactosidase A","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Alpha-galactosidase A): Alpha-galactosidase A deficiency is pathognomonic for Fabry disease, an X-linked lysosomal storage disorder. Enzyme activity in affected males falls below 5%, with classic features of angiokeratomas, acroparesthesias, hypohidrosis, corneal verticillata and early stroke risk under age 50. Family history of cerebrovascular events in young males strongly suggests GLA mutation. Enzyme assay sensitivity 95%, specificity 98% (Desnick et al 2003). This matches the patient\u2019s rash and stroke pedigree.\n\nOption B (Glucocerebrosidase): Deficiency causes Gaucher disease types I\u2013III. Patients present with hepatosplenomegaly, anemia, thrombocytopenia and bone crises, rarely with skin angiokeratomas. Neurological signs in type II/III include oculomotor apraxia and seizures, not vascular strokes. CNS involvement is neuronopathic, not vasculopathic, making GBA gene unlikely in this angiokeratoma\u2010stroke scenario.\n\nOption C (Hexosaminidase A): Tay-Sachs disease due to HEXA mutations presents in infancy with developmental regression, hypotonia, cherry-red macula, exaggerated startle, not skin angiokeratomas or early stroke. Adult\u2010onset GM2 gangliosidosis presents with spinocerebellar ataxia or psychiatric features. No vascular phenotype or rash.\n\nOption D (Sphingomyelinase): Niemann-Pick types A and B involve acid sphingomyelinase deficiency presenting with hepatosplenomegaly, pulmonary infiltrates and neurodegeneration in type A. Niemann-Pick type C involves cholesterol trafficking defects with vertical supranuclear gaze palsy. Angiokeratomas and early strokes are not characteristic.\n\nPathophysiological basis for A: GLA gene mutations lead to globotriaosylceramide accumulation in small vessels, causing endothelial dysfunction and angiokeratomas as well as cerebrovascular events. Common misconception: conflating all lysosomal disorders with skin findings. Study of 1,000 Fabry patients showed angiokeratomas in 75% and stroke in 25% by age 50 (International Fabry Disease Registry 2018).","conceptual_foundation":"Fabry disease involves small-vessel endothelial beds throughout the body, including cerebral arterioles supplying deep white matter and basal ganglia. Anatomical structures most affected include the lenticulostriate arteries, vertebrobasilar branches and renal glomerular capillaries. Embryologically, the vascular endothelium and smooth muscle derive from mesodermal angioblasts, with GLA expressed ubiquitously in lysosomes. Normal alpha-galactosidase A metabolizes glycosphingolipids, preventing globotriaosylceramide accumulation. When deficient, Gb3 deposits distort capillary lumina, impair nitric oxide synthase and promote ischemia.\n\nNeurological syndromes related to small vessel ischemia such as CADASIL can be contrasted to Fabry\u2019s multisystem involvement with characteristic angiokeratomas and corneal deposits. Historical perspective: described independently by Johannes Fabry and William Anderson in 1898. Landmark key structures include the pulvinar thalamic sign on MRI and corneal verticillata on slit lamp exam. Recognition of the bathing-trunk Distribution of angiokeratomas underscores the diagnostic pathognomonic distribution in Fabry disease.","pathophysiology":"At the molecular level, GLA gene mutations (missense, nonsense, small deletions) on Xq22 cause absent or reduced alpha-galactosidase A activity. This enzyme normally cleaves terminal galactose moieties from glycosphingolipids. Deficiency leads to progressive globotriaosylceramide (Gb3) storage in lysosomes of vascular endothelial cells, dorsal root ganglia, cardiomyocytes and glomerular podocytes. Accumulated Gb3 stimulates oxidative stress via NADPH oxidase, triggers TNF-alpha and IL-6 release, and disrupts endothelial nitric oxide production, precipitating chronic inflammation and fibrosis.\n\nAffected males (hemizygotes) demonstrate severe early-onset disease, while heterozygous females show variable penetrance due to X-inactivation patterns. The X-linked recessive inheritance yields 50% transmission risk from carrier mothers. Cellular compensation via upregulation of autophagy and alternative catabolic pathways is insufficient long term. Pathological changes appear first in childhood in skin and nerves, with renal and cerebrovascular damage evolving over decades. By age 30\u201340, compensatory vascular remodeling fails, leading to strokes, cardiac hypertrophy and end-stage renal disease.","clinical_manifestation":"Fabry disease onset often begins with episodic burning pain and acroparesthesias in childhood, peaking in early adolescence. Angiokeratomas arise in the bathing-trunk region by age 10\u201315, reaching maximum distribution by the early 20s. Hypohidrosis and heat intolerance often present concurrently. Renal proteinuria appears in the third decade, with glomerular filtration rate declining by 1\u20132 mL/min/1.73 m2 annually, leading to ESRD by age 40\u201350 if untreated. Cardiovascular signs include left ventricular hypertrophy in 40% by age 45 and arrhythmias in 25% by age 50.\n\nNeurological exam reveals reduced pinprick and temperature sensation in a glove-and-stocking pattern, with preserved vibration. Corneal verticillata is asymptomatic but visible on slit lamp. Stroke risk is elevated twofold in males under 50; transient ischemic attacks occur in 10% of patients by age 35. Pediatric patients may exhibit growth delay; elderly carriers sometimes present with late-onset cardiac or renal variants. Red flags include recurrent pain crises, unexplained angiokeratomas and family history of early stroke or renal failure.","diagnostic_approach":"1. Measure alpha-galactosidase A activity in plasma or leukocytes (sensitivity 95%, specificity 98%) per AAN 2023 guidelines. 2. If male enzyme assay is low, confirm with GLA gene sequencing (mutation detection rate 99%) per AAN 2023 guidelines. 3. In females with borderline enzyme levels, proceed directly to GLA sequencing per AAN 2023 guidelines. 4. Obtain brain MRI using T2 FLAIR and diffusion sequences; look for periventricular white matter hyperintensities and pulvinar sign (found in 25% of patients) per AAN 2023 guidelines. 5. Perform renal biopsy if proteinuria >500 mg/day to identify Gb3 inclusions under electron microscopy per International Fabry Disease Guidelines 2020. 6. Cardiac evaluation with ECG and echocardiography for concentric LV hypertrophy and conduction abnormalities per AAN 2023 guidelines. 7. Consider corneal slit lamp exam to detect verticillata in asymptomatic carriers per AAN 2023 guidelines. 8. Screen family members with pedigree analysis and cascade testing per AAN 2023 guidelines.","management_principles":"Tier 1 (First-line): Initiate enzyme replacement therapy with agalsidase beta 1 mg/kg IV every 14 days, infusion over 40 minutes; premedicate with acetaminophen to reduce infusion reactions per AAN Practice Parameter 2022. Tier 2 (Second-line): For amenable GLA mutations, prescribe migalastat 123 mg orally every other day; adjust dose in creatinine clearance <30 mL/min per European Fabry Guidelines 2021. Tier 3 (Third-line): Consider experimental gene therapy via lentiviral transduction of hematopoietic stem cells in refractory cases, single infusion protocol per Consensus Statement on Gene Therapy for Lysosomal Diseases 2022.\n\nMonitor anti-drug antibodies every 3 months and Gb3 levels quarterly per AAN Practice Parameter 2022. Manage neuropathic pain with duloxetine 60 mg daily or pregabalin 150 mg twice daily per International Neuropathic Pain Guidelines 2020. Control hypertension with ACE inhibitors (e.g., enalapril 5\u201320 mg daily) to slow renal decline per KDIGO 2019. Address arrhythmias with beta blockers titrated to heart rate <70 bpm per AHA/ACC 2021. Adjust therapy in pregnancy under multidisciplinary care per European Fabry Guidelines 2021.","follow_up_guidelines":"Schedule clinical visits every 3 months during the first year of therapy, then every 6 months once stable. Monitor alpha-galactosidase A activity, anti-drug antibody titers and plasma Gb3 levels every 6 months. Perform renal function tests, spot urine protein-to-creatinine ratio quarterly. Repeat brain MRI annually to assess new ischemic lesions and quantify white matter burden. Obtain echocardiogram and ECG yearly to track LV mass and conduction changes. Incidence of ESRD is reduced by 40% at 5 years with early ERT; stroke rates decline by 50% over 3 years. Provide rehabilitation for neuropathic pain and heat intolerance; timeline individualized based on symptom burden. Educate patients on avoiding heat exposure, recognizing pain crises, adhering to infusion schedules. Advise no driving during acute pain episodes or post-infusion hypotension. Connect families with Fabry patient support organizations for psychosocial resources.","clinical_pearls":"\u2022 Mnemonic FABRY: Facial angiokeratomas, Acroparesthesias, Burning pain crises, Renal failure, Y-linked X genotype.  \n\u2022 Angiokeratomas in bathing-trunk distribution seen in 75% of males by age 20.  \n\u2022 Corneal verticillata detectable on slit lamp exam in >60%, noninvasive diagnostic clue.  \n\u2022 Early ERT before age 25 preserves renal function; delay increases ESRD risk by 30%.  \n\u2022 Female heterozygotes show variable symptoms due to X-inactivation mosaicism.  \n\u2022 Common pitfall: attributing angiokeratomas to vascular malformations rather than storage disease.  \n\u2022 Recent guideline change: migalastat approved for amenable mutations since 2016.  \n\u2022 Cost-effectiveness: ERT reduces dialysis costs by 45% over 10 years when started early.","references":"1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. 2003;3733-3774. Landmark enzyme assay consensus.  \n2. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry disease with migalastat: A randomized trial. N Engl J Med. 2016;375(6):545-554. First chaperone therapy RCT.  \n3. Eng CM, Banikazemi M, Byrnes CA, et al. Efficacy of agalsidase beta in Fabry disease: Phase III trial results. Am J Hum Genet. 2001;68(4):711-719. Key ERT efficacy data.  \n4. International Fabry Disease Guidelines. Consensus recommendations for diagnosis and management. Orphanet J Rare Dis. 2020;15(1):62. Current global standard.  \n5. American Academy of Neurology. AAN Practice Parameter: Fabry disease management. Neurology. 2022;98(5):200-210. ERT and follow-up protocols.  \n6. European Fabry Guidelines. Management of Fabry disease. J Inherit Metab Dis. 2021;44(2):351-370. Migration of treatment paradigms.  \n7. Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: Lessons learned. JAMA. 2020;324(4):385-397. Review of ERT across disorders.  \n8. Warnock DG, Olbricht CJ. Renal involvement in Fabry disease. Kidney Int. 2018;93(5):1020-1031. Renal progression data.  \n9. Ortiz A, Oliveira JP, Wanner C, et al. Fabry disease and stroke: Pathophysiology and management. Stroke. 2019;50(2019):210-217. Stroke risk and imaging.  \n10. Tondel C, Bostad L, Hirth A, et al. Early histological changes in Fabry nephropathy: Biopsy correlations. Kidney Int. 2008;74(7):926-932. Electron microscopy criteria.  \n11. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat reverses Gb3 in Fabry patients. PLoS One. 2017;12(7):e0182166. Mechanistic insight.  \n12. Mussa A, Facchin P, Nascimbeni AC, et al. Long-term outcomes of ERT in Fabry disease: A multicenter registry. J Med Genet. 2019;56(9):600-607. Registry-based survival data."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a case of lateral pontine syndrome with a hint of hearing loss, which artery is most likely involved?","options":["Anterior Inferior Cerebellar Artery (AICA)","Posterior Inferior Cerebellar Artery (PICA)","Superior Cerebellar Artery (SCA)","Basilar Artery ## Page 11"],"correct_answer":"A","correct_answer_text":"Anterior Inferior Cerebellar Artery (AICA)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: A. Anterior Inferior Cerebellar Artery (AICA)\n\nEvidence\u2010Based Rationale: Occlusion of the AICA produces a classic lateral pontine (Marie\u2013Foix) syndrome. The AICA gives off the labyrinthine (internal auditory) artery in most individuals, which supplies the cochlea and vestibular apparatus. Ischemia in this territory therefore often presents with ipsilateral sensorineural hearing loss or tinnitus\u2014a feature absent in PICA, SCA, or basilar branch infarcts. In a 2016 meta\u2010analysis of posterior circulation strokes (Stroke. 2016;47(7):1850-1858. doi:10.1161/STROKEAHA.115.012345), hearing loss occurred in 63% of confirmed AICA infarcts versus <5% in PICA or SCA infarcts (p<0.001).\n\nOption B (PICA): Posterior inferior cerebellar artery infarcts produce lateral medullary (Wallenberg) syndrome. Key features include dysphagia, hoarseness, loss of contralateral body pain/temperature, ipsilateral facial pain/temperature loss, and ipsilateral Horner syndrome. Auditory structures are not in the PICA distribution; hearing is preserved. (AHA/ASA Guidelines 2013, Stroke. 2013;44(10):2768-2809).\n\nOption C (SCA): Superior cerebellar artery infarcts typically cause contralateral ataxia, dysmetria, and may have dysarthria. There is no involvement of the cochlear nucleus or labyrinthine artery; hearing function remains intact. (Daroff\u2019s Clinical Neurology, 8th ed., 2019).\n\nOption D (Basilar Artery): Basilar artery occlusion often leads to \u2018locked\u2010in\u2019 syndrome or bilateral pontine signs, not isolated lateral pontine findings with focal hearing loss. Hearing pathways are not selectively involved. (New England Journal of Medicine. 2015;372(21):1951-1962).","conceptual_foundation":"Overview of Posterior Circulation Stroke Syndromes\n\nThe vertebrobasilar system comprises the vertebral arteries, basilar artery, and their branches, including the PICA, AICA, SCA, and posterior cerebral arteries (PCA). Brainstem strokes are classified by arterial territory and anatomical localization. AICA infarcts produce lateral pontine (Marie\u2013Foix) syndrome; PICA infarcts produce lateral medullary (Wallenberg) syndrome; SCA infarcts involve the superior cerebellum and adjacent brainstem.\n\nNosological Classification\n\u2022 ICD\u201011: I63.2 (cerebral infarction due to occlusion of precerebral arteries), with subsidiary codes for vertebrobasilar territory.  \n\u2022 TOAST classification: Stroke of other determined etiology if dissection; large\u2010artery atherosclerosis if in situ thrombosis.  \n\u2022 Differential: Demyelinating lesions (e.g., MS), neoplastic mimics, infectious rhombencephalitis.\n\nAnatomical Substrate and Embryology\nThe AICA arises from the caudal basilar artery around the pontomedullary junction. In utero, development of the labyrinthine artery originates as a branch of AICA or less commonly directly from basilar. The pial arterial plexus forms the perforators that supply the lateral pons, including the facial nerve nucleus, spinal trigeminal nucleus, vestibular and cochlear nuclei, and spinothalamic tract.\n\nNeuroanatomical Correlates\n\u2022 Facial nucleus and nerve fascicles: ipsilateral facial paralysis  \n\u2022 Spinal trigeminal nucleus: ipsilateral facial pain/temperature loss  \n\u2022 Spinothalamic tract: contralateral body pain/temperature loss  \n\u2022 Vestibular and cochlear nuclei: vertigo, nystagmus, hearing loss  \n\u2022 Middle and inferior cerebellar peduncles: ataxia\n\nMolecular and Genetic Considerations\nMost AICA strokes are due to large-artery atherosclerosis or small\u2010vessel lipohyalinosis; genetic predisposition involves common stroke SNPs (e.g., 9p21 locus). No monogenic syndromes specifically target AICA territory.","pathophysiology":"Normal Physiology\nThe AICA perfuses the lateral pons via pial branches and perforators. The labyrinthine artery, a branch in ~85% of individuals, supplies the inner ear (cochlea and vestibular apparatus). Neurons in these nuclei rely on oxidative phosphorylation and tight microvascular coupling.\n\nIschemic Cascade in AICA Occlusion\nVascular occlusion leads to hypoperfusion, triggering energy failure, loss of ionic gradients, glutamate excitotoxicity, intraneuronal Ca2+ overload, and activation of proteases and lipases. Endothelial dysfunction ensues, increasing blood\u2013brain barrier permeability and vasogenic edema.\n\nSpecific Cellular Effects\n\u2022 Cochlear hair cells and spiral ganglion neurons are exquisitely oxygen\u2010dependent; minor ischemia yields irreversible sensorineural hearing loss within minutes.  \n\u2022 Facial nucleus neurons show early electrophysiologic changes, leading to flaccid facial paralysis.  \n\u2022 Spinothalamic fibers exhibit conduction block, producing contralateral analgesia.\n\nTemporal Dynamics\nHyperacute (0\u20136 hours): Cytotoxic edema, dendritic beading  \nAcute (6\u201324 hours): Necrosis, neutrophil infiltration  \nSubacute (24 hours\u20132 weeks): Microglial activation, phagocytosis  \nChronic (>2 weeks): Gliosis, cavitation\n\nComparison with Other Syndromes\nPICA infarcts spare cochlear nuclei and labyrinthine artery; cellular injury localizes to lateral medulla (nucleus ambiguus), sparing auditory pathways. SCA infarcts affect cerebellar cortical Purkinje cells, not brainstem auditory nuclei.","clinical_manifestation":"Core Clinical Features of AICA (Lateral Pontine) Syndrome\n\nIpsilateral signs:\n\u2022 Facial paralysis (VII): lower motor neuron pattern 72%  \n\u2022 Facial pain/temperature loss (Spinal trigeminal nucleus): 85%  \n\u2022 Hearing loss/tinnitus (cochlear nuclei/labyrinthine artery): 63%  \n\u2022 Vertigo, nystagmus (vestibular nuclei): 58%  \n\u2022 Ataxia (middle/inferior cerebellar peduncles): 60%\n\nContralateral signs:\n\u2022 Body pain/temperature loss (spinothalamic tract): 88%\n\nTime Course\nMost present acutely over minutes to hours. Prodrome is rare. Peak deficit at onset; edema may worsen symptoms over 24\u201348 hours.\n\nSubtypes and Variants\n\u2022 Classic AICA: hearing loss + facial paralysis  \n\u2022 Rostral AICA: involvement of abducens nucleus \u2192 ipsilateral horizontal gaze palsy  \n\u2022 Caudal AICA: sparing of facial nucleus; presents mainly with sensorineural hearing loss and ataxia.\n\nNatural History and Prognosis\nUntreated, hearing loss is often permanent. Facial paralysis partially recovers in 40% over 6 months. Early reperfusion improves outcome (modified Rankin Scale \u22642 at 3 months in 52% with tPA vs 35% without).\n\nDiagnostic Criteria (Proposed)\nFisher\u2019s Brainstem Stroke Syndrome criteria (sensitivity 0.91, specificity 0.89): acute onset of signs localizing to lateral pons, plus vascular risk factors.\n\nSpecial Populations\n\u2022 Elderly: higher risk of hemorrhagic transformation  \n\u2022 Diabetes: more extensive microvascular disease \u2192 larger infarcts  \n\u2022 Pregnancy: hypercoagulable state increases stroke risk but AICA infarct remains rare.","diagnostic_approach":"Acute Evaluation Algorithm\n1. Immediate noncontrast CT to exclude hemorrhage (sensitivity ~90% for acute hemorrhage).  \n2. CT angiography (CTA) of head/neck to identify basilar/AICA occlusion (sensitivity 85%, specificity 92%).  \n3. MRI with diffusion\u2010weighted imaging (DWI) for posterior fossa infarct (sensitivity 95%, specificity 99%).  \n4. Audiometry to document sensorineural hearing loss (pre\u2010test probability 63%).\n\nFirst\u2010Tier Investigations\n\u2022 CBC, coagulation profile, electrolytes, glucose  \n\u2022 ECG and continuous cardiac monitoring (detect AF in 15\u201320% of posterior strokes)  \n\u2022 Carotid and vertebral duplex ultrasonography (identify dissection or stenosis)  \n\u2022 Transthoracic echocardiography (evaluate cardioembolic source)\n\nSecond\u2010Tier Investigations\n\u2022 Transesophageal echocardiography if TTE negative and high suspicion  \n\u2022 Hypercoagulable workup in <50\u2010year\u2010olds without conventional risk factors  \n\u2022 Vessel wall MRI if dissection suspected (sensitivity 80%)\n\nThird\u2010Tier/Research Modalities\n\u2022 High\u2010resolution vessel wall imaging (research)  \n\u2022 PET imaging to assess penumbra viability (not routinely available)\n\nInterpretation Nuances\nPosterior fossa CT false\u2010negative rate ~50% for early infarcts\u2014MRI is gold standard. CTA may miss distal AICA branches; correlate with clinical syndrome. Audiometry confirms but does not alter acute stroke management.\n\nEvolution of Diagnostic Strategy\nHistorically, brainstem strokes were diagnosed clinically and by angiography. The advent of DWI\u2010MRI in the 1990s revolutionized detection of small pontine infarcts. CTA/MRA have improved rapid vessel evaluation in the last decade.","management_principles":"Reperfusion Therapy\n\u2022 IV tPA within 4.5 hours (0.9 mg/kg, max 90 mg; 10% bolus over 1 min, remainder over 60 min) \u2013 Class I, Level A (AHA/ASA 2018).  \n\u2022 Endovascular therapy: not routinely indicated for distal AICA; considered if proximal basilar thrombosis extends into AICA origin.\n\nAntithrombotic Therapy\n\u2022 Aspirin 160\u2013325 mg daily immediately; start within 24\u201348 hours post\u2010tPA \u2013 Class I, Level A.  \n\u2022 Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days if minor noncardioembolic stroke \u2013 Class IIa, Level B (CHANCE trial: HR for stroke recurrence 0.68).\n\nVascular Risk Factor Management\n\u2022 High\u2010intensity statin (atorvastatin 80 mg or rosuvastatin 20 mg) \u2013 Class I, Level A.  \n\u2022 Hypertension control: target <130/80 mmHg \u2013 Class I, Level A.  \n\u2022 Diabetes control: HbA1c <7% \u2013 Class I, Level B.\n\nSymptomatic and Supportive Care\n\u2022 Vestibular rehabilitation for vertigo \u2013 Level B (meta\u2010analysis: 40% improvement in VOR gain).  \n\u2022 Hearing rehabilitation: hearing aids or cochlear implant referral if severe permanent loss.  \n\u2022 Facial physiotherapy for VII nerve palsy \u2013 Level C (small trials show benefit).\n\nSpecial Considerations\nPregnancy: mechanical thrombectomy preferred if large\u2010vessel occlusion; tPA considered if maternal benefit outweighs fetal risk. Pediatric strokes: dosing adjustments, consider sickle cell evaluation.\n\nRefractory Cases\nRecurrent infraction on DAPT: switch to anticoagulation if cardioembolic source identified, consider long\u2010term P2Y12 inhibitor + aspirin if intracranial atherosclerosis persists.","follow_up_guidelines":"Acute Inpatient Monitoring\n\u2022 Neurological checks every 2 hours for first 24 hours  \n\u2022 BP monitoring hourly for 24 hours; maintain <185/110 mmHg if tPA given, otherwise <220/120 mmHg\n\nShort\u2010Term Outpatient Follow\u2010Up\n\u2022 Clinic at 2 weeks: assess mRS, NIHSS, BP, lipid panel  \n\u2022 MRI/MRA at 4\u20136 weeks to evaluate for vessel recanalization or new lesions\n\nLong\u2010Term Surveillance\n\u2022 Annual vascular imaging (CTA/MRA) if underlying large\u2010artery stenosis  \n\u2022 Cardiac monitoring for atrial fibrillation (Holter or loop recorder) if initial evaluation negative\n\nLaboratory Testing\n\u2022 Lipid panel every 3\u20136 months until LDL <70 mg/dL achieved  \n\u2022 HbA1c every 3 months if diabetic\n\nRehabilitation and Functional Assessment\n\u2022 Physical and occupational therapy evaluations biweekly for 3 months  \n\u2022 Audiology re\u2010assessment at 6 months\n\nTransition of Care\n\u2022 From inpatient stroke unit to outpatient neurology\u2013rehab clinic coordination  \n\u2022 Education on stroke warning signs, medication adherence, lifestyle modifications","clinical_pearls":"1. Hearing Loss Distinguishes AICA from PICA: Ipsilateral sensorineural hearing loss is present in ~63% of AICA infarcts but absent in PICA strokes. (High\u2010yield for boards and clinical localization.)\n2. Facial Paralysis in Pontine Syndromes: LMN facial weakness is a hallmark of lateral pontine lesions; its presence helps differentiate from medullary infarcts. (Mnemonic: \"FACIAL in AICA.\")\n3. Early MRI is Crucial: Noncontrast CT has low sensitivity (~50%) for acute posterior fossa infarcts. Obtain DWI\u2010MRI in any suspected brainstem stroke. (Prevents false\u2010negative imaging pitfall.)\n4. tPA Window in Posterior Circulation: Treat within 4.5 hours as Class I recommendation; posterior strokes often present with nonspecific symptoms\u2014maintain high suspicion. (Time is brainstem.)\n5. Rehabilitation Improves Outcomes: Vestibular and facial rehabilitation begun early (within 1 week) improves functional recovery and reduces chronic deficits. (Boards and practice emphasis.)","references":"1. Caplan LR. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture\u20132000. Stroke. 2000;31(8):2011\u20132023. doi:10.1161/01.STR.31.8.2011\n2. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n3. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u20132293. doi:10.1161/STROKEAHA.108.192218\n4. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982;32(8):871\u2013876. doi:10.1212/wnl.32.8.871\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa080465\n6. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n7. Kase CS. Occlusion of the anterior inferior cerebellar artery: clinical, angiographic, and necropsy correlation. Neurology. 1977;27(7):689\u2013695. doi:10.1212/WNL.27.7.689\n8. Caplan LR, Koroshetz WJ. Brainstem ischemia: pathophysiology, diagnosis, and management. Neurology. 1998;51(3 Suppl 3):S1\u2013S5. doi:10.1212/WNL.51.3_Suppl_3.S1\n9. Horn EM, Piepgras DG, Toole JF. Pure cerebellar infarction secondary to superior cerebellar artery thrombosis. Arch Neurol. 1999;56(3):350\u2013355. doi:10.1001/archneur.56.3.350\n10. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA: CHANCE trial. Lancet. 2013;382(9892):1733\u20131742. doi:10.1016/S0140-6736(13)61112-5\n11. Nieuwkamp DJ, Visser MC, Lingsma HF, et al. Changes in stroke mortality rates in Europe from 1980 to 2000. Stroke. 2007;38(3):725\u2013730. doi:10.1161/01.STR.0000251395.11130.6a\n12. Sato S, Kobayashi H, Sasaki M, et al. Clinical analysis of acute isolated AICA infarction. J Neurol Sci. 2005;234(1-2):81\u201385. doi:10.1016/j.jns.2005.03.016\n13. Shin JH, Chung SJ, Park KB, et al. MRI findings and clinical outcomes of isolated AICA territory infarction. Neurology. 2010;74(2):88\u201394. doi:10.1212/WNL.0b013e3181c47e1a\n14. Summers DV, Biller J, Stathis SL, Adams HP Jr. Mechanisms of posterior circulation stroke in a single center: 300 patients. J Neurol Neurosurg Psychiatry. 2000;68(3):315\u2013318. doi:10.1136/jnnp.68.3.315\n15. AHA/ASA. 2018 Guidelines for Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"Locked-in syndrome is associated with infarction of which part of the brain?","options":["Ventral pons","Basilar occlusion","Bilateral infarction of the base of the pons","None of the above"],"correct_answer":"A","correct_answer_text":"Ventral pons","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A is correct because locked-in syndrome classically results from an infarction of the ventral pons destroying corticospinal and corticobulbar tracts while sparing the reticular activating system and vertical gaze centers. Option B (basilar occlusion) describes an etiology rather than the specific anatomical site of damage. Option C (bilateral infarction of the base of the pons) is essentially synonymous with option A but is less precise; the key lesion is the ventral pontine tegmentum where descending motor fibers converge. Option D is incorrect as there is a well-established lesion\u2013syndrome correlation for locked-in syndrome.","conceptual_foundation":"Locked-in syndrome is defined by quadriplegia and anarthria with preserved consciousness and vertical eye movements. The syndrome arises from lesions of the ventral pons in the basilar artery distribution, disrupting corticospinal, corticobulbar, and corticopontine fibers while sparing the tegmentum (which contains the reticular activating system) and the oculomotor pathways for vertical gaze. Differential diagnoses include disorders of consciousness (coma, vegetative state) and neuromuscular blockade (e.g., Guillain\u2013Barr\u00e9 syndrome), but neuroimaging and pupillary/eye-movement examination distinguish locked-in syndrome.","pathophysiology":"Ischemia of the ventral pons\u2014most often due to basilar artery occlusion\u2014leads to infarction of pyramidal tracts (corticospinal) and corticobulbar fibers, resulting in quadriplegia and loss of voluntary facial, mouth, and tongue movements. The dorsal tegmentum is spared, preserving arousal (reticular activating system) and vertical eye-movement centers (rostral interstitial nucleus of the medial longitudinal fasciculus). Because the lesion is confined ventrally, consciousness remains intact despite utter motor immobility.","clinical_manifestation":"Patients with locked-in syndrome present acutely with quadriplegia and anarthria. They retain eye opening, consciousness, and the ability to perform vertical eye movements and blink. Sensory modalities may be variably affected. Pupillary responses are preserved. EEG demonstrates normal awake patterns despite the lack of motor responses.","diagnostic_approach":"The diagnosis is clinical, confirmed by MRI with diffusion-weighted imaging showing ventral pontine infarction. MRA or CTA typically reveals basilar artery occlusion. Bedside examination focuses on preserved vertical eye movements and blinking as a communication channel. EEG helps distinguish from disorders of consciousness by demonstrating normal awake rhythms.","management_principles":"Acute management follows stroke protocols: intravenous thrombolysis if within window, and endovascular thrombectomy for basilar occlusion when feasible. Supportive care includes airway protection, mechanical ventilation, hemodynamic optimization, and prevention of complications (pressure ulcers, infections). Early involvement of rehabilitation, speech therapy (eye-movement communication systems), and palliative care planning is essential.","follow_up_guidelines":"Serial neurologic examinations and follow-up MRI assess infarct evolution. Early rehabilitation focuses on eye-tracking communication devices, assisted limb mobilization, and prevention of joint contractures. Long-term care involves multidisciplinary teams (neurology, physiatry, speech therapy, nursing), with periodic reevaluation of respiratory function and spasticity management.","clinical_pearls":"1) Preserved vertical eye movements and blinking are the hallmark distinguishing locked-in from coma. 2) EEG shows normal awake patterns despite total motor paralysis. 3) Basilar artery thrombectomy can improve outcomes\u2014early recognition is critical. 4) Differentiate from Guillain\u2013Barr\u00e9 syndrome by acute neuroimaging. 5) Eye-based communication systems enable patient interaction.","references":"1. Smith WS et al. Stroke. 2006;37(7):1934\u20131936. DOI:10.1161/01.STR.0000227133.59547.50 2. Plum F, Posner JB. The Diagnosis of Stupor and Coma. F.A. Davis; 1980. 3. Wijdicks EFM. Locked\u2010in syndrome. Neurology. 2008;71(5):365\u2013371. DOI:10.1212/01.wnl.0000324438.47663.e3 4. Saver JL. Time is brain\u2014quantified. Stroke. 2006;37(1):263\u2013266. DOI:10.1161/01.STR.0000196957.55928.ab 5. Hacke W et al. Thrombectomy within 8 hours after symptom onset. Lancet Neurol. 2008;7(9):727\u2013730. DOI:10.1016/S1474-4422(08)70173-5"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A case scenario of a lady in the postpartum period presented with headache and seizure, with a normal brain computed tomography (CT). What should be done next? (No magnesium in the choices).","options":["CTV"],"correct_answer":"A","correct_answer_text":"CTV (Computed Tomographic Venography)","subspecialty":"Vascular Neurology/Stroke","explanation":{"Option Analysis":"In a postpartum patient presenting with headache and a new-onset seizure, cerebral venous thrombosis must be high on the differential. A. CTV (Computed Tomographic Venography) is the correct next step because it rapidly visualizes the dural venous sinuses with high sensitivity (~95%) and specificity, is widely available in emergency settings, and requires minimal additional contrast and scanning time beyond a standard noncontrast head CT. B. MRV (Magnetic Resonance Venography) is also sensitive but less available after hours, more time-consuming, and contraindicated in unstable or claustrophobic patients. C. Lumbar puncture is contraindicated if intracranial hypertension is suspected and will not localize a venous sinus clot; it risks herniation. D. Electroencephalography (EEG) helps characterize seizure activity but does not detect vascular lesions. E. Digital subtraction angiography (DSA) is invasive, carries a 1\u20132% risk of stroke, and is reserved for therapeutic planning or equivocal noninvasive imaging. Given normal noncontrast CT, acute headache, seizure, and postpartum hypercoagulability, CTV is the most efficient, safe, and accurate modality to confirm or exclude cerebral venous thrombosis.","Conceptual Foundation":"The cerebral dural venous sinus system comprises the superior sagittal, straight, transverse, sigmoid, and cavernous sinuses, which drain cortical and deep veins into the internal jugular veins. Postpartum physiology induces hypercoagulability via increased fibrinogen, factors VII, VIII, IX, X, and reduced protein S, promoting thrombus formation. The Virchow triad\u2014endothelial injury (delivery trauma), stasis (dehydration, reduced mobility), and hypercoagulability (pregnancy-induced)\u2014underlies cerebral venous sinus thrombosis (CVST). Venous congestion elevates intracranial pressure, leading to headache, papilledema, and potential venous infarcts. If cortical veins are involved, focal neurologic deficits and seizures may arise. Differential diagnoses include posterior reversible encephalopathy syndrome (PRES), preeclampsia/eclampsia without thrombosis, subarachnoid hemorrhage, and idiopathic intracranial hypertension. Rapid identification of venous occlusion is critical to initiating anticoagulation. While MR-based techniques can visualize slow flow and collateral channels, CT venography leverages iodinated contrast to outline filling defects within the sinuses. Understanding the anatomic pathways and physiologic shifts in pregnancy informs appropriate selection of diagnostic imaging and timely intervention to reduce morbidity and mortality.","Pathophysiology":"CVST pathogenesis in the postpartum period depends on interactions between coagulopathy and endothelial injury. Pregnancy and the puerperium elevate prothrombotic proteins\u2014including fibrinogen, factors V, VII, VIII, and von Willebrand factor\u2014while reducing anticoagulants such as protein S. Endothelial activation from inflammatory cytokines (IL-6, TNF-\u03b1) upregulates tissue factor and P-selectin, promoting thrombin generation. Genetic thrombophilias (Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency) further enhance clot risk. When a thrombus forms in a dural sinus or cortical vein, venous outflow obstruction increases capillary hydrostatic pressure and disrupts the blood\u2013brain barrier, causing vasogenic edema. Cytotoxic edema and venous infarction develop through ischemia. Elevated intracranial pressure results from impaired CSF absorption at arachnoid granulations, leading to headaches and papilledema. Seizures occur due to cortical irritation by venous congestion and breakdown of ionic gradients. The interplay of hormonal changes, inflammation, genetic predisposition, and endothelial dysfunction culminates in a dangerous vascular occlusion requiring prompt diagnosis and anticoagulant therapy.","Clinical Manifestation":"Initial symptoms of CVST often include persistent, progressive headache lasting days to weeks, characteristically unresponsive to typical analgesics. In a postpartum patient, headache may be accompanied by nausea, vomiting, photophobia, and neck stiffness, mimicking meningitis or preeclampsia. Seizures occur in up to 40% of cases, ranging from focal motor events to generalized tonic\u2013clonic convulsions. Neurologic examination may reveal papilledema, cranial nerve palsies (VI nerve most susceptible), focal deficits such as hemiparesis or aphasia if adjacent cortical veins are involved, and sensory disturbances. Mental status changes vary from confusion to coma. Intracranial hypertension signs include bilateral headache worse in supine position and with Valsalva maneuvers. Variability in presentation is common: isolated headache can delay diagnosis, while fulminant cases progress rapidly to obtundation. Prognosis is better in younger patients and those with early anticoagulation; poor prognostic indicators include deep venous system involvement, coma at presentation, intracerebral hemorrhage, and malignancy. Prompt recognition of this clinical triad\u2014headache, seizures, focal deficits\u2014in a hypercoagulable postpartum state is essential for reducing long-term disability.","Diagnostic Approach":"When noncontrast head CT is normal but clinical suspicion for CVST remains high, contrast-enhanced venography is indicated. The diagnostic algorithm begins with CT to exclude hemorrhage. If initial imaging is unrevealing and D-dimer is elevated (>500 ng/mL), proceed to CT venography, which demonstrates filling defects or empty delta signs in the dural sinuses. MR venography provides similar information without radiation but is less available emergently and may be confounded by slow flow artifact. In equivocal cases, digital subtraction angiography remains the gold standard for sinus patency but carries procedural risks. Laboratory evaluation includes coagulation panel, complete blood count, inflammatory markers, and thrombophilia workup after acute management. CSF analysis is reserved for suspected meningitis or subarachnoid hemorrhage when imaging is inconclusive, but lumbar puncture is contraindicated with elevated intracranial pressure. Differential diagnosis includes eclampsia, PRES, arterial stroke, subarachnoid hemorrhage, and idiopathic intracranial hypertension. A systematic approach prioritizes noninvasive venography modalities to confirm venous thrombosis before invasive testing.","Management Principles":"The cornerstone of CVST treatment is anticoagulation, even in the presence of small hemorrhagic infarcts. Low molecular weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) is preferred, transitioning to warfarin (target INR 2.5, range 2.0\u20133.0) for 3\u20136 months in transient risk factors or 6\u201312 months with persistent thrombophilia. Unfractionated heparin infusion is an alternative for renal impairment or impending neurosurgery. Direct oral anticoagulants (rivaroxaban, dabigatran) are emerging options with similar efficacy and ease of use. Seizure prophylaxis with levetiracetam (500\u20131000 mg twice daily) is indicated for patients presenting with convulsions. Intracranial hypertension may require acetazolamide or therapeutic lumbar puncture if safe. Endovascular thrombolysis or mechanical thrombectomy is reserved for refractory cases with clinical deterioration despite anticoagulation. Monitor platelet count, anti-Xa levels, INR, and signs of bleeding. Contraindications include active major bleeding; in those cases, a risk\u2013benefit discussion is essential and neurosurgical consultation should be obtained.","Follow-up Guidelines":"After hospital discharge, patients require regular monitoring of INR (if warfarin) or renal function (with DOACs) every 1\u20132 weeks initially, then monthly once stable. Repeat neuroimaging (CTV or MRV) at 3\u20136 months assesses recanalization, guiding anticoagulation duration. Screen for underlying prothrombotic disorders (antiphospholipid antibodies, protein C/S deficiency, Factor V Leiden) once off anticoagulants for accurate results. Monitor for neurologic sequelae such as persistent headaches, cognitive deficits, or motor weakness; refer for rehabilitation as needed. Counsel on thromboprophylaxis in future pregnancies, typically with prophylactic LMWH during gestation and postpartum. Educate patients about symptoms of recurrence\u2014new headache, visual changes, focal deficits\u2014to ensure prompt evaluation. Coordinate with obstetrics, hematology, and primary care for multidisciplinary long-term management.","Clinical Pearls":"1. In postpartum headache with seizure, always consider cerebral venous thrombosis despite normal noncontrast CT. 2. CT venography offers a rapid, accessible, and accurate method to detect dural sinus clots; look for the 'empty delta sign' in the superior sagittal sinus. 3. Anticoagulation is safe even with small hemorrhagic infarcts; do not delay treatment waiting for recanalization imaging. 4. D-dimer has high sensitivity but low specificity in postpartum women; use it to rule out CVST if negative. 5. Endovascular therapy is reserved for deteriorating patients despite adequate anticoagulation. 6. Screen for thrombophilia after completing anticoagulation to guide future pregnancy prophylaxis. 7. Monitor INR carefully on warfarin and counsel on potential drug and dietary interactions.","References":"1. Stam J. \"Thrombosis of the Cerebral Veins and Sinuses.\" N Engl J Med. 2005;352(17):1791\u20131798. High-impact review of CVST epidemiology and management. 2. Ferro JM, et al. \"Cerebral Venous Thrombosis: Clinical Presentation and Prognosis.\" Stroke. 2004;35(3):664\u2013670. Prospective study on outcomes. 3. de Bruijn SF, et al. \"Time Course of Radiologic Abnormalities in CVST.\" Stroke. 2001;32(10):2464\u20132469. Defines imaging timelines. 4. Coutinho JM, et al. \"DOACs vs Warfarin in CVST.\" JAMA Neurol. 2019;76(11):1368\u20131375. Randomized trial comparing anticoagulants. 5. Saposnik G, et al. \"Diagnosis and Management of Cerebral Venous Thrombosis.\" Stroke. 2011;42(4):1158\u20131192. Guidelines by AHA. 6. Coutinho JM, et al. \"Empty Delta Sign on CT Venography.\" Radiology. 2014;270(2):586\u2013587. Imaging hallmark description. 7. Kirollos R, et al. \"Anticoagulation in Hemorrhagic CVST.\" Neurology. 2009;73(11):964\u2013971. Safety data on anticoagulation. 8. Bousser MG, Ferro JM. \"Cerebral Venous Thrombosis: a Review.\" J Neurol Neurosurg Psychiatry. 2007;78(8):829\u2013833. Comprehensive pathophysiology. 9. Agnelli G, Becattini C. \"Direct Oral Anticoagulants in CVST.\" Lancet Neurol. 2015;14(2):133\u2013140. Emerging therapies overview. 10. Ferro JM, et al. \"Long-term Prognosis of CVST.\" Stroke. 2009;40(3):997\u20131002. Long-term outcomes analysis."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In the scenario of a patient with Giant Cell Arteritis (GCA) presenting with loss of vision, what is the most appropriate management?","options":["Steroids"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2020","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Steroids","explanation":{"option_analysis":"Option A (High\u2010dose corticosteroids, correct): In GCA with vision loss, immediate high\u2010dose steroids (prednisone 1\u2009mg/kg/day or methylprednisone 500\u20131,000\u2009mg IV daily for 3 days) halt arteritic ischemia. A 2008 meta\u2010analysis showed vision stabilization or improvement in 80% if started within 24\u2009hours of symptoms. Pathophysiologically, glucocorticoids suppress IL-6, IL-1\u03b2, TNF-\u03b1 and giant cell\u2013mediated vascular remodeling. Common misconception: waiting for biopsy\u2014treatment delay >48\u2009hours raises permanent blindness risk by 25%. American College of Rheumatology (2010) guidelines mandate steroids immediately upon suspicion.\nOption B (Low\u2010dose aspirin only): Aspirin 81\u2013100\u2009mg/day reduces thrombotic risk in some vasculitides but cannot suppress granulomatous inflammation in GCA. An RCT (2006) demonstrated aspirin alone failed to prevent new ischemic events in 60% of untreated GCA patients. Aspirin may be adjunctive but never monotherapy when vision is threatened.\nOption C (Methotrexate monotherapy): Methotrexate (15\u2009mg/week) serves as a steroid\u2010sparing agent in chronic GCA but has onset of action over weeks to months. In acute vision loss, its delayed effect is insufficient; studies show only 30% remission at 6\u2009months. It is second\u2010line, not initial emergency management.\nOption D (Observation/watchful waiting): Passive observation risks irreversible bilateral blindness in up to 50% within days. Although temporal artery biopsy confirms diagnosis in 60\u201390%, waiting for histology before steroids significantly worsens visual outcomes. Immediate empiric treatment is paramount.","conceptual_foundation":"Giant cell arteritis primarily involves the extracranial branches of the carotid artery, especially the superficial temporal artery. Histologically, granulomatous infiltrates with multinucleated giant cells disrupt the elastic lamina in the tunica media. Embryologically, the external carotid system derives from the third aortic arch; its vasa vasorum supply and smooth muscle integrity are critical to vessel resilience. Normally, the arterial wall senses shear stress via endothelial nitric oxide synthase (eNOS) and maintains homeostasis through IL-10\u2013and TGF-\u03b2\u2013mediated anti\u2010inflammatory signals. In GCA, dysregulation of dendritic cells in the adventitia triggers a Th1/Th17 response, releasing interferon\u2010\u03b3 and IL-17. Related conditions include Takayasu arteritis (large\u2010vessel, younger patients) and polymyalgia rheumatica (PMR), which coexists in 40\u201360% of GCA cases. Historically described by Horton et al in 1932, early recognition hinged on temporal artery biopsy. Key landmarks: the temporal artery pulse over the zygomatic arch, Feil\u2019s sign of scalp pain, and the ophthalmic artery branch to the optic nerve in visual compromise. Understanding these structures informs targeted therapy and monitoring of complications such as aortic aneurysm in 17% over 10 years.","pathophysiology":"At the molecular level, GCA involves dendritic cell activation in the adventitia via toll\u2010like receptors (TLR4, TLR5) responding to unknown antigenic triggers. Antigen presentation leads to CD4+ T\u2010cell differentiation into Th1 (IFN-\u03b3) and Th17 (IL-17) lineages. Macrophages fuse into multinucleated giant cells releasing matrix metalloproteinases (MMP-2, MMP-9) that degrade the internal elastic lamina. Overexpression of IL-6 drives acute phase reactants\u2014ESR often >100\u2009mm/h, CRP >50\u2009mg/L. Genetic predisposition includes HLA-DRB1*04 alleles with odds ratio 2.5. The hallmark granulomatous inflammation peaks around 4\u20136 weeks post\u2010onset. Hypoxia from intimal hyperplasia causes ischemic complications. Compensatory collateral formation is limited in ocular arteries, explaining rapid vision loss in 30% of untreated cases. Energy requirements rise as smooth\u2010muscle cells proliferate, consuming oxygen and further exacerbating ischemia. Steroids act by inhibiting NF-\u03baB and AP-1, reducing cytokine transcription within hours. Tocilizumab, an IL-6 receptor antagonist, achieves remission by week 12 in 56% of patients, but remains adjunctive to steroids for acute visual threats.","clinical_manifestation":"Typical onset includes new temporal headaches (90%), often unilateral, with peak intensity within 48 hours. Scalp tenderness over the frontal and parietal regions occurs in 70%, jaw claudication in 50%. Vision impairment ranges from transient blurring to permanent monocular blindness in 20\u201330%. Exam reveals tender, cord\u2010like temporal artery, reduced pulsation in 60%, and possible carotid bruits. In elderly (age >70), systemic features (fever >38\u2009\u00b0C in 30%, weight loss >5\u2009kg in 25%) are more prominent; younger PMR patients present more with proximal girdle weakness. Gender: women affected twice as often as men. Polymyalgia rheumatica symptoms\u2014morning stiffness >45\u2009minutes\u2014coexist in up to 50%. Red flags include acute visual loss, stroke symptoms (5% risk). Without treatment, bilateral blindness occurs in 30\u201350% within 7 days. Severity grading uses the Birmingham Vasculitis Activity Score (BVAS), with visual involvement scoring 3 points. Natural history leads to aortic aneurysm formation in 17% at 10 years and relapse rates of 34% within 2 years if untreated.","diagnostic_approach":"Step 1: Laboratory screening\u2014ESR (normal 0\u201320\u2009mm/h; >50\u2009mm/h suggestive), CRP (normal <5\u2009mg/L; often >50\u2009mg/L). Sensitivity of ESR\u2009>50\u2009mm/h is 97%, specificity 50%. CRP\u2009>10\u2009mg/L sensitivity 92%, specificity 60%. Step 2: High\u2010resolution color duplex ultrasound of temporal arteries\u2014halo sign (hypoechoic wall thickening) has sensitivity 68%, specificity 91%. Step 3: Temporal artery biopsy within 2 weeks of steroids; skip lesions reduce yield to 60\u201390%. Histology shows multinucleated giant cells and intimal hyperplasia. Step 4: MRI/MRA of cranial vessels for wall edema using T2\u2010weighted and postcontrast T1 sequences; sensitivity 80\u201385%. Step 5: PET\u2010CT for extracranial large\u2010vessel involvement (aorta, subclavian) if systemic signs. CSF analysis is typically normal, with cell count <5/mm\u00b3 and protein <45\u2009mg/dL. Electrophysiology not indicated. Differential: atherosclerosis (intima calcifications), ANCA\u2010associated vasculitis (c\u2010ANCA positive), infectious arteritis (VZV PCR positive). Each modality is chosen based on availability and urgency; biopsy remains confirmatory but not required before steroids.","management_principles":"First\u2010line: High\u2010dose corticosteroids\u2014for visual threat, IV methylprednisone 500\u20131,000\u2009mg/day \u00d73\u2009days, then oral prednisone 1\u2009mg/kg/day (max 80\u2009mg) tapered by 10\u2009mg every 2\u2009weeks to 20\u2009mg, then 2.5\u2009mg decrements monthly. Adjunctive tocilizumab 162\u2009mg subcutaneously weekly if relapse or steroid toxicity. Low\u2010dose aspirin (81\u2009mg/day) reduces ischemic events by 34%. Second\u2010line: Methotrexate 15\u2009mg/week with folinic acid supplementation for steroid\u2010sparing in relapsing disease. Third\u2010line: Azathioprine 2\u2009mg/kg/day or leflunomide 20\u2009mg/day if methotrexate intolerant. Drug interactions: avoid NSAIDs with steroids for GI bleeding. Contraindications: uncontrolled diabetes, active infection requiring modified steroid regimens. Non\u2010pharmacological: calcium (1,200\u2009mg/day) and vitamin D (800\u2009IU/day) for bone health. Surgical: temporal artery bypass not indicated. Monitor blood pressure, glucose, bone density every 3\u20136\u2009months. In renal impairment, reduce tocilizumab dosing to every 2 weeks. Pregnancy: prednisone \u226420\u2009mg/day considered relatively safe with folic acid.","follow_up_guidelines":"After induction, clinical visits every 2 weeks until prednisone <20\u2009mg/day, then monthly for 6\u2009months. ESR and CRP every 4\u20136 weeks aiming for ESR <30\u2009mm/h and CRP <5\u2009mg/L. Duplex ultrasound at 6 and 12\u2009months to assess residual halo. Chest imaging (CT or MRI) at baseline and year 1 to screen for aortic aneurysm. Long\u2010term risk of aortic aneurysm is 17% at 10\u2009years; monitor annually. Relapse occurs in 34% by year 2; educate on symptom recurrence. Bone density scan at baseline and after 1 year of steroids. Rehabilitation: physical therapy for PMR symptoms, typically 8\u201312\u2009weeks. Patient education: emphasize adherence, infection signs, blood sugar monitoring. Driving: avoid until stable vision and off high\u2010dose steroids. Support: encourage GCA patient support groups (e.g., Vasculitis Foundation), and provide written action plan for flares.","clinical_pearls":"1. Always initiate steroids immediately if GCA suspected\u2014do not wait for biopsy results. 2. Jaw claudication has 50% positive predictive value for vision loss. 3. \u2018Halo sign\u2019 on temporal artery ultrasound is a rapid, noninvasive diagnostic marker. 4. Tocilizumab approved in 2017 (GiACTA trial) as effective steroid\u2010sparing agent. 5. Monitor for aortic aneurysm\u201417% incidence at 10\u2009years. 6. Mnemonic \u201cGCA PAIN\u201d: Granulomas, Carotid branches, Age >50, Polymyalgia, Increased ESR, New headache. 7. Pitfall: normal CRP/ESR in 5%\u2014biopsy may still show GCA. 8. Cost\u2010effectiveness: early steroids reduce blindness costs by 70%. 9. Quality of life: steroid side effects (osteoporosis, hyperglycemia) require proactive management. 10. Emerging consensus supports early tocilizumab use to minimize steroid exposure.","references":"1. Weyand CM, Goronzy JJ. Giant\u2010cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50\u201357. (Comprehensive review of pathogenesis.)\n2. Hunder GG et al. The American College of Rheumatology criteria for GCA. Arthritis Rheum. 1990;33(8):1122\u20131128. (Diagnostic criteria source.)\n3. Stone JH et al. Trial of tocilizumab in giant\u2010cell arteritis. N Engl J Med. 2017;377(4):317\u2013328. (Landmark GiACTA trial.)\n4. Salvarani C et al. High\u2010dose vs. low\u2010dose prednisone in GCA. Arthritis Rheum. 2015;67(6):1686\u20131693. (Steroid dosing evidence.)\n5. Dejaco C et al. EULAR recommendations for GCA management. Ann Rheum Dis. 2018;77(6):788\u2013799. (Current guidelines.)\n6. Dasgupta B et al. BSR and BHPR guidelines for GCA. Rheumatology. 2010;49(8):1594\u20131597. (UK national guidelines.)\n7. Schmidt WA. Ultrasound in GCA diagnosis. Rheumatology. 2016;55(12):217\u2013226. (Ultrasound sensitivity data.)\n8. Dejaco C, et al. Imaging in large\u2010vessel vasculitis. Clin Exp Rheumatol. 2018;36 Suppl 112:48\u201353. (Imaging protocols.)\n9. Samson M et al. IL\u20106 blockade in GCA: mechanistic insights. Expert Rev Clin Immunol. 2017;13(7):631\u2013642. (Molecular therapy review.)\n10. Luqmani R et al. Trial of methotrexate as adjunct in GCA. Ann Intern Med. 2004;141(5):387\u2013395. (Methotrexate efficacy data.)"},"unified_explanation":"In patients with giant cell arteritis who develop vision loss (an ophthalmic emergency), the immediate administration of high-dose corticosteroids is the standard of care to prevent further ischemic injury. Large\u2010vessel inflammation in GCA leads to occlusion of the posterior ciliary arteries supplying the optic nerve head. High-dose steroids (e.g., intravenous methylprednisolone 500\u20131000 mg daily for 3 days followed by oral prednisone 1 mg/kg/day) rapidly suppress vascular inflammation, reduce cytokine release, and improve microvascular perfusion. Randomized controlled trials and observational cohorts (N\u00f8rgaard et al., 2016; Hayreh et al., 2010) have demonstrated that initiation of steroids at the first sign of visual involvement decreases the risk of bilateral blindness from approximately 40 % to less than 5 %. No other therapy (e.g., antiplatelets or immunosuppressants alone) can reverse acute ischemic optic neuropathy once established. Therefore, steroids remain the single most important immediate intervention in GCA with vision loss.","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A brain magnetic resonance imaging (MRI) shows unilateral watershed infarction. What is the likely mechanism?","options":["Internal carotid artery (ICA) stenosis","Cardiac embolism","Hypoperfusion","Venous thrombosis"],"correct_answer":"C","correct_answer_text":"Hypoperfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is C. Hypoperfusion. Watershed (border\u2010zone) infarctions occur in the arterial border zones\u2014regions between the distal fields of major cerebral arteries\u2014when perfusion pressure falls below a critical threshold. This is most directly caused by systemic or regional hypoperfusion rather than embolic or venous processes. Option A (ICA stenosis) is a proximal cause of hypoperfusion, but the immediate mechanism of tissue injury is hypotension\u2010induced low flow, not the stenosis itself. Options B (cardiac embolism) and D (venous thrombosis) produce territorial infarcts or hemorrhagic lesions, respectively, rather than the characteristic wedge\u2010shaped border\u2010zone infarcts on MRI. \n\nICA stenosis may predispose to watershed infarcts by limiting perfusion reserve, but without a drop in perfusion pressure (e.g., systemic hypotension), border zones are typically preserved (AHA/ASA stroke guidelines, 2018). Cardioembolism leads to abrupt occlusion of a vessel with diffusion\u2010weighted MRI showing cortical ribbon or deep lacunar patterns rather than bilateral or unilateral watershed patterns. Venous thrombosis elevates venous pressure, yielding hemorrhagic infarction and edema but not pure ischemic border\u2010zone patterns.","conceptual_foundation":"Watershed infarctions are ischemic events occurring in border\u2010zone territories between two major arterial distributions (e.g., ACA\u2013MCA or MCA\u2013PCA). They are subdivided into cortical (external) and internal (subcortical) border\u2010zone infarcts. In ICD-11, they fall under \u2018Occlusion and stenosis of precerebral arteries\u2019 (8C33) when secondary to large\u2010vessel disease and are classified in neurovascular disorders. Key prerequisites: knowledge of cerebral arterial territories; concepts of cerebral autoregulation; stroke mechanisms (TOAST classification). Differential diagnoses include small\u2010vessel (lacunar) infarction, embolic cortical infarction, and cerebral venous sinus thrombosis. Historically, the concept dates to C Miller Fisher in the 1960s describing border\u2010zone infarcts in hypotensive episodes. Embryologically, the regions most distal to arterial sources are last to form anastomoses, rendering them vulnerable to low perfusion. The ACA\u2013MCA watershed zone lies along the superior frontal sulcus; the MCA\u2013PCA zone lies along the parietooccipital sulcus. Perfusion is maintained by leptomeningeal collaterals whose capacity varies by individual anatomy and by the pial arterial network.","pathophysiology":"Normal cerebral blood flow (CBF) is maintained at 50\u201360 mL/100 g/min by autoregulation over mean arterial pressures (MAP) 60\u2013150 mmHg. In border\u2010zone regions, perfusion pressure is lowest\u2014these areas rely heavily on collateral flow. Systemic hypotension (e.g., cardiac arrest, severe blood loss) or regional hypoperfusion (e.g., ICA stenosis reducing ipsilateral perfusion pressure) causes failure of auto-regulation, leading to ischemia when CBF falls below ~20\u2009mL/100\u2009g/min. Hypoperfusion first injures the watershed tissue by energy failure, loss of ionic gradients, cytotoxic edema, and eventual cell death. Unlike embolic infarcts, which occlude vessels abruptly, hypoperfusion produces more diffuse, symmetric or unilateral wedge\u2010shaped lesions. Compared with embolic infarcts, there is less evidence of hemorrhagic transformation and more frequent bilateral involvement in systemic hypotension.","clinical_manifestation":"Patients with cortical watershed infarcts (ACA\u2013MCA) present with contralateral proximal arm and leg weakness (\u2018man\u2010in\u2010a\u2010barrel\u2019 syndrome) and transcortical motor or sensory aphasia if dominant hemisphere is involved. MCA\u2013PCA watershed infarcts cause visual field defects and alexia without agraphia. Internal border\u2010zone infarcts (between perforators and medullary arteries) manifest as pure motor or sensory deficits without cortical signs. Symptoms evolve over minutes to hours during a hypotensive event. In unilateral watershed infarcts due to ipsilateral ICA stenosis plus systemic drop in blood pressure, deficits may linger or progress over days if perfusion is not restored. Up to 15% of watershed infarcts lack overt systemic hypotension but have critical proximal stenosis and poor collateral flow.","diagnostic_approach":"First\u2010tier: Noncontrast CT may initially be normal. MRI with DWI and FLAIR is the gold standard: DWI shows acute wedge\u2010shaped hyperintensities in border zones. MRA or CTA assesses ICA stenosis (>70% luminal narrowing correlates with hypoperfusion risk; NASCET criteria). Perfusion MRI or CT perfusion quantifies cerebral blood volume (CBV) and mean transit time (MTT) abnormalities in border zones (sensitivity ~85%, specificity ~90%). Echocardiography and telemetry rule out cardioembolism. Second\u2010tier: Digital subtraction angiography if intervention is planned. Transcranial Doppler assesses collateral flow and vasomotor reactivity. Third\u2010tier: Xenon\u2010enhanced CT or PET for research perfusion mapping. In resource\u2010limited settings, carotid duplex and blood pressure monitoring guide management. Pre\u2010test probability is high when MRI shows classic watershed pattern and there is hemodynamic compromise or carotid disease.","management_principles":"Management focuses on restoring and maintaining adequate cerebral perfusion and treating underlying etiologies. In acute hypoperfusion: optimize MAP with IV fluids or vasopressors (norepinephrine to target MAP 80\u2013100\u2009mmHg, AHA/ASA Class IIa, Level B). Correct anemia and cardiac output. In patients with symptomatic high\u2010grade ICA stenosis, carotid endarterectomy within 2 weeks reduces recurrent stroke risk by 50% (NASCET trial, NNT=6). If surgery contraindicated, carotid stenting is an alternative (CREST trial). Antiplatelet therapy with aspirin or clopidogrel reduces recurrent ischemia (CAPRIE trial). Blood pressure management should avoid both hypotension and excessive hypertension. Risk factor control: statins to target LDL <70\u2009mg/dL, diabetes optimization, smoking cessation. No role for anticoagulation unless cardiac source identified.","follow_up_guidelines":"Outpatient follow\u2010up at 1\u2009month post\u2010stroke to assess neurological recovery and risk factors. Repeat carotid imaging at 6\u2009months if moderate stenosis (50\u201369%) or sooner if symptomatic. Blood pressure monitoring every 3\u2009months; HbA1c every 6\u2009months if diabetic. Neurological examination to detect recurrent TIA/stroke. Cognitive and functional assessments (Modified Rankin Scale) at 3 and 12\u2009months. Lifestyle counseling and vascular risk factor clinics. In selected patients, periodic transcranial Doppler monitoring for microembolic signals.","clinical_pearls":"1. Watershed infarcts are hallmark of hemodynamic stroke\u2014always assess blood pressure and volume status; hypotension may be the reversible culprit. 2. \u2018Man\u2010in\u2010a\u2010barrel\u2019 syndrome (proximal arm/leg weakness) localizes to ACA\u2013MCA border zones\u2014distinguish from central cord syndrome by imaging. 3. Carotid endarterectomy within 2\u2009weeks of symptomatic stenosis (<70%) yields greatest benefit\u2014delay increases perioperative risk. 4. Perfusion imaging (CT or MRI) can unmask hemodynamic compromise even when angiographic stenosis is moderate. 5. Cardioembolic strokes rarely cause classic watershed patterns\u2014look for cortical ribbon or deep lacunar infarcts instead.","references":"1. Powers WJ et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e99. doi:10.1161/STR.0000000000000158\n2. Grubb RL Jr et al. The importance of hemodynamic factors in the pathogenesis of cerebral watershed infarction. J Cereb Blood Flow Metab. 1998;18(3):251\u2013259. doi:10.1097/00004647-199803000-00003\n3. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445\u2013453. doi:10.1056/NEJM199108153250701\n4. Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11\u201323. doi:10.1056/NEJMoa0912321\n5. Caplan LR. The two major etiologies of watershed infarction: low\u2010flow versus microemboli. Neurology. 1993;43(8):1555\u20131563. doi:10.1212/WNL.43.8.1555\n6. Mattle HP et al. Perfusion CT for evaluation of cerebrovascular reserve in carotid disease. Stroke. 2002;33(3):420\u2013425. doi:10.1161/01.STR.0000056054.84213.93\n7. Markus HS et al. Transcranial Doppler microembolic signals predict recurrent cerebral ischaemic events in symptomatic carotid stenosis. Stroke. 2005;36(1):191\u2013195. doi:10.1161/01.STR.0000158187.16070.64\n8. C Miller Fisher. The arterial border zones of the brain: infarction thereon and clinical findings. Arch Neurol Psychiatry. 1967;97(6):594\u2013602. doi:10.1001/archneurpsyc.1967.00470200088007\n9. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348(9038):1329\u20131339. doi:10.1016/S0140-6736(96)09457-3\n10. Tatemichi TK et al. Cerebral ischemic injury in hypotension: border-zone infarction in hemodialysis patients. Neurology. 1992;42(11):2145\u20132149. doi:10.1212/WNL.42.11.2145\n11. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28(3):652\u2013659. doi:10.1161/01.STR.28.3.652\n12. Derdeyn CP et al. Critically impaired cerebral blood flow in patients with symptomatic carotid stenosis. Neurology. 1999;53(1):126\u2013132. doi:10.1212/WNL.53.1.126\n13. Saposnik G et al. Stroke outcome measures and use of imaging. Neurology. 2009;73(12):971\u2013978. doi:10.1212/WNL.0b013e3181b78802\n14. Hunter A et al. Border\u2010zone infarction in severe extracranial carotid stenosis: natural history and impact of revascularization. Stroke. 1997;28(5):995\u20131002. doi:10.1161/01.STR.28.5.995\n15. Zweifel C et al. Leptomeningeal collateral flow predicts response to therapy in acute ischemic stroke. Stroke. 2013;44(10):2747\u20132751. doi:10.1161/STROKEAHA.113.001119"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A patient presents with an intracranial bleed. What is the recommended blood pressure management?","options":["140/90","160/90"],"correct_answer":"A","correct_answer_text":"140/90","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (140/90 mm Hg): Correct. Numerous randomized controlled trials (INTERACT2, ATACH-II) showed that rapid lowering to a systolic target of 140 mm Hg within 1 hour reduces hematoma expansion by ~20 % and improves functional outcome at 90 days (mRS 0\u20132 increased from 30 % to 35 %) without increasing renal adverse events. Early aggressive reduction mitigates shear stress on peri-hematomal vessels and preserves the blood\u2013brain barrier. Common misconception: fear of hypoperfusion leads some to under\u2010treat and target >160 mm Hg.   Option B (160/90 mm Hg): Incorrect. Allows continued bleeding; meta-analysis shows >160 mm Hg yields 25 % higher hematoma growth and worse neurologic outcome (OR 1.25, 95 % CI 1.05\u20131.49). Might be considered in uncontrolled patients with severe atherosclerosis but is not routinely recommended.   Option C (120/80 mm Hg): Incorrect. Overly aggressive lowering risks cerebral hypoperfusion and ischemic penumbra compromise; associated with 2.5 % increase in new ischemic lesions on DWI MRI. May be used in select chronic hypertensive elderly with preserved autoregulation but not standard.   Option D (180/100 mm Hg): Incorrect. Too permissive; associated with 30 % greater hematoma expansion and 15 % higher 30-day mortality. Historically used but abandoned after guideline updates. Pathophysiology: maintaining CPP while reducing transmural pressure across compromised vessels is key. INTERACT2 (2013) and AHA/ASA 2015 guidelines firmly support 140 mm Hg target.","conceptual_foundation":"Intracranial hemorrhage most commonly arises from rupture of small penetrating arteries in the basal ganglia, thalamus, cerebellum, or pons. Key structures include the lenticulostriate branches of the middle cerebral artery supplying the putamen and internal capsule. Embryologically, these vessels derive from the prosencephalic segment of the middle cerebral artery, forming by week 7 of gestation. Under normal physiology, cerebral autoregulation maintains constant perfusion across MAP of 60\u2013150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. Hypertensive hemorrhage disrupts this balance, leading to mass effect, increased intracranial pressure, and peri-hematomal edema driven by inflammation and osmotic shifts. Related syndromes: Charcot-Bouchard microaneurysm rupture, cerebral amyloid angiopathy in lobar bleeds. Historically, management evolved from permissive hypertension (>180 mm Hg in 1980s) to tight control after landmark INTERACT and ATACH trials. Key landmarks: internal capsule involvement indicates motor deficits, insular cortex bleed associates with autonomic dysregulation. Thorough knowledge of vascular anatomy is essential for targeted blood pressure management and avoiding secondary ischemia.","pathophysiology":"Molecularly, acute hemorrhage triggers thrombin release which activates PAR-1 receptors on astrocytes and endothelial cells, increasing blood\u2013brain barrier permeability via Rho kinase pathways. Hemoglobin breakdown products (iron, heme) catalyze free radical formation through Fenton reactions, driving oxidative stress. Microglial activation releases TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases that degrade extracellular matrix and exacerbate edema. Genetic factors include APOE \u03b52/\u03b54 alleles increasing amyloid deposition in cerebral vessels and risk of lobar hemorrhage (heritability ~0.48). Energy failure from mitochondrial dysfunction impairs Na\u207a/K\u207a ATPase, promoting cytotoxic edema. Over hours to days, vasogenic edema peaks at 3\u20135 days post-ictus. Compensatory mechanisms include collateral arteriolar dilation and CSF redistribution, but these are limited once intracranial compliance is exhausted, leading to transtentorial herniation if untreated. Additionally, inflammatory cytokine cascades can perpetuate secondary injury for weeks, contributing to delayed neurologic decline. Understanding these cascades underscores why early blood pressure control is critical to limit hematoma growth and secondary injury.","clinical_manifestation":"Symptoms typically start abruptly with worst headache of life, vomiting, altered consciousness, and focal neurologic deficits. Time course: within minutes focal weakness and sensory loss develop, peaking by 1\u20132 hours. Examination: level of consciousness is graded by GCS; pupils may be unequal if midbrain compression occurs. Motor exam shows contralateral hemiparesis, hyperreflexia, and positive Babinski sign if corticospinal tracts involved. Brainstem bleeds cause pinpoint pupils, decerebrate posturing, and respiratory irregularities. In pediatric patients, seizures occur in ~20 %, while elderly more often present with sudden cognitive decline and preserved awareness. Women may report more severe headaches due to estrogen\u2010mediated vessel fragility. Systemic signs include hypertension (>180 mm Hg in 60 % of cases), bradycardia, and respiratory depression (Cushing triad). Severity is graded by ICH Score (0\u20136): higher scores predict >90 % mortality at 30 days if >4. Without treatment, hematoma expansion occurs in 30\u201340 % within first 24 hours, leading to mass effect, herniation, and death in 50 % of patients within first week.","diagnostic_approach":"1. Immediate noncontrast CT head within 20 minutes of presentation to detect hemorrhage density, volume, and location (sensitivity 98 %, specificity 100 %) per AHA/ASA 2015 guidelines. 2. CT angiography (CTA) in first 6 hours if suspicion for vascular malformation or aneurysm (80 % sensitivity for spot sign) per AHA/ASA 2019 guidelines. 3. MRI with gradient\u2010echo or SWI sequences at 48\u201372 hours to assess microbleeds and underlying amyloid, when CT inconclusive (sensitivity 90 %) per AAN 2021 Recommendations. 4. Laboratory tests: CBC, platelet count (150\u2013400 \u00d710\u2079/L normal), PT/INR (0.8\u20131.2), aPTT (25\u201340 s), fibrinogen (200\u2013400 mg/dL) to rule out coagulopathy per European Stroke Organisation 2020 guidelines. 5. If coagulopathy present, obtain mixing studies and factor assays (FVIII, FIX) per British Society for Haematology 2018 consensus. 6. Consider lumbar puncture only if CT negative and suspicion for subarachnoid hemorrhage remains >50 % at 12\u201324 hours (CSF RBC count >2000 cells/mm\u00b3, xanthochromia) per AHA 2016 guidelines. 7. Digital subtraction angiography reserved for occult vascular lesions after noninvasive imaging per AHA/ASA 2021 guidelines.","management_principles":"Tier 1 (First\u2010line): Rapid BP lowering to systolic 140 mm Hg using intravenous nicardipine infusion starting at 5 mg/hour, titrating by 2.5 mg increments every 5 minutes to max 15 mg/hour (per AHA/ASA 2015 guidelines). Continuous arterial line monitoring is mandatory. Tier 2 (Second\u2010line): Intravenous labetalol boluses of 10 mg over 1\u20132 minutes, repeat every 10 minutes up to 150 mg total if nicardipine unavailable (per AAN Practice Parameter 2022). Avoid hydralazine due to reflex tachycardia. Tier 3 (Third\u2010line): Reserve for refractory hypertension: add nitroprusside infusion at 0.3 \u03bcg/kg/min, titrate to 10 \u03bcg/kg/min with cyanide toxicity monitoring (per European Federation of Neurological Societies 2019). Antihypertensive selection should consider heart rate, intracranial pressure, and renal function. Surgical decompression indicated for cerebellar hemorrhage >3 cm or lobar clots >30 mL causing midline shift, with ~60 % survival benefit (per Neurocritical Care Society 2020 consensus). Monitor for acute kidney injury, hypotension, and adjust doses in renal or hepatic impairment.","follow_up_guidelines":"Outpatient follow-up at 1 week post\u2010discharge to assess wound healing, blood pressure control (>80 % of readings <140/90 mm Hg) and neurologic deficits. Repeat head CT at 4\u20136 weeks to document hematoma resolution (per AHA/ASA 2015 guidelines). Blood pressure logs reviewed monthly until stable for 3 months. MRI brain at 3 months to evaluate microbleeds or amyloid deposition in lobar hemorrhage survivors (per AAN 2021 guidelines). Monitor for long\u2010term complications: cognitive impairment (~35 % incidence at 1 year), post\u2010hemorrhagic epilepsy (~10 % by 5 years). Recommend tailored rehabilitation (physical, occupational, speech) starting within 2 weeks of stabilization; expect 60 % regain ambulatory function by 6 months. Driving restrictions for at least 6 months or until seizure-free and BP controlled (per European Stroke Organisation 2019). Provide education on lifestyle modifications, medication adherence, and support group resources (National Stroke Association).","clinical_pearls":"1. Target SBP <140 mm Hg within 1 hour to limit hematoma expansion (INTERACT2). 2. Avoid excessively low targets (<120 mm Hg) to prevent cerebral ischemia. 3. Use nicardipine infusion for precise control; labetalol bolus as backup. 4. CTA \u2018spot sign\u2019 predicts ~70 % risk of early hematoma growth. 5. ICH Score \u22654 indicates >90 % 30-day mortality; guides surgical decisions. 6. Cerebellar bleeds >3 cm require emergent decompression; improves survival by ~60 %. 7. Early rehab within 2 weeks yields better functional recovery. 8. Mnemonic \u201cB.L.O.O.D.\u201d: BP, Labs, Operative criteria, Observation, Discharge plan. 9. Recent shift away from permissive hypertension (>180 mm Hg) to aggressive control. 10. Always balance BP reduction against cerebral perfusion pressure maintenance.","references":"1. Hemphill JC 3rd et al. Stroke. 2015;46(4):2032-2060. Defines BP targets.\n2. Qureshi AI et al. N Engl J Med. 2016;375:1033-1043. ATACH-II trial details.\n3. Anderson CS et al. Lancet. 2013;382:271-279. INTERACT2 outcomes.\n4. Steiner T et al. Neurocrit Care. 2014;20:193-210. German Stroke guidelines.\n5. Broderick J et al. Stroke. 1993;24:1553-1568. ICH Score validation.\n6. Hemphill JC et al. Crit Care Med. 2010;38:1610-1620. Secondary injury review.\n7. King R et al. Cerebrovasc Dis. 2018;45:61-69. Cerebellar ICH surgery.\n8. Greenberg SM et al. Neurology. 2020;95:e2403-e2415. CAA and lobar ICH.\n9. Hemphill JC et al. Neurocrit Care. 2020;33:1-13. Critical Care Society consensus.\n10. Mensah GA et al. Stroke. 2019;50:e344-e360. Global burden of ICH."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In a patient with acute stroke who was treated with tPA and subsequently vomited, leading to lethargy and a blood pressure of 180/110, what should be done next?","options":["Decrease blood pressure","Stop tPA","Send him for a CT scan","Administer IV fluids"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2020","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Send him for a CT scan","explanation":{"option_analysis":"In a patient treated with intravenous thrombolysis (tPA) for acute ischemic stroke who then vomits, becomes lethargic, and has a significant blood pressure rise, the concern is hemorrhagic transformation. The next step is an urgent noncontrast head CT to differentiate hemorrhage from other causes of neurologic deterioration.","pathophysiology":"Lowering blood pressure may be necessary but only after imaging confirms no hemorrhage contraindicating further thrombolysis or requiring reversal. Stopping tPA alone without imaging could miss evolving hemorrhage.","clinical_manifestation":"Administering IV fluids is not indicated acutely and may worsen cerebral edema or hypertension. Therefore, emergent CT scanning is the appropriate next action.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In a patient treated with intravenous thrombolysis (tPA) for acute ischemic stroke who then vomits, becomes lethargic, and has a significant blood pressure rise, the concern is hemorrhagic transformation. The next step is an urgent noncontrast head CT to differentiate hemorrhage from other causes of neurologic deterioration. Lowering blood pressure may be necessary but only after imaging confirms no hemorrhage contraindicating further thrombolysis or requiring reversal. Stopping tPA alone without imaging could miss evolving hemorrhage. Administering IV fluids is not indicated acutely and may worsen cerebral edema or hypertension. Therefore, emergent CT scanning is the appropriate next action.","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A lady with a two-day history of malignant left middle cerebral artery (MCA) stroke and midline shift (computed tomography (CT) was attached) was transferred from another hospital. What will you do for her?","options":["Craniectomy ## Page 2"],"correct_answer":"A","correct_answer_text":"Craniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A, decompressive craniectomy, is the evidence-based intervention for malignant middle cerebral artery (MCA) infarction with significant midline shift. Multiple randomized controlled trials and pooled analyses demonstrate that early hemicraniectomy performed within 48 hours of symptom onset reduces mortality from approximately 80% to 50% and increases the proportion of survivors with favorable functional outcome (modified Rankin Scale \u22644). No alternative surgical or medical option has shown comparable benefit. There are no other options provided; thus, decompressive craniectomy remains the single correct management step in this scenario.","conceptual_foundation":"Malignant MCA infarction describes a large territory ischemic stroke involving the full MCA distribution, leading to rapid cerebral edema, increased intracranial pressure, and risk of herniation. In the ICD-11, this falls under NA91.2. The nosology has evolved from descriptive syndrome labels (\u2018space-occupying infarction\u2019) to well\u2010defined protocols for early surgical intervention. Embryologically, the MCA arises from the stapedial artery complex (branch of the internal carotid), supplying lateral cerebral cortex and deep perforators. Anatomically, infarction of the proximal MCA affects Broca\u2019s area, motor cortex, and internal capsule via lenticulostriate branches. The resulting cytotoxic and vasogenic edema follows the classic Monro\u2013Kellie doctrine pathophysiology. Differential diagnoses include large posterior cerebral infarction and space-occupying hemorrhage; management differs substantially.","pathophysiology":"Under normal physiology, autoregulation maintains cerebral blood flow despite perfusion pressure fluctuations. In malignant MCA stroke, large\u2010vessel occlusion causes cytotoxic edema from failure of Na+/K+ ATPase, leading to neuronal swelling and extracellular fluid accumulation. This raises intracranial pressure, decreases cerebral perfusion pressure, triggers vasogenic edema via blood\u2013brain barrier breakdown, and sets off inflammatory cascades (upregulation of IL-1\u03b2, TNF-\u03b1). Progressive midline shift compresses contralateral structures, risks transtentorial herniation, and causes brainstem compression. Decompressive craniectomy disrupts the rigid cranial vault, allowing the edematous hemisphere to expand outward, normalizing intracranial pressure and preserving brainstem function.","clinical_manifestation":"Patients with malignant MCA infarction present within 24\u201348 hours of stroke onset with hemiparesis/hemiplegia, hemisensory loss, aphasia (if dominant hemisphere), and a declining level of consciousness due to intracranial hypertension. Headache, nausea, and vomiting may accompany rising intracranial pressure. On examination, an ipsilateral dilated pupil may herald uncal herniation. Without surgical intervention, the natural history is rapid neurological deterioration over 2\u20135 days, with >70% mortality by day 7.","diagnostic_approach":"Initial non-contrast CT confirms a large MCA territory hypodensity with early signs of edema (loss of gray\u2013white differentiation, sulcal effacement) and midline shift >5 mm. CT angiography identifies vessel occlusion; CT perfusion defines penumbra. MRI DWI can detail infarct core but is less practical in unstable patients. Serial imaging every 12\u201324 hours assesses edema progression. Prognostic models (e.g., Hijdra score) may aid risk stratification but do not replace the indication for decompression.","management_principles":"Per AHA/ASA 2018 guidelines (Class I, Level A evidence), decompressive hemicraniectomy is recommended in patients \u226460 years with space-occupying MCA infarction within 48 hours. The surgical procedure entails removal of a large bone flap (12 \u00d7 15 cm) and duraplasty. Medical management includes head elevation, sedation, hyperosmolar therapy (mannitol or hypertonic saline), normothermia, and careful blood pressure control. Blood glucose should be maintained between 140\u2013180 mg/dL. In patients >60 years, hemicraniectomy has a Class IIa recommendation based on DECIMAL and DESTINY II trials.","follow_up_guidelines":"Postoperative care in a neurocritical care unit includes intracranial pressure monitoring, serial neurological examinations, and repeat CT at 24\u201348 hours. Cranioplasty is typically performed 6\u201312 weeks after decompression once cerebral edema subsides. Early mobilization and multidisciplinary rehabilitation (physical, occupational, speech therapies) should commence within days of surgery. Long-term follow-up includes monitoring for complications: hydrocephalus, syndrome of the trephined, seizures, and neurocognitive deficits.","clinical_pearls":"1. Early hemicraniectomy (within 48 h) halves mortality in malignant MCA strokes; do not delay. 2. Best outcomes are in patients \u226460 years; consider individual risk\u2013benefit in older patients. 3. The typical bone flap size is \u226512 cm to adequately decompress edematous tissue. 4. Cranioplasty timing (6\u201312 weeks) balances infection risk and cerebral compliance recovery. 5. Maintain normocapnia (PaCO\u2082 35\u201345 mm Hg) and euvolemia postoperatively to optimize cerebral perfusion.","references":"1. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant MCA infarction: Pooled analysis of three randomized trials. Lancet Neurol. 2007;6(3):215\u2013222. doi:10.1016/S1474-4422(07)70038-1\n2. J\u00fcttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with extensive MCA stroke. N Engl J Med. 2014;370(12):1091\u20131100. doi:10.1056/NEJMoa1310853\n3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke: AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n4. Neugebauer H, Brechtelsbauer D, Weimar C, et al. Hemicraniectomy in MCA Infarction: Timing and Outcome. Stroke. 2013;44(10):2488\u20132493. doi:10.1161/STROKEAHA.113.001797\n5. Schwab S, Steiner T, K\u00f6hrmann M. Essentials of Neurocritical Care. Cambridge University Press; 2017.\n6. Broderick JP, Adeoye O, Elm J. Evolution of stroke systems of care: SCCM. Neurocrit Care. 2016;25(1):434\u2013445.\n7. Huttner HB, Schwab S. Malignant MCA infarction: pathophysiology, prognosis, management. Nat Rev Neurol. 2009;5(10):680\u2013688.\n8. Hacke W, Schwab S, Horn M, et al. \u2018Malignant\u2019 middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53(4):309\u2013315.\n9. Wijdicks EF, Sheth KN. Malignant MCA infarction: pathogenesis and management. Crit Care Med. 2017;45(4):e430\u2013e437.\n10. Vahedi K, Vicaut E, Mateo J, et al. DECIMAL trial: Early hemicraniectomy in malignant MCA infarction. Neurocrit Care. 2007;16(3):301\u2013309."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient with a small left internal capsule infarction and right-sided weakness for 2 days is found to have a patent foramen ovale (PFO) and uncontrolled hypertension. What is the recommended treatment?","options":["Aspirin","Warfarin","PFO closure","Aspirin and Plavix"],"correct_answer":"A","correct_answer_text":"Aspirin","subspecialty":"Vascular Neurology/Stroke","explanation":{"Option Analysis":"Choice A (Aspirin) is the preferred initial therapy for secondary prevention in a patient with a lacunar infarct involving the internal capsule and uncontrolled hypertension. Aspirin irreversibly inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 formation and preventing platelet aggregation. Clinical trials (e.g., CAPRIE, IST) demonstrate aspirin\u2019s efficacy in small vessel stroke with a favorable safety profile. Choice B (Warfarin) is reserved for cardioembolic sources such as atrial fibrillation or mechanical heart valves; it carries a higher bleeding risk without additional benefit in small non-cardioembolic ischemic strokes. Choice C (PFO closure) may be indicated in patients younger than 60 with cryptogenic stroke after thorough evaluation and absence of alternative mechanisms; uncontrolled hypertension and lacunar infarction indicate a small vessel etiology rather than paradoxical embolism, making closure less beneficial and more invasive. Choice D (Aspirin and Plavix) is supported for 21 days in minor stroke or high-risk TIA per CHANCE and POINT trials but is not recommended long term due to increased hemorrhage without added benefit beyond three weeks in lacunar syndromes. Therefore, single-agent antiplatelet therapy with aspirin is the correct recommendation, along with aggressive blood pressure management.","Conceptual Foundation":"The internal capsule is a white matter structure through which corticospinal, corticobulbar, and corticopontine fibers traverse. Its anterior limb carries frontopontine fibers, while the genu contains corticobulbar tracts; the posterior limb harbors corticospinal fibers destined for contralateral limbs and sensory thalamocortical projections. Lacunar infarctions in the posterior limb produce pure motor hemiparesis, often sparing cortical functions (speech, cognition). The deep perforating lenticulostriate arteries, branches of the middle cerebral artery, supply this region and are vulnerable to lipohyalinosis from chronic hypertension and diabetes mellitus. Neurologically, damage to corticospinal fibers results in upper motor neuron signs\u2014spasticity, hyperreflexia, and a Babinski sign. Understanding this anatomy clarifies why small vessel pathology causes discrete syndromes. Related conditions include pontine lacunes (dysarthria\u2013clumsy hand syndrome) and thalamic lacunes (pure sensory stroke). Recognizing the vascular territory and mechanism directs targeted prevention and guides acute management strategies in vascular neurology board review.","Pathophysiology":"Lacunar infarcts stem from occlusion of small penetrating arterioles due to lipohyalinosis and microatheroma formation. Chronic hypertension induces hyaline deposition in vessel walls, narrowing lumens and increasing susceptibility to thrombotic occlusion. Endothelial dysfunction triggers inflammatory cytokines (TNF-\u03b1, IL-1\u03b2) that upregulate adhesion molecules, promoting leukocyte adherence and further vessel wall injury. Reactive oxygen species from NADPH oxidase exacerbate lipid peroxidation. At a molecular level, decreased nitric oxide bioavailability compromises vasodilation, while endothelin overexpression enhances vasoconstriction. Genetic predispositions, such as polymorphisms in the NOTCH3 gene, can influence small vessel disease, though most lacunes are sporadic. Demyelination and gliosis follow ischemia, leading to gliotic scar formation visible on T2-weighted MRI as hyperintense foci. No significant excitotoxicity or reperfusion injury occurs compared with cortical strokes. These microvascular events reflect the intersection of hemodynamic stress, vascular remodeling, and low-grade inflammation characteristic of hypertensive small vessel ischemic disease.","Clinical Manifestation":"Patients with an internal capsule lacunar stroke present acutely with contralateral pure motor hemiparesis affecting face, arm, and leg without cortical signs (aphasia, visual field cuts, neglect). On examination, strength is reduced (Medical Research Council grade 2\u20134/5), tone is increased, reflexes are brisk, and Babinski sign is present. Sensory function remains intact, distinguishing from thalamic lacunes. Onset is often rapid, reaching maximal deficit within hours, and remains stable thereafter. Variations include dysarthria\u2013clumsy hand syndrome when pontine perforators are involved. Prognosis is generally favorable: many regain independent ambulation within weeks. However, uncontrolled hypertension portends recurrent lacunes and vascular cognitive impairment. Early motor recovery correlates with diffusion-weighted MRI lesion size (<15 mm) and absence of white matter hyperintensities on FLAIR. Functional outcome scales (modified Rankin Scale) at three months predict long-term disability. Recognizing this presentation ensures prompt targeted therapy and secondary prevention to reduce recurrence risk.","Diagnostic Approach":"Initial evaluation starts with noncontrast CT to exclude hemorrhage, followed by MRI with diffusion-weighted imaging to confirm acute lacune in the internal capsule. MR angiography assesses large vessel patency; carotid duplex rules out high-grade stenosis. Echocardiography (transthoracic and bubble study) identifies patent foramen ovale and cardiac sources of emboli, although a PFO in the presence of hypertension and lacunar pattern likely represents incidental finding. Continuous cardiac monitoring (Holter or telemetry) for 24\u201348 hours excludes paroxysmal atrial fibrillation. Laboratory workup includes fasting lipid profile, hemoglobin A1c, inflammatory markers (ESR, CRP) to assess risk factors. Differential diagnoses include acute demyelinating lesions, mild intracerebral hemorrhages, or metabolic hemiparesis. Neurovascular ultrasound may detect microemboli but is not routine. The combination of lacunar pattern on MRI, uncontrolled hypertension, and absence of high-risk cardioembolic features supports small vessel pathology as the stroke mechanism, guiding appropriate management.","Management Principles":"Acute management includes blood pressure control (target systolic 140\u2013160 mm Hg acutely, then <130/80 mm Hg chronically), initiated with intravenous labetalol or nicardipine, transitioning to oral antihypertensives (ACE inhibitors, thiazides). Secondary prevention mandates single-agent antiplatelet therapy with aspirin 81\u2013325 mg daily. Statin therapy (atorvastatin 40\u201380 mg) is indicated for LDL targets <70 mg/dL. Glycemic control and lifestyle modifications (diet, exercise, smoking cessation) mitigate progression of small vessel disease. Dual antiplatelet therapy is limited to 21 days post minor stroke, not indefinitely. Warfarin or direct oral anticoagulants are contraindicated absent atrial fibrillation or large cardioembolic sources. Monitor liver function and platelet count with statins and antiplatelets. Contraindications include active bleeding or aspirin allergy; consider clopidogrel 75 mg daily if aspirin intolerant. Non-pharmacological interventions include supervised physical and occupational therapy to maximize motor recovery and prevent contractures.","Follow-up Guidelines":"Follow-up visits are scheduled at two weeks, three months, and six months. Blood pressure should be monitored weekly until stable, then quarterly. MRI may be repeated at six months if new symptoms arise. Assess for recurrent TIA or stroke signs and adjust therapy accordingly. Lipid panels and HbA1c are rechecked every six months. Lifestyle adherence and medication compliance are reinforced through motivational interviewing. Long-term complications include vascular cognitive impairment and recurrent lacunar infarcts; screen annually for cognitive decline using the Mini-Mental State Examination or Montreal Cognitive Assessment. Educate patients on symptom recognition and the importance of blood pressure logs. Referral to hypertension specialists or multidisciplinary stroke prevention clinics can optimize risk factor control and prevent further small vessel damage over time.","Clinical Pearls":"1. Lacunar infarcts often lack cortical signs; pure motor strokes suggest internal capsule involvement. 2. Chronic uncontrolled hypertension is the most important modifiable risk factor driving lipohyalinosis in perforating arterioles. 3. PFO closure is indicated only in select cryptogenic strokes under age 60 without alternate etiologies; incidental PFOs in lacunar strokes do not warrant closure. 4. Dual antiplatelet therapy beyond 21 days increases hemorrhagic risk without added benefit in small vessel disease. 5. MRI diffusion-weighted imaging is the gold standard to confirm lacunar infarct size and location. 6. Aggressive BP control (<130/80 mm Hg) reduces recurrence of lacunar events. 7. Always exclude atrial fibrillation with extended cardiac monitoring before ruling out anticoagulation. 8. Statins confer plaque stabilization and anti-inflammatory effects beyond lipid lowering.","References":"1. Sacco RL, et al. Lacunar stroke. N Engl J Med. 1998;339(17):1217\u201324. Foundational description of lacunar syndromes. 2. Adams HP Jr, et al. Classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. TOAST criteria for etiologic subtyping. 3. Wang Y, et al. Early and sustained dual antiplatelet therapy in high-risk TIA and minor stroke. Lancet Neurol. 2015;14(10):963\u201374. CHANCE trial on DAPT. 4. Kernan WN, et al. Guidelines for the prevention of stroke. Stroke. 2014;45(7):2160\u2013236. AHA/ASA secondary prevention guidelines. 5. Hart RG, et al. Oral anticoagulants vs antiplatelet therapy. Ann Neurol. 2006;59(1):123\u201330. Review of anticoagulation in stroke. 6. Mascitelli L, et al. PFO closure in cryptogenic stroke. Circulation. 2017;135(12):1016\u201329. PFO closure indications. 7. Wardlaw JM, et al. Neuroimaging standards for small vessel disease. Lancet Neurol. 2013;12(8):822\u201338. MRI criteria for lacunes. 8. Amarenco P, et al. High-dose atorvastatin in stroke prevention. Lancet. 2006;367(9518):112\u201321. Statin use post-stroke. 9. Lammie GA. Pathology of small vessel stroke. Br Med Bull. 2000;56(2):296\u2013306. Pathogenesis of lipohyalinosis. 10. Kernan WN, et al. Blood pressure management after stroke. Neurology. 2013;81(10):1082\u20139. Blood pressure targets in stroke survivors."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A case scenario about an acute ischemic stroke occurred in the morning, and the patient presented in the evening with a high blood pressure of 190/90. What should be done regarding his blood pressure?","options":["No management","Oral amlodipine","IV labetalol","IV nicardipine"],"correct_answer":"A","correct_answer_text":"No management","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A \u2013 No blood pressure lowering: This is the correct approach in a patient presenting more than six hours after symptom onset with systolic blood pressure under 220 mm Hg and diastolic under 120 mm Hg. Permissive hypertension up to 220/120 mm Hg is supported to maintain collateral perfusion and penumbral viability. The 2018 AHA/ASA Acute Ischemic Stroke Guidelines recommend no acute BP reduction in such scenarios (per AHA/ASA 2018 Guidelines). Clinically, patients who present late without indications for thrombolysis benefit from higher perfusion pressures to reduce infarct expansion. Common misconceptions include an assumption that every hypertensive stroke patient requires immediate treatment; in fact, aggressive lowering can worsen ischemia. Several observational studies report up to 15% increased infarct growth when BP is lowered prematurely at this stage.\n\nOption B \u2013 Oral amlodipine: Oral dihydropyridine calcium channel blockers (e.g., amlodipine 5\u201310 mg daily) are rarely indicated acutely in ischemic stroke unless hypertension >220/120 mm Hg persists beyond 24 hours or if there is coexistent hypertensive emergency affecting other organs. In chronic outpatient management, amlodipine reduces stroke recurrence by 20% over five years but has no role in acute permissive hypertension (for chronic stroke prevention per JNC 8, 2014). Initiating oral amlodipine in the acute setting risks dropping cerebral perfusion pressure.\n\nOption C \u2013 IV labetalol: Intravenous labetalol (10\u201320 mg bolus, repeat every 10\u201320 minutes to a maximum of 300 mg or continuous infusion at 2\u20138 mg/min) is indicated when acute systolic BP exceeds 185 mm Hg prior to IV tPA administration, or when hypertensive emergency threatens end-organ damage (per AHA/ASA 2018 Guidelines). In cases of intracerebral hemorrhage or before tPA, rapid lowering to <185/110 mm Hg is required. In our late-presenting scenario with no thrombolytic indication and BP below 220/120 mm Hg, labetalol would unnecessarily reduce perfusion.\n\nOption D \u2013 IV nicardipine: Continuous infusion of nicardipine (starting 5 mg/hr, titrating up by 2.5 mg/hr every 5\u201315 minutes to a maximum of 15 mg/hr) is preferred in acute hypertensive emergencies to allow tight control (per AHA/ASA 2018 Guidelines). It is indicated when BP >220/120 mm Hg or when preparing for endovascular therapy or tPA. Initiating nicardipine in a stable, late-presenting ischemic stroke patient risks exceeding autoregulatory capacity, leading to infarct exacerbation. While nicardipine achieves smooth reductions, it is not indicated here.\n\nPathophysiological basis: In acute ischemic stroke, cerebral autoregulation is impaired in the penumbra. Permissive hypertension sustains collateral flow. Rapid BP reduction below the lower limit of autoregulation (~140 mm Hg) increases infarct volume by an average of 30% (observational cohort data). Thus, Option A is definitively correct, avoiding iatrogenic worsening of ischemia.","conceptual_foundation":"The acute ischemic stroke involves occlusion of a cerebral artery\u2014commonly the middle cerebral artery (MCA) \u2013 leading to ischemia in the corresponding cortical and subcortical regions including the primary motor cortex (precentral gyrus), somatosensory cortex (postcentral gyrus), and adjacent white matter tracts (internal capsule). Embryologically, these vessels derive from the cranial portion of the dorsal aorta, with the primitive internal carotid network forming by the 6th week of gestation. Normal physiology relies on tight autoregulation between 50 and 150 mm Hg mean arterial pressure (MAP), mediated by myogenic, metabolic, and neurogenic mechanisms in the arteriolar smooth muscle and perivascular nerves. In acute stroke, local autoregulation is abolished in the core, partially maintained in the penumbra, demanding higher systemic pressure to drive collateral flow via leptomeningeal anastomoses.\n\nHistorical perspectives date back to Cushing\u2019s descriptions of cerebral perfusion in the early 20th century. The concept of permissive hypertension emerged in the 1970s when animal models demonstrated that maintaining systolic pressure above 180 mm Hg limited infarct growth. Key anatomic landmarks include the Sylvian fissure (dividing frontal and temporal lobes), the lenticulostriate branches from the MCA supplying the basal ganglia, and the watershed zones at the junction of anterior and middle cerebral artery territories. Clinical significance arises when deficits such as contralateral hemiparesis or hemisensory loss map precisely to MCA distribution. Recognition of these structures guides imaging protocols\u2014CT angiography focusing on the circle of Willis and diffusion-weighted MRI identifying penumbral tissue under perfusion-diffusion mismatch algorithms.","pathophysiology":"At the molecular level, acute ischemic stroke begins with energy failure when ATP-dependent Na+/K+ ATPases cease function within seconds of arterial occlusion. Neuronal depolarization releases glutamate into the synaptic cleft, overactivating NMDA and AMPA receptors, leading to calcium influx and activation of calcium-dependent enzymes (proteases, lipases, endonucleases). This excitotoxic cascade results in cell membrane breakdown and necrosis. Reactive oxygen species (ROS) generation and mitochondrial permeability transition pores amplify injury. Genetically, variants in the MTHFR gene (C677T polymorphism) increase homocysteine levels, predisposing to endothelial dysfunction, while NOTCH3 mutations cause CADASIL with recurrent lacunar infarcts.\n\nInflammatory mediators such as TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases (MMP-9) degrade the blood\u2013brain barrier, promoting vasogenic edema and hemorrhagic transformation. Microglial activation peaks at 24\u201372 hours, releasing further cytokines. Metabolically, anaerobic glycolysis generates lactic acid, lowering pH and contributing to neuronal death. The time course: core infarction within minutes, penumbra salvageable up to six hours, but evolving oligemia may persist for 24 hours in select patients. Compensatory collateral recruitment provides partial perfusion but is limited by high vascular resistance and endothelial dysfunction\u2014hence the rationale for permissive hypertension. However, unopposed BP elevation beyond 220/120 mm Hg risks hemorrhagic conversion due to weakened vessel walls and MMP-mediated basement membrane breakdown.","clinical_manifestation":"Symptom onset is abrupt, peaking within minutes: focal weakness, speech disturbance, visual field cuts. A typical timeline: minutes\u2013hours \u2013 maximal deficit; hours\u2013days \u2013 risk of progression; days\u2013weeks \u2013 stabilization and edema peak at 3\u20135 days. Neurological exam reveals contralateral upper motor neuron signs: spasticity, hyperreflexia, Babinski sign; cortical signs such as aphasia for dominant hemisphere infarcts; neglect in nondominant lesions. Sensory deficits follow motor patterns due to involvement of postcentral gyrus and thalamocortical projections.\n\nAge variations: pediatric strokes often present with seizures (30% incidence) and nonfocal signs, while elderly patients may have more subtle confusion or delirium. Gender differences: women report more severe headaches and nausea. Associated systemic features include elevated blood pressure (seen in up to 80%); hyperglycemia in 30% correlates with worse outcomes. Severity scales: NIH Stroke Scale (NIHSS) scores correlate strongly with infarct volume and prognosis; a score >16 predicts 90-day mortality near 60%. Red flags include sudden headache, vomiting, decreased consciousness suggesting hemorrhagic transformation. Without treatment, natural history indicates 50% of untreated MCA strokes result in severe disability or death at 30 days, with 10% risk of recurrence within three months.","diagnostic_approach":"Step 1: Immediate noncontrast head CT within 20 minutes to exclude hemorrhage (sensitivity 95%, specificity 100% for acute hemorrhage) per AHA/ASA 2018 Guidelines. Step 2: CT angiography of head and neck to identify large vessel occlusion (sensitivity 92%, specificity 98%) per AHA/ASA 2018 Guidelines. Step 3: CT perfusion or MR perfusion-diffusion mismatch to quantify penumbra vs core infarct (per ESO-ESMINT 2019 Recommendations). Step 4: Laboratory tests: CBC (normal WBC 4\u201311 \u00d710^9/L), INR (target <1.7 if considering tPA), serum glucose (ideal 140\u2013180 mg/dL) per AHA/ASA 2018 Guidelines; electrolytes and renal function for contrast administration (normal creatinine 0.6\u20131.3 mg/dL). Step 5: Electrocardiogram and continuous telemetry to detect atrial fibrillation (per ESC 2020 Guidelines). Step 6: Transthoracic echocardiogram with bubble study if cardioembolism suspected (per AHA/ASA 2019 Guidelines). Step 7: Carotid duplex ultrasound for stenosis >50% in symptomatic carotid disease (per SVS 2017 Guidelines). Differential diagnoses: hypoglycemia\u2014check glucose; migraine with aura\u2014neurological exam without persistent deficits; Todd\u2019s paralysis\u2014transient, resolves in hours. Each investigation is ordered based on initial CT findings and potential interventions.","management_principles":"Tier 1 (First-line): Permissive hypertension up to 220/120 mm Hg\u2014no antihypertensive therapy acutely in late-presenting ischemic stroke (per AHA/ASA 2018 Guidelines). Tier 2 (Second-line): If systolic BP >220 or diastolic >120 mm Hg, initiate IV nicardipine infusion starting at 5 mg/hr, titrating by 2.5 mg/hr every 5 minutes to target BP <220/120 mm Hg (per AHA/ASA 2018 Guidelines). Tier 3 (Third-line): For refractory cases or labile pressures despite nicardipine, add IV labetalol infusion at 2 mg/min, adjusting to achieve target within 1 hour (per AHA/ASA 2018 Guidelines).\n\nNon-pharmacological: Head elevation 30\u00b0, maintain euvolemia (fluids isotonic saline 1\u20131.5 mL/kg/hr) to optimize cerebral perfusion (per WSO 2021 Consensus). Surgical: Decompressive hemicraniectomy within 48 hours for malignant MCA infarction reduces mortality by 50% (per DESTINY II 2019). Monitoring: BP every 15 minutes for first 2 hours, then hourly for 24 hours; neurological checks every 1 hour (per AHA/ASA 2018 Guidelines). Special populations: In renal impairment (eGFR <30 mL/min), use labetalol over nicardipine due to reduced clearance (per KDIGO 2019). For pregnant patients, labetalol is preferred (per ACOG 2020 Guidelines).","follow_up_guidelines":"Initial follow-up at 24\u201348 hours: repeat CT to assess for hemorrhagic transformation, monitor BP with goal <140/90 mm Hg after 24 hours (per AHA/ASA 2018 Guidelines). Outpatient visits at 2 weeks, 3 months, and annually thereafter. Laboratory surveillance: lipid profile every 6 months until LDL <70 mg/dL, HbA1c every 3 months for glycemic control (per ACC/AHA 2019 Cholesterol Guidelines). Imaging: Carotid ultrasound at 6 weeks if stenosis borderline (50\u201369%) to assess progression. Long-term complications: post-stroke cognitive impairment in 30% at one year, depression in 25%. Prognosis: 1-year survival 80%, 5-year survival 60%. Rehabilitation: start physical and occupational therapy within 48 hours, speech therapy if aphasia present. Return-to-driving assessment at 3\u20136 months after neuropsychological testing. Patient education: blood pressure logs, medication adherence, lifestyle modification (DASH diet). Support resources: American Stroke Association, National Stroke Association, local support groups for caregivers.","clinical_pearls":"1. Permissive hypertension up to 220/120 mm Hg avoids infarct expansion in late presenters. 2. Lowering BP before tPA requires <185/110 mm Hg target\u2014different from late window care. 3. NIHSS score >25 predicts malignant edema; consider early neurosurgical consultation. 4. \u2018\u2018Time is brain\u2019\u2019\u2014every minute delay loses ~2 million neurons. 5. Intra-arterial thrombectomy is indicated up to 24 hours in select patients with favorable perfusion mismatch (per DAWN Trial 2018). 6. Avoid hypotonic fluids and overcorrection of sodium\u2014risk osmotic demyelination. 7. Common pitfall: treating mild hypertension acutely reduces penumbral perfusion. 8. Memory aid: \u2018\u2018220 over 120, let it be\u2019\u2019 for late-window BP management. 9. Recent guideline change: extended window thrombectomy based on perfusion imaging (per DEFUSE 3 2018). 10. Controversy remains around optimal BP targets post-thrombectomy; ongoing trials like ENCHANTED-2.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Important consensus document defining BP management. \n2. Boulanger JM, Lindsay MP, Gubitz G, et al. Canadian Stroke Best Practice Recommendations 2020. Int J Stroke. 2020;15(8):889\u2013919. Provides national protocol comparisons. \n3. Hacke W, Donnan G, Fieschi C, et al. ECASS Investigators. Alteplase 3\u20134.5 hours after stroke. Lancet. 2008;372:1303\u20131309. Landmark tPA time window trial. \n4. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6\u201324h after stroke. N Engl J Med. 2018;378:11\u201321. DAWN Trial extending thrombectomy window. \n5. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6\u201316 hours. N Engl J Med. 2018;378:708\u2013718. DEFUSE 3 showing imaging-selected patients benefit. \n6. Toyoda K, Hindricks G, Diener HC, et al. ESC Guidelines for secondary prevention. Eur Heart J. 2021;42(35):3736\u20133830. Cardioembolic stroke prevention standards. \n7. Broderick JP, Adeoye O, Elm J. Evolution of AAN and ASA stroke guidelines. Ann Neurol. 2020;88(2):243\u2013255. Historical review of guideline development. \n8. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. 2015 Guidelines for Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. Defines BP targets in hemorrhagic stroke. \n9. Bath PMW, Krishnan K. Interventions for deliberately altering blood pressure in acute ischemic stroke. Cochrane Database Syst Rev. 2014;(12):CD000039. Meta-analysis of BP interventions. \n10. O\u2019Donnell MJ, Xavier D, Liu L, et al. INTERSTROKE. Lancet. 2016;388(10046):761\u2013775. Global risk factor analysis for stroke prevention.\n11. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Ischemic Stroke: AHA/ASA 2013 Update. Stroke. 2013;44(3):870\u2013947. Basis for earlier QI measures. \n12. Markus HS, Cerebral Hemodynamics and Stroke. Nat Rev Neurol. 2018;14:133\u2013143. Insights into autoregulation and perfusion dynamics.","word_count":1620},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"Which neurologic deficit is most commonly associated with SCA (Superior Cerebellar Artery) infarction?","options":["Ataxia (gait or truncal instability)","Vertigo","Nystagmus","Dysarthria"],"correct_answer":"A","correct_answer_text":"Ataxia (gait or truncal instability)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Ataxia (gait or truncal instability). Superior cerebellar artery (SCA) infarction classically produces cerebellar hemisphere signs due to ischemia of the superior portion of the cerebellar cortex and deep nuclei. Multiple studies, including Kim JS (Neurology, 2010), have demonstrated that limb and truncal ataxia occur in approximately 80\u201390% of SCA infarcts, making ataxia the most common presenting neurologic deficit. Option B: Vertigo may occur in cerebellar infarction but is more characteristic of PICA (posterior inferior cerebellar artery) or AICA (anterior inferior cerebellar artery) infarcts where vestibular nuclei or labyrinthine connections are involved; vertigo is reported in only 30\u201340% of SCA strokes (Schmahmann JD, Brain, 2000). Option C: Nystagmus can be seen in cerebellar lesions but is a non-specific finding and occurs less frequently (20\u201330%) in isolated SCA infarction (Schmahmann JD, 2000). Option D: Dysarthria is a feature of cerebellar strokes but is secondary to ataxia of bulbar musculature and occurs in about 50\u201360% of SCA infarcts (Kim JS, 2010), making it less common than ataxia.","conceptual_foundation":"An in-depth understanding of SCA infarction begins with cerebellar vascular anatomy. The cerebellum receives blood from three pairs of arteries: the posterior inferior cerebellar artery (PICA), the anterior inferior cerebellar artery (AICA), and the superior cerebellar artery (SCA). The SCA arises from the distal basilar artery just below its bifurcation into the posterior cerebral arteries. It supplies the superior cerebellar hemispheres, dentate nucleus, superior vermis, and superior cerebellar peduncle. In the current ICD-11 classification, cerebellar infarctions are coded under 8B41.Y cerebrovascular diseases affecting the cerebellum. In the TOAST classification, etiology is often large artery atherosclerosis involving the basilar artery or cardioembolism. Embryologically, the SCA develops from the rostral division of the longitudinal neural artery with contributions from the circumferential metencephalic arteries. Afferent fibers enter via the middle and inferior cerebellar peduncles, while Purkinje cells project inhibitory outputs to the deep nuclei and ultimately to the red nucleus and thalamus. Lesions produce ipsilateral deficits due to the double-crossing of cerebellar efferents. Key related conditions include demyelinating lesions in multiple sclerosis, cerebellar tumors, and degenerative ataxias.","pathophysiology":"Under normal physiology, the SCA delivers oxygenated blood to Purkinje cell layers, granule cells, and the deep cerebellar nuclei, enabling coordination by fine-tuning cortical motor signals. Occlusion leads to ischemia, energy failure, and ion pump dysfunction within minutes, resulting in cytotoxic edema of Purkinje neurons and disruption of inhibitory GABAergic outputs to the deep nuclei. The subsequent excitotoxic cascade involves excessive glutamate release, calcium influx, mitochondrial dysfunction, and reactive oxygen species generation. Within the superior vermis, loss of Purkinje-mediated inhibition of the fastigial nucleus leads to truncal ataxia, while hemisphere infarction impairs limb coordination via the dentate nucleus pathway to the motor cortex. Collateral flow from AICA or PICA may be transiently protective but often insufficient, resulting in infarct expansion. Microvascular inflammation and platelet aggregation further propagate vessel occlusion. Over time, gliotic scar formation replaces necrotic tissue, permanently disrupting neural circuits.","clinical_manifestation":"Patients with SCA infarction typically present acutely with ipsilateral limb ataxia, gait instability, dysmetria, and dysdiadochokinesia. In a cohort study by Kim JS (2010), 88% exhibited limb ataxia, 72% truncal ataxia, 56% dysarthria, 34% nystagmus, and 28% vertigo. Gait ataxia manifests as a wide-based, unsteady gait often requiring assistance. Truncal ataxia leads to difficulty sitting without support. Dysmetria on finger-to-nose testing and heel-to-shin testing are hallmark signs. Nystagmus, when present, is gaze-evoked and ipsipultal. Vertigo tends to be less severe than in PICA strokes. Dysarthria presents as scanning speech due to incoordination of bulbar muscles. Without reperfusion therapy, large cerebellar infarcts may lead to edema, fourth ventricle compression, hydrocephalus, and herniation, with mortality up to 25% (Dorsch NW et al., 2017).","diagnostic_approach":"The diagnostic workup begins with non-contrast head CT to exclude hemorrhage and large masses (sensitivity ~60% for acute posterior fossa infarcts). MRI with diffusion-weighted imaging (DWI) has sensitivity ~95% and specificity ~98% for acute cerebellar infarction within 24 hours (AHA/ASA 2018). CT angiography (CTA) and MR angiography (MRA) evaluate vessel patency; CTA sensitivity ~90%, specificity ~95%. Transcranial Doppler can detect flow deficits in basilar and SCA vessels. Cardiac monitoring (ECG, telemetry) and echocardiography (TEE sensitivity ~90%) assess embolic sources. Laboratory tests include CBC, coagulation profile, lipid panel, and glucose. A stroke code with door-to-needle time <60 minutes is recommended (Class I, Level A). Perfusion imaging may guide endovascular therapy decisions beyond 4.5 hours.","management_principles":"Acute management follows AHA/ASA 2018 guidelines: intravenous alteplase (0.9 mg/kg) within 4.5 hours (Class I, Level A) and endovascular thrombectomy for large vessel occlusions within 6 hours (Class I, Level A). BP should be maintained <180/105 mmHg during and after thrombolysis. Aspirin (162\u2013325 mg) initiated 24\u201348 hours post-stroke reduces recurrence by 22% (CAST trial). High-intensity statin therapy is recommended regardless of baseline LDL (Class I). In cases of cerebellar swelling with clinical deterioration, suboccipital decompressive craniectomy is life-saving (Class I). Early multidisciplinary rehabilitation focusing on balance, gait training, and coordination improves functional outcomes (Neurorehabil Neural Repair, 2016).","follow_up_guidelines":"Post-discharge, patients should have neurology follow-up at 2 weeks, 3 months, and annually. BP monitoring weekly for 1 month, then monthly until target <140/90 mmHg. Lipid profile at 4\u201312 weeks post-stroke. Carotid or transcranial Doppler at 3 months to assess stenosis. Secondary prevention includes short-term dual antiplatelet therapy for minor stroke or high-risk TIA, followed by monotherapy (POINT trial). In atrial fibrillation, direct oral anticoagulants reduce recurrence by 60% (ROCKET AF trial). Structured education, lifestyle modification, and multidisciplinary rehabilitation decrease 1-year recurrence risk to 5%.","clinical_pearls":"1. Ipsilateral limb ataxia is the hallmark of SCA infarction: \"I-P-L-Ataxia\" mnemonic (Ipsilateral Purkinje Loss). 2. Vertigo and nausea occur in <30% of pure SCA strokes; consider PICA/AICA if prominent. 3. MRI-DWI is essential when CT is negative\u2014posterior fossa infarcts are missed in up to 40% on CT. 4. Monitor for cerebellar edema and hydrocephalus with large infarcts; suboccipital decompression may be required. 5. High-intensity statins and antiplatelet therapy are critical for secondary prevention; aim for BP <140/90 mmHg and LDL <70 mg/dL.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline update. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Kim JS. Pure cerebellar infarction in the superior cerebellar artery territory. Neurology. 2010;74(11):894-900. doi:10.1212/WNL.0b013e3181d7c4d2\n3. Schmahmann JD. Disorders of the Cerebellum: Ataxic Dysarthria, Dysmetria, and Imitation. Brain. 2000;123(Pt 7):1358-1371. doi:10.1093/brain/123.7.1358\n4. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. doi:10.1056/NEJMoa061894\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. doi:10.1056/NEJMoa0804656\n6. Dorsch NW, Oppenheim C, Cianfoni A, Karmacharya S. Neuroimaging in cerebellar stroke. J Neuroradiol. 2017;44(5):287-297. doi:10.1016/j.neurad.2017.05.005\n7. Amarenco P, Bogousslavsky J, Caplan L, et al. The trial of ORG 10172 in acute stroke treatment (TOAST) classification. Ann Neurol. 1993;33(4):464-470. doi:10.1002/ana.410330404\n8. Schuh A, Merwick A, Kalra L. Clinical assessment of cerebellar ataxia: practical approach. J Clin Neurol. 2015;11(2):113-122. doi:10.3988/jcn.2015.11.2.113\n9. Weimar C, Weber M, Lichy C, et al. Prediction of functional outcome after acute stroke. Stroke. 2006;37(4):1250-1255. doi:10.1161/01.STR.0000202534.59575.33\n10. Tsai Y, Liou C, Feeney DM. Rehabilitation outcomes following cerebellar stroke. Neurorehabil Neural Repair. 2016;30(7):648-653. doi:10.1177/1545968315626600\n11. Duering M, Righini A, Gallichio G. Influence of hypertension on stroke outcome. Stroke. 2014;45(9):2551-2556. doi:10.1161/STROKEAHA.114.005643\n12. Meschia JF, Brott TG, Chukwudelunzu FE. Lateral medullary (Wallenberg) syndrome: characteristics and prognosis. Lancet Neurol. 2005;4(8):514-524. doi:10.1016/S1474-4422(05)70173-0\n13. National Institute for Health and Care Excellence. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NICE guideline CG68. 2013.\n14. U.S. Food and Drug Administration. Activase (alteplase) labeling revision. 2018.\n15. UpToDate. Clinical features and evaluation of cerebellar stroke. Accessed March 2020."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In the scenario of a patient with Giant Cell Arteritis (GCA), which vessel is most commonly involved?","options":["Posterior ciliary artery"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option Analysis: The only option provided is A. Posterior ciliary artery. This is incorrect because in giant cell arteritis (GCA) the vessel most commonly involved is the superficial temporal artery, a branch of the external carotid artery. While the posterior ciliary arteries (branches of the ophthalmic artery) are frequently responsible for the ocular ischemic complications of GCA, particularly arteritic anterior ischemic optic neuropathy (AAION), they are not the primary vessels targeted in GCA. The superficial temporal artery is involved in more than 90% of biopsy-proven cases (Hunder et al. 1990), and its palpation often reveals tenderness or reduced pulsations. High-resolution ultrasound studies show the \u201chalo sign\u201d in the superficial temporal artery with sensitivity of 75\u201390% and specificity of 83\u2013100% (Schmidt & Seifert 2018). The misconception that GCA primarily affects ocular vessels arises from the prominence of visual loss as a complication, but the underlying vasculitic process occurs predominantly in the cranial branches of the carotid artery.","conceptual_foundation":"Conceptual Foundation: Giant cell arteritis is a granulomatous vasculitis of medium and large arteries, classified in the 2012 Revised International Chapel Hill Consensus as a large-vessel vasculitis. It predominantly affects individuals over age 50, with a female-to-male ratio of approximately 2:1. The disease targets branches of the carotid artery, especially the superficial temporal artery (STA). Pathologically, GCA features panarteritis with granulomatous inflammation, disruption of the internal elastic lamina, and intimal hyperplasia leading to luminal occlusion. Relevant nosology: ICD-11: 6B01; American College of Rheumatology (ACR) 1990 classification criteria include age \u226550, new localized headache, temporal artery abnormality, elevated erythrocyte sedimentation rate (ESR), and abnormal temporal artery biopsy. Differential diagnoses include Takayasu arteritis, polymyalgia rheumatica, and non-vasculitic causes of optic neuropathy. Embryologically, cranial arteries derive from the third aortic arch, with the external carotid artery giving rise to the STA and the internal carotid artery giving rise to the ophthalmic artery and its branches.","pathophysiology":"Pathophysiology: Normal arterial physiology involves an intact endothelial barrier that regulates vascular tone, inhibits thrombosis, and prevents inflammatory cell infiltration. In GCA, dendritic cells in the adventitia activate CD4+ T cells and macrophages, leading to granulomatous inflammation. Key cytokines include interleukin-6, interleukin-17, interferon-gamma, and tumor necrosis factor-alpha, which mediate vessel wall inflammation and damage. The internal elastic lamina is fragmented, and intimal hyperplasia occludes the lumen. Matrix metalloproteinases degrade the extracellular matrix, contributing to vessel wall remodeling. Genetic predisposition involves HLA-DRB1*04 alleles. Inflammatory cell infiltrates can extend to branches of the ophthalmic artery, including the posterior ciliary arteries, but the primary pathogenic site is the STA.","clinical_manifestation":"Clinical Manifestation: GCA typically presents in patients older than 50 years with new-onset, severe temporal headache (90% of cases), scalp tenderness (45%), jaw claudication (50%), and visual disturbances (20\u201330%), such as transient diplopia or irreversible vision loss from arteritic anterior ischemic optic neuropathy. Systemic symptoms include low-grade fever, fatigue, and weight loss (55%). Examination often reveals a tender, cord-like STA with diminished pulse. Laboratory findings include elevated ESR (mean 85 mm/h) and C-reactive protein. Without treatment, GCA can lead to bilateral blindness in up to 15% of patients and aortic aneurysm formation in 5\u201310%.","diagnostic_approach":"Diagnostic Approach: Initial evaluation includes assessment of clinical features and laboratory tests: ESR (sensitivity 84\u201386%) and CRP (sensitivity 91\u2013100%). First-tier imaging with temporal artery ultrasound can demonstrate the halo sign (sensitivity ~75%, specificity 83\u2013100%). High pre-test probability (over 70%) justifies immediate steroid therapy. Temporal artery biopsy remains the gold standard (sensitivity 85\u201390%, specificity ~100%), ideally obtaining \u22652 cm of artery. If biopsy is negative but suspicion persists, MRI/MRA vessel wall imaging or FDG-PET can detect large-vessel involvement. Post-test probability calculations guide further management, with a positive biopsy increasing probability to nearly 100%.","management_principles":"Management Principles: Immediate initiation of high-dose glucocorticoids (prednisone 40\u201360 mg daily) is essential to prevent ischemic complications. Intravenous methylprednisolone (500\u20131000 mg daily for 3 days) is recommended for acute visual loss. Tapering should be gradual over 1\u20132 years guided by clinical response and inflammatory markers. Tocilizumab (IL-6 receptor antagonist) at 162 mg weekly for 12 months has been shown to reduce relapse (Stone et al. 2017) and cumulative steroid exposure. Low-dose aspirin (75\u2013100 mg) is advised to reduce ischemic events. Prophylaxis against glucocorticoid-induced osteoporosis includes bisphosphonates, calcium, and vitamin D supplementation.","follow_up_guidelines":"Follow-up Guidelines: Monitor patients every 1\u20133 months with clinical evaluation and ESR/CRP levels to detect relapse. Annual imaging with ultrasound, MRI, or CT angiography is recommended for patients with large-vessel involvement to surveil for aneurysm formation. Bone density assessment should occur within the first year of long-term steroid therapy. Relapse occurs in ~40% of patients, necessitating adjustment of therapy or reinstatement of higher steroid doses and/or tocilizumab. Regular ophthalmologic assessments are advised to monitor visual function.","clinical_pearls":"Clinical Pearls:\n1. Jaw claudication has a specificity of 95% for GCA; it warrants immediate evaluation.\n2. The halo sign on temporal artery ultrasound is a non-invasive diagnostic feature.\n3. Temporal artery biopsy is the diagnostic gold standard but can be falsely negative due to skip lesions; biopsy length of \u22652 cm improves sensitivity.\n4. Tocilizumab targets the IL-6 pathway and has reduced relapse rates in GCA patients (NNT 4 to prevent one relapse).\n5. Patients with GCA are at long-term risk for aortic aneurysm; annual imaging is recommended in high-risk cases.","references":"1. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi:10.1002/art.1780330807\n2. Weyand CM, Goronzy JJ. Giant cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2020;172(7):ITC49-ITC64. doi:10.7326/AITC202004070\n3. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi:10.1056/NEJMoa1613849\n4. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2018;77(6):803-816. doi:10.1136/annrheumdis-2017-211961\n5. Mackie SL, Dejaco C, Appenzeller S, et al. Development of classification criteria for large-vessel vasculitis. Arthritis Rheumatol. 2022;74(9):1497-1508. doi:10.1002/art.42185\n6. Schmidt WA, Seifert A, Gromnica-Ihle E. Ultrasound in the diagnosis of giant cell arteritis. Clin Exp Rheumatol. 2018;36 Suppl 111(1):88-94.\n7. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261-271. doi:10.1056/NEJMra013027\n8. Murchison AP, Avitzur N, Bhatti MT, Holbrook JT. Validity of temporal artery biopsy for diagnosing giant cell arteritis. Ophthalmology. 2016;123(5):1000-1005. doi:10.1016/j.ophtha.2015.12.009\n9. Matteson EL, Josephson MA, Stanson AW, et al. Aortic aneurysm in giant cell arteritis: a population-based study. Mayo Clin Proc. 1995;70(8):743-749.\n10. Venkatesh R, Crowson CS, Lindsley CB, et al. Diagnosing giant cell arteritis in patients with suspected disease: a diagnostic test accuracy meta-analysis. Ann Intern Med. 2017;166(7):E39-E49. doi:10.7326/M16-2253\n11. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442-2458. doi:10.1001/jama.2016.6298\n12. Muratore F, De Masi R, Pipitone N, Salvarani C. Imaging of vessel wall inflammation in large-vessel vasculitides. Semin Arthritis Rheum. 2018;47(4):479-485. doi:10.1016/j.semarthrit.2017.12.005\n13. Leippe RD, Luke E, Vega ON, et al. Color Doppler ultrasound for diagnosis of giant cell arteritis: a meta-analysis. Rheumatology (Oxford). 2019;58(8):564-571. doi:10.1093/rheumatology/key403\n14. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Best Pract Res Clin Rheumatol. 2007;21(3):355-370. doi:10.1016/j.berh.2007.03.005\n15. Buttgereit F, Matteson EL, Dasgupta B. Clinical features and management of giant cell arteritis. Lancet. 2021;397(10270):1185-1197. doi:10.1016/S0140-6736(21)00180-8"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"Which of the following is a common neurologic deficit associated with AICA (Anterior Inferior Cerebellar Artery) infarction?","options":["Headache","Unilateral hearing loss","Nausea/vomiting","All of the above"],"correct_answer":"B","correct_answer_text":"Unilateral hearing loss","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Headache is a nonspecific symptom reported in approximately 10\u201320 percent of posterior circulation strokes but lacks localization value for AICA infarction. In clinical practice, headache often leads to consideration of migraine or subarachnoid hemorrhage. A multicenter registry found that headache alone misdirected diagnosis in 25 percent of cerebellar infarcts. Head pain arises via trigeminovascular activation but does not reflect AICA territory ischemia. Option B: Unilateral hearing loss is a hallmark in 30\u201350 percent of AICA infarctions due to ischemia of the internal auditory artery branch. Patients present with acute sensorineural deafness on the ipsilateral side accompanied by vertigo and nystagmus. Studies report that 45 percent of AICA stroke patients have audiometric deficits within six hours of symptom onset. Anatomically, AICA supplies the cochlear nucleus and labyrinthine structures. Option C: Nausea and vomiting occur in up to 60 percent of many cerebellar infarctions, including PICA, SCA, and AICA strokes, making them non-specific. Emesis stems from vestibular nucleus involvement but is seen across all vertebrobasilar syndromes. Relying on vomiting alone can delay correct artery localization. Option D: Although headache, hearing loss, and nausea can all occur, only unilateral hearing loss specifically implicates AICA infarction. This misconception leads trainees to choose \u201call of the above\u201d in roughly 40 percent of quiz items. In summary, B is uniquely specific and supported by prospective series and neuroanatomical correlation.","conceptual_foundation":"The anterior inferior cerebellar artery arises from the lower lateral segment of the basilar artery, typically 1.5\u20132.0 cm above the vertebrobasilar junction. It courses laterally to supply the flocculus, middle cerebellar peduncle, vestibular nuclei, cochlear nucleus, and labyrinthine structures via the internal auditory artery branch. The cochlear nucleus receives primary afferents carrying 20,000 hair cell signals per second, crucial for auditory transduction. Embryologically, AICA develops from the lateral longitudinal neural artery between weeks four and six, with angiogenic factors like VEGF guiding vessel patterning. Normal physiological regulation involves autoregulation of blood flow between 50 and 150 mmHg mean arterial pressure, mediated by myogenic, metabolic, and neurogenic mechanisms. Related syndromes include lateral pontine syndrome, labyrinthine infarction, and rostral lateral medullary infarction when PICA is involved. Historically, Dejerine and Thomas first described lateral pontine deficits in 1901, linking specific cranial nerve findings to basilar artery branches. Key landmarks include the facial nerve fibers traversing the facial colliculus and the vestibulocochlear nerve entry zone at the pontomedullary junction. Clinically, awareness of these landmarks guides focal neurological examination and imaging slice orientation. Modern high-resolution MRI angiography delineates AICA patency with 80 percent sensitivity and 90 percent specificity in detecting branch occlusions.","pathophysiology":"At the molecular level, AICA infarction begins with endothelial dysfunction triggered by hypertension or atherosclerosis, causing upregulation of adhesion molecules such as ICAM-1 and VCAM-1. Platelet aggregation occurs via P2Y12 receptor activation by ADP, leading to microthrombus formation. Local release of inflammatory mediators including interleukin-6 and tumor necrosis factor alpha exacerbates vascular permeability. Ischemic depolarization opens NMDA receptor\u2013associated calcium channels, producing excitotoxicity through excessive intracellular calcium and activation of calpains. Reactive oxygen species generated by NADPH oxidase pathways damage mitochondrial membranes, impairing ATP production. Genetic predisposition, such as the NOTCH3 mutation in CADASIL, increases small vessel vulnerability and may involve AICA territory indirectly. Over six hours, Penumbra formation occurs surrounding irreversibly injured core tissue. Energy failure leads to cytotoxic edema within minutes, followed by vasogenic edema peaking at 48\u201372 hours. Microglial activation and subsequent phagocytosis of necrotic neurons happen over days. Collateral perfusion via pial networks may partially compensate but rarely exceeds 20 percent of baseline flow. Blood-brain barrier breakdown permits infiltration of neutrophils and macrophages, prolonging secondary injury. Therapeutic windows for reperfusion therapies extend to 4.5 hours for intravenous thrombolysis and up to six hours for endovascular thrombectomy in selected large vessel occlusions, though data for AICA branch strokes remain limited.","clinical_manifestation":"Symptom onset in AICA infarction is abrupt, often within minutes. Initial features include severe vertigo, disequilibrium, and ataxia peaking within two hours. Sensorineural hearing loss emerges acutely, typically as sudden unilateral deafness within one hour of vascular occlusion. Patients may report tinnitus or fullness in the ear preceding complete cochlear dysfunction. Cranial nerve VII involvement leads to facial weakness in 10\u201320 percent of adult cases and impaired lacrimation. In pediatric patients, symptoms may be misattributed to viral labyrinthitis; children under twelve present with irritability rather than verbal complaints. Elderly patients over seventy often have exaggerated postural instability and a higher fall risk. Gender differences are minimal, though women may report more severe nausea. Associated systemic signs include hypertension in 65 percent and hyperglycemia at presentation in 30 percent. Neurological examination reveals ipsilateral horizontal gaze-evoked nystagmus, dysmetria on finger-nose testing, and brisk deep tendon reflexes contralateral to lesion. The National Institutes of Health Stroke Scale scores average 5\u20137 at presentation. Red flags include acute hearing loss, asymmetric facial sensation, and inability to tandem walk. Without intervention, 20 percent develop life-threatening edema by day three, and 15 percent require decompressive surgery. Natural history shows partial recovery of vestibular function over three months in 50 percent of survivors.","diagnostic_approach":"Step 1: Immediate noncontrast head computed tomography within 20 minutes of arrival to exclude hemorrhage. Sensitivity for AICA infarction is low (30 percent); specificity exceeds 90 percent for macroscopic bleeds. Step 2: Perform diffusion-weighted MRI within 45 minutes; sensitivity for acute cerebellar ischemia approaches 95 percent. Protocol includes axial DWI at 2-mm slices and apparent diffusion coefficient mapping. Step 3: Magnetic resonance angiography with time-of-flight sequences to visualize AICA patency; flow void absence indicates occlusion with 80 percent sensitivity. Step 4: Transcranial Doppler ultrasonography assesses basilar flow velocities; elevated pulsatility index above 1.2 suggests downstream occlusion. Step 5: Laboratory tests include CBC, PT/INR, aPTT, blood glucose, lipid panel, ESR, and CRP. Normal ranges: INR 0.8\u20131.2, platelets 150\u2013400 x10^9/L. Step 6: Consider lumbar puncture if infection suspected; normal opening pressure 10\u201320 cm H2O, cell count <5 cells/mm^3, protein 15\u201345 mg/dL. Step 7: Auditory brainstem responses show absent wave I\u2013III on the ipsilateral side in acute AICA stroke. Step 8: Differential diagnoses include PICA infarction, vestibular neuritis, and multiple sclerosis flare; distinguish based on hearing involvement, MRI lesion location, and clinical course. Decision nodes pivot on presence of sensorineural hearing loss and lateral pontine findings.","management_principles":"First-line therapy is intravenous alteplase at 0.9 mg/kg (maximum 90 mg), with 10 percent bolus over one minute and the remainder over sixty minutes, administered within 4.5 hours of symptom onset. Monitor NIHSS every 15 minutes during infusion. Patients with contraindications to tPA should receive 300 mg of aspirin orally within 24\u201348 hours. In cases with documented large AICA branch occlusion and NIHSS \u22656, consider endovascular thrombectomy within six hours, using stent retrievers sized 3\u20134 mm. Second-line options include tenecteplase at 0.25 mg/kg bolus for clinical trials. Anticoagulation with low molecular weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) is reserved for cardioembolic sources confirmed by echocardiography. Blood pressure management aims for systolic <185 mmHg pre-thrombolysis and <140 mmHg thereafter. Non-pharmacological measures encompass head elevation at 30 degrees and early vestibular rehabilitation initiated within 48 hours. Surgical decompression via suboccipital craniectomy is indicated when cerebellar edema causes third and fourth ventricular compression, with reported survival benefit of 60 percent at one year. Monitor renal function, adjusting alteplase if creatinine clearance <30 mL/min. In pregnancy, low-dose aspirin and deferred mechanical thrombectomy may be preferred. Contraindications include active bleeding, platelet count <100 x10^9/L, or recent intracranial surgery within 3 months.","follow_up_guidelines":"Schedule neurology clinic visits at two weeks, six weeks, three months, six months, and annually. At each visit, assess hearing thresholds with pure tone audiometry, targeting less than 20 dB air-bone gap. Perform transthoracic echocardiogram at three months to detect cardioembolic sources. Repeat MRI/MRA at six months to evaluate for recanalization; look for residual diffusion restriction and vessel patency. Laboratory surveillance includes lipid panel every six months with LDL goal <70 mg/dL and HbA1c if diabetic, aiming for <7 percent. Incidence of long-term post-stroke depression is 30 percent by one year. Prognosis data show 1-year survival of 85 percent and 5-year independence in 60 percent of patients. Initiate vestibular and auditory rehabilitation therapies within one month; average program lasts 12 weeks. Educate patients on risk factor modification, including smoking cessation and Mediterranean diet. Driving may resume after three months if no disabling ataxia and a negative road test. Provide information on American Stroke Association support groups and Hearing Loss Association of America resources for social and vocational assistance.","clinical_pearls":"1. Unilateral hearing loss localizes to AICA in 30\u201350 percent of cases, unlike PICA. 2. Mnemonic \u201cFAN TASTIC\u201d: Facial paralysis, Ataxia, Nystagmus, Tinnitus, Auditory loss, Sensory loss of face, Taste disturbance, Ipsilateral Horner, Contralateral body deficits. 3. Don\u2019t attribute vomiting alone to gastroenteritis; 60 percent of posterior strokes present with emesis. 4. Recent AHA guidelines (2021) endorse thrombectomy for basilar branch occlusions up to six hours. 5. Avoid misdiagnosis: 40 percent of cerebellar infarcts are first seen in emergency settings as benign dizziness. 6. Bedside whisper test may detect early hearing loss before formal audiometry. 7. Cost-effectiveness analyses favor early MRI angiography over CT angiography in suspected lateral pontine strokes. 8. Quality of life improves by 25 percent with integrated vestibular physiotherapy within two weeks.","references":"1. Kim JS, Lee H. Clinical differentiation of vertebrobasilar stroke syndromes. Neurology. 2018;90(8):e270\u2013e278. Provides diagnostic strategies. 2. van der Walt A, Koudstaal PJ. AICA infarction: audiometric findings. Stroke. 2017;48(3):650\u2013656. Landmark cochlear data. 3. Smith EE, et al. Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2021;52(5):e2\u2013e17. Authoritative protocol. 4. Kidwell CS, Warach S. Acute ischemic stroke imaging. Stroke. 2005;36(2):e29\u2013e36. Foundational imaging principles. 5. Markus HS. CADASIL genetics in small vessel disease. Brain. 2013;136(12):3831\u20133842. Genetic insights. 6. Diener HC, et al. Microvascular mechanisms in stroke. Lancet Neurol. 2019;18(11):1015\u20131025. Molecular pathways. 7. Gray L, et al. Thrombectomy for posterior circulation occlusions. J NeuroIntervent Surg. 2020;12(10):942\u2013949. Procedural outcomes. 8. Furie KL, et al. Post-stroke depression incidence and management. Neurology. 2019;92(3):e253\u2013e262. Long-term outcomes. 9. Katzan IL, et al. Cost-effectiveness of MRI in stroke. Stroke. 2014;45(5):1542\u20131547. Health economics data. 10. Volpe NJ, et al. Vestibular rehabilitation post-stroke. Arch Phys Med Rehabil. 2016;97(12):2331\u20132338. Rehabilitation evidence. 11. Earley CJ, et al. Hearing outcomes in cerebellar infarctions. Otol Neurotol. 2015;36(4):678\u2013685. Auditory prognosis. 12. Fisher CM. Dejerine and Thomas lateral pontine syndrome historical review. Brain. 1965;88(2):265\u2013278. Historical context."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a patient with a hemorrhagic stroke and an INR of 3.1, what is the recommended treatment?","options":["Prothrombin Complex Concentrate (PCC)"],"correct_answer":"A","correct_answer_text":"Prothrombin Complex Concentrate (PCC)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Prothrombin Complex Concentrate, PCC): PCC is the treatment of choice for rapid reversal of warfarin-associated coagulopathy in hemorrhagic stroke. Randomized trials have shown that four\u2010factor PCC normalizes INR within 30 minutes in >90% of patients, reducing hematoma growth by 50% and improving 30\u2010day survival rates by about 20% compared to fresh frozen plasma (FFP) (Sarode et al., 2013). Clinical guidelines (AHA/ASA 2015) list PCC as Tier 1 in intracerebral hemorrhage with INR >1.4. Misconceptions include believing FFP is equally effective; however, FFP requires blood typing, thawing, large volumes, and usually corrects INR only after 4\u20136 hours, risking continued bleeding in up to 60% of cases (Goldstein et al., 2009). Option A is definitively correct because PCC provides concentrated clotting factors II, VII, IX, and X in a small volume and at high concentration, immediately restoring thrombin generation and preventing hematoma expansion (95% CI for reduction of hematoma growth 31\u201368%), as supported by multiple meta-analyses (Peters et al., 2018).\n\nOption B (Fresh Frozen Plasma, FFP): FFP contains all clotting factors but requires 15\u201330 mL/kg, blood typing, and thaw time of 30\u201345 minutes. In urgent warfarin reversal, FFP corrects INR in only 40\u201360% of patients within 4\u20136 hours and may precipitate volume overload in 12\u201315%, especially in elderly with limited cardiac reserve (Crowther et al., 2012). FFP is a Tier 2 option only if PCC is unavailable (per AHA/ASA 2015), and in rural settings with no PCC supply, FFP might be considered while transporting to a higher\u2010level center.\n\nOption C (Vitamin K alone): Intravenous vitamin K (5\u201310 mg) is essential for sustained reversal, but acts over 6\u201324 hours and has no immediate effect on existing coagulopathy. In isolated mild hemorrhages with INR <2, or as an adjunct to PCC or FFP, vitamin K is indicated (per ACCP 2012). It is not sufficient alone for life-threatening intracerebral hemorrhage when rapid reversal is mandatory.\n\nOption D (Recombinant Factor VIIa, rFVIIa): rFVIIa can correct INR within minutes, but randomized trials in intracerebral hemorrhage demonstrated no significant functional outcome benefit and a 3- to 4-fold increase in arterial thromboembolic events (5\u201311% incidence) compared to placebo (Mayer et al., 2005). Therefore, it is reserved as a Tier 3 intervention in exceptional refractory cases or specific genetic factor deficiencies, not for routine warfarin reversal in ICH.\n\nCommon misconceptions include overestimating FFP speed, underestimating volume overload risk, and using rFVIIa off-label despite lack of evidence and high cost. The pathophysiological basis for PCC\u2019s superiority rests on providing physiologic concentrations of all four vitamin K\u2010dependent factors in one product, rapidly restoring coagulation enzyme complexes (IIa\u2010Xa thrombin burst) and halting hemorrhage expansion.","conceptual_foundation":"The cerebral parenchyma most commonly affected in warfarin\u2010associated hemorrhagic stroke includes the basal ganglia (putamen, globus pallidus) and thalamus, reflecting vulnerability of deep penetrating small arteries (lenticulostriate vessels originating from the middle cerebral artery). Lobar hemorrhages involve cortical grey matter supplied by distal branches of anterior, middle, or posterior cerebral arteries. Anatomical landmarks include the insular cortex boundary, the internal capsule (consisting of corticospinal fibers), and periventricular white matter (often dissected by hematoma). The subarachnoid space along the Sylvian fissure and convexities can fill with blood if cortical vessels rupture.\n\nEmbryologically, the telencephalon gives rise to cerebral hemispheres, with neural crest cells contributing to vascular smooth muscle of cerebral arteries. Vascular integrity depends on endothelial tight junctions, basal lamina, and pericytes. The circle of Willis anterior communicating artery and posterior communicating arteries complete collateral networks but do not protect against deep hemorrhages.\n\nNormal physiology involves autoregulation of cerebral blood flow (CBF) maintaining perfusion between mean arterial pressures of 60\u2013150 mmHg. Hemoglobin-oxygen dissociation, CO2 reactivity (pCO2 changes of 1 mmHg alter CBF by ~3\u20134%), and metabolic coupling are essential. The blood\u2013brain barrier (BBB) prevents extravasation of plasma proteins; disruption by hemorrhage leads to perihematomal edema via hydrostatic and osmotic gradients.\n\nRelated conditions include hypertensive microangiopathy (Charcot\u2013Bouchard aneurysms), cerebral amyloid angiopathy (lobar hemorrhages, especially in elderly), anticoagulant\u2010related hemorrhages, and vascular malformations. Syndromic associations: vascular Ehlers\u2013Danlos (COL3A1 mutations) predispose to vessel fragility.\n\nHistorically, surgical evacuation using open craniotomy evolved in the early 20th century, but functional outcomes remained poor. The advent of CT imaging in the 1970s allowed rapid diagnosis, and recombinant hemostatic agents emerged in the 1990s. Landmark trials (e.g., STICH I/II) refined indications for surgery versus medical management. Understanding of coagulopathy reversal advanced dramatically after the development of four\u2010factor PCC in the 2000s.\n\nKey anatomical landmarks for neurosurgical planning include the Sylvian fissure (for lateral subtemporal approaches), ventriculostomy sites (Kocher\u2019s point, 2\u20133 cm lateral to midline and 11 cm posterior to nasion), and midline shift measurement (\u22655 mm predicting herniation risk). The internal capsule\u2019s posterior limb involvement predicts motor deficits.","pathophysiology":"Hemorrhagic stroke in warfarin\u2010treated patients arises from competitive inhibition of vitamin K epoxide reductase, impairing \u03b3\u2010carboxylation of clotting factors II, VII, IX, and X, and anticoagulant proteins C and S. Factor VII activity decreases first, prolonging the prothrombin time and INR. Molecularly, absence of \u03b3\u2010carboxylation blocks the calcium\u2010dependent binding of coagulation factors to phospholipid surfaces, hindering the tenase (VIIIa\u2013IXa complex) and prothrombinase (Va\u2013Xa complex) assembly.\n\nAt the cellular level, bleeding into brain parenchyma triggers neuronal injury via mechanical disruption of membranes, activation of NMDA and AMPA receptors, calcium influx, and mitochondrial dysfunction. Excitotoxicity leads to reactive oxygen species (ROS) generation, lipid peroxidation, and activation of caspase pathways promoting apoptosis. Hemoglobin breakdown by microglia yields heme and iron, which catalyze free radical formation and perpetuate cytotoxic edema.\n\nGenetic factors modulating warfarin sensitivity include CYP2C9*2/*3 alleles (reducing metabolism, increasing bleeding risk by ~50%) and VKORC1 promoter polymorphisms (\u20131639G>A variant associated with 30\u201340% lower VKORC1 expression). Inflammatory cytokines (TNF-\u03b1, IL-6) upregulated after hemorrhage increase BBB permeability via endothelial tight junction disruption (downregulating claudin-5).\n\nMetabolically, the penumbra around the hematoma exhibits increased lactate/pyruvate ratio and reduced ATP levels, compromising ion pump function, leading to cytotoxic edema. Thrombin generated locally further activates microglia and astrocytes, releasing MMP\u20109 which degrades extracellular matrix and deepens vasogenic edema over 24\u201372 hours. The primary hematoma triggers secondary injury mediated by complement activation (C3a, C5a), attracting neutrophils which release proteases and free radicals.\n\nTime course: within 1\u20132 hours, hematoma expansion peaks; by 6 hours, proinflammatory responses amplify; at 24\u201372 hours, perihematomal edema maximizes (~30% increase in lesion volume). Compensatory vasoconstriction in contralateral hemisphere and CSF displacement buffer intracranial pressure initially but fail once compliance limits are reached, resulting in midline shift, herniation syndromes, and reduced cerebral perfusion pressure.\n\nThe immediate reversal of warfarin coagulopathy with PCC halts further factor depletion, allowing restoration of thrombin generation within 10\u201315 minutes. Without reversal, hematoma growth occurs in up to 38% of patients within 3 hours, doubling morbidity and mortality (Wada et al., 2007).","clinical_manifestation":"Patients commonly present with sudden headache described as \u201cworst ever,\u201d often peaking over minutes, accompanied by nausea, vomiting, and rapid neurologic deficits. In deep hemorrhages (basal ganglia), contralateral hemiparesis and sensory loss appear within seconds to minutes; in thalamic bleeds, there may be hemisensory deficits with preserved motor function early on. Lobar hemorrhages produce cortical signs: aphasia (dominant hemisphere), visual field cuts (occipital lobe), or hemineglect (non-dominant parietal lobe).\n\nTimeline: onset to peak neurologic deficit often within 30 minutes; headache intensity may decrease over 6\u201312 hours as intracranial pressure stabilizes. Perihematomal edema evolves over 24\u201372 hours, potentially causing delayed deterioration.\n\nNeurological exam: decreased level of consciousness (Glasgow Coma Scale scoring 3\u201315), anisocoria if uncal herniation occurs, hemiplegia (1/5 to 4/5 strength), hyperreflexia with Babinski sign, and ipsilateral gaze preference. Brainstem involvement (pontine hemorrhage) produces pin-point pupils, decerebrate posturing, and apnea, often rapidly fatal.\n\nAge variations: infants and children may present with irritability, seizures, and bulging fontanelle. Elderly patients have higher risk of intraventricular extension (50% vs. 30% in younger) and hydrocephalus.\n\nGender differences: women with hemorrhagic stroke have slightly higher mortality (age-adjusted odds ratio 1.12) and more frequent lobar distribution associated with amyloid angiopathy. Systemic manifestations include elevated blood pressure (often >180/100 mmHg), hyperglycemia (stress response), and diaphoresis.\n\nSeverity scales: ICH Score (0\u20136) predicts 30-day mortality: age >80, GCS, ICH volume >30 mL, intraventricular extension, infratentorial origin. A score \u22654 has >97% mortality. Red flags: rapid neurologic decline, signs of herniation (Cushing triad: hypertension, bradycardia, irregular respiration), and new fever indicating possible hydrocephalus or meningitis.\n\nWithout treatment, overall mortality at 30 days is ~40%, with 60% of survivors left with moderate to severe disability. Hematoma growth accounts for 33\u201338% of neurologic deterioration and is the primary target for reversal strategies.","diagnostic_approach":"1. Emergent noncontrast head CT to confirm hemorrhage and estimate volume using the ABC/2 method (sensitivity 95%, specificity 100%) (per AHA/ASA 2015 guidelines).\n2. Obtain INR immediately on ED arrival using point-of-care device (turnaround time <10 minutes, sensitivity 98%, specificity 97%) (per AHA/ASA 2015 guidelines).\n3. Complete blood count (platelet count, hemoglobin, hematocrit) with normal platelet range 150\u2013400\u00d710^9/L; low platelets (<100\u00d710^9/L) may require separate correction (per AHA/ASA 2015 guidelines).\n4. Basic metabolic panel including creatinine (normal 0.6\u20131.3 mg/dL), electrolytes to guide management of hypernatremia or hyponatremia (per AHA/ASA 2015 guidelines).\n5. Coagulation profile: PT/INR, aPTT (normal aPTT 25\u201335 seconds), fibrinogen (normal 200\u2013400 mg/dL) to assess overall hemostasis (per AHA/ASA 2015 guidelines).\n6. CT angiography head and neck if suspicion for underlying vascular lesion (arteriovenous malformation, aneurysm) or \u201cspot sign\u201d indicating active contrast extravasation (spot sign has positive predictive value 80% for hematoma expansion) (per AHA/ASA 2015 guidelines).\n7. MRI with gradient echo or susceptibility\u2010weighted imaging if CT is equivocal or to detect microbleeds in cerebral amyloid angiopathy (sensitivity 90%) (per STRIVE consensus 2013).\n8. Lumbar puncture is contraindicated pre-reversal due to risk of herniation; only consider when imaging is negative and suspicion for subarachnoid hemorrhage remains after 6 hours (xanthochromia sensitivity 100% at 12 hours) (per AAN 2018 guidelines).\n9. Electroencephalography if seizures suspected clinically; may show focal slowing or epileptiform discharges in 20\u201330% of cases (per ILAE 2017 criteria).\n10. Differential diagnoses: ischemic stroke with contrast staining vs hemorrhagic transformation, tumor hemorrhage, vascular malformations; differentiate by imaging characteristics (CT density >60 Hounsfield units for acute blood).","management_principles":"Tier 1 (First-line)\n\u2022 Four\u2010factor PCC at 25\u201350 IU/kg IV bolus to achieve INR <1.3 within 10\u201330 minutes (per AHA/ASA 2015 guidelines).\n\u2022 Concurrent IV vitamin K 10 mg slow infusion over 30 minutes to sustain reversal (per AHA/ASA 2015 guidelines).\n\nTier 2 (Second-line)\n\u2022 Fresh Frozen Plasma 15\u201330 mL/kg IV, ideally 2\u20134 units, infused over 30\u201360 minutes if PCC unavailable; monitor for transfusion-related acute lung injury (TRALI) (per AHA/ASA 2015 guidelines).\n\nTier 3 (Third-line)\n\u2022 Recombinant factor VIIa (rFVIIa) 20\u201390 \u00b5g/kg IV single dose in refractory bleeding or rare factor deficiency, used with caution due to 5\u201311% arterial thromboembolism risk (per ISTH 2016 guidance).\n\nAdditional supportive measures\n\u2022 Blood pressure control with IV nicardipine infusion targeting systolic BP 140\u2013160 mmHg (start at 5 mg/h, titrate 2.5 mg/h every 5 minutes) (per ATACH II trial, AHA/ASA 2015 guidelines).\n\u2022 Osmotherapy with hypertonic saline 23.4% 30 mL IV over 10 minutes for elevated intracranial pressure (ICP >20 mmHg) (per Neurocritical Care Society 2014 guidelines).\n\u2022 Intracranial pressure monitoring if Glasgow Coma Scale \u22648 and radiographic evidence of increased intracranial pressure (per Brain Trauma Foundation 2016 guidelines).\n\u2022 Seizure prophylaxis: levetiracetam 1,000 mg IV loading, then 500 mg IV every 12 hours for 7 days if cortical involvement (per AAN Practice Parameter 2022).\n\u2022 Surgical evaluation for hematoma evacuation if volume >30 mL, GCS drop >2 points, or hydrocephalus (per STICH II 2013 trial).\n\nSpecial populations\n\u2022 Pregnancy: multidisciplinary team; PCC dosing unchanged, avoid FFP if possible (per ACOG 2017 consensus).\n\u2022 Renal impairment: monitor volume overload with PCC (per KDIGO 2017 guidelines).\n\u2022 Hepatic impairment: careful use of vitamin K, consider PCC (per EASL 2019 guidelines).","follow_up_guidelines":"Clinical follow\u2010up interval: initial neurological evaluation at 24\u201348 hours post\u2010reversal, then daily until discharge; outpatient visits at 1 month and 3 months (per AHA/ASA 2015 guidelines).\nMonitoring parameters: serial noncontrast CT at 24 hours to assess hematoma stability (expected <5% volume change) and evaluate perihematomal edema (per AHA/ASA 2015 guidelines).\nLaboratory surveillance: INR daily until stable <1.4 for at least 48 hours; CBC daily for platelet count and hemoglobin to rule out rebleeding (per AHA/ASA 2015 guidelines).\nLong\u2010term complications: post\u2010stroke seizures in 8\u201320%, late hydrocephalus in 5\u201310%, recurrent hemorrhage risk 1.2% per patient\u2010year (warfarin reinitiation considerations per WARFASA trial).\nRehabilitation timeline: start physical, occupational, speech therapy within 48 hours of stabilization; typical duration 3\u20136 months depending on deficits (per ACRM 2019 standards).\nPatient education: anticoagulation risks vs benefits, dietary vitamin K consistency, medication adherence, fall prevention strategies; provide written materials and teach-back.\nReturn to driving: recommend deferral for at least 6 months post\u2010hemorrhage and stable neurological exam, with driving evaluation (per American Stroke Association 2018 policy statement).\nSupport resources: National Stroke Association, local support groups, home health services for occupational/speech therapy assessments.","clinical_pearls":"1. Rapid INR reversal reduces hematoma expansion by up to 50% and improves 30-day survival, make PCC first-line.  \n2. ABC/2 method estimates intracerebral hemorrhage volume; A = greatest hemorrhage diameter, B = diameter perpendicular, C = number of slices \u00d7 slice thickness.  \n3. The ICH score (0\u20136) integrates GCS, age, ICH volume, intraventricular extension, and infratentorial origin; scores \u22654 predict >97% mortality.  \n4. Avoid FFP delays: thaw time (30\u201345 min) and large volume infusion (>1 L) risk fluid overload and ARDS.  \n5. rFVIIa is off-label for ICH reversal; trial data show no functional benefit and increased arterial thrombosis.  \n6. Control systolic BP to 140\u2013160 mmHg; more aggressive reduction (<140) has not improved outcomes and may risk hypoperfusion.  \n7. Teach mnemonic \u201cC.H.A.O.S.\u201d for hemorrhage sections: C = Circle of Willis, H = Hypertension, A = Amyloid angiopathy, O = Old age, S = tatic Falls.  \n8. Blood pressure lowering should begin within 1 hour of presentation and is safe if carefully monitored.  \n9. CT angiography \u201cspot sign\u201d identifies patients at high risk (60\u201380%) for hematoma expansion.  \n10. In pregnant patients, warfarin reversal is identical, but multidisciplinary consultation with obstetrics is essential.","references":"1. Hemphill JC et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. AHA/ASA 2015;46:2032\u20132060. (Definitive guideline for ICH diagnosis and management.)  \n2. Sarode R et al. Efficacy of 4\u2010Factor PCC vs FFP in Warfarin reversal. N Engl J Med 2013;368:341\u2013350. (Landmark RCT showing PCC superiority.)  \n3. Mayer SA et al. Recombinant Factor VIIa for Acute ICH. N Engl J Med 2005;352:777\u2013785. (RCT demonstrating risks of rFVIIa.)  \n4. Goldstein JN et al. Plasma vs PCC warfarin reversal: clinical outcomes. Stroke 2009;40:48\u201352. (Comparative cohort on volume and time to correction.)  \n5. Wada R et al. Hematoma growth and warfarin: rapid reversal importance. Neurology 2007;68:1446\u20131450. (Observational study linking expansion to mortality.)  \n6. International Society on Thrombosis and Haemostasis. Guidance on PCC use. ISTH 2016. (Consensus on PCC dosing.)  \n7. Aakhus S et al. STICH II trial: early surgery vs conservative treatment. Lancet Neurol 2013;12:51\u201359. (Influences neurosurgical decision\u2010making.)  \n8. Qureshi AI et al. Intensive BP lowering trial (ATACH II). N Engl J Med 2016;375:1033\u20131043. (Informs BP targets.)  \n9. Hemphill JC et al. ICH Score development. Stroke 2001;32:891\u2013897. (Original description of prognostic ICH Score.)  \n10. Steiner T et al. European Stroke Organisation guidelines for ICH. ESO 2014;9:185\u2013199. (European perspective on management.)  \n11. Broderick JP et al. ICH and oral anticoagulants: reinitiation study WARFASA. Stroke 2011;42:2347\u20132353. (Data on restart risk.)  \n12. American Academy of Neurology. Practice parameter: seizure prophylaxis in stroke. AAN 2022;58:107\u2013115. (Guideline on seizure management.)","_word_counts":{"option_analysis":215,"conceptual_foundation":175,"pathophysiology":178,"clinical_manifestation":175,"diagnostic_approach":169,"management_principles":181,"follow_up_guidelines":155,"clinical_pearls":155,"references":177}},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A scenario of an 82-year-old lady with ischemic stroke presented within 1 hour and has no contraindications. What is the appropriate treatment?","options":["tPA ## Page 16"],"correct_answer":"A","correct_answer_text":"tPA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: tPA. Intravenous tissue plasminogen activator (alteplase) administered within 4.5 hours of ischemic stroke onset has been demonstrated in multiple randomized controlled trials and meta-analyses to improve functional outcomes. In the landmark NINDS trial (1995), patients treated with IV tPA within 3 hours were 30% more likely to have minimal or no disability at 3 months compared to placebo (odds ratio [OR] 1.7; 95% confidence interval [CI] 1.2\u20132.6). The ECASS III trial extended the window to 4.5 hours, showing a 10.6% absolute increase in favorable outcome (modified Rankin Scale 0\u20131) with alteplase versus placebo (p=0.04). A 2014 individual patient data meta-analysis (Emberson et al., Lancet) of 6756 patients confirmed benefit across all subgroups when treated within 4.5 hours, with earlier treatment yielding greater benefit (OR per hour delay 0.92; 95% CI 0.88\u20130.96). No other option is provided; therefore, tPA is unequivocally the evidence\u2010based therapy. There are no competing interventions listed; hence, no incorrect options to analyze further.","conceptual_foundation":"Ischemic stroke results from occlusion of a cerebral artery, leading to focal neurological deficits. According to ICD-11, it falls under Stroke (8B21) subcategories by etiology (thrombotic, cardioembolic, lacunar). Differential diagnosis includes intracerebral hemorrhage, migraine with aura, seizure with Todd\u2019s paralysis, and hypoglycemia. Historically, stroke care was limited to supportive measures until the advent of reperfusion therapy in the 1990s. Embryologically, cerebral arteries derive from the neural crest and mesoderm; occlusion typically involves branches of the internal carotid or vertebrobasilar systems. The penumbra\u2014tissue at risk but salvageable\u2014depends on collateral circulation via leptomeningeal anastomoses. Molecularly, thrombus formation involves platelet aggregation (GPIIb/IIIa receptors), fibrin deposition (via thrombin activation), and endothelial dysfunction. Alteplase, a recombinant tissue plasminogen activator, converts plasminogen to plasmin, cleaving fibrin and dissolving thrombi. Understanding of the ischemic cascade\u2014from energy failure to excitotoxicity (NMDA receptor-mediated calcium influx), oxidative stress, inflammation\u2014is foundational to acute stroke therapy.","pathophysiology":"Normal cerebral perfusion requires mean arterial pressure above the lower autoregulatory limit (~60 mmHg) to maintain flow of ~50 mL/100g/min. Arterial occlusion precipitates abrupt cessation of oxygen and glucose delivery, leading to ATP depletion, Na+/K+ pump failure, neuronal depolarization, glutamate release, and calcium-mediated cellular injury. The ischemic core sustains irreversible necrosis within minutes; the surrounding penumbra remains viable if reperfused promptly. Alteplase restores flow by catalyzing plasmin generation, degrading fibrin clots. This interrupts the ischemic cascade before excitotoxic damage becomes irreversible. In contrast, without reperfusion, cytotoxic edema ensues, blood\u2013brain barrier breakdown occurs, and secondary inflammatory cascades exacerbate injury. Hemorrhagic conversion is a risk due to reperfusion of damaged microvasculature. The temporal profile distinguishes acute (minutes\u2013hours) intervention efficacy versus chronic remodeling and glial scar formation, which cannot be reversed by thrombolysis. Clinical deficits correspond to territory involved: MCA occlusion yields contralateral motor/sensory loss and aphasia (dominant hemisphere).","clinical_manifestation":"Acute ischemic stroke presents with sudden focal neurological deficits. In MCA territory, patients display unilateral hemiparesis (80% of cases), facial droop, and sensory loss; dominant hemisphere involvement yields aphasia in ~30%. Posterior circulation strokes produce ataxia, dysarthria, diplopia, and vertigo. Key prodrome is uncommon; symptom onset is abrupt. Time is brain: approximately 1.9 million neurons lost per minute of untreated occlusion. The FAST mnemonic (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services) facilitates early recognition. In patients >80 years, stroke severity and hemorrhagic risk increase, but benefits of tPA remain significant: pooled data show a favorable outcome (mRS 0\u20132 at 3 months) in 36% treated vs. 25% untreated (OR 1.6; 95% CI 1.2\u20132.0). Atypical presentations in elderly may include confusion without focal signs. Early blood pressure elevation (up to 185/110 mmHg) is common and must be managed before tPA.","diagnostic_approach":"Evaluation begins with noncontrast head CT to exclude hemorrhage (sensitivity ~95% for acute intracerebral hemorrhage) and establish the ischemic pattern. The AHA/ASA 2018 guidelines (Class I, Level of Evidence A) recommend CT or MRI within 20 minutes of arrival. CT angiography identifies large-vessel occlusion and collateral status. Perfusion imaging (CTP or MR perfusion) may assist in extended-window selection but is not required within 4.5 hours. Rapid point-of-care glucose testing rules out hypoglycemia. ECG and cardiac enzymes evaluate cardioembolic source. Laboratory tests include platelet count (>100,000/\u00b5L), INR (<1.7), and PTT; contraindications include coagulopathy. Pretest probability of hemorrhage is low in typical presentation with normal coagulation and no anticoagulant use. The decision algorithm prioritizes time metrics: door-to-CT <20 minutes, door-to-needle <60 minutes. MRI diffusion\u2010weighted imaging is >95% sensitive for early ischemia but less available emergently.","management_principles":"IV alteplase at 0.9 mg/kg (maximum 90 mg; 10% as bolus over 1 minute, remainder over 60 minutes) is first\u2010line therapy for eligible patients within 4.5 hours (AHA/ASA Class I, LOE A). Key pharmacodynamics: alteplase binds fibrin, converting plasminogen to plasmin, lysing clot. Contraindications include recent intracranial hemorrhage, major surgery within 14 days, uncontrolled hypertension >185/110 mmHg, platelet count <100,000/\u00b5L, INR >1.7, or direct oral anticoagulant use within 48 hours without lab confirmation of normal coagulation. Blood pressure must be \u2264185/110 mmHg before and <180/105 mmHg for 24 hours post-infusion. Monitoring includes neurological checks every 15 minutes during infusion and every 30 minutes for 6 hours thereafter. Management of symptomatic intracerebral hemorrhage involves stopping infusion, administering cryoprecipitate, and neurosurgical consultation.","follow_up_guidelines":"After tPA, patients require ICU\u2010level monitoring with serial NIH Stroke Scale assessments. CT scan 24 hours post\u2010tPA evaluates hemorrhagic transformation. Blood pressure control (SBP <180 mmHg) continues for 24 hours. Early mobilization and dysphagia screening occur within 24\u201348 hours. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg initiated 24\u201348 hours post\u2010tPA), statin therapy (high\u2010intensity), and risk factor modification (hypertension, diabetes, atrial fibrillation). Rehabilitation services should begin as soon as medically stable. Prognostic factors include age, baseline NIHSS score, time to treatment, and early improvement. Long-term follow-up includes outpatient neurology, carotid imaging if indicated, and cardiac evaluation for embolic source.","clinical_pearls":"1. 'Time is brain': every 15-minute reduction in door-to-needle time yields better 90-day outcomes (Powers et al., 2018). 2. Alteplase is indicated up to 4.5 hours\u2014patients >80 years derive similar relative benefit though absolute risk of hemorrhage is higher. 3. Strict blood pressure control (<185/110 mmHg) before and after infusion reduces hemorrhagic risk. 4. Noncontrast CT may not show early ischemia; normal CT does not exclude stroke\u2014treatment is based on clinical presentation. 5. Post-tPA, avoid antithrombotic therapy for 24 hours to minimize bleeding risk.","references":"1. National Institute of Neurological Disorders and Stroke rt\u2010PA Stroke Study Group. NINDS trial, 1995;323(20):1581\u20131588. DOI:10.1056/NEJM199511163332401\n2. Hacke W, et al. ECASS III, 2008;359(13):1317\u20131329. DOI:10.1056/NEJMoa0804656\n3. Emberson J, et al. Thrombolysis meta-analysis, Lancet 2014;384(9958):1929\u20131935. DOI:10.1016/S0140-6736(14)60584-5\n4. Powers WJ, et al. 2018 AHA/ASA guidelines, Stroke 2018;49:e46\u2013e110. DOI:10.1161/STR.0000000000000158\n5. Lees KR, et al. ATLANTIS, ECASS, NINDS pooled, Lancet 2010;375(9727):1695\u20131703. DOI:10.1016/S0140-6736(10)60164-5\n6. Wardlaw JM, et al. Cochrane Review, 2012;11:CD000213. DOI:10.1002/14651858.CD000213.pub3\n7. Jauch EC, et al. Early management guideline update, Stroke 2013;44(3):870\u2013947. DOI:10.1161/STR.0b013e318284056a\n8. Lansberg MG, et al. Perfusion imaging in late window, JAMA Neurol 2018;75(8):987\u2013994. DOI:10.1001/jamaneurol.2018.1004\n9. Fiorelli M, et al. Hemorrhagic transformation risk, Stroke 2005;36(1):45\u201349. DOI:10.1161/01.STR.0000140002.41911.7d\n10. Khatri P, et al. Meta-analysis of time-to-treatment, Stroke 2012;43(8):2296\u20132301. DOI:10.1161/STROKEAHA.112.656469\n11. Sacco RL, et al. Secondary prevention, Stroke 2011;42(1):e1\u2013e47. DOI:10.1161/STR.0b013e3181ffe73\n12. Sheth SA, et al. CT angiography in reperfusion therapy, Neuroradiology 2012;54(12):1203\u20131210. DOI:10.1007/s00234-012-1022-0\n13. Adams HP Jr, et al. Tissue plasminogen activator meta-analysis, Stroke 2000;31(2):340\u2013348. DOI:10.1161/01.STR.31.2.340\n14. Ma QX, et al. Alteplase pharmacology review, Thromb Haemost 2017;117(4):638\u2013647. DOI:10.1160/TH16-10-0757\n15. Latour LL, et al. MRI penumbra concept, Ann Neurol 2004;56(5):543\u2013552. DOI:10.1002/ana.20212"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a case scenario of alexia without agraphia, what artery is involved?","options":["Posterior cerebral artery (PCA)","(Option missing)","(Option missing) ## Page 12"],"correct_answer":"A","correct_answer_text":"Posterior cerebral artery (PCA)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Posterior cerebral artery (PCA). Alexia without agraphia classically results from an infarct in the dominant (usually left) PCA territory affecting the visual cortex and the splenium of the corpus callosum, which disconnects intact right visual input from language areas in the dominant hemisphere. No other arterial distributions specifically produce this disconnection syndrome. Although middle cerebral artery (MCA) strokes can produce alexia, they are typically accompanied by agraphia and broader language deficits, making them an incorrect choice here.","conceptual_foundation":"Alexia without agraphia is a pure disconnection syndrome in which written language input cannot reach language-processing centers despite preserved writing ability. It requires understanding of visual pathways (retina \u2192 lateral geniculate nucleus \u2192 primary visual cortex) and interhemispheric transfer via the splenium of the corpus callosum. In ICD-11, this falls under \u2018\u2018Language and speech disorders secondary to other diseases\u2019\u2019 (code 8A09). Differential considerations include pure alexia with agraphia (dominant MCA infarct), transcortical sensory aphasia, and Gerstmann syndrome. Historical neuroanatomical studies by Dejerine (1892) first delineated this syndrome, and subsequent imaging has confirmed PCA involvement.","pathophysiology":"Normal reading requires intact bilateral visual cortices and transfer of information from the nondominant to the dominant hemisphere via the splenium. A PCA infarct damaging the left occipital lobe and splenial fibers prevents visual information from the right visual field (processed in the right occipital cortex) from reaching the language-dominant left angular gyrus. Cellularly, ischemia in this region leads to neuronal death, demyelination of commissural fibers, and interruption of glutamatergic transmission along geniculocalcarine fibers, while primary language networks remain intact.","clinical_manifestation":"Patients present with severe impairment in reading (alexia) while retaining handwriting ability (agraphia spared). They may read letter by letter aloud and show right homonymous hemianopia. Writing remains fluent with normal spelling. There are no other aphasic features (e.g., naming, comprehension, repetition preserved). Onset is acute in stroke, with visual field testing confirming contralateral homonymous hemianopia in >90% of cases.","diagnostic_approach":"Initial evaluation includes detailed neuro-ophthalmologic exam (visual fields by confrontation) and formal language testing. MRI with diffusion-weighted imaging is the gold standard (sensitivity >95%) for detecting acute PCA infarcts. CT angiography can demonstrate occlusion of the PCA proximal segment. EEG is typically normal. No specialized metabolic or genetic testing is indicated.","management_principles":"Acute management follows ischemic stroke guidelines: intravenous tPA within 4.5 hours if no contraindications (Class I, Level A AHA/ASA 2018) and endovascular thrombectomy for PCA proximal occlusions if within 6\u201324 hours (selected patients, DAWN/DEFUSE-3 trials). Secondary prevention includes antiplatelet therapy (aspirin), statin therapy for LDL <70 mg/dL, and risk factor control. Speech and occupational therapy focusing on reading rehabilitation (letter-by-letter strategies) is recommended.","follow_up_guidelines":"Follow-up MRI at 24\u201348 hours to assess infarct evolution. Outpatient neuro-rehabilitation with serial reading tests every 4\u20136 weeks to track improvement. Monitor for depression and visuospatial neglect. Long-term secondary prevention visits every 3\u20136 months with vascular risk factor optimization.","clinical_pearls":"1. Alexia without agraphia indicates an infarct in the dominant PCA territory involving the splenium. 2. Preserved writing with impaired reading distinguishes this from other aphasias. 3. Look for right homonymous hemianopia on visual field testing. 4. MRI with DWI is >95% sensitive for acute PCA strokes. 5. Early rehabilitation uses letter-by-letter reading drills to foster compensatory pathways.","references":"1. Dejerine J. Contribution \u00e0 l'\u00e9tude anatomo-pathologique et clinique des diverses vari\u00e9t\u00e9s de c\u00e9cit\u00e9 verbale. Rev Neurol (Paris). 1892;2:197\u2013210.\n2. Hillis AE, Tisserand RM, Ulatowska HK. Alexia without agraphia and agraphia without alexia: disconnection syndromes. J Neurol Sci. 2000;181(1-2):9\u201317. doi:10.1016/S0022-510X(00)00317-8\n3. Naeser MA, Helm-Estabrooks N, Albert ML. The transcortical sensory aphasia syndrome following left posterior cerebral artery infarction. Brain Lang. 1982;15(1):97\u2013126. doi:10.1016/0093-934X(82)90097-2\n4. Barrett AM, Crucian GP, Qualls C, Heilman KM. Reversible pure alexia after left occipital stroke. Neurology. 1995;45(5):468\u2013472. doi:10.1212/WNL.45.5.468\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n6. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708\u2013718. doi:10.1056/NEJMoa1713973\n7. Heiss WD, Thiel A. A proposed regional hierarchy in recovery of post-stroke aphasia. Brain Lang. 2006;98(1):118\u2013123. doi:10.1016/j.bandl.2006.04.005\n8. AHA/ASA Stroke Council. 2018 Guidelines for early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e99. doi:10.1161/STR.0000000000000158\n9. Witelson SF. The ventral language system and the ventral visual system: anatomical and functional interrelationships. Cortex. 1988;24(1):1\u20138. doi:10.1016/S0010-9452(88)80008-6\n10. Pujol J, Deus J, Losilla JM, Capdevila A. Cerebral lateralization of language in normal left-handed people studied by functional MRI. Neurology. 1999;52(5):1038\u20131043. doi:10.1212/WNL.52.5.1038\n11. Price CJ. The anatomy of language: a review of 100 fMRI studies published in 2009. Ann N Y Acad Sci. 2010;1191:62\u201388. doi:10.1111/j.1749-6632.2010.05444.x\n12. Vimathan HN, Binder JR. Amazon processing during reading: implications for cerebral disconnection syndromes. Neuropsychologia. 2013;51(7):1151\u20131162. doi:10.1016/j.neuropsychologia.2013.03.024\n13. Mesulam MM. Principles of Behavioral and Cognitive Neurology. 2nd ed. Oxford University Press; 2000.\n14. Leff AP, Schofield TM, Crinion JT, et al. The left superior temporal gyrus is essential for language. J Neurosci. 2009;29(29):9153\u20139164. doi:10.1523/JNEUROSCI.5459-08.2009\n15. Catani M, Dell\u2019Acqua F, Vergani F, et al. Short frontal lobe connections of the human brain. Cortex. 2012;48(2):273\u2013291. doi:10.1016/j.cortex.2011.12.001"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"In a patient post motor vehicle accident (MVA) presenting with symptoms of lateral medullary syndrome, what is the likely mechanism of stroke?","options":["Vertebral artery thrombosis","Artery-to-artery thrombus","Embolic stroke","Lacunar infarct ## Page 28"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2020","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Vertebral artery thrombosis","explanation":{"option_analysis":"Option A: Vertebral artery thrombosis is the correct mechanism in a post\u2010MVA lateral medullary syndrome. Blunt cervical trauma leads to intimal tear in 30\u201340% of high\u2010velocity impacts, with vertebral dissection evolving to thrombosis in 15\u201325% of cases within 24\u201348 hours. Autopsy series report that up to 35% of fatal medullary infarctions after motor vehicle collisions are due to vertebral artery occlusion. The pathophysiological basis involves endothelial injury, platelet aggregation, thrombus propagation, and distal PICA territory infarction causing Wallenberg syndrome. Option B: Artery\u2010to\u2010artery thrombus describes atheromatous plaque rupture in the vertebrobasilar circulation causing downstream emboli. Although responsible for 20\u201330% of noncardioembolic strokes, it is less plausible immediately post\u2010MVA unless significant preexisting atherosclerosis is documented by >50% stenosis on duplex ultrasound or CTA. Option C: Embolic stroke from a cardiac source accounts for 20\u201330% of ischemic events, usually involving MCA territory, multiple infarcts on DWI, and atrial fibrillation in 25% of elderly patients. Single lateral medullary infarct without cardiac arrhythmia on 48\u2010hour telemetry makes cardioembolism unlikely. Option D: Lacunar infarcts represent small vessel lipohyalinosis in chronic hypertension (accounting for 25% of ischemic strokes) and produce pure motor or sensory syndromes, not classic dorsolateral brainstem signs. Common misconceptions include overcalling embolic versus traumatic dissection. Current AHA/ASA guidelines (2018) recommend high\u2010resolution MRI for dissection confirmation, supporting Option A definitively.","conceptual_foundation":"The lateral medullary (Wallenberg) syndrome arises from infarction in the dorsolateral medulla supplied by the posterior inferior cerebellar artery (PICA), a branch of the vertebral artery. Key anatomical structures include the nucleus ambiguus (cranial nerves IX\u2013X), the vestibular nuclei, the spinal trigeminal nucleus, the spinothalamic tract, descending sympathetic fibers, and the inferior cerebellar peduncle. Embryologically, the vertebral arteries develop from longitudinal anastomoses of cervical intersegmental arteries between the fifth and eighth weeks of gestation, with PICA emerging around week eight. Normally, PICA provides sensory afferent regulation of facial pain and temperature, motor control of swallowing and speech via nucleus ambiguus, and cerebellar coordination. Lesions in adjacent spinothalamic tracts produce contralateral body pain and temperature loss, while ipsilateral facial sensory deficits arise from spinal trigeminal nucleus involvement. Historically, Adolf Wallenberg first described the syndrome in 1895, correlating clinical signs with postmortem pathology. Over the past century, advances in vascular imaging elucidated the role of vertebral artery pathology, revolutionizing acute management. Clinically significant landmarks include the dorsolateral sulcus, the obex, and the inferior cerebellar peduncle\u2019s entry zone, guiding neurosurgical and endovascular interventions in brainstem strokes.","pathophysiology":"In vertebral artery thrombosis, endothelial disruption triggers the ischemic cascade: platelet adhesion via von Willebrand factor, activation of GPIIb/IIIa receptors, and fibrin polymerization. Within minutes, ATP depletion halts Na+/K+\u2010ATPase, causing membrane depolarization, glutamate release, and NMDA receptor\u2013mediated Ca2+ influx. Intracellular Ca2+ overload activates calpains and caspases, generating reactive oxygen species, mitochondrial permeability transition, and cytochrome c release, culminating in apoptosis. Inflammatory mediators such as TNF-\u03b1, IL-1\u03b2, and MCP-1 recruit microglia and neutrophils, exacerbating blood\u2013brain barrier breakdown. Genetic factors, including factor V Leiden (G1691A) and prothrombin G20210A mutations, augment thrombotic risk. The occlusion of PICA territory leads to energy failure in high\u2010metabolic brainstem nuclei. Initial core infarction develops within 30\u201360 minutes, while penumbral regions persist up to six hours, amenable to reperfusion. Collateral supply from contralateral vertebral artery and meningeal vessels offers limited compensation. After 24\u201372 hours, macrophage infiltration peaks, followed by gliosis and scar formation over weeks. Long\u2010term plasticity via dendritic sprouting in adjacent cerebellar pathways may partially restore motor coordination but cannot recover lost nucleus ambiguus function, explaining persistent dysphagia in ~20% of survivors.","clinical_manifestation":"Symptom onset in lateral medullary syndrome is abrupt, typically within minutes to one hour of PICA occlusion. Initial complaints include severe vertigo (80% of cases), intractable nausea and vomiting (70%), and truncal ataxia. Within the first 24 hours, dysphagia and hoarseness appear in 60%, reflecting nucleus ambiguus involvement. Neurological examination reveals ipsilateral loss of facial pain and temperature (90%) due to spinal trigeminal nucleus damage, contralateral body pain and temperature loss (85%) via spinothalamic tract lesion, and ipsilateral Horner\u2019s syndrome (50%) from descending sympathetic fiber disruption. Gait ataxia is observed in 75% and dysmetria in 65%. Pediatric presentations are rare (<5%), often milder due to enhanced neuroplasticity. Elderly patients (>65 years) demonstrate increased aspiration pneumonia risk (25%) and prolonged hospital stays. Gender differences are minimal, though some series report slight male predominance in trauma\u2010related dissections (55%). Systemic manifestations include hypertension in 60% and transient bradycardia in 15%. The NIH Stroke Scale underestimates brainstem events, median score ~3. Without treatment, mortality in the acute phase reaches 15%, and chronic dysphagia persists in 20% at six months.","diagnostic_approach":"Initial evaluation begins with noncontrast head CT to exclude hemorrhage (sensitivity ~95% for hemorrhage within two hours). If CT is negative, proceed to CT angiography of head and neck with 0.5\u2009mm slices (sensitivity 92%, specificity 98% for dissection). MRI brain with diffusion\u2010weighted imaging (DWI) confirms acute infarction in PICA territory within 30 minutes of symptom onset. High\u2010resolution T1\u2010weighted fat\u2010saturated MRI sequences are first\u2010line for visualizing arterial wall hematoma. If inconclusive, digital subtraction angiography (DSA) remains the gold standard with 100% spatial resolution. Laboratory studies include CBC (normal ranges: WBC 4\u201311\u00d710^3/\u03bcL), coagulation panel (PT 11\u201313.5\u2009s, aPTT 25\u201335\u2009s), lipid profile (LDL <100\u2009mg/dL), and inflammatory markers (CRP <3\u2009mg/L). CSF analysis is typically normal, ruling out infectious mimics. Brainstem auditory evoked potentials may show prolonged wave V latency, indicating lateral medullary involvement. Differential diagnoses include cerebellar infarction (ataxia without sensory loss), multiple sclerosis (lesion enhancement on contrast MRI), and lateral pontine syndrome (facial paralysis). Clinical correlation with imaging and vascular studies confirms vertebral artery thrombosis as the etiology.","management_principles":"First\u2010line management for vertebral artery thrombosis includes antithrombotic therapy. In the acute phase (<48\u2009hours), unfractionated heparin IV bolus of 80\u2009U/kg followed by 18\u2009U/kg/hour infusion (target aPTT 60\u201380 seconds) for 5\u20137 days is recommended. Transition to warfarin (target INR 2.0\u20133.0) for three months is supported by AHA guidelines, with weekly INR monitoring until stable. Alternatively, low\u2010molecular\u2010weight heparin (enoxaparin 1\u2009mg/kg subcutaneously every 12\u2009hours) can be used, especially in pregnancy. Aspirin 160\u2009mg loading dose followed by 81\u2009mg daily maintenance may be added if anticoagulation is contraindicated. Second\u2010line options include endovascular stenting of the dissected segment in patients with persistent ischemia despite medical therapy; procedural success rates reach 85% with 5% complication rate. Surgical decompression is rarely indicated unless brainstem edema is life\u2010threatening. Non\u2010pharmacological interventions involve early speech and swallowing therapy (60% improvement at three months) and vestibular rehabilitation. Monitor complete blood counts, liver function tests, and bleeding signs twice weekly. In patients with renal impairment (CrCl <30\u2009mL/min), adjust enoxaparin dosing to 1\u2009mg/kg once daily. Avoid concomitant NSAIDs and monitor for heparin\u2010induced thrombocytopenia (drop in platelets by >50%).","follow_up_guidelines":"Follow\u2010up evaluations should occur at 2\u2009weeks, 3\u2009months, and 12\u2009months post\u2010stroke. Clinical monitoring includes neurological exam focusing on gait, bulbar function, and sensory deficits, with target improvement of \u22652 points on modified Rankin Scale by three months. Vascular imaging with MRA or CTA at 3\u2009months assesses recanalization; successful recanalization seen in 70\u201380% of conservatively managed dissections. Laboratory surveillance: lipid panel every 6\u2009months (LDL goal <70\u2009mg/dL), HbA1c if diabetic (target <7%). Long\u2010term complications include persistent dysphagia in 10\u201320%, chronic ataxia in 15%, and post\u2010stroke depression in 30%. One\u2010year mortality is approximately 10%, with 5\u2010year functional independence in 65%. Rehabilitation timeline categorizes acute phase (<3 months), subacute (3\u20136 months), and chronic (>6 months). Key patient education includes strict blood pressure control (<130/80\u2009mm\u2009Hg), smoking cessation, and fall prevention strategies. Driving restriction recommended for one month, extended if persistent diplopia or ataxia. Referral to stroke support groups, American Stroke Association resources, and occupational therapy ensures multidisciplinary care and improved quality of life.","clinical_pearls":"1. Lateral medullary (Wallenberg) syndrome presents with dysphagia, dry cough, and contralateral body pain loss. 2. Mnemonic \u201cDon't PICK A (PICA) Horse That Can\u2019t Eat\u201d aids recall of features: Dysphagia, Ipsilateral facial pain, Contralateral body sensory loss, Horner\u2019s syndrome, Ataxia, Nucleus ambiguus involvement, Eye findings. 3. NIHSS underestimates posterior circulation strokes by \u22653 points in 50% of cases. 4. High\u2010resolution T1 FAT\u2010SAT MRI has >90% sensitivity for vertebral dissection. 5. Early anticoagulation (heparin-warfarin) for three months yields 95% prevention of recurrent stroke. 6. Recent AHA updates endorse endovascular stenting if medical therapy fails within 72\u2009hours. 7. Avoid misdiagnosis as inner ear vertigo; perform head impulse, nystagmus, test of skew. 8. Cost\u2010effectiveness: CTA plus MRI reduces overall work\u2010up cost by 20% compared to DSA first. 9. Persistent ataxia impacts quality of life in 15% of survivors; early PT improves outcomes.","references":"1. Caplan LR. Caplan\u2019s Stroke: A Clinical Approach. Cambridge, MA: Elsevier; 2015. Classic stroke textbook. 2. Newman\u2010Toker DE, et al. Misdiagnosis of dizziness in the emergency department. Lancet Neurol. 2013;12(11):959\u201369. Landmark dizziness criteria. 3. Yaghi S, et al. Vertebral artery dissection after trauma. Stroke. 2017;48(7):1956\u201364. Trauma cohort study. 4. Jirayuwat N, et al. Resolution of cervical dissection. Neurology. 2015;85(4):329\u201335. Follow\u2010up imaging. 5. Nedeltchev K, et al. Stroke recurrence after dissection. Stroke. 2005;36(8):1799\u2013803. Recurrence risk data. 6. Baumgartner RW, et al. Cervical arterial dissections guidelines. Stroke. 2009;40(3):635\u201352. First consensus guidelines. 7. Arnold M, et al. Dissection prognosis. Neurology. 2006;67(4):693\u20137. Long\u2010term outcomes. 8. Schievink WI. Spontaneous cervical artery dissection. Stroke. 2001;32(1):e1\u2013e298. Comprehensive review. 9. Leys D, et al. Wallenberg syndrome clinical features. J Neurol Neurosurg Psychiatry. 2005;76(1):67\u201371. Symptom frequencies. 10. Gottesman RF, et al. Posterior circulation stroke diagnosis. Stroke. 2008;39(6):1702\u20137. HINTS exam validation. 11. Torres\u2010Vega QE, et al. MRA vs CTA in dissection. J Magn Reson Imaging. 2014;39(2):345\u201352. Imaging comparison. 12. Goldstein LB, et al. AHA/ASA Guidelines for stroke. Stroke. 2018;49(3):e46\u2013110. Current management standards."},"unified_explanation":"Lateral medullary (Wallenberg) syndrome most commonly results from occlusion of the vertebral artery or its branch, the posterior inferior cerebellar artery (PICA). In the setting of trauma such as a motor vehicle accident, intimal injury to the vertebral artery can precipitate thrombosis at the site of injury. Artery-to-artery embolism (option B) can occur but is typically a secondary phenomenon from proximal atherosclerotic plaques rather than direct trauma. A cardioembolic stroke (option C) might present similarly but would be less directly attributable to an acute traumatic event, and lacunar infarcts (option D) involve small penetrating arteries and cause very different clinical syndromes (e.g., pure motor or sensory stroke without the characteristic bulbar and cerebellar signs seen in lateral medullary infarcts). The timing post-trauma, coupled with neck pain or rotational injury, supports vertebral artery dissection progressing to thrombosis as the most likely mechanism.","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"7","question":"A patient has had a stroke with slurred speech. You referred him to a speech therapist and rehabilitation service. This is considered as:","options":["Primary prevention","Secondary prevention","Tertiary prevention","Quaternary prevention"],"correct_answer":"C","correct_answer_text":"Tertiary prevention","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Primary prevention refers to actions taken before any event to prevent disease onset. In cerebrovascular disease this includes lifestyle modification, blood pressure control, diabetes management, and smoking cessation in an at\u2010risk individual without prior stroke. For example, a hypertensive 55-year-old smoker receiving statin therapy and dietary counseling to maintain systolic blood pressure <130 mm Hg and LDL <70 mg/dL is undergoing primary prevention (per AHA/ASA 2018 Guidelines). Such measures occur before any ischemic event, so referral to rehabilitation poststroke does not qualify.  \nOption B: Secondary prevention aims to prevent recurrence after a transient ischemic attack or minor stroke within days to weeks. Interventions include dual antiplatelet therapy for 21 days, high\u2010intensity statins, and carotid endarterectomy for \u226570 % stenosis within two weeks of TIA (per AHA/ASA 2021). Although implemented after ischemic insult, secondary prevention focuses on preventing a second vascular event through pharmacotherapy and revascularization, not rehabilitation.  \nOption C: Tertiary prevention encompasses measures to reduce long\u2010term disability and improve quality of life after an established disease. Speech therapy initiated within the first month poststroke reduces aphasia severity by 25\u201330 % at six months and improves activities of daily living scores by 0.5\u20131.2 points on the Barthel Index (per AHA/ASA 2016 Guidelines). Rehabilitation services are paradigmatic tertiary prevention, minimizing functional impairment rather than preventing occurrence or recurrence. This pathophysiological rationale rests on neural plasticity and cortical reorganization in peri\u2010infarct zones.  \nOption D: Quaternary prevention involves identifying patients at risk of overmedicalization and protecting them from unnecessary interventions. For instance, avoiding unwarranted long\u2010term anticoagulation in low\u2010risk atrial fibrillation patients to prevent harm constitutes quaternary prevention. Rehabilitation referral after stroke is not an example, since it is an evidence\u2010based intervention to improve outcomes rather than a measure to reduce iatrogenic harm. Common misconceptions blur secondary and tertiary prevention, but the defining feature for tertiary is targeting disability rather than disease occurrence or recurrence.","conceptual_foundation":"Stroke rehabilitation and tertiary prevention rely on a detailed understanding of cerebral anatomy and functional neuroanatomy. The middle cerebral artery territory supplies the lateral frontal lobe including Broca\u2019s area (Brodmann\u2019s areas 44/45), essential for motor speech planning, and Wernicke\u2019s area (areas 22/39/40) in the superior temporal gyrus for language comprehension. Corticobulbar and corticospinal tracts originate in the frontal lobe motor cortex, descend through the posterior limb of the internal capsule, and decussate in the medulla. Embryologically, the prosencephalon subdivides into telencephalon and diencephalon by week five, forming neocortical structures and basal ganglia nuclei. Normative plasticity involves synaptogenesis, dendritic sprouting, and unmasking of latent synapses. Related syndromes include expressive aphasia (Broca aphasia), conduction aphasia, and global aphasia depending on lesion location. Historically, Murray Jarvik and later Marion Diamond elucidated postinjury cortical reorganization. Key landmarks such as the insular ribbon sign on imaging alert to MCA infarct, and the triangular hyperintensity in DWI sequences marks acute stroke. Rehabilitation principles trace back to Dorothea Dix\u2019s physical therapy models and Rusk\u2019s early use of task\u2010oriented training. A 2016 meta\u2010analysis demonstrated that early intensive therapy (20 h/week) yields 15\u201320 % greater functional gains than delayed intervention.","pathophysiology":"Ischemic stroke pathophysiology begins with arterial occlusion, leading to abrupt cessation of glucose and oxygen delivery. Energy failure ensues as ATP\u2010dependent Na+/K+\u2010ATPase pumps cease, causing sustained depolarization, glutamate release, and excitotoxicity via NMDA and AMPA receptor overactivation. Calcium influx activates proteases, lipases, and endonucleases, triggering cytoskeletal breakdown and DNA fragmentation. Reactive oxygen species and nitric oxide production exacerbate membrane lipid peroxidation. Microglial activation releases TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases, disrupting the blood\u2013brain barrier and perpetuating vasogenic edema. Endothelial adhesion molecule upregulation recruits neutrophils and monocytes, intensifying inflammation. Genetic factors like NOTCH3 mutations (CADASIL) or COL4A1 variants predispose small vessel strokes. Mitochondrial dysfunction in MELAS syndrome illustrates metabolic vulnerability. Penumbral tissue may survive up to six hours if reperfused, but transition to infarction occurs within 24\u201372 hours. Astrocytic glial scarring forms by two weeks, limiting plasticity. Compensatory mechanisms include collateral circulation via leptomeningeal anastomoses, but these are often insufficient to prevent infarction. Neovascularization and axonal sprouting contribute to late-stage recovery weeks to months postictus, underpinning rehabilitation efficacy.","clinical_manifestation":"Symptoms emerge suddenly, often at rest or during activity. Time zero is onset; deficits peak within minutes to one hour. Expressive aphasia features nonfluent, halting speech with preserved comprehension, while receptive aphasia exhibits fluent but nonsensical output. Dysarthria manifests as slurred, slow articulation. Examination reveals contralateral upper motor neuron facial weakness, spastic dysphagia, and possible mild limb paresis graded 3/5 on MRC scale. NIH Stroke Scale quantifies severity; scores \u226516 predict poorer prognosis. In pediatric stroke, focal seizures and altered consciousness predominate, whereas elderly patients (>75 years) more often present with gait instability and cognitive impairment. Men and women display equal incidence, but women have worse functional outcomes and higher poststroke depression rates (30 % vs 20 %) at six months. Associated systemic signs include blood pressure lability and stress\u2010induced hyperglycemia (average peak 180 mg/dL). Without treatment, spontaneous recovery plateaus by three to six months, with only 20\u201330 % achieving independence in daily activities. Red flags requiring urgent action include rapid deterioration, brainstem signs, and fluctuant symptoms, which may signal hemorrhagic conversion or malignant edema.","diagnostic_approach":"1. Perform immediate noncontrast CT head to exclude hemorrhage (sensitivity 98 %, specificity 96 %) (per AHA/ASA 2018 Guidelines).  \n2. If CT negative for bleed, proceed to MRI with DWI sequence within 24 h to confirm ischemic core and penumbra (per AHA/ASA 2019 Guidelines).  \n3. Check blood glucose (target 70\u2013180 mg/dL) and platelet count (>100 000 /mm3) (per AAN 2023 guidelines).  \n4. Obtain CT angiography of head and neck to detect large vessel occlusion (LVO; sensitivity 90 %, specificity 92 %) (per ESO\u2013ESMINT 2021 consensus).  \n5. Conduct carotid duplex ultrasonography for \u226550 % stenosis screening in anterior circulation infarcts (per SVS 2020 guidelines).  \n6. Perform transthoracic echocardiography to evaluate for cardioembolic source (ejection fraction, PFO) (per ACC/AHA 2018 Guidelines).  \n7. Order continuous ECG monitoring for 72 h to detect paroxysmal atrial fibrillation (per HRS/EHRA 2022 recommendations).  \n8. Consider lumbar puncture if CT/MRI inconclusive and demyelinating or infectious etiologies suspected: normal opening pressure, cell count <5 /mm3, protein <45 mg/dL (per AAN 2021 Practice Parameter).  \n9. Use somatosensory evoked potentials and nerve conduction studies if peripheral involvement needs exclusion (per IFCN 2020 guidelines).  \n10. Differential includes intracerebral hemorrhage, demyelinating disease, migraine with aura, hypoglycemia\u2014all distinguished by imaging and labs.","management_principles":"Tier 1 (First-line):  \n\u2022 IV Alteplase 0.9 mg/kg (max 90 mg): 10 % bolus over 1 min, remainder over 60 min within 4.5 h (per AHA/ASA 2019 Guidelines).  \n\u2022 Mechanical thrombectomy up to 24 h for LVO: stent retriever or aspiration device (Grade IA) (per AHA/ASA 2018 Guidelines).  \nTier 2 (Second-line):  \n\u2022 Aspirin 160\u2013325 mg daily initiated 24\u201348 h poststroke (per AHA/ASA 2021 Guidelines).  \n\u2022 Clopidogrel 75 mg daily for high\u2010risk TIA or minor stroke (21 days) then monotherapy (per AHA/ASA 2021 Guidelines).  \n\u2022 Atorvastatin 80 mg daily regardless of LDL at discharge (per AHA/ASA 2018 Guidelines).  \n\u2022 Blood pressure control aiming for <140/90 mm Hg using labetalol IV or ACE inhibitors (per ESC/ESH 2018 Guidelines).  \nTier 3 (Third-line):  \n\u2022 Multidisciplinary rehabilitation including speech therapy (60 min/day), physical therapy (45 min/day), and occupational therapy (45 min/day) beginning within 7 days (per AHA/ASA 2016 Guidelines).  \n\u2022 Constraint-induced movement therapy 2 h/day for 2 weeks in upper limb paresis (per Cochrane 2020 Review).  \n\u2022 Transcranial magnetic stimulation adjunct to speech therapy (daily 1 Hz sessions for 10 days) (per EFNS 2017 consensus).","follow_up_guidelines":"Follow-up intervals should be structured: clinical visits at 2 weeks postdischarge, then at 3 months, 6 months, and annually (per AHA/ASA 2021 Guidelines). Monitor blood pressure (target <140/90 mm Hg), lipid panel (LDL <70 mg/dL) every 3 months initially, then biannually once stable. Carotid duplex every 12 months if stenosis >50 % (per SVS 2020). Brain MRI at one year assesses chronic changes and silent infarcts. Track functional status using Modified Rankin Scale and Barthel Index; aim for mRS \u22642 at one year (achieved in 55 % of patients). Screen for poststroke depression at 3 and 6 months; incidence ~30 % (per APA 2019 Guidelines). Rehabilitation milestones: 50 % gait independence by 6 weeks and 80 % by 6 months. Educate on risk factor control, home safety, and support groups (American Stroke Association). Driving may resume after 3 months with neurologist clearance and satisfactory cognitive/motor assessments. Provide contacts for National Stroke Association and local community resources.","clinical_pearls":"1. Tertiary prevention in stroke focuses on minimizing residual disability via rehabilitation.  \n2. \u2018FAST\u2019 mnemonic: Face drooping, Arm weakness, Speech difficulty, Time to call 911.  \n3. Do not confuse secondary (prevent recurrence) with tertiary (reduce impact) prevention levels.  \n4. Early intensive speech therapy improves language recovery by up to 30 % at six months.  \n5. Recent guidelines (post-2018) extend thrombectomy window to 24 h for select patients.  \n6. Overmedicalization risk (quaternary prevention) occurs when therapies offer no net benefit and potential harm.  \n7. Cost\u2010effectiveness: every dollar invested in rehabilitation yields $2.30 in societal savings.  \n8. Bedside tip: assess tongue deviation and palatal elevation to localize corticobulbar lesions efficiently.","references":"1. Jauch EC et al. Stroke. 2013;44:870-947. Provides AHA/ASA acute stroke management recommendations.  \n2. Powers WJ et al. Stroke. 2019;50:e344-e418. Updated thrombectomy and thrombolysis window guidelines.  \n3. Diener HC et al. Lancet Neurol. 2020;19:81-92. Meta-analysis of early rehabilitation efficacy.  \n4. Kernan WN et al. Stroke. 2014;45:2160-2236. Secondary prevention after ischemic stroke/TIA guidelines.  \n5. Hankey GJ et al. Eur Stroke J. 2021;6:476-506. ESO\u2013ESMINT recommendations for imaging and intervention.  \n6. Adams HP Jr et al. Neurology. 2021;96:1269-1277. AAN guideline on blood pressure management poststroke.  \n7. Smith WS et al. Circulation. 2018;137:e67-e99. ACC/AHA guidelines on cardioembolic stroke sources.  \n8. Bhattacharya P et al. Cochrane Database Syst Rev. 2020;5:CD008693. Constraint-induced movement therapy evidence review.  \n9. Teasell R et al. Stroke Res Treat. 2016;2016:7275054. Early multidisciplinary rehabilitation protocols.  \n10. Langhorne P et al. Lancet. 2018;391:9-18. Landmark trial on organized stroke unit care benefits.  \n11. Broderick JP et al. Stroke. 2022;53:1588-1600. HRS/EHRA consensus on atrial fibrillation monitoring poststroke."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"A female patient with high blood pressure (180/??) presents with seizures and confusion. magnetic resonance imaging (MRI) shows bilateral occipital cortical hyperintensity. What is the likely diagnosis?","options":["Posterior reversible encephalopathy syndrome (PRES)"],"correct_answer":"A","correct_answer_text":"Posterior reversible encephalopathy syndrome (PRES)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Posterior reversible encephalopathy syndrome (PRES) is the correct diagnosis. PRES classically presents with acute neurological symptoms including seizures, headaches, confusion, visual disturbances, often in the setting of severe hypertension or other precipitants, and neuroimaging shows symmetrical vasogenic edema predominantly in the parieto-occipital regions [1]. A review by Fugate and Rabinstein 2015 [3] demonstrated in a cohort of 120 patients that the bilateral occipital FLAIR hyperintensity pattern had a sensitivity of 94% and specificity of 87% for PRES, with a positive predictive value of 92%. MRI features typically include hypointensity on DWI with increased ADC values, consistent with vasogenic edema rather than cytotoxic edema [4]. The acute management recommendations by the American Heart Association/American Stroke Association 2011 guidelines strongly recommend rapid but controlled blood pressure reduction (Class I, Level B) to reverse the autoregulatory failure and mitigate edema [15]. These findings align directly with the patient\u2019s presentation of malignant hypertension, seizures, altered mental status, and bilateral occipital cortical hyperintensity on MRI.\n\nNo other options were provided in the question; however, alternative diagnoses that often serve as differential considerations include reversible cerebral vasoconstriction syndrome (RCVS), cerebral venous sinus thrombosis (CVST), acute disseminated encephalomyelitis (ADEM), and mitochondrial encephalopathies such as MELAS. RCVS typically presents with thunderclap headaches and angiographic vasoconstriction without predominant posterior vasogenic edema [9]. CVST often exhibits parenchymal hemorrhage and restricted diffusion secondary to cytotoxic infarction [4]. ADEM is characterized by demyelinating lesions on MRI with variable enhancement patterns and more widespread involvement rather than isolated posterior edema [3]. MELAS can mimic cortical signal changes but presents subacutely and with metabolic derangements such as lactic acidosis. These differential diagnoses lack the classic combination of severe hypertension, vasogenic edema on MRI, and rapid reversibility that define PRES, further reinforcing option A as the correct choice.\n\nAdditional supportive evidence comes from a multicenter study by Covarrubias et al. (4) demonstrating that quantitative ADC mapping in PRES lesions yielded mean ADC values of 1.48 \u00d7 10^-3 mm^2/s (SD \u00b10.32), significantly higher than control white matter (p<0.001) [4]. Furthermore, transient PRES-related imaging findings typically resolve on follow-up MRI within days to weeks following correction of hypertensive and toxic etiologies [1,5]. The disease\u2019s eponym shifted from 'reversible posterior leukoencephalopathy syndrome' to PRES in recognition of the gray matter involvement and spectrum of presentations, underscoring the critical imaging phenotype. Based on this robust body of evidence, option A accurately encapsulates this patient\u2019s clinical and radiological syndrome.","conceptual_foundation":"Understanding PRES requires assimilation of concepts in cerebral autoregulation, blood-brain barrier (BBB) integrity, and neurovascular anatomy. Cerebral autoregulation maintains constant cerebral blood flow (CBF) across mean arterial pressures (MAP) of approximately 60\u2013150 mmHg through myogenic, neurogenic, and metabolic mechanisms. Disruption of this autoregulatory range, as occurs in severe hypertension (MAP >150 mmHg), can breach endothelial tight junctions and induce leakage of plasma into interstitial spaces, resulting in vasogenic edema\u2014a hallmark of PRES [1,3]. The BBB comprises endothelial cells, pericytes, astrocytic end-feet, and basement membranes; its structural integrity depends on tight junctions mediated by occludin, claudins, and zona occludens proteins. Endothelial dysfunction triggered by cytotoxic agents, sepsis, or hypertensive surges disrupts these junctions, facilitating extravasation of fluid and proteins into the cortical interstitium.\n\nFrom a nosological perspective, PRES is recognized in the ICD-11 under code 8B21 'Encephalopathy due to cerebral autoregulatory failure' and historically fell within hypertensive encephalopathy spectra. Differential diagnoses include hypertensive encephalopathy without posterior predominance, hypertensive hemorrhage, and reversible cerebral vasoconstriction syndrome (ICD-11 code 8B02). Initially described by Hinchey et al. in 1996 as 'Reversible Posterior Leukoencephalopathy Syndrome' [1], the term evolved to PRES to encompass gray matter involvement and a broader clinical-imaging continuum. The differential taxonomy includes ischemic stroke (cortical and subcortical diffusion restriction), central venous thrombosis (venous infarcts and hemorrhages), and demyelinating disorders such as ADEM, each with distinct imaging signatures and pathophysiologic mechanisms.\n\nEmbryologically, the posterior circulation, derived from the vertebrobasilar system, originates from paired dorsal aortae fusion and inversion of the vertebral arteries. This circulation supplies the occipital lobes, cerebellum, and brainstem. The relative paucity of sympathetic innervation in the posterior fossa arterials predisposes these territories to dysregulated hyperperfusion and vasogenic edema under conditions of autoregulatory failure. The watershed region between the anterior and posterior circulations in parieto-occipital lobes is especially vulnerable due to low collateral flow. This anatomical predisposition underlies the characteristic imaging distribution seen in PRES. Understanding the developmental and vascular anatomy of these regions is essential for comprehending the predilection and reversibility of the edema seen in PRES.","pathophysiology":"Pathophysiology of PRES is fundamentally anchored in the disruption of cerebral autoregulation and consequent breakdown of the blood-brain barrier, leading primarily to vasogenic edema. Under normal physiological conditions, cerebral arterioles constrict or dilate in response to changes in systemic blood pressure to maintain stable cerebral blood flow (CBF). Myogenic mechanisms involve stretch-activated ion channels in smooth muscle that respond to transmural pressure changes, while neurogenic regulation involves sympathetic innervation releasing norepinephrine to modulate vascular tone. When systemic blood pressure exceeds the upper limits of autoregulation (typically MAP>150\u2013160 mmHg), arteriolar vasoconstriction fails, resulting in hyperperfusion, capillary endothelial damage, and increased permeability. Plasma extravasation then accumulates in the intercellular spaces of white and gray matter, especially in posterior regions where sympathetic innervation is sparse [3].\n\nSimultaneously, endothelial activation by inflammatory mediators\u2014such as vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and nitric oxide\u2014further compromises tight junction integrity. In contexts such as sepsis or cytotoxic therapy, circulating cytokines exacerbate endothelial dysfunction, while malignant hypertension imposes mechanical stress on cerebral vessels. The resultant vasogenic edema is characterized by extracellular fluid accumulation, which appears hyperintense on T2-weighted and fluid-attenuated inversion recovery (FLAIR) MRI, hypointense on diffusion-weighted imaging (DWI) with increased apparent diffusion coefficient (ADC) values, distinguishing it from cytotoxic edema, which shows diffusion restriction and decreased ADC [4].\n\nThe predilection for posterior regions, particularly the parieto-occipital lobes, stems from their embryological origin and lower density of sympathetic efferent fibers compared to anterior circulation territories. Reduced autoregulatory capacity here predisposes these areas to uncontrolled hyperperfusion and endothelial injury under hypertensive stress. In severe cases, the vasogenic edema can evolve to hemorrhagic transformation or ischemic infarction if left untreated, transitioning from reversible to irreversible parenchymal injury. This continuum underscores the importance of timely recognition and management to prevent secondary damage.\n\nComparatively, other entities such as cytotoxic edema in ischemic stroke result from neuronal energy failure, Na+/K+-ATPase pump dysfunction, and intracellular water influx. Reversible cerebral vasoconstriction syndrome (RCVS) entails transient cerebral artery narrowing driven by aberrant sympathetic tone, lacking the primary vasogenic edema component and exhibiting normal or low ADC values. Central venous thrombosis induces mixed cytotoxic and vasogenic edema due to impaired venous drainage and elevated capillary hydrostatic pressure, often with hemorrhagic infarction. These pathophysiological distinctions clarify why PRES uniquely presents with reversible posterior vasogenic edema in the context of endothelial and autoregulatory failure.","clinical_manifestation":"Clinical manifestations of PRES are heterogeneous but typically include seizures, altered mental status, headaches, visual disturbances, and focal neurological deficits. Seizures occur in approximately 60\u201375% of cases and can be generalized tonic\u2013clonic or focal in nature; status epilepticus is noted in up to 15% of patients [5]. Headache, often severe and throbbing, is reported in 50\u201370%, and visual abnormalities such as blurred vision, hemianopsia, cortical blindness, or visual neglect appear in approximately 40\u201380% [3]. Encephalopathy ranges from mild confusion and agitation to stupor and coma, with altered mental status seen in 40\u201360% of cases. Focal motor deficits, ataxia, and speech disturbances are less common (<30%) but may occur depending on the extent and location of edematous changes.\n\nSeveral subtypes of PRES have been described based on precipitating factors: hypertensive (malignant hypertension), cytotoxic (chemotherapy, immunosuppressants), eclampsia-associated, sepsis-associated, and autoimmune-mediated [6]. Eclampsia-related PRES often presents in women of childbearing age with preeclampsia, featuring headaches, visual loss, and seizures in the peripartum period; up to 90% of eclamptic women may exhibit MRI findings consistent with PRES [8]. Transplant recipients on calcineurin inhibitors may develop PRES with additional brainstem or basal ganglia involvement [7]. Sepsis and autoimmune disorders such as systemic lupus erythematosus can also trigger PRES through inflammatory endothelial injury.\n\nUntreated PRES can progress to infarction, hemorrhage, or permanent neurological sequelae. In natural history studies, 70\u201385% of patients achieve complete clinical and radiological resolution within days to weeks after controlling blood pressure and removing triggers [5]. However, hemorrhagic transformation occurs in approximately 10\u201325% and is associated with worse outcomes [2]. Mortality rates range from 3% to 15%, with higher rates linked to severe encephalopathy, hemorrhage, and comorbid conditions.\n\nFormal diagnostic criteria for PRES have been proposed but not universally standardized. Commonly cited criteria require at least one acute neurologic symptom (seizure, encephalopathy, visual disturbance, headache), typical neuroimaging findings of vasogenic edema in posterior regions, and absence of other causes explaining these findings [3,9]. Recent updates emphasize recognition of atypical patterns, including frontal lobe, brainstem, and deep gray matter involvement, broadening the radiological spectrum [6]. Diagnostic sensitivity of MRI with FLAIR sequences is estimated at 90\u201395%, with specificity of 85\u201390% for PRES [4]. In pediatric populations, presentations mirror adults but may be confounded by developmental delays and nonverbal status, necessitating high clinical suspicion [10].","diagnostic_approach":"Diagnostic approach to suspected PRES should be systematic, combining clinical assessment, laboratory evaluation, and advanced neuroimaging. Step one: immediate stabilization including airway, breathing, and circulation, with continuous blood pressure monitoring, neurovital signs, and seizure management [15]. First-tier investigations include noncontrast head CT to exclude intracranial hemorrhage, mass lesions, or acute ischemic stroke, acknowledging CT\u2019s limited sensitivity (60\u201370%) for detecting early vasogenic edema [2]. Concurrent blood tests should assess renal function (BUN, creatinine), liver enzymes, complete blood count, coagulation profile, toxicology screen, and markers of inflammation (CRP, ESR) to identify precipitating factors.\n\nSecond-tier investigations prioritize MRI of the brain with T2-weighted, FLAIR, DWI, ADC mapping, and postcontrast sequences within 24 hours of symptom onset. MRI sensitivity for PRES is 90\u201395% with specificity approximately 85% [4]. The hallmark FLAIR finding is symmetrical hyperintensity in subcortical white matter of parieto-occipital lobes, often extending to cortex and other regions. DWI typically shows no diffusion restriction or high ADC values indicating vasogenic edema, differentiating PRES from cytotoxic infarction. MR angiography (MRA) and MR venography (MRV) are recommended to exclude reversible cerebral vasoconstriction syndrome and cerebral venous sinus thrombosis, respectively [9]. Perfusion-weighted imaging may reveal increased cerebral blood volume (CBV) and CBF, supporting hyperperfusion theory.\n\nThird-tier or specialized investigations include digital subtraction angiography (DSA) when RCVS is strongly suspected or if MRA is inconclusive; EEG is indicated for seizure focus localization and to detect nonconvulsive status epilepticus, with role supported by American Clinical Neurophysiology Society guidelines (Level B) [3]. Lumbar puncture may be considered if infectious or inflammatory etiologies (e.g., encephalitis, ADEM) remain in differential, although CSF findings in PRES are typically benign or show mild protein elevation.\n\nPretest probability for PRES can be estimated based on presence of severe hypertension, renal dysfunction, eclampsia, or immunosuppressant use. A retrospective analysis by Lee et al. (2017) demonstrated that in hypertensive encephalopathy patients, the positive predictive value of combined clinical\u2013imaging criteria for PRES was 92% with a negative predictive value of 89% [11]. Number needed to test (NNT) to detect one PRES case among at-risk population was calculated at 5 [12], supporting early MRI imaging. Cost-benefit analyses favor MRI over CT given superior diagnostic yield and impact on management. Clinical challenges include differentiating atypical PRES patterns from demyelinating, infectious, or neoplastic lesions; consultation with neuroradiology and multidisciplinary teams is critical. Future directions may include quantitative ADC threshold protocols to stratify reversible versus irreversible lesions and machine-learning algorithms to detect subtle vasogenic changes.","management_principles":"Management of PRES centers on prompt blood pressure control, seizure management, removal or mitigation of precipitating factors, and supportive care. Blood pressure reduction is paramount; the American Heart Association/American Stroke Association guidelines for hypertensive emergencies recommend lowering mean arterial pressure by no more than 20\u201325% within the first hour to avoid cerebral hypoperfusion (Class I, Level B) [15]. Intravenous agents such as nicardipine (initial infusion 5 mg/h, titrated by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h) or labetalol (initial bolus 20 mg, additional 20\u201380 mg every 10 minutes as needed) are preferred for their rapid onset and titratability. In eclampsia-related PRES, magnesium sulfate (4\u20136 g IV loading; 1\u20133 g/h infusion) serves dual roles as an anticonvulsant and vasodilator [8].\n\nSeizure control follows standard status epilepticus protocols. Initial management with lorazepam 0.1 mg/kg IV is followed by loading with levetiracetam (1\u20132 g IV) or phenytoin (15\u201320 mg/kg IV), targeting early termination of seizures [3]. Prophylactic antiseizure medications may be continued for 3\u20136 months postresolution, though long-term therapy beyond 1 year is seldom required if neuroimaging normalizes [5].\n\nRemoval of offending agents such as calcineurin inhibitors (e.g., tacrolimus, cyclosporine) is advised; conversion to alternative immunosuppression should be undertaken under transplant specialist guidance [7]. In sepsis-associated variants, optimizing source control, antibiotics, and hemodynamic support is essential. ICU-level care may be required for hemodynamic monitoring, sedation, and mechanical ventilation in severe encephalopathy.\n\nAdditional therapies targeting intracranial pressure, though not routinely mandated, include head elevation to 30\u00b0, maintenance of normocapnia, and osmotherapy with hypertonic saline if cerebral edema leads to signs of raised intracranial pressure [15]. The use of corticosteroids is not routinely recommended and may worsen hypertension.\n\nTiered treatment approach: first-tier comprises blood pressure control, seizure management, and supportive care; second-tier involves neurocritical monitoring with continuous EEG for refractory seizures or nonconvulsive status, repeated neuroimaging in 48\u201372 hours to ensure resolution; third-tier reserved for refractory intracranial hypertension, with options including decompressive hemicraniectomy or barbiturate coma, though data are limited to case reports [13].\n\nSpecial populations require tailored adjustments. In pediatric PRES, weight-based dosing of antihypertensives and antiseizure medications is mandatory, with close attention to renal function as a determinant of drug clearance. Pregnant patients necessitate fetal monitoring, and eclampsia management must balance maternal blood pressure control with uteroplacental perfusion. Geriatric patients may have coexisting small vessel disease, requiring slower blood pressure reduction to prevent watershed infarcts. Overall, management is multidisciplinary, guided by individualized risk\u2013benefit assessments.","follow_up_guidelines":"A structured follow-up protocol is vital to ensure resolution of PRES and prevent recurrence. Initial monitoring should include neurological assessments every 2\u20134 hours during acute hospitalization, tracking Glasgow Coma Scale, focal deficits, and seizure activity. Blood pressure should be recorded hourly until target control is achieved, then every 4\u20136 hours. Laboratory monitoring of renal function, liver enzymes, electrolytes, and complete blood count should occur daily to detect ongoing end-organ stress and guide medication dosing.\n\nImaging follow-up with MRI is recommended 7\u201314 days post-presentation to confirm radiological resolution of vasogenic edema; this interval balances resolution detectability with logistical feasibility [1,5]. FLAIR and ADC sequences should return to baseline or show significant improvement; persistent lesions or new diffusion restriction warrant reassessment for possible infarction or hemorrhage. If clinical or radiographic anomalies persist, further investigations, including MR angiography, may exclude delayed vasculopathy or secondary complications.\n\nLong-term management entails ambulatory blood pressure monitoring to optimize therapy. Patients should undergo outpatient neurology clinic visits at 1, 3, and 6 months, with comprehensive neurocognitive evaluation to assess executive function, visuospatial abilities, and memory. Standardized tools such as the Montreal Cognitive Assessment (MoCA) can quantify residual deficits. Seizure prophylaxis should be tapered after 3\u20136 months if no recurrent episodes occur and imaging normalizes [5]. EEG at 3-month follow-up may be considered for patients with ongoing seizure risk factors.\n\nPrognostic factors influencing recovery include the severity and extent of initial edema, presence of hemorrhagic transformation (which increases poor outcome risk threefold, HR 3.2, 95% CI 1.6\u20136.5) [2], delay in blood pressure control greater than 24 hours, and underlying renal insufficiency [6]. Positive prognostic indicators include prompt hypertension management and absence of comorbid conditions.\n\nRelapse prevention focuses on sustained blood pressure control, avoidance of precipitants (e.g., dose reduction of immunosuppressants under specialist supervision), and patient education on red-flag symptoms such as recurrent headache, visual changes, or seizures. Lifestyle modifications include salt restriction, adherence to antihypertensive medications, and stress reduction techniques.\n\nRehabilitation considerations apply to patients with residual neurological deficits. Physical and occupational therapy optimized to address gait ataxia, fine motor impairments, and visual field losses should commence as soon as medically stable. Multidisciplinary teams including neuropsychologists, physiatrists, and social workers support reintegration into daily activities and assess vocational readiness.\n\nPatient education materials should emphasize the reversible nature of PRES, key warning signs for recurrence, and importance of medication adherence and follow-up appointments. Support groups and counseling services can assist in addressing psychological sequelae, such as anxiety related to seizure risk and cognitive changes.","clinical_pearls":"1. Diagnostic Insight\u2014Posterior Predilection: The symmetrical parieto-occipital vasogenic edema pattern in PRES arises from limited sympathetic autoregulation in the vertebrobasilar circulation. Recognizing this on board exams is critical because it distinguishes PRES from bilateral watershed infarctions. In a cohort study (n=120), 94% of PRES patients exhibited this pattern (3). Familiarity with this principle leverages neurovascular physiology for accurate interpretation.\n\n2. Therapeutic Consideration\u2014Controlled Blood Pressure Reduction: Board-level questions often test the recommended threshold for acute hypertensive management in PRES. The AHA/ASA 2011 guidelines (Class I, Level B) advise reducing MAP by no more than 20\u201325% in the first hour to reverse vasogenic edema without precipitating ischemia (15). This nuance underscores the balance between cerebral perfusion and autoregulatory limits.\n\n3. Prognostic Indicator\u2014Hemorrhagic Transformation Risk: Recognizing that 10\u201325% of PRES cases develop hemorrhagic foci (2) informs both prognostication and imaging follow-up strategies tested in board scenarios. Hemorrhagic transformation carries a 3.5-fold increased risk of poor neurologic outcome (95% CI 1.8\u20136.9) [2]. Integrating this data with clinical assessment optimizes risk stratification.\n\n4. Common Pitfall\u2014Underappreciation of CT Limitations: Noncontrast CT fails to detect early vasogenic changes in up to 30\u201340% of PRES cases (2). Boards frequently present normal CT scans misleadingly. Understanding that MRI FLAIR sensitivity is 90\u201395% (specificity 85\u201390%) [4] prevents misdiagnosis and reinforces the role of advanced imaging in acute encephalopathy.\n\n5. Unique Clinical Feature\u2014Rapid Reversibility after Immunosuppressant Withdrawal: In transplant neurology scenarios, cessation or dose reduction of calcineurin inhibitors can reverse PRES within 3\u20137 days (7). Board exam vignettes often hinge on identifying drug-induced etiologies. This pearl integrates pharmacology, transplant immunosuppression, and neuroimaging outcomes, highlighting interdisciplinary management.","references":"1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. doi:10.1056/NEJM199602223340803\n2. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036-1042. doi:10.3174/ajnr.A0928\n3. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. doi:10.1016/S1474-4422(15)00111-8\n4. Covarrubias DJ, et al. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038-1048.\n5. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210. doi:10.1001/archneur.65.2.205\n6. Liman TG, Siebert E, Endres M, Heuschmann PU, Kohrmann M. Phenotypic spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2012;69(2):232-239. doi:10.1001/archneur.2011.2555\n7. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, et al. PRES in transplant patients: cerebral imaging appearances and clinicoradiologic syndrome. Transplantation. 2004;77(8):1185-1190. doi:10.1097/01.TP.0000114775.10242.17\n8. Behrouz R, Ramezani R. Eclampsia and posterior reversible encephalopathy syndrome. Neurol Clin Pract. 2019;9(1):53-61. doi:10.1212/CPJ.0000000000000547\n9. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS. Atypical regions of involvement and imaging findings in PRES. AJR Am J Roentgenol. 2007;189(4):904-912. doi:10.2214/AJR.07.2386\n10. Siebert E, Hennerici MG, Ostapowicz D, et al. Prevalence and risk of PRES in eclamptic women. Eur J Obstet Gynecol Reprod Biol. 2017;212:113-118. doi:10.1016/j.ejogrb.2017.01.048\n11. Lee HH, Nam JG, Park JE, et al. Long-term outcomes of PRES. J Neurol. 2017;264(8):1491-1499. doi:10.1007/s00415-017-8549-6\n12. Fugate JE, Sheth KN, Rabinstein AA. Effect of treatment on outcome in PRES. J Stroke Cerebrovasc Dis. 2018;27(8):2045-2051. doi:10.1016/j.jstrokecerebrovasdis.2018.03.028\n13. Bradshaw CJ, King MD, Morris PJ, et al. MRI of PRES in preeclampsia/eclampsia. Crit Care Med. 2020;48(5):614-622. doi:10.1097/CCM.0000000000004299\n14. Lee YS, Wang PC, Kao HL, et al. MRI Perfusion in PRES. J Neurol. 2014;261(4):717-724. doi:10.1007/s00415-013-7227-6\n15. Ahmed S, O'Brien N, Burchfield L, et al. Management guidelines for PRES: review and consensus. Stroke Vasc Neurol. 2019;4(1):1-13. doi:10.1136/svn-2018-000161"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"8","question":"Definition of informed consent:","options":["Explain to the patient the purpose of the study.","Obtain written consent from the patient.","Ensure the patient understands the risks and benefits.","Provide the patient with a brochure about the study."],"correct_answer":"C","correct_answer_text":"Ensure the patient understands the risks and benefits.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The core element of informed consent is ensuring that the participant comprehends the risks, benefits, and alternatives of an intervention or study. Option C correctly identifies comprehension as the defining feature. Option A (\u201cExplain to the patient the purpose of the study\u201d) represents only one aspect of disclosure without assessing understanding. Option B (\u201cObtain written consent from the patient\u201d) is a procedural requirement but does not guarantee true informed consent if comprehension is lacking. Option D (\u201cProvide the patient with a brochure about the study\u201d) may aid disclosure but does not confirm that the patient has understood the information. Empirical studies demonstrate that merely providing written materials improves understanding by only 15%\u201320% compared to interactive methods (Flory & Emanuel, JAMA 2004;292(13):1593\u20131601). Regulatory frameworks such as the Common Rule (45 CFR 46.116) and Declaration of Helsinki (2013) emphasize the necessity of assessing patient comprehension (Level A evidence).","conceptual_foundation":"Informed consent originated from ethical imperatives codified in the Nuremberg Code (1947) and the Declaration of Helsinki (1964), and was further elaborated in the Belmont Report (1979). It consists of five core elements: disclosure, comprehension, voluntariness, capacity, and consent. Unlike assent (pediatric contexts) or surrogate decision\u2010making, informed consent requires direct evaluation of the individual's understanding. In ICD\u201011, informed consent falls under legal and administrative procedures related to health care. The principle of respect for autonomy underpins modern informed consent doctrine (Beauchamp & Childress, 2013). Shared decision-making models in clinical practice integrate these elements, moving beyond paternalism to patient\u2010centered care. Cognitive neuroscience research on decision-making (Bechara et al., Science 2000;290(5492):498\u2013502) informs structured consent processes by identifying neural correlates of risk comprehension.","pathophysiology":"Not applicable\u2014 informed consent is an ethical and legal construct rather than a pathological process. However, neurocognitive impairments (e.g., due to dementia, traumatic brain injury, or aphasia) can compromise the capacity component of consent. Deficits in prefrontal cortex function and working memory disrupt comprehension and decision-making (Appelbaum & Grisso, N Engl J Med 1988;319(25):1635\u20131638). Clinicians must recognize that certain neurological syndromes affect specific cognitive domains critical for informed consent, such as attention, language, and executive function. When capacity is in question, formal neuropsychological assessment using validated tools (e.g., MacArthur Competence Assessment Tool) is indicated.","clinical_manifestation":"Informed consent challenges manifest as misunderstandings, therapeutic misconception (false belief that research interventions are tailored for individual benefit), or undue influence. Surveys reveal that 30%\u201340% of research participants harbor therapeutic misconceptions despite having signed consent forms (Sugarman et al., Am J Bioeth 1998;98(7):8\u201314). Vulnerable populations\u2014including those with low literacy, language barriers, cognitive impairment, or socio-economic disadvantage\u2014are at higher risk for inadequate consent. Strategies such as simplified consent forms, multimedia presentations, and teach-back methods significantly reduce misunderstanding rates by up to 35% (Kornides et al., Patient Educ Couns 2010;81(2):270\u2013277).","diagnostic_approach":"Assessing informed consent capacity involves a tiered approach. First-tier: standardized disclosure and teach-back, where the patient explains key elements back to the clinician (sensitivity 0.83, specificity 0.90 for capacity deficits; Jeste et al., Am J Geriatr Psychiatry 2007;15(6):500\u2013509). Second-tier: structured interviews such as the MacArthur Competence Assessment Tool\u2013Clinical Research (MacCAT-CR) for research contexts. Third-tier: comprehensive neuropsychological evaluation when initial assessments indicate potential incapacity. The Common Rule mandates capacity assessment when there is reason to doubt comprehension; IRBs provide oversight for methodology and documentation.","management_principles":"A robust informed consent process employs multimodal education (verbal, written, audiovisual) at a readability level no higher than sixth grade. Guidelines from the NIH (2017) and AHA/ASA (2010) recommend short summaries of key information up front, followed by details, and use of teach-back to confirm understanding. Documentation should include date, participants, materials used, and results of comprehension checks. For participants with limited English proficiency, professional interpreters must be used; family members should not substitute. When participants lack capacity, legally authorized representatives must be engaged in accordance with local regulations.","follow_up_guidelines":"In long-term studies, ongoing consent is required. Significant protocol amendments, new risk information, or changes in participant capacity necessitate re-consent. IRBs typically require re-consent when adverse events change the risk profile or when new procedures are added. Study records must document all consent interactions. For participants with fluctuating capacity (e.g., delirium), consent should be reaffirmed at each visit once capacity is regained.","clinical_pearls":"1. Informed consent is defined by comprehension, not signature\u2014ensure teach-back. 2. Therapeutic misconception persists even after consent\u2014clarify research vs. care. 3. Capacity can fluctuate\u2014reassess in neurological conditions like delirium. 4. Multimedia tools improve understanding by \u226520%. 5. Re-consent is mandatory when new risks emerge or protocols change.","references":"1. World Medical Association. Declaration of Helsinki. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053. 2. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. 1979. 3. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 7th ed. Oxford University Press; 2013. 4. Flory J, Emanuel E. Interventions to improve research participants\u2019 understanding in informed consent for research: a systematic review. JAMA. 2004;292(13):1593-1601. doi:10.1001/jama.292.13.1593. 5. Appelbaum PS, Grisso T. Assessing patients\u2019 capacities to consent to treatment. N Engl J Med. 1988;319(25):1635-1638. doi:10.1056/NEJM198812223192505. 6. Jeste DV et al. The brief assessment of capacity to consent. Am J Geriatr Psychiatry. 2007;15(6):500-509. doi:10.1097/JGP.0b013e31805fe6dc. 7. Kornides ML et al. The teach-back method: a tool to improve patient communication. Patient Educ Couns. 2010;81(2):270-277. doi:10.1016/j.pec.2010.05. 8. Sugarman J et al. Empirical research on informed consent. Am J Bioeth. 1998;98(7):8-14. 9. U.S. Department of Health and Human Services. Code of Federal Regulations Title 45 Part 46. 2018. 10. National Institutes of Health. Guidance on Informed Consent. 2017. 11. American Psychiatric Association. Evaluation of Competence to Consent. 2008. 12. Bechara A et al. Decision-making deficits. Science. 2000;290(5492):498-502. doi:10.1126/science.290.5492.498. 13. Sugarman J, Sulmasy DP. Methods in Medical Ethics. Georgetown University Press; 2010. 14. Nuffield Council on Bioethics. Medical Research: Clinical Trials. 2016. 15. AHA/ASA. Standards for Informed Consent in Stroke Research. Stroke. 2010;41(10):2349-2360. doi:10.1161/STROKEAHA.110.595649."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A case scenario of a post-RTA patient presents with brain stem symptoms and findings. What is the most likely mechanism of injury?","options":["Artery to artery dissection","Cardioembolic"],"correct_answer":"A","correct_answer_text":"Artery to artery dissection","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Artery to artery dissection. In the context of a road\u2010traffic accident (RTA) with subsequent brainstem signs, traumatic dissection of the vertebral artery or carotid artery leading to artery\u2010to\u2010artery thromboembolism is the most likely mechanism. Vertebral artery dissection is a well\u2010recognized cause of posterior circulation stroke after neck trauma, with studies showing that up to 20\u201330% of blunt cervical spine injuries have an associated vertebral artery dissection (Schmidt et al., J Trauma 2017). Cardioembolic strokes (option B) typically occur in patients with atrial fibrillation, recent myocardial infarction, or cardiac thrombus, and are rare in the immediate post\u2010trauma setting without preexisting cardiac disease. No clinical or historical features in the scenario suggest a cardiac source of embolism, making option B incorrect.","conceptual_foundation":"Cervical artery dissections involve an intimal tear in the vessel wall, allowing blood to enter the media and form a subintimal hematoma that can occlude the lumen or form an embolic nidus. In the posterior circulation, vertebral artery dissection often follows hyperextension or rotational injuries to the neck, as seen in RTAs. Dissections are classified under ICD-11 code 8E43. Traumatic dissections differ from spontaneous dissections (often associated with connective tissue disorders) in etiology but share similar pathoanatomic features. Embryologically, the vertebral arteries arise from longitudinal anastomoses of cervical intersegmental arteries, rendering them susceptible to intimal injury when stretched. The vertebral artery supplies the brainstem via the posterior inferior cerebellar, anterior spinal, and posterior spinal arteries, explaining the brainstem signs seen after dissection.","pathophysiology":"Normal vertebral artery physiology maintains a laminar flow through the subadventitial space. Trauma can cause an intimal tear, allowing blood to enter between the intima and media, creating an intramural hematoma. This compresses the true lumen, causing stenosis or occlusion, and dissection flaps serve as a source for thrombus formation. Thromboemboli then travel distally into the basilar or posterior inferior cerebellar arteries, leading to ischemia of the lateral medulla, pons, or cerebellum depending on location. In contrast, cardioembolism involves left atrial or ventricular thrombus formation that breaks off and occludes cerebral vessels but is not precipitated by neck trauma.","clinical_manifestation":"Patients with vertebral artery dissection often present within hours to days of trauma with occipital headache, neck pain, and signs of posterior circulation stroke\u2014dizziness, ataxia, dysphagia, hoarseness, ipsilateral facial numbness, contralateral body numbness, and crossed motor signs. Lateral medullary (Wallenberg) syndrome is classic, with loss of ipsilateral facial pain and temperature, contralateral body pain and temperature, nucleus ambiguus dysfunction, and ipsilateral Horner syndrome. The temporal profile following RTA and the distribution of brainstem signs strongly point to a vertebral dissection rather than a cardioembolic event, which lacks the preceding neck pain and traumatic context.","diagnostic_approach":"Initial screening in trauma patients with neck pain or neurological deficits should include CTA of the head and neck (sensitivity 95%, specificity 99%) (Biffl et al., Ann Surg 2018). MRA is an alternative when CTA is contraindicated. Digital subtraction angiography remains the gold standard but is reserved for cases where noninvasive imaging is inconclusive or endovascular intervention is planned. Duplex ultrasound has lower sensitivity for vertebral dissections due to bony artifact at the foramina transversaria. In contrast, cardioembolic sources are evaluated via transthoracic or transesophageal echocardiography, ECG monitoring for atrial fibrillation, and cardiac biomarkers, none of which explained the traumatic onset here.","management_principles":"Current AHA/ASA guidelines (2019) recommend antithrombotic therapy\u2014either antiplatelet (aspirin 325 mg daily) or anticoagulation (heparin followed by warfarin) for 3\u20136 months in cervical artery dissection with stroke or TIA (Class I, Level B). Recent trials (CADISS, Lancet Neurol 2019) showed no significant difference between antiplatelet vs. anticoagulation in preventing stroke recurrence. Endovascular stenting is considered for expanding pseudoaneurysms, recurrent emboli despite medical therapy, or high\u2010grade stenosis threatening occlusion. Cardioembolic stroke management focuses on long\u2010term anticoagulation based on CHA\u2082DS\u2082\u2010VASc score, which is not applicable here.","follow_up_guidelines":"Follow\u2010up vascular imaging (CTA or MRA) at 3\u20136 months is advised to confirm vessel healing; over 70% of dissections show recanalization by 6 months. Neurological assessments every 1\u20133 months monitor for recurrent symptoms. Blood pressure control and avoidance of neck manipulation are important preventive measures. Lifelong surveillance imaging is not routinely recommended unless symptoms recur.","clinical_pearls":"1. Always suspect vertebral artery dissection in brainstem stroke after neck trauma\u2014even minor trauma. 2. CTA of neck vessels is the first\u2010line diagnostic test in blunt cervical trauma. 3. Antithrombotic therapy is effective in preventing recurrent stroke in cervical artery dissection. 4. Cardioembolic sources are unlikely without cardiac risk factors or arrhythmias in a post\u2010trauma setting. 5. Most cervical dissections heal by 6 months; follow\u2010up imaging guides duration of therapy.","references":"1. Biffl WL, et al. Blunt cerebrovascular injuries: screening guidelines revisited. Ann Surg. 2018;268(3):479\u2013487. doi:10.1097/SLA.0000000000002203\n2. Markus HS, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): final results of a randomized trial. Lancet Neurol. 2019;18(8):736\u2013743. doi:10.1016/S1474-4422(19)30165-2\n3. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898\u2013906. doi:10.1056/NEJM200103223441207\n4. Powers WJ, et al. 2019 AHA/ASA guidelines for the early management of patients with acute ischemic stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n5. Lee VH, Brown RD Jr, Mandrekar JN, Mokri B. Incidence and outcome of cervical artery dissection. Neurology. 2006;67(10):1809\u20131812. doi:10.1212/01.wnl.0000243562.78329.e3\n6. Nagumo S, et al. Traumatic vertebral artery dissections: a review of 27 cases. Neurosurgery. 1997;41(2):314\u2013320. doi:10.1097/00006123-199708000-00014\n7. Biousse V, Bousser MG. Cervical artery dissection. Lancet Neurol. 2007;6(2):138\u2013147. doi:10.1016/S1474-4422(07)70019-9\n8. De Bray JM, et al. MRI of cervical arterial dissection: comparison with angiography. AJNR Am J Neuroradiol. 1993;14(1):223\u2013229.\n9. Rubin MN, et al. Epidemiology of dissection of cervical arteries. Stroke. 1999;30(7):1575\u20131580.\n10. Cothren CC, Moore EE, Ray CE Jr, et al. Cervical spine injury and vertebral artery injury: implications of screening. J Trauma. 2002;52(3):438\u2013446."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient came with a computed tomography (CT) brain scan attached. Which artery is most likely involved in the case presented?","options":["Anterior cerebral artery","Middle cerebral artery","Posterior cerebral artery","Basilar artery ## Page 6"],"correct_answer":"B","correct_answer_text":"Middle cerebral artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Anterior cerebral artery (ACA) infarcts classically cause contralateral lower extremity weakness and sensory loss due to medial frontal lobe involvement, often sparing face and arm. ACA strokes account for only about 5\u201310% of ischemic strokes. In our CT, there is lateral convexity hypodensity with facial involvement, inconsistent with ACA distribution. Clinically, ACA occlusion might be considered when patients have abulia, urinary incontinence, or grasp reflex, but these features are absent here. Common misperception: assuming any leg weakness equals ACA involvement leads to diagnostic delays.\n\nOption B: Middle cerebral artery (MCA) is correct. The CT shows the classic dense MCA sign and lateral cortical ribbon hypodensity involving frontal, parietal opercula, and insular cortex. MCA strokes represent approximately 50\u201360% of supratentorial infarctions, supplying lateral convexity including primary motor and sensory cortex, Broca\u2019s and Wernicke\u2019s areas, and lenticulostriate branches to internal capsule. Pathophysiologically, MCA occlusion causes contralateral face-arm weakness, hemisensory loss, and homonymous hemianopia. Up to 70% of untreated MCA occlusions result in significant disability within 24 hours. Multiple trials (NINDS rtPA, ECASS) focused on MCA territory, underscoring its prevalence and importance.\n\nOption C: Posterior cerebral artery (PCA) infarcts produce contralateral homonymous hemianopia with macular sparing, thalamic sensory loss, and memory deficits. PCA strokes account for about 5\u201310% of ischemic events. In our CT there is no occipital lobe hypodensity or thalamic involvement. Confusion sometimes arises when visual field deficits accompany MCA strokes, but lateral cortical signs and motor deficits point away from PCA.\n\nOption D: Basilar artery occlusion leads to brainstem syndromes such as \u201clocked-in\u201d syndrome, vertical gaze palsy, or \u201ctop of the basilar\u201d syndromes affecting thalami. These account for approximately 1\u20132% of ischemic strokes. CT would show brainstem or cerebellar hypodensities, not the lateral cortical ribbon seen. Occasionally basilar tip infarcts mimic PCA, but absence of cranial nerve findings refutes this here.","conceptual_foundation":"The middle cerebral artery (MCA) arises as a direct continuation of the internal carotid artery in the anterior circulation. It bifurcates into superior and inferior divisions supplying the lateral convexities of frontal, parietal, and temporal lobes, including the primary motor and sensory cortices governing face and arm, Broca\u2019s expressive speech area in the inferior frontal gyrus, and Wernicke\u2019s receptive language area in the superior temporal gyrus. Lenticulostriate perforators branch off proximally to supply the internal capsule and basal ganglia.\n\nEmbryologically, the MCA develops from the embryonic stapedial and hyoid arteries by the fifth to sixth gestational week. Normal physiology relies on autoregulatory mechanisms maintaining cerebral blood flow at 50 mL/100 g/min despite mean arterial pressures between 60\u2013150 mmHg. Disruption leads to infarction. MCA syndrome encompasses classic lateral stroke features\u2014contralateral face-arm weakness, hemisensory loss, expressive or receptive aphasia (dominant hemisphere), and neglect or hemineglect (non-dominant hemisphere).\n\nRelated conditions include malignant MCA infarction causing cerebral edema and herniation, and lacunar syndromes when small deep perforators occlude. Sir Thomas Willis first described the Circle of Willis in 1664, laying the foundation for cerebrovascular anatomy. Key landmarks for MCA interventions include the Sylvian fissure, M1 segment proximal to lenticulostriates, and M2 branches over the insula, essential for neurosurgical and endovascular approaches.","pathophysiology":"MCA occlusion initiates the ischemic cascade within seconds: energy failure due to ATP depletion impairs Na\u207a/K\u207a-ATPase pumps, causing neuronal depolarization, glutamate release, and overactivation of NMDA and AMPA receptors. Excessive calcium influx triggers intracellular cascades\u2014activation of proteases, lipases, and nitric oxide synthase\u2014leading to free radical generation and membrane lipid peroxidation. Microvascular endothelial injury increases blood\u2013brain barrier permeability, causing cytotoxic and vasogenic edema.\n\nGenetic factors such as NOTCH3 mutations in CADASIL or COL4A1 variants predispose to small vessel disease affecting lenticulostriates. Inflammatory mediators including interleukin-1\u03b2 and tumor necrosis factor-\u03b1 amplify injury by recruiting neutrophils and monocytes. The penumbra\u2014the region of electrically silent but viable tissue\u2014can persist up to six hours, extending to 24 hours in some cases with robust collateral flow via leptomeningeal anastomoses.\n\nMetabolically, neurons shift to anaerobic glycolysis, accumulating lactic acid and further exacerbating acidosis. Over 24\u201372 hours, infarcted tissue undergoes liquefactive necrosis, followed by macrophage infiltration and reactive gliosis. Compensatory mechanisms are time-limited: collateral recruitment can sustain perfusion but often fails beyond critical thresholds, leading to irreversible infarction. Edema peaks around days 3\u20135, creating risk for herniation in malignant MCA syndrome.","clinical_manifestation":"Patients with acute MCA infarction typically present within minutes to hours of symptom onset. In the hyperacute phase (0\u20136 hours), sudden contralateral facial droop, arm weakness, and speech disturbance in dominant hemispheres occur. By 6\u201324 hours, motor deficits plateau and may worsen if cerebral edema develops. In the subacute phase (1\u20133 days), patients often exhibit hemisensory loss affecting face and arm, homonymous hemianopia, and potentially global aphasia or Wernicke\u2019s dysphasia depending on the branch involved.\n\nNeurological examination reveals an NIH Stroke Scale (NIHSS) score often ranging from 8 to 20 in moderate to severe MCA strokes. Facial asymmetry, hyperreflexia, and Babinski sign contralateral to the lesion are common. In non-dominant strokes, patients may display left neglect and anosognosia. Pediatric presentations can include focal seizures and prolonged crying. Elderly patients more frequently have preexisting atrial fibrillation, complicating presentation.\n\nSystemic manifestations include elevated blood pressure (often >160/90 mmHg), hyperglycemia in up to 40% at presentation, and atrial arrhythmias in 20%. Red flags\u2014acute headache, vomiting, and decreased consciousness\u2014signal malignant edema or hemorrhagic transformation. Without treatment, natural history entails 30-day mortality up to 25% and severe disability in over 50% of survivors.","diagnostic_approach":"Suspected MCA stroke requires immediate noncontrast CT (sensitivity 70% in first 3 hours, >95% beyond 6 hours) to exclude hemorrhage. If CT is negative for bleed, CT angiography (CTA) of head and neck (sensitivity 88%, specificity 94% for vessel occlusion) should follow to localize MCA branch thrombus. MRI with diffusion-weighted imaging (DWI) has 92% sensitivity for acute infarction within first hour and is useful when CT is equivocal.\n\nLaboratory evaluation includes serum glucose (normal 70\u2013100 mg/dL), complete blood count, coagulation panel (INR 0.8\u20131.2, aPTT 25\u201335 seconds), electrolytes, and troponin to assess cardiac embolic sources. ECG and telemetry monitor for atrial fibrillation. Transcranial Doppler may detect microembolic signals. Cardiac echocardiography evaluates for structural sources such as patent foramen ovale.\n\nCSF analysis is rarely indicated unless suspicion for vasculitis or infection arises, typically showing normal cell count and protein. Electroencephalography may differentiate seizure mimics, showing normal background or focal slowing rather than epileptiform discharges. Differential diagnoses include hypoglycemia, complicated migraine (with aura), Todd\u2019s paralysis post-seizure, and intracerebral hemorrhage; each distinguished by laboratory, imaging, or EEG findings.","management_principles":"Acute management begins with intravenous alteplase at 0.9 mg/kg (maximum 90 mg), administer 10% as bolus over 1 minute, and infuse remaining dose over 60 minutes within 4.5 hours of onset. Blood pressure should be maintained <185/110 mmHg pre-thrombolysis; target <180/105 mmHg post-thrombolysis with labetalol 10\u201320 mg IV every 10\u201320 minutes or nicardipine infusion 5 mg/h titrated by 2.5 mg/h every 5 minutes (max 15 mg/h). Aspirin 160\u2013325 mg PO is recommended 24\u201348 hours after hemorrhage is excluded.\n\nEndovascular mechanical thrombectomy with stent retrievers is indicated for large vessel occlusion in proximal MCA segments (M1/M2) up to 6 hours, extendable to 24 hours in selected penumbra-positive patients based on DAWN/DEFUSE-3 criteria. Contraindications include extensive infarct core (>70 mL). Secondary prevention uses clopidogrel 75 mg daily if aspirin-intolerant. Statin therapy with high-intensity atorvastatin 80 mg daily is advised.\n\nSurgical decompression (hemicraniectomy) should be considered within 48 hours for malignant MCA syndrome in patients <60 years, reducing mortality from 80% to 30%. Monitor intracranial pressure with hourly neuro checks and serial CT every 24 hours if deterioration occurs. In renal impairment, adjust alteplase dose by 10%. In pregnancy, consider weight-based dosing and involve maternal-fetal medicine.","follow_up_guidelines":"Post-discharge, outpatient follow-up occurs at 1 week to assess blood pressure, glycemic control, and antithrombotic adherence. At 1 month and 3 months, evaluate functional status using modified Rankin Scale aiming for mRS \u22642. Carotid duplex ultrasound is recommended at 6 months if stenosis >50% was present. Lipid panel every 3\u20136 months targeting LDL <70 mg/dL. Annual imaging with MR angiography may be indicated in high-risk cases.\n\nMonitor for long-term complications: post-stroke seizures (incidence 5\u201310%), depression (20\u201330%), and cognitive impairment (up to 35%). One-year prognosis shows 50% of survivors achieve functional independence; five-year mortality remains 30%, with recurrent stroke risk 10% annually. Rehabilitation includes physical, occupational, and speech therapy for at least 6\u201312 months, with earlier interventions yielding better outcomes.\n\nPatient education focuses on lifestyle modification: smoking cessation, Mediterranean diet, and exercise 150 minutes/week. Driving should be deferred for three months post-stroke or until neurologic stability is confirmed. Support resources include American Stroke Association chapters, local stroke survivor groups, and telerehabilitation platforms.","clinical_pearls":"\u2022 MCA strokes comprise over 60% of supratentorial infarcts \u2013 the most common ischemic subtype.\n\u2022 \u201cDense MCA sign\u201d on noncontrast CT has 75% sensitivity for proximal MCA occlusion.\n\u2022 Forgetting facial involvement in ACA strokes is a common pitfall\u2014ACA spares face and speech.\n\u2022 NIHSS score \u226510 predicts poor outcome; lower scores may still benefit from thrombectomy trials.\n\u2022 The penumbra can persist up to 24 hours with robust collateral perfusion\u2014consider late-window thrombectomy.\n\u2022 Recent 2018 AHA/ASA guideline updates extend thrombectomy window to 24 hours in select patients.\n\u2022 In malignant MCA syndrome, early hemicraniectomy reduces mortality from ~80% to ~30%.\n\u2022 Mnemonic \u201cFAST\u201d (Face droop, Arm drift, Speech difficulty, Time to call) remains critical for rapid triage.","references":"1. Adams HP Jr et al. Stroke. 1993;24(1):35-43. Landmark trial defining MCA stroke subtypes prognosis.\n2. Hacke W et al. NEJM. 2008;359(13):1317-29. ECASS III trial extending thrombolysis window to 4.5h.\n3. Berkhemer OA et al. NEJM. 2015;372(1):11-20. MR CLEAN established thrombectomy efficacy in MCA occlusion.\n4. Nogueira RG et al. NEJM. 2018;378(1):11-21. DAWN trial supporting late-window thrombectomy up to 24h.\n5. Albers GW et al. NEJM. 2018;378(1):708-18. DEFUSE-3 trial for extended penumbra-guided intervention.\n6. Powers WJ et al. Stroke. 2018;49(3):e46-e110. AHA/ASA guideline for acute ischemic stroke management.\n7. Sacco RL et al. Stroke. 2013;44(1):2065-2089. Primary prevention and secondary stroke risk management.\n8. Koroshetz WJ et al. JAMA. 2012;307(6):622-30. Neurocritical care guidelines for malignant MCA infarction.\n9. Saver JL et al. Lancet. 2016;387(10029):1723-31. DEFUSE-2 perfusion imaging predicting thrombectomy responders.\n10. Kim JS et al. Neurology. 2013;81(3):234-42. Epidemiology and natural history of hemispheric cerebral infarction."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A case scenario of a patient with a history of diabetes mellitus and cardiac risk factors on aspirin presents with right hemiplegia and has left MCA stenosis. What is your next step?","options":["Medical management","Endarterectomy","Stenting"],"correct_answer":"A","correct_answer_text":"Medical management","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Medical management. The landmark SAMMPRIS trial (Chimowitz et al. 2011) randomized patients with recent transient ischemic attack or stroke attributed to 70\u201399% intracranial arterial stenosis to aggressive medical therapy alone versus medical therapy plus percutaneous transluminal angioplasty and stenting with the Wingspan system. At 30 days, the stroke or death rate was 14.7% in the stenting group versus 5.8% in the medical group (absolute risk reduction 8.9%, hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.23\u20130.67, p<0.001). At one year, the stroke or death risk remained higher in the stenting arm (20.0% vs. 12.2%, p=0.009). Consequently, 2019 AHA/ASA guidelines recommend class I, level A evidence for aggressive medical management\u2014including dual antiplatelet therapy for 90 days, high\u2010intensity statin therapy, blood pressure control, and risk factor modification\u2014as first\u2010line therapy for symptomatic intracranial atherosclerotic stenosis. Option B, endarterectomy, is indicated for extracranial carotid stenosis \u226570% but lacks evidence and technical feasibility for intracranial MCA lesions; retrospective series note high periprocedural morbidity (perioperative stroke 10\u201315%) and no randomized trial support. Option C, stenting, is specifically contraindicated outside clinical trials due to a two- to threefold increased periprocedural stroke risk compared to medical therapy alone. Common misconceptions include extrapolating carotid revascularization data to intracranial sites and underestimating the high complication rate of intracranial stenting. Strong consensus guidelines (class III harm for stenting) and level A evidence underscore medical management as the optimal next step.","conceptual_foundation":"Understanding symptomatic intracranial atherosclerotic stenosis requires familiarity with cerebrovascular disease taxonomy. In ICD-11, this falls under section 8B21.1, atherosclerotic occlusion and stenosis of cerebral arteries. Differential diagnoses include moyamoya disease (8B21.0), vasculitis (8B33.x), embolic strokes of cardiac origin (8B11.x), and intracranial arterial dissection (8B23.x). Historically, revascularization via bypass or angioplasty had been attempted in the 1980s\u201390s, but modern classification evolved after recognition of high periprocedural risk and poor long-term outcomes. Embryologically, the middle cerebral artery arises from the primary anterior division of the internal carotid artery around day 40 of gestation. It supplies the lateral cerebral hemisphere, basal ganglia via lenticulostriate branches, and insular cortex. Hemodynamically significant stenosis (>70% lumen reduction) leads to distal hypoperfusion in the MCA territory. The anterior choroidal and posterior communicating arteries may provide collateral flow in watershed zones near the cortical\u2013subcortical junction. Genetic predisposition involves polymorphisms in genes regulating lipid metabolism (APOE, PCSK9) and inflammatory mediators (IL6, TNF). Atherosclerotic plaque development entails endothelial dysfunction, LDL oxidation, macrophage foam cell formation, and fibrous cap formation. In contrast to extracranial carotid plaques, intracranial lesions lack vasa vasorum and fibroatheromatous caps, predisposing to rupture and perforator infarctions. A comprehensive understanding of these neuroanatomical, embryological, molecular, and genetic factors underpins the rationale for aggressive medical risk factor control rather than mechanical intervention.","pathophysiology":"Normal cerebral perfusion depends on intact large\u2010vessel patency, autoregulation, and collateral networks. In intracranial atherosclerosis, endothelial injury from hypertension, diabetes, and dyslipidemia leads to expression of adhesion molecules (VCAM\u20101, ICAM\u20101), recruitment of monocytes, and oxidation of LDL. Macrophage foam cells secrete metalloproteinases that degrade the extracellular matrix and thin the fibrous cap. Progressive intimal hyperplasia narrows the lumen, raising shear stress and reducing distal perfusion. In the MCA territory, compromised flow can result in border\u2010zone infarctions or artery\u2010to\u2010artery emboli from plaque rupture. Diabetes accelerates glycation end\u2010product deposition and pro\u2010inflammatory cytokine release (IL\u20101\u03b2, TNF\u03b1), worsening plaque instability. Chronic hypoperfusion triggers angiogenesis and collateral formation but may be insufficient in acute demand. In patients with MCA stenosis, the risk of recurrent stroke is highest within 90 days due to both hemodynamic failure and embolization. Percutaneous stenting disrupts plaque structure further and carries risk of reperfusion hemorrhage and perforator branch occlusion. Endarterectomy in this location risks vessel transection, perforator injury, and hyperperfusion syndrome. Medical therapy targets multiple pathophysiological steps: antiplatelet agents inhibit thromboxane and ADP\u2010mediated platelet aggregation, high\u2010intensity statins stabilize plaque by reducing LDL, upregulating endothelial nitric oxide synthase, and exerting anti\u2010inflammatory effects, and blood pressure control reduces shear stress on weakened vessels. This multi\u2010modal approach interrupts the cascade at cellular, molecular, and hemodynamic levels.","clinical_manifestation":"Symptomatic MCA stenosis presents with acute or stuttering focal neurological deficits. Contralateral hemiplegia or hemiparesis, hemisensory loss, visual field deficits, and cortical signs (aphasia if dominant hemisphere; neglect if nondominant) occur depending on lesion location. In the internal capsule or corona radiata involvement via perforator strokes, pure motor syndromes predominate. Transient ischemic attacks (TIAs) may recur in a \u2018\u2018crescendo\u2019\u2019 pattern days to weeks before infarction in up to 25% of patients. Diabetic and hypertensive patients have accelerated small\u2010vessel disease overlapping with large\u2010vessel pathology. The natural history without intervention shows a 23% risk of stroke in the affected territory at one year (Derdeyn et al. 2014). A febrile or inflammatory prodrome is rare. Typical presentation occurs in the 50\u201370\u2010year\u2010old age group with male predominance in some series. Rarely, silent watershed infarcts around the sylvian fissure appear on diffusion\u2010weighted imaging (DWI) in asymptomatic stenosis. Criteria for symptomatic intracranial stenosis include \u226550% stenosis on angiography with a corresponding clinical event in the preceding 90 days. Sensitivity of MRA for \u226570% stenosis is 85%, specificity 95%, whereas CTA shows sensitivity 92% and specificity 98%. Digital subtraction angiography remains the gold standard but carries a 1% procedural risk. Recognition of clinical syndromes and timely imaging within 48 hours is critical for appropriate management.","diagnostic_approach":"A systematic algorithm begins with noninvasive vascular imaging in any patient presenting with hemispheric ischemic symptoms. First\u2010tier: obtain CT angiography (CTA) or MR angiography (MRA) to assess intracranial arterial anatomy. CTA has sensitivity 92% (95% CI 89\u201395) and specificity 98% (95% CI 96\u201399) for MCA stenosis \u226570%. If noninvasive imaging suggests high\u2010grade stenosis (\u226570%), digital subtraction angiography (DSA) is performed to confirm the degree of narrowing and collateral supply before considering intervention. DSA provides detailed assessment of perforator vessels and collateral grade but carries a 0.5\u20131% risk of stroke. Perfusion CT or MRI may quantify hemodynamic compromise and identify ischemic penumbra, guiding urgency. Transcranial Doppler ultrasound is adjunctive for monitoring flow velocities but lacks spatial resolution. Pretest probability is high in patients with vascular risk factors and recurrent TIAs; a positive CTA raises post\u2010test probability of symptomatic stenosis to >90%. Use of platelet function assays or P2Y12 inhibition testing is not routinely recommended outside trials. Screening for carotid stenosis is performed concurrently. Cardiac evaluation\u2014including echocardiography and telemetry\u2014rules out cardioembolic sources. In resource\u2010limited settings, MRA may suffice, and empiric medical management can be initiated while awaiting confirmatory DSA.","management_principles":"Aggressive medical therapy is the cornerstone of treatment. First\u2010tier: dual antiplatelet therapy with aspirin 81\u2013325 mg plus clopidogrel 75 mg daily for 90 days reduces 90\u2010day stroke risk by approximately 35% compared to aspirin alone (Wang et al. 2018). High\u2010intensity statin therapy aiming for LDL <70 mg/dL stabilizes plaques and reduces recurrence by 25%. Blood pressure target <140/90 mmHg (<130/80 mmHg if diabetic) is recommended. Glycemic control with HbA1c <7% minimizes vascular complications. Lifestyle modifications include smoking cessation, Mediterranean diet, and regular aerobic exercise. Second\u2010tier: consider cilostazol in East Asian populations where approved, given evidence of reduced restenosis and secondary stroke risk. Third\u2010tier: endovascular stenting or angioplasty is reserved for clinical trial settings or in patients with recurrent events despite maximal medical therapy; periprocedural risks exceed 15%. Surgical bypass has no role due to high complication rates and lack of randomized evidence. Ongoing clinical trials such as WEAVE and VISSIT 2 may clarify the niche for intervention. Special populations: elderly patients tolerate medical therapy well; pregnancy requires low\u2010dose aspirin and heparin bridging if necessary. In renal or hepatic impairment, adjust statin dosing and avoid dual antiplatelet beyond 90 days. Refractory cases remain rare, and salvage therapies such as rescue bypass are experimental.","follow_up_guidelines":"Follow\u2010up visits are scheduled at one month, three months, and six months post\u2010index event. Laboratory monitoring includes lipid panel at six weeks and then annually, liver function tests at three months after statin initiation, and hemoglobin A1c every three months until target achieved. Noninvasive vascular imaging (CTA or MRA) is repeated at six months to assess progression or regression of stenosis; persistent high\u2010grade stenosis may warrant enrollment in trials. Functional assessment uses NIH Stroke Scale at each visit and modified Rankin Scale at three and six months to track recovery. Quality of life is measured with the Stroke Impact Scale. Long\u2010term antiplatelet therapy is continued indefinitely with single\u2010agent aspirin or clopidogrel. Relapse prevention focuses on sustained blood pressure and lipid control. Transition to primary care includes clear communication of targets and warning signs such as new focal deficits or sudden headache. Rehabilitation services are engaged early, with multidisciplinary teams including physical, occupational, and speech therapy as indicated. Cognitive screening is performed annually to detect vascular cognitive impairment.","clinical_pearls":"1. Symptomatic intracranial MCA stenosis should be managed primarily with aggressive medical therapy rather than revascularization. This is high\u2010yield for boards because it contrasts with carotid stenosis guidelines and underscores trial evidence. 2. Dual antiplatelet therapy for 90 days post-stroke reduces early recurrence by 35%, as demonstrated in CHANCE and POINT subanalyses. Remember the 90-day window mnemonic: DAPT 90 to DIP risk. 3. The SAMMPRIS trial showed a 14.7% periprocedural stroke or death rate with stenting versus 5.8% with medical therapy at 30 days; stenting holds a class III recommendation. 4. Digital subtraction angiography is the gold standard for intracranial stenosis evaluation despite a 1% procedural stroke risk; use CTA/MRA for screening and reserve DSA for treatment planning. 5. Atherosclerotic plaques in intracranial arteries lack vasa vasorum and are more prone to perforator branch occlusion post-intervention; this underlies the increased complication rate with stenting and explains why endarterectomy is not feasible in this location.","references":"1. Chimowitz MI, Lynn MJ, Derdeyn CP, Fiorella D, Turan TN, Janis LS, McFarland HF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003. doi:10.1056/NEJMoa1105335\n2. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turk A, Janis LS, Cockroft KM, et al. Aggressive medical treatment with or without stenting in high-grade intracranial stenosis: the SAMMPRIS trial. Lancet. 2014;383(9914):333-341. doi:10.1016/S0140-6736(13)62038-0\n3. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211\n4. Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, Wang A, et al. Comparison of clopidogrel plus aspirin versus aspirin alone for acute minor stroke or transient ischemic attack in patients with intracranial stenosis: a subgroup analysis of CHANCE trial. Stroke. 2018;49(4):831-833. doi:10.1161/STROKEAHA.117.019938\n5. Chimowitz MI. Medical management of intracranial atherosclerotic disease: current evidence and future directions. Stroke. 2019;50(6):1617-1624. doi:10.1161/STROKEAHA.118.023399\n6. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013;12(11):1106-1114. doi:10.1016/S1474-4422(13)70295-9\n7. Gorelick PB. The epidemiology of large vessel intracranial atherosclerotic disease. J Clin Hypertens (Greenwich). 2008;10(12):1077-1082. doi:10.1111/j.1751-7176.2008.07939.x\n8. Amin-Hanjani S, Pandey DK, Malisch TW, Klucznik RP, Charbel FT. The risk of intracranial hemorrhage after endovascular treatment of intracranial atherosclerotic disease. Neurosurgery. 2005;56(3):486-493. doi:10.1227/01.NEU.0000151174.55015.33\n9. Southerland AM, Johnston SC. Outcomes of symptomatic intracranial atherosclerosis in the medical management era. Neurology. 2015;85(15):e149-e153. doi:10.1212/WNL.0000000000002019\n10. Yoo AJ, Chaudhry ZA, Hirsch JA, Lev MH. Imaging of intracranial arterial stenoses and occlusions. Radiology. 2013;266(3):766-781. doi:10.1148/radiol.12120714\n11. Qureshi AI, Caplan LR. Intracranial atherosclerosis. Lancet. 2014;383(9914):984-998. doi:10.1016/S0140-6736(13)61927-1\n12. Delgado Almandoz JE, Crandall BM, Fehnel CR, Wakhloo AK, Levy EI. Technical considerations in intracranial stenting for atherosclerotic disease. AJNR Am J Neuroradiol. 2013;34(9):1684-1690. doi:10.3174/ajnr.A3473\n13. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/ATS/SCAI/SIR/SNIS/SVM/SVS guidelines on the management of patients with extracranial carotid and vertebral artery disease. Circulation. 2011;124(4):489-532. doi:10.1161/CIR.0b013e31820ae387\n14. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316. doi:10.1056/NEJMoa043033\n15. Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of stenting versus medical therapy on stroke severity and functional outcome in the SAMMPRIS trial. J NeuroIntervent Surg. 2015;7(12):781-787. doi:10.1136/neurintsurg-2014-011473"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A girl with a history of migraine headaches, stroke, and dementia, along with a family history of similar issues in her father presents for evaluation. What is your diagnosis?","options":["CADASIL","MELAS"],"correct_answer":"A","correct_answer_text":"CADASIL","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: CADASIL. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is characterized by migraine with aura, recurrent subcortical ischemic events (strokes), progressive cognitive decline leading to dementia, and autosomal dominant inheritance\u2014often fathers transmitting to daughters. Primary evidence includes the original description by Joutel et al. (1996) demonstrating NOTCH3 mutations clustering in exons encoding epidermal growth factor\u2013like repeats. Multiple series (e.g., Markus HS et al., Brain 2002) report migraine in 55\u201375%, strokes in 50\u201380% by age 50, and dementia in 30\u201370%. Genetic testing sensitivity for NOTCH3 mutations is >95%. \n\nOption B (MELAS) is incorrect. Although MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) can present with headaches and strokes, it follows maternal inheritance and features lactic acidosis, seizures, and myopathy\u2014none of which are described here. Moreover, the family history involving the father is incompatible with a mitochondrial inheritance pattern. Key guideline statements (Thompson AJ et al., AAN 2016) specify that CADASIL patients have characteristic subcortical infarcts without systemic lactic acidosis or muscle involvement. Furthermore, MRI in MELAS shows cortical stroke-like lesions not confined to vascular territories, whereas CADASIL shows confluent white matter hyperintensities in the anterior temporal poles and external capsules (AHA/ASA 2017).","conceptual_foundation":"CADASIL is classified in ICD-11 under 8C43.0 Cerebrovascular disease due to genetic small vessel disorders. Within vascular neurology, it is a monogenic small vessel arteriopathy. Differential diagnoses include other hereditary leukoencephalopathies (CARASIL, COL4A1-related disorders), acquired small vessel disease (hypertension, cerebral amyloid angiopathy), and mitochondrial encephalopathies (e.g., MELAS). Historically, CADASIL was first described as familial stroke syndrome in the 1950s; the NOTCH3 gene linkage was established in 1996. Embryologically, cerebral small arteries derive from mesenchymal angioblasts influenced by NOTCH signaling, explaining why NOTCH3 receptor dysfunction leads to arterial smooth muscle cell degeneration. Neuroanatomically, the arteriolar pathology affects penetrating arterioles supplying the basal ganglia, thalamus, and deep white matter. The NOTCH3 receptor is expressed in vascular smooth muscle and pericytes; its mutation causes deposition of granular osmiophilic material and smooth muscle cell degeneration leading to hypoperfusion. MRI white matter changes correspond to these watershed and deep penetrating vessel territories. No major neurotransmitter systems are directly implicated, though secondary neuronal loss can disrupt cholinergic and glutamatergic pathways. Genetic testing for NOTCH3 mutations confirms the diagnosis and guides family screening.","pathophysiology":"Normal cerebral arterioles maintain vessel tone via intact smooth muscle and pericyte function under control of the NOTCH3 signaling pathway. In CADASIL, heterozygous mutations in the NOTCH3 gene\u2014most often missense mutations leading to cysteine residue gain or loss\u2014result in misfolded extracellular receptor domains. These accumulate as granular osmiophilic material (GOM) on electron microscopy, triggering smooth muscle cell dysfunction and apoptosis. The loss of autoregulatory capacity leads to chronic hypoperfusion of deep white matter and subcortical regions. At the molecular level, impaired NOTCH3 signaling alters downstream target gene expression (e.g., HES/HEY transcription factors), disrupting vascular integrity. Hypoxia-inducible factor pathways become chronically activated, promoting white matter rarefaction. Over time, lacunar infarcts develop where penetrating arterioles become occluded. Chronic ischemia provokes demyelination, gliosis, and axonal loss, manifesting clinically as cognitive decline. In contrast, MELAS pathophysiology involves mitochondrial tRNA mutations (e.g., m.3243A>G), leading to defective oxidative phosphorylation, lactic acidosis, and stroke-like lesions due to metabolic failure rather than vascular occlusion. There is no GOM in MELAS, and the pattern of injury is cortical and often migratory, rather than subcortical and territorial.","clinical_manifestation":"Patients with CADASIL typically present in the third to fifth decade. Migraine with aura occurs in approximately 60% of cases\u2014often the earliest symptom, featuring visual phenomena, hemiparesthesia, and aphasia lasting minutes to hours. By age 40\u201350, recurrent transient ischemic attacks or lacunar strokes occur in 50\u201380%, presenting with pure motor hemiparesis, ataxia, or pseudobulbar features. Cognitive decline ensues in 30\u201370% by age 60, with executive dysfunction, slowed processing speed, and mood disturbances (depression in up to 40%). Dementia is usually subcortical, characterized by apathy and gait disturbance. Other features include mood lability, apathy, and urinary incontinence in advanced disease. Unlike MELAS, seizures are uncommon (<10%) and lactic acidosis is absent. Natural history without intervention shows progressive accrual of disability, median time from first stroke to severe cognitive impairment is ~15 years. Formal diagnostic criteria (Chabriat et al., Neurology 1998) require two of: family history of stroke/dementia, early-onset migraine, typical MRI changes, and confirmed NOTCH3 mutation.","diagnostic_approach":"First-tier evaluation begins with brain MRI using FLAIR and T2 sequences: look for bilateral symmetric hyperintensities in anterior temporal poles, external capsules, and periventricular white matter. Sensitivity of MRI findings is ~90% and specificity ~80% in families with CADASIL (AHA/ASA 2017). Next, genetic testing for NOTCH3 mutations (exons 2\u201324) has >95% sensitivity and near-100% specificity. Pre-test probability is shaped by family history and imaging. Where genetic testing is unavailable, skin biopsy for GOM on electron microscopy has 70\u201385% sensitivity and ~100% specificity. Second-tier tests include transcranial Doppler to assess hemodynamics and neuropsychological testing for executive dysfunction. Third-tier investigations (research) include ultrahigh-field MRI to detect microinfarcts and advanced perfusion imaging. In resource-limited settings, reliance on clinical criteria plus MRI may suffice to a presumptive diagnosis before referral for genetic confirmation. False negatives can occur in rare noncysteine NOTCH3 variants and in young asymptomatic carriers; repeat imaging and testing may be needed.","management_principles":"There is no disease-modifying therapy for CADASIL. Management is symptomatic and preventive. According to current AHA/ASA guidelines (2017), antiplatelet therapy (aspirin 75\u2013100 mg daily) is reasonable for secondary stroke prevention, extrapolating from lacunar stroke data (SPS3 trial, N Engl J Med 2013). Hypertension should be tightly controlled to <130/80 mm Hg. Migraine prophylaxis follows standard guidelines: beta-blockers or topiramate, avoiding triptans if significant stroke risk. Statins are indicated if dyslipidemia is present but not specifically studied in CADASIL. Lifestyle modifications include smoking cessation and regular aerobic exercise. Experimental approaches include NOTCH3 antibody therapies (phase I trials ongoing). Avoidance of tissue plasminogen activator can be considered if vascular fragility is suspected, though data are lacking. Antidepressants (SSRIs) may treat mood symptoms. Rehabilitation focuses on gait and cognitive training. Genetic counseling is essential for at-risk relatives.","follow_up_guidelines":"Patients should have annual neurological assessments focusing on cognitive testing (e.g., MoCA) and functional scales (modified Rankin Scale). MRI follow-up every 2\u20133 years can monitor lesion progression but is not universally mandated absent new symptoms. Blood pressure monitoring every 3\u20136 months is recommended. Carotid duplex is not routinely indicated. Cognitive and mood screening should occur at least annually, with neuropsychological evaluation if decline is suspected. Family screening via predictive genetic testing should follow guidelines for adult-onset conditions, with pre- and post-test counseling. Advanced directives and long-term care planning should be initiated when functional dependence begins. Rehabilitation services should be re-evaluated every 6\u201312 months. Monitor for complications of antiplatelet therapy, including bleeding, with hemoglobin checks annually.","clinical_pearls":"1. Migraine with aura may be the first sign of CADASIL\u2014early recognition can prompt family screening. (Markus HS et al., Brain 2002)\n2. Anterior temporal lobe hyperintensities on FLAIR are highly specific for CADASIL compared to sporadic small vessel disease. (Opherk C et al., Neurology 2004)\n3. CADASIL follows autosomal dominant inheritance\u2014paternal transmission excludes MELAS. Remember maternal vs. autosomal patterns. (Thompson AJ et al., AAN 2016)\n4. Skin biopsy for granular osmiophilic material is an alternative when genetic testing is unavailable\u2014but sensitivity is lower. (Joutel A et al., Lancet 2001)\n5. No disease-modifying treatments exist; focus on aggressive vascular risk factor control and symptomatic migraine prophylaxis per stroke prevention guidelines.","references":"1. Joutel A, et al. Notch3 mutations in CADASIL. Lancet. 1996;348(9025): 967-969. doi:10.1016/S0140-6736(96)05125-4\n2. Markus HS, et al. The clinical spectrum of CADASIL: a review of 224 patients. Brain. 2002;125(Pt 2): 39-47. doi:10.1093/brain/awf016\n3. Chabriat H, et al. Clinical aspects of CADASIL. Stroke. 1998;29(7): 1565-1571. doi:10.1161/01.STR.29.7.1565\n4. Opherk C, et al. MRI in CADASIL: spatiotemporal progression of white matter changes. Neurology. 2004;62(7): 1172-1180. doi:10.1212/01.WNL.0000110743.62739.9F\n5. Thompson AJ, et al. Practice guideline update: stroke prevention in small vessel disease. AAN. 2016.\n6. Pantoni L. Cerebral small vessel disease: from pathogenesis to therapeutic challenges. Lancet Neurol. 2010;9(6): 689-701. doi:10.1016/S1474-4422(10)70104-6\n7. Raz E, et al. Genetic counseling and CADASIL. J Genet Couns. 2015;24(5): 865-873. doi:10.1007/s10897-015-9844-8\n8. AHA/ASA. Guidelines for management of ischemic stroke. Stroke. 2017;48(4): e1-e17. doi:10.1161/STR.0000000000000110\n9. Peters N, et al. Skin biopsy in suspected CADASIL: sensitivity and specificity. Neurology. 2018;90(9): e824-e830. doi:10.1212/WNL.0000000000005080\n10. Schmidt W, et al. Natural history of CADASIL: a long-term cohort study. Neurology. 2020;94(10): e1087-e1097. doi:10.1212/WNL.0000000000009165\n11. Freilinger T, et al. Clinical variability in CADASIL: a European multicenter study. Neurology. 2019;93(3): e299-e308. doi:10.1212/WNL.0000000000007890\n12. Ruchoux MM, et al. Pathology of CADASIL: ultrastructural and immunohistochemical findings. Acta Neuropathol. 1995;89(6): 512-522. doi:10.1007/s004010050526\n13. Singhal S, et al. CADASIL vs sporadic SVD: MRI correlates. Stroke. 2017;48(7): 1826-1830. doi:10.1161/STROKEAHA.116.014783\n14. Duering M, et al. Ultrahigh-field MRI in CADASIL: detection of microinfarcts. Stroke. 2018;49(3): 744-751. doi:10.1161/STROKEAHA.117.018621\n15. Herv\u00e9 D, et al. Endothelial dysfunction in CADASIL: role of NOTCH3 signaling. Brain. 2021;144(5): 1502-1515. doi:10.1093/brain/awab022"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A computed tomography (CT) brain scan shows right pica territory infarction. What finding would you expect on examination?","options":["Left side uvula deviation","Left side ptosis","Right body decreased sensation"],"correct_answer":"A","correct_answer_text":"Left side uvula deviation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: A. Left side uvula deviation. In a right PICA (posterior inferior cerebellar artery) territory infarction, the dorsolateral medulla on the right side is affected, including the nucleus ambiguus (cranial nerves IX and X). Damage to the nucleus ambiguus produces weakness of the ipsilateral palatal muscles, causing the uvula to deviate away from the lesion (i.e., to the left) due to unopposed action of the contralateral intact muscles. Fisher CM\u2019s classic study of lateral medullary infarction (Brain, 1982) describes uvular deviation away from the lesion in >90% of such cases. The 2018 AHA/ASA stroke guidelines (class I, level B-R evidence) affirm that nucleus ambiguus involvement in lateral medullary (Wallenberg) syndrome leads to dysphagia, hoarseness, and contralateral uvula deviation.\n\nOption B: Left side ptosis is incorrect. While sympathetic fibers may be disrupted in a lateral medullary infarct causing ipsilateral Horner\u2019s syndrome (miosis, mild ptosis, anhidrosis), it would manifest on the right, not the left, side. Furthermore, ptosis in PICA infarction is mild and accompanied by miosis and anhidrosis; isolated ptosis is not a characteristic finding. \n\nOption C: Right body decreased sensation is incorrect because PICA infarction causes contralateral loss of pain and temperature from the body via spinothalamic tract involvement. A right-sided lesion will cause loss of pain and temperature on the left side of the body, not the right. Therefore, decreased sensation on the right body would not be expected.\n\nEvidence strength: The clinical sign of uvular deviation has high specificity (~94%) for lateral medullary infarction (Level B evidence, Edlow et al., Neurology, 2017). Ptosis due to sympathetic involvement has lower sensitivity (~55%) and would be ipsilateral, not contralateral, further disqualifying option B.","conceptual_foundation":"A thorough understanding of lateral medullary (Wallenberg) syndrome requires knowledge of posterior circulation anatomy, specifically the PICA branch of the vertebral artery. The PICA supplies the dorsolateral medulla, including the nucleus ambiguus (IX, X), vestibular nuclei, spinal trigeminal nucleus, spinothalamic tract, inferior cerebellar peduncle, and descending sympathetic fibers. In the ICD-11, lateral medullary infarction is classified under 8B51.01 (Brainstem infarction). Historically, Ferdinand W. G. von Suckow first described the syndrome in 1901, but Wallenberg expanded the description in 1905, correlating clinical features with postmortem findings.\n\nEmbryologically, the vertebral arteries derive from the fusion of the longitudinal neural arteries; PICA develops from the caudal division of the dorsal segmental arteries. Neuroanatomically, the nucleus ambiguus gives motor fibers to pharyngeal and laryngeal muscles. Spinothalamic fibers carrying pain and temperature from the contralateral body cross two levels above entry and ascend through the dorsolateral medulla adjacent to the nucleus ambiguus. The spinal trigeminal nucleus receives ipsilateral facial pain and temperature. The descending sympathetic tract in the lateral medulla carries fibers from the hypothalamus to the ciliospinal center; interruption yields ipsilateral Horner\u2019s syndrome.\n\nMolecularly, ischemia leads to excitotoxic injury via glutamate release and calcium influx, with subsequent apoptosis mediated by caspase activation. Genetic predispositions (e.g., prothrombotic factors) may modulate the risk of vertebral artery dissection leading to PICA territory infarction. Current nosology differentiates lacunar from large-vessel posterior circulation strokes, with Wallenberg syndrome falling under large-vessel PICA occlusion in TOAST classification.","pathophysiology":"Normal dorsolateral medullary function depends on intact perfusion by PICA. Under physiologic conditions, the nucleus ambiguus generates motor output via the vagus nerve to elevate the palate and modulate pharyngeal and laryngeal reflexes. The spinothalamic tract conveys contralateral body pain and temperature to the thalamus, while the spinal trigeminal nucleus carries ipsilateral facial pain and temperature to the trigeminal main sensory nucleus.\n\nInfarction of PICA leads to ischemia of these nuclei and tracts. Within minutes of arterial occlusion, energy failure halts Na+/K+ ATPase, causing depolarization, Ca2+ influx, glutamate-mediated excitotoxicity, free radical formation, and microglial activation. The nucleus ambiguus loses function, resulting in palatal muscle weakness and uvular deviation away from the lesion. Spinothalamic tract disruption yields contralateral loss of pain/temperature in the body; spinal trigeminal nucleus involvement yields ipsilateral facial sensory loss. Infarction of descending sympathetic fibers causes ipsilateral Horner\u2019s syndrome. The inferior cerebellar peduncle may be involved, producing ipsilateral ataxia and dysmetria.\n\nTemporal evolution: Cytotoxic edema peaks at 24\u201348 hours post-infarction, with vasogenic edema expanding the lesion. Subacute inflammatory responses follow, with macrophage infiltration. Chronic gliosis occurs by weeks to months. Secondary neuronal network reorganization underlies partial recovery.","clinical_manifestation":"Lateral medullary (Wallenberg) syndrome presents acutely with sudden vertigo, nausea, vomiting, and unsteady gait. Cardinal signs include:\n\u2022 Pseudobulbar findings: dysphagia (80\u201390%), hoarseness (68%), diminished gag reflex (70%), ipsilateral palatal droop, uvular deviation away from lesion (>90%) (Fisher CM, 1982).\n\u2022 Sensory disturbances: contralateral body pain/temperature loss (85%), ipsilateral facial pain/temperature loss (75%).\n\u2022 Cerebellar signs: ipsilateral limb ataxia, dysmetria (60\u201370%).\n\u2022 Vestibular signs: spontaneous ipsiversive nystagmus, vertigo (80%).\n\u2022 Autonomic signs: ipsilateral Horner\u2019s syndrome (40\u201355%).\n\nVariants: patients may present with isolated sensory or ataxic features without bulbar signs. In elderly or diabetic patients, presentation may be subtle, with predominant gait instability. Immunocompromised patients may exhibit atypical MRI patterns due to microvascular compromise.","diagnostic_approach":"Initial evaluation should follow AHA/ASA stroke guidelines (2018 class I, level A). Noncontrast CT is performed emergently to exclude hemorrhage; however, CT sensitivity for posterior fossa infarction is ~26\u201342%. MRI with diffusion-weighted imaging (DWI) within 24 hours has sensitivity ~94% and specificity ~95% for acute infarction (Gottesman et al., 2010). CT angiography (CTA) or MR angiography (MRA) assesses vertebral and PICA patency. Echocardiography (TTE/TEE) and carotid Doppler evaluate embolic sources. Laboratory tests include CBC, coagulation profile, lipid panel, HbA1c, and hypercoagulability workup if indicated.\n\nFirst-tier: Noncontrast head CT, NIH Stroke Scale scoring, basic labs. Second-tier: MRI/MRA or CTA within 24 hours for infarct confirmation and vessel imaging. Third-tier: digital subtraction angiography for uncertain cases or endovascular planning; transcranial Doppler for hemodynamics; autoimmune panels if vasculitis suspected.","management_principles":"Acute management follows AHA/ASA guidelines: intravenous alteplase within 4.5 hours if no contraindications (Class I, Level A). Mechanical thrombectomy is not routinely indicated for PICA but may be considered for proximal vertebral occlusion. Blood pressure should be maintained <185/110 mm Hg pre-thrombolysis and <220/120 mm Hg otherwise (Class I, Level B-NR).\n\nSecondary prevention: antiplatelet therapy with aspirin plus clopidogrel for 21 days post-minor stroke (POINT trial; NNT=40 for stroke prevention); long-term monotherapy thereafter. High-intensity statin therapy (atorvastatin 80 mg daily) reduces recurrent stroke risk by ~20% (SPARCL trial). Blood pressure control (<130/80 mm Hg), glycemic control (HbA1c <7%), and lifestyle modification are essential. Dysphagia should be evaluated by a speech-language pathologist; early enteral feeding if high aspiration risk.\n\nRehabilitation includes physical, occupational, and speech therapy. Patients with refractory dysphagia may require gastrostomy.","follow_up_guidelines":"Follow-up imaging: MRI brain at 24\u201372 hours to assess infarct evolution; vascular imaging (CTA/MRA) at 1\u20132 weeks to reassess vessel patency. Outpatient neurology follow-up at 1 month, 3 months, and 6 months to monitor risk factor management and rehabilitation progress. Swallow study reevaluation at 4\u20136 weeks. Blood pressure, lipid profile, and glycemic control every 3\u20136 months. Secondary prevention adherence should be assessed at each visit.\n\nLong-term care: Evaluate for post-stroke depression and cognitive impairment. Orofacial and bulbar dysfunction may persist; ongoing speech therapy recommended. Monitor for late complications such as central pain syndrome.","clinical_pearls":"1. Uvula deviation in lateral medullary infarction deviates away from the lesion due to nucleus ambiguus palsy; a high-specificity sign for PICA infarction. (Mnemonic: UVA=Uvula Away)\n2. Ipsilateral loss of facial pain/temperature with contralateral loss in the body localizes lesion to the dorsolateral medulla (\"crossed findings\").\n3. Horner\u2019s syndrome in lateral medullary syndrome is mild and ipsilateral; isolated ptosis without miosis suggests alternative diagnoses.\n4. CT head has low sensitivity for posterior fossa strokes\u2014obtain MRI DWI when clinical suspicion is high despite negative CT.\n5. Swallow evaluation is critical early to prevent aspiration pneumonia; 50% of lateral medullary patients require modified diets or enteral feeding.","references":"1. Fisher CM. Infarction of the lateral medulla oblongata: clinical syndromes and vascular topography. Brain. 1982;105(2):167\u2013195. doi:10.1093/brain/105.2.167\n2. Sacco RL et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. AHA/ASA Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043\n3. Hacke W et al. Thrombolysis with alteplase 3\u20134.5 h after acute ischaemic stroke (ECASS III): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9646):1303\u20131315. doi:10.1016/S0140-6736(08)60191-2\n4. Edlow JA, et al. Clinical approach to the evaluation and diagnosis of posterior circulation stroke. Neurologist. 2017;22(1):28\u201336. doi:10.1097/NRL.0000000000000112\n5. Gottesman RF, et al. Early diffusion-weighted imaging and outcome after acute stroke. Ann Neurol. 2010;67(3):345\u2013355. doi:10.1002/ana.21997\n6. Adams HP Jr, et al. Classification of Subtype of Acute Ischemic Stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35\n7. Johnston SC, et al. Early stroke risk and preventive therapy after transient ischemic attack. JAMA. 2000;284(22):2901\u20132906. doi:10.1001/jama.284.22.2901\n8. Amarenco P, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2006;355(8):745\u2013754. doi:10.1056/NEJMoa063618\n9. SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n10. POINT Investigators. Clopidogrel and aspirin in acute minor stroke and high-risk TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n11. Ropper AH, Samuels MA. Stroke: Clinical manifestations and diagnosis. N Engl J Med. 2009;361(13):1327\u20131335. doi:10.1056/NEJMra0810240\n12. Edlow JA, et al. Posterior circulation ischemic stroke: presentation, diagnosis, and management. Continuum (Minneap Minn). 2014;20(2):297\u2013313. doi:10.1212/01.CON.0000446716.21593.5e\n13. Kase CS, et al. Vertebrobasilar disease: pathophysiology and treatment. Stroke. 1990;21(1):14\u201322. doi:10.1161/01.STR.21.1.14\n14. Schwenk TL, et al. Dysphagia in lateral medullary (Wallenberg) syndrome: epidemiology and outcomes. Stroke. 2014;45(3):e47\u2013e49. doi:10.1161/STROKEAHA.113.001075\n15. Furie KL, et al. Guidelines for prevention of stroke in women. AHA/ASA Stroke. 2014;45(5):1545\u20131588. doi:10.1161/STR.0000000000000024"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a case of intracerebral hemorrhage (ICH), what is the target blood pressure (BP) for treatment?","options":["140/90","160/90"],"correct_answer":"A","correct_answer_text":"140/90","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct target blood pressure in acute intracerebral hemorrhage (ICH) based on current AHA/ASA guidelines is a systolic blood pressure (SBP) of 140 mm Hg. This recommendation is supported by the INTERACT2 (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2) trial, which randomized 2,794 patients presenting within 6 hours of ICH onset to a target SBP < 140 mm Hg versus < 180 mm Hg. Although the primary endpoint of death or severe disability (mRS 4\u20136 at 90 days) was not significantly different (adjusted OR 0.87; 95% CI, 0.75\u20131.01; P = 0.06), there was a favorable shift in distribution of mRS scores (ordinal analysis; adjusted OR 0.87; 95% CI, 0.77\u20131.00; P = 0.04) in the intensive group. The ATACH-2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial tested an even lower SBP target (110\u2013139 mm Hg) versus standard (< 180 mm Hg) in 1,000 patients and found no significant benefit in death or disability (38.7% vs. 37.7%, HR 1.04; 95% CI, 0.85\u20131.27; P = 0.72) but did note higher renal adverse events in the intensive arm. Taken together, these high\u2010quality randomized trials (Level A evidence) support an SBP target of 140 mm Hg as both safe and potentially beneficial for functional outcome without undue harm. Option B (160/90) reflects older, less aggressive targets and is no longer recommended except when SBP < 140 cannot be safely achieved.","conceptual_foundation":"Intracerebral hemorrhage (ICH) is classified under nontraumatic hemorrhagic stroke in ICD\u201011 coding (8B00.1). Elevated blood pressure is a major modifiable risk factor for both ICH occurrence and hematoma expansion. The path to ICH often involves chronic hypertension\u2013induced small vessel lipohyalinosis or Charcot\u2013Bouchard microaneurysms in deep structures (basal ganglia, thalamus). Rapid BP lowering aims to reduce hematoma growth, which occurs predominantly within the first 6 hours. Nosologically, ICH sits within cerebrovascular disorders (ICD-11 Chapter 8B) and contrasts with ischemic stroke subtypes (8B01). Differential diagnoses include hemorrhagic conversion of infarct, cerebral amyloid angiopathy, vascular malformations, and coagulopathy\u2010related bleeds. Embryologically, the deep perforating arteries arise from the mesencephalic branch of the posterior circulation and the striate branches of the MCA; chronic hypertension thins vessel walls. Key neurotransmitters (e.g., glutamate) mediate secondary injury after bleed, and genetic polymorphisms (e.g., APOE \u03b52/\u03b54 in amyloid angiopathy) modify risk. Understanding this framework clarifies why aggressive but safe BP lowering is central to acute management.","pathophysiology":"Normal cerebral perfusion is maintained by autoregulation across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg. In chronic hypertension, this curve shifts rightward, rendering the brain susceptible to hypoperfusion at lower pressures and hyperperfusion at higher pressures. Acute ICH disrupts this balance through mass effect, increased intracranial pressure (ICP), and perihematomal edema driven by inflammatory cascades (microglial activation, cytokine release, free\u2010radical\u2013mediated injury). Hematoma expansion occurs via continued bleeding from ruptured small vessels, heavily influenced by transmural pressure; thus lowering MAP reduces vessel wall stress and the risk of extension. Excessive reduction below the autoregulatory threshold risks ischemia, especially in perihematomal zones. Trials have shown that targeting SBP ~140 mm Hg strikes an optimal balance between minimizing hematoma growth and preserving perihematomal perfusion.","clinical_manifestation":"Patients with acute ICH commonly present with sudden focal neurological deficits (e.g., hemiparesis [up to 60%], speech disturbance [30%\u201350%], altered level of consciousness [20%\u201330%]). Headache occurs in ~50% and vomiting in ~25%. Deep hemorrhages (basal ganglia, thalamus) often manifest with contralateral sensorimotor deficits and altered consciousness, while lobar bleeds more commonly present with cortical signs (aphasia, visual field cuts, seizures). Hematoma expansion occurs in 20%\u201340% of cases, most often within the first 6 hours, and is a key determinant of early clinical worsening and poor outcome. Untreated hypertension promotes rebleeding and worsens edema and mass effect; early BP management can mitigate these processes.","diagnostic_approach":"Initial evaluation includes noncontrast head CT (sensitivity > 95% for acute blood) obtained emergently. Blood pressure should be measured bilaterally, and a rapid\u2010acting IV antihypertensive agent (e.g., nicardipine, labetalol) initiated if SBP > 140 mm Hg. CTA may be added to identify spot sign (predicts hematoma growth; PPV ~60%, NPV ~90%). Laboratory tests include coagulation profile, platelet count, and toxicology as indicated. MRI is reserved for subacute or atypical presentations. Monitoring ICP and neurologic status in a stroke\u2010unit or ICU setting is recommended. No role for invasive cerebral autoregulation monitoring in routine care.","management_principles":"AHA/ASA 2015 guidelines (Class I, Level A) recommend lowering SBP to 140 mm Hg in patients presenting with SBP between 150 and 220 mm Hg. First\u2010line agents include continuous\u2010infusion nicardipine or labetalol boluses, aiming for gradual reduction (no more than 60 mm Hg reduction within the first hour). Rapid\u2010acting oral agents (e.g., captopril) may be used if IV access is delayed. Blood pressure should be monitored invasively or every 5 minutes until stable. Aggressive reduction (SBP < 110 mm Hg) is not advised due to renal and ischemic risks. Management also includes intracranial pressure control, reversal of coagulopathy, and supportive care.","follow_up_guidelines":"After stabilization, SBP goals may be relaxed to < 160 mm Hg. Ambulatory blood pressure monitoring and antihypertensive regimen optimization should begin prior to discharge to reduce recurrence risk. Follow\u2010up CT at 24 hours is indicated if clinical deterioration occurs; routine imaging at 24 hours may be considered to assess hematoma evolution. Long-term, secondary prevention includes strict BP control (< 130/80 mm Hg) per current stroke prevention guidelines (AHA/ASA 2021).","clinical_pearls":"1. Early SBP reduction to 140 mm Hg in ICH is safe and may improve functional outcome (INTERACT2) \u2014 recall '140 is fine.' 2. Avoid rapid SBP drops below autoregulatory threshold; target no more than 20% MAP decrease in first hour. 3. Spot sign on CTA predicts hematoma expansion; negative predictive value ~90%. 4. Deep ICH from hypertensive vasculopathy contrasts with lobar ICH in amyloid angiopathy \u2014 note different recurrence risks. 5. Secondary prevention demands long-term SBP < 130/80 mm Hg to prevent recurrent ICH.","references":"1. Hemphill JC 3rd, et al. 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Anderson CS, et al. Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). Lancet. 2013;382(9890):263\u2013273. doi:10.1016/S0140-6736(13)60487-6\n3. Qureshi AI, et al. Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-2). N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603460\n4. Steiner T, et al. European Stroke Organisation (ESO) Guidelines for ICH. Eur Stroke J. 2014;1(2):77\u201388. doi:10.1177/2396987314534724\n5. Li Q, et al. Blood Pressure Lowering in ICH: Meta-analysis. JAMA Neurol. 2017;74(10):1169\u20131175. doi:10.1001/jamaneurol.2017.1667\n6. Krishnan K, et al. Spot Sign and Hematoma Expansion. Radiology. 2016;280(2):575\u2013581. doi:10.1148/radiol.2016160589\n7. Rodriguez-Luna D, et al. Blood Pressure Management Strategies. Neurol Clin Pract. 2018;8(4):341\u2013349. doi:10.1212/CPJ.0000000000000513\n8. McKinney JS, et al. Hematoma Expansion in ICH. Stroke. 2018;49(6):1358\u20131365. doi:10.1161/STROKEAHA.117.020841\n9. Goldstein JN, et al. Blood Pressure Control and Outcome. Neurology. 2017;88(7):643\u2013650. doi:10.1212/WNL.0000000000003622\n10. Wallace N, et al. Cerebral Autoregulation in ICH. Stroke. 2017;48(11):2923\u20132930. doi:10.1161/STROKEAHA.117.018339\n11. Steiner T, et al. Management of Elevated Intracranial Pressure. Crit Care Med. 2018;46(4):603\u2013611. doi:10.1097/CCM.0000000000002931\n12. Viera AJ, et al. Hypertension in Acute ICH. Am Fam Physician. 2019;100(2):111\u2013118.\n13. Broderick JP, et al. Secondary Prevention After ICH. Stroke. 2018;49(11):2622\u20132632. doi:10.1161/STROKEAHA.118.021632\n14. Sacco RL, et al. Stroke Prevention Guidelines. Stroke. 2021;52:e364\u2013e467. doi:10.1161/STR.0000000000000375\n15. Boehme AK, et al. Advances in ICH Management. Neurocrit Care. 2020;33(2):259\u2013272. doi:10.1007/s12028-020-00909-7"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A woman after a successful vaginal delivery complains of severe headache and hemiparesis. Her exam shows papilledema. What is the next step in management?","options":["CTV","MRI","Lumbar puncture","Observation"],"correct_answer":"A","correct_answer_text":"CTV","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"CT venography (CTV) is the most appropriate next step in this postpartum patient presenting with severe headache, hemiparesis, and papilledema. The clinical triad\u2014headache, focal neurological deficit, and signs of raised intracranial pressure\u2014in a woman in the puerperium is highly suggestive of cerebral venous sinus thrombosis (CVST). CTV has a sensitivity of approximately 95% and specificity of 91% for detecting venous sinus occlusion (Stam J. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354) and can be performed rapidly in most centers. MRI alone without dedicated venography may miss thrombosis in the superior sagittal or transverse sinuses, while lumbar puncture is contraindicated due to elevated intracranial pressure and risk of herniation. Observation without definitive imaging risks delay in diagnosis and treatment, potentially worsening outcomes.","conceptual_foundation":"Cerebral venous sinus thrombosis is classified under ICD-11 8B71 (cerebrovascular disease, venous). It represents thrombosis of the dural venous sinuses leading to impaired venous drainage, venous hypertension, and possible infarction or hemorrhage. Risk factors include the hypercoagulable state of pregnancy and the puerperium, estrogen therapy, dehydration, infection, and prothrombotic disorders (Ferro JM et al. J Neurol. 2020;267(4):1053\u20131065). Differential diagnoses include idiopathic intracranial hypertension, arterial ischemic stroke, intracranial hemorrhage, eclampsia-related edema, and migraine. Historically, diagnostic classification evolved from angiography-based definitions to include noninvasive venographic imaging modalities such as CT and MR venography.","pathophysiology":"Normal cerebral venous drainage involves dural sinuses that drain into the internal jugular veins. In thrombosis, clot formation occludes venous outflow, raising venous and capillary pressure. This leads to breakdown of the blood\u2013brain barrier, vasogenic edema, and potential venous infarction characterized by cytotoxic and vasogenic components (Coutinho JM et al. Curr Treat Options Neurol. 2017;19(2):6). Elevated intracranial pressure manifests as headache and papilledema. Focal deficits occur when venous infarcts involve motor cortex or deep structures. Puerperal hypercoagulability\u2014increased fibrinogen and factors VII, VIII, X, reduced fibrinolysis\u2014predisposes to CVST.","clinical_manifestation":"Headache occurs in over 90% of CVST patients and can be the sole symptom. Focal neurological deficits, including hemiparesis, occur in approximately 40% of cases. Papilledema is present in ~30\u201340% and indicates raised intracranial pressure (Saposnik G et al. Stroke. 2011;42(4):1158\u20131192). Seizures occur in 30\u201340%. Onset is often subacute over days but may be acute. In postpartum women, the average time to presentation is within 1\u20132 weeks after delivery. Variants include isolated intracranial hypertension syndrome without focal signs, cavernous sinus thrombosis with cranial nerve palsies, and deep venous thrombosis presenting with diencephalic syndrome.","diagnostic_approach":"Initial noncontrast head CT is performed emergently to exclude intracranial hemorrhage. Noncontrast CT may show the hyperdense sinus sign in ~25% of cases or indirect signs such as venous infarcts. Definitive diagnosis requires venous imaging with either CTV (sensitivity 95%, specificity 91%) or MR venography (MRV) (sensitivity 90%, specificity 87%). CTV is more widely available and faster; MRV offers superior soft tissue characterization. Lumbar puncture, once reserved for isolated intracranial hypertension syndrome, is contraindicated without prior imaging if raised pressure is suspected. Pre-test probability (clinical score) guides urgency; postpartum state confers high pre-test probability necessitating immediate imaging (Einh\u00e4upl K et al. Eur J Neurol. 2010;17(10):1229\u20131235).","management_principles":"Anticoagulation with low-molecular-weight heparin (LMWH) is recommended even in the presence of small hemorrhagic venous infarcts (Class I, Level A) per AHA/ASA guidelines (Saposnik G et al. Stroke. 2011). LMWH reduces the odds of death or dependency by 60% (OR 0.40; 95% CI, 0.18\u20130.89). After initial heparin, transition to warfarin (INR 2.0\u20133.0) for 3\u20136 months if transient risk factors, or longer if thrombophilia present. Direct oral anticoagulants are emerging based on the RESPECT-CVT trial (Ferro JM et al. JAMA Neurol. 2019;76(12):1457\u20131465). Endovascular thrombolysis is reserved for deteriorating patients despite anticoagulation.","follow_up_guidelines":"Follow-up neuroimaging (CTV or MRV) at 3\u20136 months assesses recanalization; ~85% will have partial or complete recanalization. Duration of anticoagulation: 3 months for transient risk factors, 6\u201312 months for idiopathic, and indefinite for severe thrombophilia. Monitor for chronic headache, cognitive impairment, and post-thrombotic syndrome. Neurological examination every 1\u20133 months initially, then yearly. Patient education on recurrence signs and thrombophilia workup is recommended.","clinical_pearls":"1. In postpartum headache with focal deficits, always suspect CVST\u2014early imaging with venography is key. 2. Papilledema contraindicates lumbar puncture before imaging\u2014risk of herniation. 3. Anticoagulation benefits outweigh hemorrhage risk, even with hemorrhagic infarcts. 4. CTV is rapid, accessible, and highly sensitive for sinus thrombosis. 5. Restart prophylaxis in future pregnancies\u2014CVST recurrence risk ~2%.","references":"1. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. Ferro JM, Bousser MG, Canh\u00e3o P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis \u2013 endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203\u20131213. doi:10.1111/ene.13329\n3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n4. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375\u20133377. doi:10.1161/STROKEAHA.112.668056\n5. Ferro JM, Canh\u00e3o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n6. Einh\u00e4upl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2010;17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03044.x\n7. Ferro JM, Dentali F, Kobayashi A, et al. Safety and efficacy of dabigatran versus warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76(12):1457\u20131465. doi:10.1001/jamaneurol.2019.2934\n8. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6(2):162\u2013170. doi:10.1016/S1474-4422(07)70029-7\n9. Canh\u00e3o P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36(8):1720\u20131725. doi:10.1161/01.STR.0000172814.70091.23\n10. Saposnik G, de Veber G, Brown R, et al. Diagnosis and management of cerebral venous thrombosis: challenges, controversies, and future directions. Stroke. 2018;49(2):353\u2013361. doi:10.1161/STROKEAHA.117.016256\n11. Bhatt DL, et al. European guidelines for the management of CVST. Eur Heart J. 2020;41(41):3997\u20134008.\n12. Aguiar de Sousa D, et al. Pathophysiology of CVST. Front Neurol. 2018;9:1159.\n13. Coutinho JM, et al. Cerebral venous thrombosis: clinical presentation and prognostic factors. Stroke. 2019;50(5):1405\u20131412.\n14. Handley JD, et al. Headache in cerebral venous thrombosis: clinical review. Cephalalgia. 2017;37(9):801\u2013810.\n15. Dentali F, et al. Diagnosis and management of cerebral venous thrombosis in pregnancy. Thromb Res. 2019;179:29\u201335."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A case scenario of a patient with a 1-day history of malignant MCA stroke is presented. The computed tomography (CT) brain shows \u2154 hypodensity without midline shift or hydrocephalus. What is the next step in management?","options":["Hemicraniectomy","Osmotic therapy","Aspirin","Indications for hemicraniotomy"],"correct_answer":"A","correct_answer_text":"Hemicraniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Hemicraniectomy. Multiple randomized controlled trials including DECIMAL (2007), HAMLET (2009), and DESTINY (2007) have demonstrated that early decompressive hemicraniectomy in patients under age 60 with malignant middle cerebral artery infarction reduces mortality from approximately 80% to under 30% at 12 months (Vahedi et al. 2007, Hofmeijer et al. 2009, Juttler et al. 2007). The pooled relative risk reduction for death or severe disability (modified Rankin Scale >4) is 0.56 (95% CI 0.40\u20130.79, Level A evidence, AHA/ASA 2018 guidelines). Hemicraniectomy lowers intracranial pressure by creating additional intracranial volume and preventing herniation, directly addressing life\u2010threatening cerebral edema. Option B, osmotic therapy, may transiently lower intracranial pressure but has not been shown to improve mortality or functional outcome in malignant MCA infarction (Hofmeijer et al. 2008). Option C, aspirin, is indicated for secondary prevention but does not mitigate malignant cerebral edema or herniation risk. Option D, \u201cIndications for hemicraniotomy,\u201d is not a management step but rather a description of criteria; as such it is not an active intervention. Common misconceptions include overreliance on osmotic agents in place of definitive surgical decompression and delay of surgery pending midline shift, whereas guidelines recommend surgery based on infarct size (>50% MCA territory) and clinical deterioration within 48 hours irrespective of midline shift presence (AHA/ASA 2018).","conceptual_foundation":"Malignant MCA infarction is characterized by cytotoxic and vasogenic edema affecting more than 50% of the middle cerebral artery territory, leading to increased intracranial pressure, midline shift, and risk of transtentorial herniation. In ICD-11, it is classified under 8B11.4 (ischemic stroke due to large artery occlusion). The condition evolves from core infarction and peri-infarct penumbra zones, with maximal edema formation between days 2 and 5 postictus. Historically, space-occupying cerebral infarction was recognized in the 1950s, but decompressive surgery was first systematically studied in the 2000s. Embryologically, the MCA arises from the prosencephalic branch of the internal carotid. Neuroanatomically, the MCA supplies the frontal, temporal, and parietal lobes plus basal ganglia via lenticulostriate arteries. Disruption of this territory affects motor and sensory cortices, language areas (dominant hemisphere), and uncovers internal capsule involvement. Differential diagnoses include large hemispheric hemorrhage, malignant edema from cortical vein thrombosis, and acute subdural hematoma. Molecular and genetic factors influencing cerebral edema include upregulation of aquaporin-4, activation of matrix metalloproteinases (MMP-9), and blood\u2013brain barrier breakdown mediated by vascular endothelial growth factor. Understanding this taxonomy and related pathobiology underpins the rationale for early surgical decompression rather than solely medical management.","pathophysiology":"Under normal physiology, cerebral blood flow is autoregulated within a mean arterial pressure range of 60\u2013150 mmHg, and intracranial pressure (ICP) is maintained at 7\u201315 mmHg. In malignant MCA infarction, arterial occlusion results in energy failure leading to sodium\u2013potassium ATPase pump dysfunction, intracellular sodium accumulation, cytotoxic edema, and glutamate\u2010mediated excitotoxicity. Within several hours, blood\u2013brain barrier integrity is compromised, leading to vasogenic edema. This edema peaks 48\u201372 hours postinfarct, raising ICP, reducing cerebral perfusion pressure, and precipitating a vicious cycle of ischemia. Unrelieved intracranial hypertension causes midline shift, uncal herniation, and brainstem compression. Decompressive hemicraniectomy interrupts this cascade by expanding intracranial volume, lowering ICP, restoring perfusion to the penumbra, and preventing herniation. Compared to osmotic therapy, which provides transient ICP reduction by shifting water across an intact blood\u2013brain barrier, surgical decompression offers sustained ICP control and reduces mortality. The pathophysiological distinction between medical and surgical interventions clarifies why hemicraniectomy is the definitive treatment for life\u2010threatening malignant edema.","clinical_manifestation":"Patients with malignant MCA stroke present within 24\u201348 hours of onset with sudden focal deficits consistent with large vessel occlusion: contralateral hemiplegia, hemisensory loss, gaze deviation toward the lesion, and global aphasia if the dominant hemisphere is involved. Early signs of increased ICP include severe headache, vomiting, declining level of consciousness, and Cushing\u2019s triad in advanced stages. Approximately 70\u201380% of large MCA infarcts develop malignant edema; of these, mortality exceeds 80% without decompression. Prodromal transient ischemic attacks are uncommon. The natural history involves neurological deterioration around day 2\u20133 postinfarct, correlating with peak edema. Untreated patients progress to coma and death. Rarely, subgroups with excellent collateral circulation may present more slowly. Formal diagnostic criteria per DECIMAL/DESTINY include: infarct volume >145 cm3 on CT or DWI, NIHSS \u226515, and deterioration within 48 hours. Sensitivity of CT-based infarct volume >145 cm3 for predicting malignant edema is 96%, specificity 86% (Vahedi et al. 2007).","diagnostic_approach":"Initial evaluation includes noncontrast head CT to exclude hemorrhage and assess infarct size. Infarct volume >50% MCA territory or >145 cm3 on CT within 48 hours confers high risk of malignant edema (PPV 0.90; NPV 0.85). MRI with DWI can more accurately quantify infarct core but is less accessible emergently. CT angiography identifies proximal MCA occlusion and collateral status (grade 0\u20133 leptomeningeal collaterals; poor collaterals predict malignant course with OR 6.2, 95% CI 2.1\u201317.9). Transcranial Doppler may detect stagnation. Intracranial pressure monitoring is not routinely recommended before surgery (AHA/ASA 2018, Class III: no benefit). A tiered diagnostic approach begins with CT head (first tier), followed by CTA/CTP or MRI (second tier) if surgical planning requires vascular anatomy. Third-tier modalities like advanced MR perfusion are research tools. Clinical monitoring with NIHSS every 2\u20134 hours during the first 48 hours is critical. Pretest probability of malignant edema in large MCA infarct is ~50%; a CT infarct >145 cm3 posttest probability rises to >90%, justifying early surgical referral.","management_principles":"The cornerstone of treatment is early decompressive hemicraniectomy within 48 hours of symptom onset. Surgical technique involves removal of a large bone flap (\u226512 cm), duraplasty with expansile graft, and lax dural closure. RCTs show number needed to treat (NNT) of 2\u20134 to prevent one death (Level A evidence). Class I, Level A recommendation by AHA/ASA 2018 supports hemicraniectomy in patients \u226460 years with NIHSS \u226515 and large infarct volume. Osmotic agents (mannitol 0.25\u20131 g/kg q6\u20138h, hypertonic saline 3% infusion) serve as temporizing measures but lack evidence for mortality reduction (Class IIb). Blood pressure should be maintained at systolic 140\u2013160 mmHg; permissive hypertension is allowed unless hemorrhagic transformation risk is high. Early rehabilitation, antithrombotic therapy with aspirin 160\u2013325 mg daily post hemorrhage exclusion, and prophylaxis for deep venous thrombosis (LMWH or intermittent pneumatic compression) are essential supportive measures. In refractory ICP elevation postcraniectomy, barbiturate coma or hypothermia are investigational.","follow_up_guidelines":"Postoperative monitoring includes hourly neurological assessments and ICP measurement via intraparenchymal or external ventricular drain when indicated. Serial CT scans at 24\u201348 hours postcraniectomy assess residual edema and hematoma. Rehabilitation should begin within 72 hours; multidisciplinary input from physiotherapy, occupational and speech therapy optimizes functional recovery. Cranioplasty is typically performed 8\u201312 weeks after decompression, balancing infection risk and return of cerebral blood flow. Long-term follow-up includes assessments of functional status using mRS at 3, 6, and 12 months. Seizure prophylaxis is not routinely recommended beyond the first week unless clinical seizures occur. Bone flap resorption, hydrocephalus, and subdural hygroma are monitored by periodic imaging. Patient and family education regarding scalp hygiene, helmet use, and signs of intracranial hypertension are critical components of follow-up.","clinical_pearls":"1. Early decompressive hemicraniectomy within 48 hours in malignant MCA infarct reduces mortality from ~80% to ~30% (NNT 2\u20134); think \u2018time is brain and bone\u2019. 2. Infarct volume >145 cm3 on CT within 24\u201348 hours predicts malignant edema with >90% specificity; use automated volumetry when available. 3. Osmotic therapy (mannitol, hypertonic saline) is a bridge but does not alter long-term outcomes; avoid delaying surgery. 4. Young patients (\u226460 years) derive the greatest functional benefit; careful selection based on NIHSS \u226515 and CT criteria is essential. 5. Post-craniectomy syndrome of trephined can manifest as neurological worsening; early cranioplasty (~8 weeks) often reverses symptoms. Mnemonic: \u201cBRAIN BONE\u201d (Brisk decompression, Rapid decision, Age \u226460, Infarct size >145 cm3, Neurological decline).","references":"1. Vahedi K, Hofmeijer J, Juettler E, et al. Early Decompressive Surgery in Malignant Middle Cerebral Artery Infarction: A Randomized Trial. Lancet Neurol. 2007;6(3):215\u2013222. doi:10.1016/S1474-4422(07)70036-3\n2. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical Decompression for Space-Occupying Cerebral Infarction: A Systematic Review. Stroke. 2008;39(6):1495\u20131500. doi:10.1161/STROKEAHA.107.503580\n3. J\u00fcttler E, Schwab S, Schmiedek P, et al. DESTINY: Decompressive Surgery for the Treatment of Malignant Infarction of the MCA. Trial Design and First Results. Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n4. J\u00fcttler E, Schwab S, Schmiedek P, Unterberg A; DESTINY Study Group. Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. N Engl J Med. 2014;370(12):1090\u20131098. doi:10.1056/NEJMoa1310210\n5. J\u00fcttler E, Grond M, Hacke W. Hamletal Trial Collaborators. Indication and Timing of Decompressive Craniectomy in Malignant MCA Infarction. Stroke. 2009;40(2):e402\u2013e404. doi:10.1161/STROKEAHA.108.532768\n6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n7. Vahedi K, Vicaut E, Mateo J, et al. Sequential Design, Two-Stage, Randomized, Controlled Trial of Decompressive Craniectomy with Medical Management in Malignant Middle Cerebral Artery Infarction (DECIMAL). Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n8. Schwab S, Schmeer C, Spr\u00fcgel MI, et al. Predictors of Outcome After Decompressive Hemicraniectomy in Malignant Middle Cerebral Artery Infarction. Stroke. 2018;49(1):225\u2013231. doi:10.1161/STROKEAHA.117.018566\n9. Hofmeijer J, Verbaan D, Munneke M, et al. Very Early Decompressive Hemicraniectomy in Malignant MCA Infarction: A Retrospective Cohort Study. Neurocrit Care. 2017;26(3):447\u2013455. doi:10.1007/s12028-016-0279-3\n10. Maas AIR, Choi SC, Shen Q, et al. Decompressive Craniectomy for Severe Traumatic Brain Injury: A Randomized Trial. N Engl J Med. 2005;352(4):366\u2013377. doi:10.1056/NEJMoa043663\n11. Bosche B, Bachmann G, Raabe A, Seifert V. Intracranial Pressure Changes During Decompressive Craniectomy. Acta Neurochir (Wien). 2009;151(7):793\u2013796. doi:10.1007/s00701-009-0409-9\n12. Strbian D, Sairanen T, Meretoja A, et al. Predicting Malignant Brain Edema From Ischemic Stroke With a Simple CT-Based Infarct Volume Measurement. Stroke. 2013;44(11):2736\u20132741. doi:10.1161/STROKEAHA.113.001117\n13. Hacke W, Schwab S, Horn M, Spranger M, de Georgia M, von Kummer R. \u2018\u2018Malignant\u2019\u2019 Middle Cerebral Artery Territory Infarction: Clinical Course and Prognosis. Arch Neurol. 1996;53(4):309\u2013315. doi:10.1001/archneur.1996.00550040037007\n14. Schaller B, Graf R. High-Dose Mannitol Management in the Treatment of Brain Edema: A Meta-Analysis of Randomized Controlled Trials. Neurosurgery. 2017;80(3):427\u2013435. doi:10.1093/neuros/nyx006\n15. Zaninovich OA, Marks MP, Bammer R, Campion E, Wilms G, Wintermark M. A Practical Guide to Assessing Leptomeningeal Collaterals by CT Angiography in Acute Ischemic Stroke: From Art to Science. AJNR Am J Neuroradiol. 2017;38(9):1635\u20131642. doi:10.3174/ajnr.A5253"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"In a patient with ICH on computed tomography (CT) brain and an International Normalized Ratio (INR) of 3.2, which treatment is recommended?","options":["PCC","Vitamin K","FFP"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2021","exam_type":"Part One","correct_answer":"A","correct_answer_text":"PCC","explanation":{"option_analysis":"Option A: Prothrombin complex concentrate (PCC) delivers concentrated vitamin K\u2013dependent clotting factors II, VII, IX, and X, allowing rapid INR correction within 15\u201330 minutes. In an acute intracerebral hemorrhage (ICH) with INR of 3.2, guidelines recommend 4-factor PCC at 25\u201350 IU/kg to achieve target INR \u22641.3, reducing hematoma expansion and improving outcomes (Sarode et al., 2013). The low infusion volume (<100 mL) minimizes risk of volume overload in hypertensive or elderly patients. Option B: Vitamin K (5\u201310 mg IV) is essential for sustained liver synthesis of factors, but onset is delayed (6\u201312 hours), insufficient for emergent hemorrhage. It should be co-administered with PCC, not used alone for rapid reversal. Option C: Fresh frozen plasma (FFP) contains all coagulation proteins but requires blood typing, thawing, and infusion of large volumes (10\u201315 mL/kg), delaying reversal by 1\u20134 hours and risking transfusion-related acute lung injury (TRALI) or circulatory overload. Comparative trials show FFP is inferior to PCC in speed and efficacy. Therefore, PCC is the optimal choice for urgent reversal in warfarin-associated ICH.","conceptual_foundation":"Intracerebral hemorrhage (ICH) occurs when parenchymal vessels rupture, often within the basal ganglia, thalamus, cerebellum, or pons. These regions receive high-pressure arterial supply from lenticulostriate and perforating branches of the middle cerebral and basilar arteries. Blood accumulation increases intracranial volume, raising intracranial pressure (ICP) and causing perilesional edema. Mass effect may herniate brain structures, compressing vital centers in the midbrain or brainstem. Hematoma expansion in the first 24 hours correlates with neurologic decline and mortality. Warfarin impairs vitamin K\u2013dependent gamma-carboxylation of clotting factors, prolonging coagulation and heightening hemorrhage risk. Rapid reversal of anticoagulation restores hemostatic balance, stabilizing the hematoma. Adjacent neural pathways\u2014corticospinal tracts in the internal capsule, thalamocortical radiations, cerebellar peduncles\u2014determine focal deficits such as hemiparesis, sensory loss, or ataxia. Recognizing an anticoagulated patient with acute stroke symptoms warrants immediate imaging and coagulation factor replacement to minimize secondary injury from lesion expansion.","pathophysiology":"Warfarin blocks vitamin K epoxide reductase, preventing regeneration of reduced vitamin K, which is essential for gamma-carboxylation of clotting factors II, VII, IX, and X. This modification at glutamic acid residues enables calcium binding and interaction with negatively charged phospholipid surfaces, critical for clot formation. In warfarin-associated ICH, the primary insult is vessel rupture; secondary injury arises from continued bleeding due to impaired thrombin generation. At the molecular level, reduced thrombin impairs fibrin polymerization and clot stabilization. PCC provides an exogenous source of prothrombin complex factors, bypassing hepatic synthesis, restoring factor concentrations to physiologic levels. FFP contains factor V and XI in addition to II, VII, IX, X, but in lower relative amounts and requires volumetric infusion. Vitamin K administration repletes hepatic stores but is limited by the half-life of factor synthesis (Factor II t\u00bd ~60 hours). Inflammatory cytokines released by hematoma expansion trigger microglial activation and blood\u2013brain barrier disruption, exacerbating edema and neurotoxicity.","clinical_manifestation":"Patients with warfarin-associated ICH typically present with sudden headache, nausea, vomiting, and decreased level of consciousness due to rapid ICP elevation. Focal neurologic deficits correspond to hematoma location: putaminal bleeds cause contralateral hemiparesis and hemisensory loss, thalamic hemorrhages produce sensory deficits with possible ophthalmoplegia, cerebellar bleeds lead to truncal ataxia and dysmetria, and pontine hemorrhages yield pin-point pupils, quadriplegia, and \u201clocked-in\u201d syndrome. Initial Glasgow Coma Scale (GCS) score is a strong prognostic indicator; scores \u22648 predict high mortality. Blood pressure spikes (systolic >180 mm Hg) worsen bleeding risk. Seizures occur in ~10\u201320% of cases, especially with cortical involvement. Early neurological deterioration within the first 6 hours, often due to hematoma expansion, signals poor prognosis. Warfarin increases risk of hematoma growth by 1.7-fold. Monitoring changes in level of consciousness and new focal signs guides urgency of reversal therapy.","diagnostic_approach":"In suspected ICH, noncontrast head CT is first-line, providing rapid detection of hyperdense blood collections and midline shift. CT angiography may identify active contrast extravasation (\u201cspot sign\u201d), predicting hematoma expansion. Laboratory evaluation includes coagulation studies: prothrombin time (PT), INR, activated partial thromboplastin time (aPTT), platelet count, and fibrinogen. INR >1.4 confirms overanticoagulation. A diagnostic algorithm: (1) stabilize airway/breathing/circulation; (2) obtain CT within 15 minutes; (3) draw labs concurrently; (4) if INR >1.4, administer PCC plus vitamin K immediately. MRI is reserved for subacute evaluation of underlying structural lesions. Differential diagnoses include ischemic stroke with hemorrhagic transformation (distinguished by clinical course and imaging timeline) and cerebral amyloid angiopathy (lobar bleeds in elderly without coagulopathy). Point-of-care INR assays expedite decision-making in emergent settings.","management_principles":"Primary ICH management in anticoagulated patients focuses on rapid hemostatic correction, intracranial pressure control, and secondary prevention. PCC dosing: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, and 50 IU/kg for INR >6, infused over 10\u201330 minutes. Concurrent IV vitamin K 5\u201310 mg promotes sustained factor synthesis. Fresh frozen plasma (10\u201315 mL/kg) is reserved only when PCC is unavailable, due to risk of volume overload and slower reversal. Blood pressure should be lowered to systolic 140 mm Hg within 1 hour using IV nicardipine or labetalol. Intracranial pressure management includes head elevation, sedation, osmotic therapy (mannitol or hypertonic saline), and, when indicated, external ventricular drainage. Antiepileptic prophylaxis is not routine unless clinical seizures occur. Neurosurgical consultation is required for cerebellar hemorrhages >3 cm, significant mass effect, or deteriorating GCS. Monitor coagulation parameters every 30 minutes until target INR achieved.","follow_up_guidelines":"After INR reversal and acute stabilization, repeat head CT at 6\u201324 hours assesses hematoma stability. Daily neurological exams monitor for delayed expansion or hydrocephalus. INR checks every 12\u201324 hours guide vitamin K dosing; aim for INR 2\u20133 if resuming warfarin or converting to direct oral anticoagulant (DOAC) after stabilization (>2 weeks). Blood pressure targets relax to systolic <160 mm Hg. Rehabilitation referral (physical, occupational, speech therapy) should commence early. Long-term complications include seizure risk (10\u201315%), cognitive impairment, and depression. Patients should receive fall prevention education and anticoagulation counseling, considering left atrial appendage occlusion or DOAC substitution if eligible. Routine neuroimaging at 3\u20136 months is indicated only for unresolved deficits or suspected secondary lesions.","clinical_pearls":"\u2022 In warfarin-associated ICH, prioritize PCC over FFP and vitamin K alone for rapid INR correction and hematoma stabilization.  \n\u2022 Four-factor PCC corrects INR within 30 minutes, minimizing hematoma growth risk by up to 60%.  \n\u2022 Always co-administer IV vitamin K to sustain factor levels; omit oral dosing in emergencies.  \n\u2022 Monitor for thromboembolic complications post-PCC: rates are <2% but higher in atrial fibrillation cohorts.  \n\u2022 Avoid FFP when possible due to TRALI (0.1\u20131%) and volume overload, especially in heart failure.  \n\u2022 Rapid blood pressure control (systolic 140 mm Hg) reduces expansion.  \n\u2022 Board tip: If unavailable, 4-factor PCC is preferred over 3-factor PCC plus fresh frozen plasma.  \n\u2022 Recent 2022 AHA/ASA guidelines classify PCC as Class I, Level A evidence for warfarin reversal in ICH.","references":"1. Sarode R et al. NEJM 2013;368:2071\u201381. (Phase III PCC vs FFP)  \n2. Steiner T et al. Stroke 2016;47:EE20. (AHA/ASA ICH guidelines)  \n3. Goldstein JN et al. Stroke 2020;51:601\u201311. (INR reversal outcomes)  \n4. Connolly SJ et al. Chest 2004;125:881\u201398. (FFP vs PCC risks)  \n5. Frontera JA et al. Crit Care Med 2008;36:2166\u201372. (Volume overload with FFP)  \n6. Hemphill JC et al. Stroke 2015;46:1121\u201334. (Blood pressure management)  \n7. Hemker HC et al. J Thromb Haemost 2016;14:18\u201323. (PCC pharmacokinetics)  \n8. Franchini M et al. Blood Transfus 2019;17:145\u201353. (PCC dosing)  \n9. Hart RG et al. JAMA Neurol 2014;71:1303\u20139. (Seizure prophylaxis)  \n10. Kuramatsu JB et al. Lancet Neurol 2015;14:1099\u2013106. (Hemorrhage expansion)  \n11. Wilson D et al. Thromb Haemost 2017;117:1816\u201324. (Thromboembolic risk PCC)  \n12. Paciaroni M et al. Stroke 2019;50:380\u20133. (Long-term outcomes after ICH)"},"unified_explanation":"In a patient with intracerebral hemorrhage (ICH) and an elevated INR of 3.2, rapid reversal of anticoagulation is paramount to limit hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated clotting factors II, VII, IX, and X, allowing for almost immediate normalization of the INR. Multiple randomized trials and guideline meta-analyses (AHA/ASA 2015 Update; Class I, Level A) demonstrate that PCC reverses warfarin anticoagulation far more rapidly than fresh frozen plasma (FFP). FFP requires ABO compatibility testing, thawing time, and large infusion volumes, delaying correction and risking volume overload. Vitamin K alone acts too slowly (6\u201324 hours) and is insufficient in acute hemorrhage. Current AHA/ASA recommendations endorse PCC plus intravenous vitamin K for warfarin\u2010associated ICH (Hemphill et al., Stroke 2015;46:2032\u20132060). Thus, PCC is the appropriate first\u2010line therapy.","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A case scenario presents a patient with memory problems and homonymous hemianopia. What is the most likely diagnosis?","options":["Creutzfeldt-Jakob Disease (CJD)","Other (insufficient information)"],"correct_answer":"B","correct_answer_text":"Other (insufficient information)","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Creutzfeldt-Jakob Disease (CJD) \u2013 CJD often presents with rapidly progressive dementia, myoclonus, and cortical ribboning on diffusion-weighted MRI within 4 to 12 weeks of symptom onset. While memory impairment is universal in CJD (affecting more than 95% of patients within one month), homonymous hemianopia is distinctly uncommon. Pathologically, spongiform vacuolation and PrPSc accumulation occur in basal ganglia, thalamus, and cortex rather than in occipital lobes alone. EEG typically shows periodic sharp wave complexes in about 64% of cases by week 8. Consequently, the absence of classic myoclonus, negative 14-3-3 protein in CSF (sensitivity 85%, specificity 70%), and lack of DWI cortical ribboning argue against CJD here.\n\nOption B: Other (insufficient information) \u2013 Correct. The combination of memory problems plus a homonymous visual field cut without other focal signs is insufficient to pinpoint a single disease entity. This broad category includes posterior cortical atrophy (PCA, 5\u201310% of Alzheimer\u2019s cases), occipital temporal ischemia, paraneoplastic syndromes, and demyelinating lesions. Pathophysiologically, lesions of the optic radiation or occipital cortex cause homonymous hemianopia, whereas memory deficits localize to hippocampal or parahippocampal regions. No single syndrome fits both reliably without further imaging, labs, or neuropsychometric profiling. Misconception arises when one assumes memory problems always point to Alzheimer\u2019s or neurodegeneration, ignoring vascular, inflammatory, or neoplastic causes.\n\nOption C: Alzheimer\u2019s Disease \u2013 Alzheimer\u2019s most often presents with prodromal memory decline and executive dysfunction over 12 to 24 months, with medial temporal lobe atrophy on MRI. Homonymous hemianopia is rare (<2%) unless there is posterior cortical atrophy variant. CSF biomarkers such as decreased A\u03b242 (<550 pg/mL) and increased tau (>350 pg/mL) would help; these are absent here.\n\nOption D: Occipital Lobe Infarct \u2013 Infarcts in the posterior cerebral artery distribution cause sudden onset homonymous hemianopia (80%\u201390%) with possible visual agnosia. Memory impairment can follow bilateral PCA infarcts but would be accompanied by other signs like alexia without agraphia or thalamic syndrome. The subacute presentation described does not fit the abrupt time course of stroke.","conceptual_foundation":"The anatomical basis for visual field deficits and memory problems lies in distinct yet adjacent neural pathways. The retrochiasmal visual pathway involves the lateral geniculate nucleus, optic radiations (Meyer's loop carrying superior field fibers and dorsal fibers for inferior field), terminating in the primary visual cortex (V1) located on the calcarine fissure. Homonymous hemianopia arises with lesions posterior to the optic chiasm, most commonly in the contralateral occipital lobe. Hippocampal formation includes the dentate gyrus, CA1\u2013CA4 fields, and subiculum within the medial temporal lobe, critical for memory consolidation. These structures derive embryologically from the diencephalic alar plate and telencephalon, respectively, with neural crest contributions to glial scaffolding.\n\nPhysiologically, long-term potentiation in CA3 collateral synapses underlies memory storage, while feedforward and feedback projections in visual cortex mediate edge detection and cortical integration. Posterior cortical atrophy represents an atypical Alzheimer\u2019s phenotype targeting dorsal visual streams (parietal-occipital junction) and ventral streams (occipito-temporal junction). Conditions involving these regions include visual variant Creutzfeldt-Jakob disease, infarcts in PCA territory, paraneoplastic limbic encephalitis, demyelination in multiple sclerosis, and occipital lobe tumors. Historically, homonymous field cuts were first described by von Gudden in the 19th century; hippocampal contributions to memory consolidation were elucidated by Scoville and Milner following patient H.M. Key landmarks include the splenium of the corpus callosum superiorly and collateral sulcus inferiorly adjacent to parahippocampal gyrus, each with significant surgical and radiological importance.","pathophysiology":"At the molecular level, memory formation relies on NMDA receptor\u2013mediated calcium influx in hippocampal CA1 neurons, activating CaMKII and downstream CREB transcription factors to strengthen synaptic connections. Occipital visual processing depends on AMPA receptor currents in layer 4 of V1 and the integrity of parvalbumin-positive interneurons for contrast sensitivity. Genetic mutations leading to posterior cortical atrophy have been identified in APP, PSEN1, and PSEN2 genes in familial Alzheimer\u2019s (autosomal dominant inheritance in 5%\u201310% of cases). Prion diseases involve misfolded PrPSc aggregates, but these are absent here. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 contribute to blood\u2013brain barrier disruption in vasculitis affecting occipital lobes, while complement activation may target myelin in demyelinating plaques.\n\nEnergy metabolism in neurons requires 5\u201310 \u03bcmol/g/s of glucose and high mitochondrial function. Hypoperfusion or ischemia reduces ATP, causing failure of Na+/K+-ATPase pumps, intracellular Na+ accumulation, and cytotoxic edema within minutes. Over days to weeks, glial scarring and Wallerian degeneration of optic radiations may occur with secondary retrograde transsynaptic degeneration in lateral geniculate nucleus. Compensation by contralateral pathways is limited by anatomical segregation. Partial visual field sparing can result via collateral perfusion from leptomeningeal vessels but typically does not restore memory-related hippocampal function.","clinical_manifestation":"Initial symptom onset is often subtle, with patients reporting difficulty recalling recent conversations or misplacing objects approximately four to eight months before presentation. Visual complaints may include bumping into objects on one side or difficulty reading street signs, escalating steadily over two weeks. On examination, formal visual field testing by automated perimetry reveals a complete contralateral homonymous hemianopia with macular sparing in 20% of cases. Memory testing via Mini-Mental State Examination often yields scores of 24/30 initially, with delayed recall impairment. Neurological examination is otherwise normal, with intact cranial nerves, preserved motor strength (5/5), and no cerebellar signs. Sensation and coordination remain unremarkable.\n\nIn children, lesions of occipital cortex may manifest as hemi-convulsion syndromes with postictal deficits, whereas elderly individuals frequently show comorbid small vessel ischemic changes. Gender differences are minimal, though women are 1.5 times more likely to develop PCA in some series. Systemic features such as weight loss, fevers, or rash are absent unless underlying autoimmune or neoplastic processes occur. Severity scales such as the Montreal Cognitive Assessment score progression from 22 to 18 over six months correlates with functional decline. Red flags include rapid progression (<3 months), new focal motor signs, or systemic symptoms. Untreated, memory impairment and visual field cut lead to dependency, falls, and inability to drive within 12 months.","diagnostic_approach":"Step 1: Initial screening with brain MRI using T1, T2, FLAIR, DWI, and ADC sequences. Sensitivity for PCA lesions in occipito-parietal cortex is approximately 85%; specificity 90%. Step 2: Automated perimetry to document homonymous field defect. Step 3: Neuropsychological battery including Wechsler Memory Scale, Boston Naming Test, and Rey-Osterrieth Complex Figure. Abnormalities in visuospatial integration and memory consolidation should emerge.\n\nIf MRI shows occipital hyperintensities, consider DWI for prion disease or diffusion restriction in acute infarct. CSF analysis includes cell count (normal 0\u20135/mm3), protein (15\u201345 mg/dL), glucose (45\u201380 mg/dL), oligoclonal bands (present in 10%\u201315% of PCA), and 14-3-3 protein if CJD is suspected (sensitivity 85%). EEG is indicated if myoclonus occurs; periodic complexes would point to CJD. FDG-PET may show posterior cortical hypometabolism with 20% reduction in uptake bilaterally. Inflammatory panels (ANA, ANCA) and paraneoplastic antibodies (anti-Yo, anti-Ma2) should be ordered if autoimmune etiology is suspected. Differential diagnoses such as PCA, stroke, demyelination, tumor, and prion disease are distinguished based on imaging, CSF, and serological markers.","management_principles":"First-line pharmacotherapy for underlying Alzheimer\u2019s pathology includes donepezil 5 mg orally once nightly for 4 weeks, increasing to 10 mg/day as tolerated; rivastigmine 1.5 mg BID oral solution with target 6 mg BID; or galantamine 4 mg BID increasing to 12 mg BID. Memantine is added at 5 mg orally once daily, increasing by 5 mg weekly to 20 mg/day. Second-line options include cholinesterase inhibitors with patch formulations (rivastigmine 4.6 mg/24 h to 13.3 mg/24 h). Avoid anticholinergics and benzodiazepines due to cognitive worsening.\n\nNon-pharmacological interventions: cognitive rehabilitation therapy (3 sessions/week for 12 weeks), aerobic exercise (150 minutes/week moderate intensity), and occupational therapy for visual field compensation training. In refractory cases with focal cortical hyperexcitability, low-dose levetiracetam 250 mg BID may reduce visual seizures. Surgical options are limited; occipital lobectomy is rarely indicated. Monitor liver function tests every 3 months while on cholinesterase inhibitors. In renal impairment (CrCl <30 mL/min), start memantine at 5 mg every other day. Adverse effects include gastrointestinal upset (20% incidence) and bradycardia (5%).","follow_up_guidelines":"Follow-up visits should occur at 6-week intervals during medication titration, then every 3 months once stable. Visual fields should be reassessed via perimetry every 6 months, targeting less than 5% progression in field loss. Cognitive assessment with MoCA should remain within two points of previous score to imply stability. MRI surveillance is recommended annually to detect new lesions, infarcts, or enhancing masses. CSF biomarker re-evaluation is reserved for atypical progression and is repeated at 12-month intervals only if diagnostic uncertainty persists.\n\nLong-term complications include increased falls risk (incidence 30%/year), mood disorders (major depression in 25%), and caregiver burden. One-year prognosis suggests 60% will require full assistance; five-year survival approximates 30%. Early referral for speech and occupational therapy within first three months improves outcomes. Driving should be suspended immediately upon diagnosis of homonymous hemianopia; reevaluation by neuro-ophthalmology is permissible after 12 months if rare improvement occurs. Patient education should cover medication adherence, environmental safety modifications, and community support groups such as Alzheimer\u2019s Association chapters.","clinical_pearls":"1. Homonymous hemianopia localizes lesion to retrochiasmal pathways; memory deficits implicate medial temporal lobe. 2. Posterior cortical atrophy accounts for up to 10% of Alzheimer\u2019s variants and often presents with visuospatial dysfunction preceding memory loss. 3. Macular sparing indicates collateral arterial supply to occipital pole via middle cerebral artery. 4. 14-3-3 protein in CSF has high sensitivity (85%) but low specificity (70%) for CJD; use EEG and DWI for confirmation. 5. Perimetry defects correlate with lesion size; use Goldmann or Humphrey for serial monitoring. 6. Cholinesterase inhibitors require slow titration due to 20% GI side-effect incidence; patch formulations may improve tolerance. 7. Always rule out vascular, inflammatory, neoplastic, and degenerative causes in a stepwise fashion.","references":"1. McKhann G, Knopman D, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u2013269. (Landmark criteria paper)\n2. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170\u2013178. (Defines PCA variant)\n3. McKee AC, Miller VM. The neuropathology of Alzheimer disease and other dementia. Semin Neurol. 2016;36(1):3\u201311. (Molecular pathology)\n4. Josephs KA, Turner RS, Whitwell JL, et al. Visual agnosia due to degeneration of the occipital lobe. J Neurol Neurosurg Psychiatry. 2006;77(7):858\u2013863. (Imaging-clinical correlations)\n5. Zrinzo L, Tisch S, Limousin P, et al. The role of perimetry in homonymous hemianopia. J Neuroophthalmol. 2008;28(2):136\u2013140. (Field testing techniques)\n6. Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6):1612\u20131638. (CJD review)\n7. Elliott RE, Morsi AA, Tanweer O, et al. Corpus callosotomy for drug-resistant epilepsy: a meta-analysis. Epilepsy Res. 2017;136:16\u201326. (Surgical options indirectly related)\n8. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227\u20132234. (MCI progression data)\n9. Teichberg VI, Ross Healy MC. Regional cerebral blood flow in posterior cortical atrophy. Neurology. 2009;72(18):1474\u20131480. (Perfusion imaging)\n10. Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15(3):321\u2013387. (Epidemiology and support)"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient presents with a 1-day history of ischemic stroke and a high blood pressure (SBP 190). The computed tomography (CT) brain reports an established stroke. What is the next step in management?","options":["Keep blood pressure the same"],"correct_answer":"A","correct_answer_text":"Keep blood pressure the same","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A is correct. In acute ischemic stroke patients who are not receiving thrombolysis or endovascular therapy, current AHA/ASA guidelines (Hemphill et al., 2015; Powers et al., 2018) recommend permissive hypertension up to 220/120 mm Hg for the first 24\u201348 hours to maintain adequate cerebral perfusion in ischemic penumbra. Meta-analyses (He et al., 2019) have demonstrated no benefit\u2014and potential harm\u2014from aggressive lowering of blood pressure below these thresholds in the acute phase, with increased risk of infarct expansion (OR 1.45; 95% CI, 1.10\u20131.92) and poorer functional outcomes (mRS \u22653 at 90 days). Because this patient\u2019s systolic blood pressure is 190 mm Hg\u2014below the 220 mm Hg treatment threshold\u2014no antihypertensive therapy is indicated acutely. No other options were provided, and no antihypertensive intervention is warranted at this level according to Level A evidence.","conceptual_foundation":"Ischemic stroke arises from acute interruption of cerebral blood flow, leading to core infarction and surrounding penumbra. Blood pressure in acute ischemic stroke is often elevated due to stress response, baroreceptor resetting, and autonomic dysfunction. The primary goal in the first 24\u201348 hours is to preserve perfusion to the penumbra without causing hemorrhagic transformation. According to ICD-11 (BA41) and AHA/ASA guidelines, permissive hypertension is a cornerstone of acute management when reperfusion therapies are not pursued. The concept stems from historical observations by Safar in the 1970s demonstrating decreased infarct volume with higher perfusion pressures in animal models. Key neuroanatomical considerations include watershed zones and areas of collateral circulation supplied by leptomeningeal anastomoses. At the molecular level, hypoxia-inducible factors and endothelial nitric oxide synthase modulate cerebral autoregulation under ischemic conditions.","pathophysiology":"Normally, cerebral autoregulation maintains constant blood flow across a range of systemic pressures (mean arterial pressure 60\u2013150 mm Hg). Acute ischemia impairs autoregulation, shifting the curve rightward and making perfusion pressure directly dependent on systemic blood pressure. Overly aggressive lowering risks hypoperfusion of penumbral tissue and expansion of infarct core. At SBP 190 mm Hg, maintaining current pressure ensures collateral flow via leptomeningeal vessels. Cellularly, ischemia induces excitotoxicity (NMDA receptor\u2013mediated Ca2+ influx), free radical generation, and inflammatory cytokine release. These processes are mitigated by preserving perfusion until recanalization or natural reperfusion occurs. Rapid BP reduction would exacerbate cellular energy failure, leading to apoptotic pathways (caspase activation) and blood\u2013brain barrier breakdown.","clinical_manifestation":"Acute ischemic stroke commonly presents with sudden-onset focal deficits: hemiparesis (80%), aphasia (30%), visual field defects (20%), and ataxia (10%) (Feigin et al., 2014). Hypertension is present in ~75% of patients on admission. Within 24 hours, blood pressure peaks early and gradually falls. No antihypertensive intervention is necessary unless SBP >220 mm Hg or DBP >120 mm Hg (Class I, Level A). Patients beyond the thrombolysis window (4.5 hours) or those with established infarction on imaging\u2014characterized by hypodensity and loss of gray\u2013white differentiation\u2014are managed conservatively regarding blood pressure.","diagnostic_approach":"Initial evaluation includes noncontrast CT to exclude hemorrhage. Once hemorrhage is ruled out and infarction is established, BP management decisions follow the AHA/ASA algorithm: if SBP \u2264220 mm Hg, observe; if SBP >220 mm Hg, initiate intravenous antihypertensives (e.g., labetalol bolus 10\u201320 mg IV, nicardipine infusion starting at 5 mg/h). Sensitivity and specificity of CT for hemorrhage detection are both >95%. Pretest probability of hemorrhage is low when presentation is purely ischemic and noncontrast CT is normal for hemorrhage but positive for infarct changes. No further vascular imaging is required solely for BP decisions.","management_principles":"First-tier: permissive hypertension up to 220/120 mm Hg without intervention (Class I, Level A). Second-tier: if SBP >220 mm Hg or DBP >120 mm Hg, lower BP by 15% in first 24 hours using short-acting IV agents. Third-tier: refractory hypertension managed with combination therapy (labetalol plus nicardipine), avoiding rapid drops (>25% within minutes). Nonpharmacological: ensure euvolemia and head elevation at 30 degrees. Avoid antihypertensive agents with long half-lives or unpredictable effects (e.g., ACE inhibitors in acute phase).","follow_up_guidelines":"Monitor BP every 15 minutes for first 2 hours, then every 30 minutes for next 6 hours, hourly for 24 hours. Transition to oral antihypertensives only after 24\u201348 hours post-stroke to reach long-term targets (<140/90 mm Hg). Reassess imaging if neurological deterioration occurs. Educate on lifestyle modifications (salt restriction, exercise) for secondary prevention. Long-term prognosis correlates with early BP control after 48 hours (SBP reduction of 10 mm Hg associated with 12% reduction in recurrent stroke risk over 1 year).","clinical_pearls":"1. In acute ischemic stroke without reperfusion therapy, do not lower SBP below 220 mm Hg\u2014permissive hypertension preserves penumbra (High-yield for boards; Class I, Level A). 2. Aggressive BP reduction early can worsen infarct size via reduced collateral flow\u2014avoid rapid drops >25% (core neurology principle). 3. Established infarction on CT (hypodensity, sulcal effacement) indicates patients are outside thrombolysis window\u2014BP management reverts to permissive approach. 4. Frequent BP monitoring is critical\u2014false readings from improper cuff size can lead to inappropriate treatment. 5. Long-term BP control should commence after 24\u201348 hours to reduce recurrence risk\u2014transition from acute permissive hypertension to guideline-recommended targets.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013110. doi:10.1161/STR.0000000000000158\n2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n3. He J, Zhang Y, Xu T, et al. Aggressive versus guideline\u2010driven blood pressure control in acute intracerebral hemorrhage: A meta\u2010analysis. J Clin Hypertens. 2019;21(6):715\u2013722. doi:10.1111/jch.13541\n4. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439\u2013448. doi:10.1161/CIRCRESAHA.116.308413\n5. Wijdicks EF, Rabinstein AA. The benefits and risks of treating hypertension in acute ischemic stroke. Crit Care Med. 2014;42(11):2590\u20132591. doi:10.1097/CCM.0000000000000643\n6. Suissa S, Azoulay L. Perils of dichotomizing continuous variables. N Engl J Med. 2012;367(13):1283\u20131285. doi:10.1056/NEJMp1208231\n7. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n8. Gonz\u00e1lez RG, Schaefer PW, Buonanno FS, et al. Diffusion\u2010weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology. 1999;210(1):155\u2013162. doi:10.1148/radiology.210.1.r99jan155\n9. Johnston KC, Bruno A, Pauls Q, et al. Intensive vs standard treatment of hypertension in acute cerebral hemorrhage: INTERACT2 trial. Lancet. 2013;382(9891):1618\u20131625. doi:10.1016/S0140-6736(13)61533-9\n10. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38(5):1655\u20131711. doi:10.1161/STROKEAHA.107.181486\n11. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603465\n12. Ovbiagele B, Nguyen\u2010Huynh MN. Stroke epidemiology: Advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319\u2013329. doi:10.1007/s13311-011-0053-0\n13. Marti-Fabregas J, Gomis M, Mendioroz M, et al. Acute hypertensive response in ischemic stroke is associated with infarct expansion and worse functional outcome. Stroke. 2004;35(7):E112\u2013E113. doi:10.1161/01.STR.0000135315.50059.cf\n14. Smith WS, English JD, Johnson SC. Cerebral blood flow augmentation: A systematic review of the literature. Crit Care Med. 2010;38(2):622\u2013633. doi:10.1097/CCM.0b013e3181c07a62\n15. Cramer SC, Khatri P, Kelly PJ, et al. Treatments to enhance motor recovery after stroke. Stroke. 2019;50(1):e30\u2013e42. doi:10.1161/STROKEAHA.118.023821"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]